

[illegible]

Information5Item 1. Financial Information5Condensed Consolidated Balance Sheets as of June 30, 2024 and December 31, 2023 (Unaudited)53Condensed Consolidated Statements of Operations and Comprehensive Loss for the Three and Six Months Ended June 30, 2024 and 2023 (Unaudited)6Condensed Consolidated Statements of Shareholdersâ€™ Equity for the Three and Six Months Ended June 30, 2024 and 2023 (Unaudited)7Condensed Consolidated Statements of Cash Flows for the Six Months Ended June 30, 2024 and 2023 (Unaudited)9Notes to the Unaudited Condensed Consolidated Financial Statements11Item 2. Managementâ€™s Discussion and Analysis of Financial Condition and Results of Operations30Item 3. Quantitative and Qualitative Disclosures About Market Risk43Item 4. Controls and Procedures44Part II â€œ Other Information45Item 1. Legal Proceedings45Item 1A. Risk Factors45Item 2. Unregistered Sales of Equity Securities and Use of Proceeds46Item 3. Defaults Upon Senior Securities46Item 4. Mine Safety Disclosures46Item 5. Other Information46Item 6. Exhibits46Signatures47CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTSThis Quarterly Report on Form 10-Q contains forward-looking statements about us and our industry that involve substantial risks and uncertainties. All statements other than statements of historical facts contained in this Quarterly Report on Form 10-Q, including statements regarding our strategy, future financial condition, future operations, research and development costs, plans and objectives of management, are forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as â€œaim,â€ â€œanticipate,â€ â€œassume,â€ â€œbelieve,â€ â€œcontemplate,â€ â€œcontinue,â€ â€œcould,â€ â€œdesign,â€ â€œdue,â€ â€œestimate,â€ â€œexpect,â€ â€œgoal,â€ â€œintend,â€ â€œmay,â€ â€œobjective,â€ â€œplan,â€ â€œpredict,â€ â€œpositioned,â€ â€œpotential,â€ â€œseek,â€ â€œshould,â€ â€œtarget,â€ â€œwill,â€ â€œwouldâ€ and other similar expressions that are predictions of or indicate future events and future trends, or the negative of these terms or other comparable terminology. Although we believe that we have a reasonable basis for each forward-looking statement contained in this Quarterly Report on Form 10-Q, we caution you that these statements are based on a combination of facts and factors currently known by us and our expectations of the future, about which we cannot be certain.The forward-looking statements in this Quarterly Report on Form 10-Q include, among other things, statements about:â€¢the development of our product candidates, including statements regarding the initiation, timing, progress and the results of clinical studies or trials and related preparatory work, the period during which the results of the trials will become available and our research and development programs;â€¢our estimates regarding expenses, future revenue, capital requirements and needs for additional financing;â€¢our ability to advance our product candidates into, and successfully complete, clinical trials;â€¢our ability to obtain and maintain regulatory approval of our product candidates in the indications for which we plan to develop them, and any related restrictions, limitations or warnings in the label of an approved drug or therapy;â€¢the impacts of public health crises and their effects on our operations and business, including interruption of key clinical trial activities, such as clinical trial site monitoring, access to capital, and potential disruption in the operations and business of 3Table of contentsthird-party manufacturers, clinical sites, contract research organizations (â€œCROsâ€), other service providers and collaborators with whom we conduct business;â€¢our ability to license additional intellectual property relating to our product candidates from third parties and to comply with our existing license agreement;â€¢our plans to research, develop, manufacture and commercialize our product candidates;â€¢the potential benefits of our product candidates;â€¢the timing or likelihood of regulatory filings and approvals for our product candidates, along with regulatory developments in the United States (â€œUSâ€), European Union (â€œEUâ€), the United Kingdom (â€œUKâ€) and other foreign countries;â€¢the size and growth potential of the markets for our product candidates, if approved, and the rate and degree of market acceptance of our product candidates, including reimbursement that may be received from payors;â€¢our need for and ability to obtain additional funding, on favorable terms or at all, including as a result of worsening macroeconomic conditions, including changes inflation and interest rates and unfavorable general market conditions, and the impacts thereon of the war in Ukraine, the conflict between Hamas and Israel, and global geopolitical tension;â€¢our commercialization, marketing and manufacturing capabilities and strategy;â€¢our plans to collaborate, or statements regarding our current collaborations with BioNTech SE (â€œBioNTechâ€) and others; â€¢our license and option agreement with BioNTech, including our potential to receive milestone payments and royalties under the agreement;â€¢our ability to attract collaborators with development, regulatory and commercialization expertise;â€¢our expectations regarding our ability to obtain and maintain intellectual property protection;â€¢our ability to identify, recruit and retain qualified employees and key personnel;â€¢our ability to contract with third-party suppliers and manufacturers and their ability to perform adequately;â€¢the scalability and commercial viability of our manufacturing methods and processes;â€¢the success of competing therapies that are or may become available;â€¢whether we are classified as a Passive Foreign Investment Company (â€œPFICâ€), for current and future periods;â€¢additional costs and expenses related to our decision to voluntarily comply with certain U.S. domestic issuer reporting obligations before we are required to do so; andâ€¢any other factors which may impact our financial results or future trading prices of our American Depositary Shares (â€œADSsâ€), and the impact of securities analystsâ€™ reports on these prices. Although we believe that the expectations reflected in these forward-looking statements are reasonable, these statements relate to our strategy, future operations, future financial position, future revenue, projected costs, prospects, plans, objectives of management and expected market growth, and involve known and unknown risks, uncertainties and other factors including, without limitation, risks, uncertainties and assumptions regarding the impact of worsening macroeconomic events, including changes in inflation and interest rates and unfavorable general market conditions and the impacts of the war in Ukraine, the conflict between Hamas and Israel, and global geopolitical tensions, on our business, operations, strategy, goals and anticipated timelines, our ongoing and planned preclinical activities, our ability to initiate, enroll, conduct or complete ongoing and planned clinical trials, our timelines for regulatory submissions and our financial position that may cause our actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. You are urged to carefully review the disclosures we make concerning these risks and other factors that may affect our business and operating results in this Quarterly Report on Form 10-Q. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this document. Except as required by law, we do not intend, and undertake no obligation, to update any forward-looking information to reflect events or circumstances.4Table of contentsPART I - FINANCIAL INFORMATIONItem 1. Financial statementsAUTOLUS THERAPEUTICS PLCUnaudited Condensed Consolidated Balance Sheets(In thousands, except share and per share amounts)NoteJune 30, 2024December 31, 2023AssetsCurrent assets:Cash and cash equivalents\$705,939\$ 239,566Â Restricted cash, 1,020\$ 769\$ Prepaid expenses and other current assets\$751,641\$ 34,967\$ Total current assets\$758,600\$ 275,302\$ Non-current assets:Property and equipment, net\$832,860\$ 34,862\$ Prepaid expenses and other non-current assets\$284\$ 380\$ Long-term deposits\$977\$ 983\$ Operating lease right-of-use assets, net\$57,678\$ 60,791\$ Deferred tax asset\$3,221\$ 3,063\$ Total assets\$853,620\$ 375,381\$ Liabilities and shareholders' equityCurrent liabilities:Accounts payable\$1,098\$ 1,034\$ Accrued expenses and other liabilities\$935,579\$ 39,581\$ Operating lease liabilities, current\$4,224\$ 5,053\$ Total current liabilities\$4,224\$ 44,737\$ Non-current liabilities:Operating lease liabilities, non-current\$45,794\$ 47,914\$ Liabilities related to future royalties and milestones, net\$1,223\$ 663\$ 170,899\$ Other long-term payables\$415\$ 357\$ Total liabilities\$325,776\$ 263,907\$ Commitments and contingencies 14\$Shareholders' equity:Ordinary shares, \$0.00042 par value; 490,909,783 shares authorized as of June 30, 2024 and 290,909,783 as of December 31, 2023; 266,045,468 and 174,101,361, shares issued at June 30, 2024 and December 31, 2023, respectively; 266,045,568 and 174,158,985, shares outstanding at June 30, 2024 and December 31, 2023, respectively 12\$ 8\$ Deferred shares, Â£0.00001 par value; 34,425 shares authorized, issued and outstanding at June 30, 2024 and December 31, 2023\$ 4\$ 1\$ Deferred B shares, Â£0.00099 par value; 88,893,548 shares authorized, issued and outstanding at June 30, 2024 and December 31, 2023\$ 18\$ 1\$ Deferred C shares, Â£0.000008 par value; 1 share authorized, issued and outstanding at June 30, 2024 and December 31, 2023\$ 3\$ 4\$ Additional paid-in capital\$1,545,146\$ 1,018,902\$ Accumulated other comprehensive loss(27,908)(28,992)\$ Accumulated deficit(989,524)(878,562)\$ Total shareholders' equity\$527,844\$ 111,474\$ Total liabilities and shareholders' equity\$853,620\$ 375,381\$ The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.5Table of contentsAUTOLUS THERAPEUTICS PLCUnaudited Condensed Consolidated Statements of Operations and Comprehensive Loss(In thousands, except share and per share amounts)Three Months Ended June 30, Six Months Ended June 30, Note2024202320242023License revenue\$3\$ 4\$ 10,091\$ 1,292\$ Operating expenses:Research and development(36,612)(33,232)(67,283)(60,620)\$ General and administrative(21,903)(11,122)(40,080)(20,406)\$ Loss on disposal of property and equipment\$ 4\$ (23)\$ 1\$ (3,791)\$ Impairment of operating lease right-of-use assets and related property and equipment(414)\$ 4\$ (414)\$ Total operating expenses, net(58,929)(44,377)(97,686)(83,525)\$ Other income (expense), net1,226\$ 482\$ (379)\$ 1,264\$ Interest income, 6,564\$ 3,403\$ 16,589\$ 6,849\$ Interest expense(4,104)(5,020)(29,443)(9,925)\$ Total other income (expense), net708\$ (1,135)(13,233)(1,812)\$ Net loss before income tax(58,221)(45,512)(110,919)(85,337)\$ Income tax expense(51)(40)(43)(26)\$ Net loss(58,272)(45,552)(110,962)(85,363)\$ Other comprehensive income (loss):Foreign currency exchange translation adjustment1,026\$ 5,300\$ 1,084\$ 1,041\$ Total comprehensive loss(57,246)(40,252)(109,878)(74,422)\$ Basic and diluted net loss per ordinary share\$(0.22)\$(0.26)\$(0.43)\$(0.49)\$ Weighted-average basic and diluted ordinary shares5266,025,783\$ 173,860,491\$ 255,131,873\$ 173,843,249\$ The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.6Table of contentsAUTOLUS THERAPEUTICS PLC Unaudited Condensed Consolidated Statements of Shareholdersâ€™ Equity(In thousands, except share amounts)Ordinary SharesDeferred SharesDeferred B SharesDeferred C SharesAdditional Paid in CapitalAccumulated other comprehensive lossAccumulated deficitTotal Shareholders' EquitySharesAmountSharesAmountSharesAmountSharesAmountBalance at December 31, 2023174,101,361\$ 8\$ 34,425\$ 4\$ 1\$ 88,893,548\$ 1\$ 1\$ 1\$ 1,018,902\$ (28,992)\$(878,562)\$(111,474)\$ Issuance of ordinary shares, net of issuance costs91,666,669\$ 4\$ 1\$ 4\$ 1\$ 2,935\$ 4\$ 1\$ 2,935\$ Vesting of restricted stock unit awards net of shares withheld to cover tax expense\$ 4\$ 1\$ 4\$ 1\$ 2,935\$ 4\$ 1\$ 2,935\$ Vesting of restricted stock unit awards net of shares withheld to cover tax withholding57,524\$ 4\$ 1\$ 4\$ 1\$ 2,686\$ 4\$ 1\$ 2,686\$ Vesting of restricted stock unit awards net of shares withheld to cover tax translation\$ 4\$ 1\$ 4\$ 1\$ 2,686\$ 4\$ 1\$ 2,686\$ Exercise of share options102,469\$ 4\$ 1\$ 4\$ 1\$ 2,686\$ 4\$ 1\$ 2,686\$ Net loss\$ 4\$ 1\$ 4\$ 1\$ 58\$ 4\$ 1\$ 58\$ Net loss\$ 4\$ 1\$ 4\$ 1\$ 58\$ 4\$ 1\$ 58\$ Net loss\$ 4\$ 1\$ 4\$ 1\$ 58\$ 4\$ 1\$ 58\$ Net loss\$ 4\$ 1\$ 4\$ 1\$ 58\$ 4\$ 1\$ 58\$ Balance at March 31, 2024265,928,023\$ 12\$ 34,425\$ 4\$ 1\$ 88,893,548\$ 1\$ 1\$ 1\$ 1,542,086\$ (28,934)\$(931,252)\$(582,030)\$ Share-based compensation expense\$ 4\$ 1\$ 4\$ 1\$ 2,935\$ 4\$ 1\$ 2,935\$ Vesting of restricted stock unit awards net of shares withheld to cover tax withholding73,604\$ 4\$ 1\$ 4\$ 1\$ 2,935\$ 4\$ 1\$ 2,935\$ Exercise of share options43,841\$ 4\$ 1\$ 4\$ 1\$ 2,686\$ 4\$ 1\$ 2,686\$ Net loss\$ 4\$ 1\$ 4\$ 1\$ 125\$ 4\$ 1\$ 125\$ Net loss\$ 4\$ 1\$ 4\$ 1\$ 125\$ 4\$ 1\$ 125\$ Net loss\$ 4\$ 1\$ 4\$ 1\$ 125\$ 4\$ 1\$ 125\$ Balance at June 30, 2024266,045,468\$ 12\$ 34,425\$ 4\$ 1\$ 88,893,548\$ 1\$ 1\$ 1\$ 1,545,146\$ (27,908)\$(989,524)\$(527,844)\$ The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.7Table of contentsAUTOLUS THERAPEUTICS PLCUnaudited Condensed Consolidated Statements of Shareholdersâ€™ Equity(In thousands, except share amounts)Ordinary SharesDeferred SharesDeferred B SharesDeferred C SharesAdditional Paid in CapitalAccumulated other comprehensive lossAccumulated deficitTotal Shareholders' EquitySharesAmountSharesAmountSharesAmountSharesAmountBalance at December 31, 2023174,101,361\$ 8\$ 34,425\$ 4\$ 1\$ 88,893,548\$ 1\$ 1\$ 1\$ 1,007,625\$ (38,898)\$(670,179)\$(298,674)\$ Share-based compensation expense\$ 4\$ 1\$ 4\$ 1\$ 2,935\$ 4\$ 1\$ 2,935\$ Vesting of restricted stock unit awards net of shares withheld to cover tax translation\$ 4\$ 1\$ 4\$ 1\$ 2,686\$ 4\$ 1\$ 2,686\$ Net loss\$ 4\$ 1\$ 4\$ 1\$ 5\$ 4\$ 1\$ 5\$ Net loss\$ 4\$ 1\$ 4\$ 1\$ 5\$ 4\$ 1\$ 5\$ Net loss\$ 4\$ 1\$ 4\$ 1\$ 5\$ 4\$ 1\$ 5\$ Net loss\$ 4\$ 1\$ 4\$ 1\$ 5\$ 4\$ 1\$ 5\$ Balance at March 31, 2023173,074,510\$ 8\$ 34,425\$ 4\$ 1\$ 88,893,548\$ 1\$ 1\$ 1\$ 1,010,041\$ (33,257)\$(709,990)\$(266,920)\$ Share-based compensation expense\$ 4\$ 1\$ 4\$ 1\$ 2,668\$ 4\$ 1\$ 2,668\$ Vesting of restricted stock unit awards net of shares withheld to cover tax withholding606,362\$ 4\$ 1\$ 4\$ 1\$ 2,668\$ 4\$ 1\$ 2,668\$ Net loss\$ 4\$ 1\$ 4\$ 1\$ 5,300\$ 4\$ 1\$ 5,300\$ Net loss\$ 4\$ 1\$ 4\$ 1\$ 5,300\$ 4\$ 1\$ 5,300\$ Net loss\$ 4\$ 1\$ 4\$ 1\$ 5,300\$ 4\$ 1\$ 5,300\$ Net loss\$ 4\$ 1\$ 4\$ 1\$ 5,300\$ 4\$ 1\$ 5,300\$ Balance at June 30, 2023173,680,872\$ 8\$ 34,425\$ 4\$ 1\$ 88,893,548\$ 1\$ 1\$ 1\$ 1,012,709\$ (27,957)\$(755,542)\$(229,336)\$ The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.8Table of contentsAUTOLUS THERAPEUTICS PLCUnaudited Condensed Consolidated Statements of Cash Flows(In thousands)Six Months Ended June 30, 20242023Cash flows from operating activities:Net loss(110,962)\$(85,363)\$ Adjustments to reconcile net loss to net cash used in operating activities:Depreciation and amortization3,701\$ 3,411\$ Share-based compensation net of amounts capitalized\$5,219\$ 5,069\$ Interest expense on liabilities related to future royalties and milestones, net\$29,428\$ 9,864\$ Foreign exchange differences1,142\$ (6,283)\$ Non-cash operating lease expense\$2,898\$ 1,895\$ Loss on termination of operating lease\$ 4\$ 95\$ Loss on disposal of property and equipment\$ 4\$ 3,812\$ Impairment of operating lease right-of-use assets and related property and equipment\$414\$ 4\$ Deferred income tax(158)(282)\$ Changes in operating assets and liabilities:Increase in prepaid expenses and other current assets(16,936)(1,591)\$ Decrease in prepaid expenses and other non-current assets\$159\$ 1,817\$ Decrease in long-term deposits\$ 4\$ 51\$ Increase in accounts payable\$983\$ 3,263\$ Decrease in accrued expenses and other liabilities(4,276)(9,530)\$ Decrease in operating lease liability(2,600)(6,794)\$ Net cash used in operating activities(91,597)(80,566)\$ Cash flows from investing activities:Purchases of property and equipment(1,374)(8,011)\$ Net cash used in investing activities(1,374)(8,011)\$ Cash flows from financing activities:Proceeds of issuance of ordinary shares\$49,977\$ 4\$ Payments of equity issuance costs(29,360)(910)\$ Proceeds from the exercise of share options\$410\$ 4\$ Proceeds from liabilities related to future royalties and milestones, net\$40,000\$ 4\$ Payments of issuance costs related to the liabilities related to the sale of future royalties and milestones, net(1,665)\$ 4\$ Net cash provided by (used in) financing activities\$559,362\$ (910)\$ 4\$ Effect of exchange rate changes on cash, cash equivalents and restricted cash\$233\$ 14,558\$ Net increase (decrease) in cash, cash equivalents and restricted cash\$466,624\$ (74,929)\$ Cash, cash equivalents and restricted cash, beginning of period\$240,335\$ 382,761\$ Cash, cash equivalents and restricted cash, end of period\$706,959\$ 307,832\$ 9Table of contentsSix Months Ended June 30, 20242023Unaudited supplemental cash flow informationCash paid for income taxes\$964\$ 274\$ Unaudited supplemental non-cash flow informationProperty and equipment purchases included in accounts payable or accrued expenses\$989\$ 2,262\$ Leased assets terminated and obtained in exchange for operating lease liabilities, net\$ 4\$ (1,110)\$ Leased assets obtained in exchange for operating lease liabilities\$ 4\$ 32,903\$ Capitalized share-based compensation, net of forfeitures\$2\$ 15\$ Capitalized implementation costs included in accrued expenses\$168\$ 116\$ Reconciliation of cash, cash equivalents and restricted cash reported within the consolidated balance sheets:Cash and cash equivalents\$705,939\$ 307,500\$ Restricted cash, 1,020\$ 332\$ Total cash, cash equivalents and restricted cash\$706,959\$ 307,832\$ The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.10Table of contentsAUTOLUS THERAPEUTICS PLCNotes to the Unaudited Condensed Consolidated Financial Statements Note 1. Nature of the BusinessAutolus Therapeutics plc (with its subsidiaries, collectively, â€œAutolusâ€ or the â€œCompanyâ€) is a biopharmaceutical company developing next-generation programmed T cell therapies for the treatment of cancer and autoimmune diseases. Using its broad suite of proprietary and modular T cell programming technologies, the Company is engineering precisely targeted, controlled and highly active T cell therapies that are designed to better recognize target cells, break down their defense mechanisms and attack and kill these cells. The Company believes its programmed T cell therapies have the potential to be best-in-class and to offer patients substantial benefits over the existing standard of care, including the potential for cure in some patients. In November 2023, the Company submitted a Biologics License Application (â€œBLAâ€) to the U.S. Food and Drug Administration (â€œFDAâ€) for its lead product candidate obcagene autoleucel (â€œobe-celâ€) for the treatment of relapsed/refractory (â€œr/râ€) adult B-cell acute Lymphoblastic Leukemia (â€œB-ALLâ€), with a Prescription Drug User Fee Act (â€œPDUFAâ€) target action date of November 16, 2024.Autolus Therapeutics plc is registered in England and Wales. Its registered office is The MediaWorks, 191 Wood Lane, London, W12 7FP, United Kingdom.The Company is subject to risks and uncertainties common to companies in the biotechnology industry, including, but not limited to, development by competitors of new technological innovations, dependence on key personnel, protection of proprietary technology, compliance with government regulations and the ability to secure additional capital to fund operations. Obe-cel and the Companyâ€™s other product candidates currently under development will require significant additional research and development efforts, including preclinical and clinical testing and regulatory approval, prior to commercialization. Even if obe-cel is approved by the FDA, the Company will need to incur significant additional costs to prepare for its commercialization. These efforts will require significant amounts of capital, adequate personnel and infrastructure and extensive compliance capabilities. Even if the Companyâ€™s product development efforts for obe-cel and its other product candidates are successful, it is uncertain when, if ever, the Company will realize revenue from its product sales.BioNTech AgreementsOn February 6, 2024 (the â€œExecution Dateâ€), the Company concurrently entered into a (i) Securities Purchase Agreement (the

ÆBioNTech Securities Purchase Agreementâ€¸), (ii) a Registration Rights Agreement (the ÆBioNTech Registration Rights Agreementâ€¸), (iii) a Letter Agreement (the ÆBioNTech Letter Agreementâ€¸) and (iv) a License and Option Agreement (the ÆBioNTech License and Option Agreementâ€¸), collectively called the ÆBioNTech Agreementsâ€¸, with BioNTech. The BioNTech Agreements were entered into and in contemplation of one another and, accordingly, the Company assessed the accounting for these agreements in the aggregate. The following descriptions of the BioNTech Agreements do not purport to be complete and are qualified in their entirety by reference to the full text of such agreements.(i) BioNTech Securities Purchase AgreementPursuant to the BioNTech Securities Purchase Agreement the Company sold to BioNTech ADSs, each representing one ordinary share with a nominal value of \$0.00042 per share, of the Company (the ÆOrdinary Sharesâ€¸) in a private placement transaction (the ÆPrivate Placementâ€¸). On February 13, 2024, the Company completed the Private Placement of 33,333,333 ADSs (the ÆInitial ADSsâ€¸), representing 33,333,333Â Ordinary Shares at an offering price of \$6.00 per Initial ADS. Aggregate net proceeds to the Company, after underwriting discounts and offering expenses, were \$193.8Â million. In the event that BioNTech and the Company enter into a Manufacturing and Commercial Services Agreement (as defined below) within 18 months of the initial closing of the Private Placement, BioNTech will purchase additional ADSs (the ÆSubsequent ADSsâ€¸ and, together with the Initial ADSs, the ÆPrivate Placement ADSsâ€¸), not to exceed 15,000,000 ADSs, for an aggregate purchase price of up to \$20.0Â million. The total number of Subsequent ADSs that may be issued is subject to additional limitations and restrictions.TheBioNTech Securities Purchase Agreement contains customary representations, warranties, and covenants of each of the Company and BioNTech.(ii) BioNTech Registration Rights Agreement Pursuant to the BioNTech Registration Rights Agreement the Company agreed to file a registration statement with the SEC to register the resale of the Private Placement ADSs. 11Table of contentsAUTOLUS THERAPEUTICS PLCNotes to Condensed Consolidated Financial Statements (Unaudited) - Continued(iii) BioNTech Letter AgreementTheBioNTech Letter Agreement provides BioNTech with certain additional rights and subjects BioNTechâ€™s investment in the Company to certain restrictions. BioNTech received the right to nominate a director to the Companyâ€™s board of directors. If BioNTech acquires beneficial ownership of at least 30% of the issued and outstanding Ordinary Shares of the Company (including in the form of ADSs) within five years of the Execution Date, BioNTech will have the right to designate an additional director who shall be independent. BioNTechâ€™s director nomination rights shall automatically terminate upon BioNTechâ€™s ownership of Ordinary Shares dropping below certain specified percentages. Additionally, BioNTech has the right to purchase equity securities sold by the Company in bona fide financing transactions in amounts that are based on BioNTech maintaining specified ownership thresholds following such financing transactions.Subject to specified exceptions, BioNTech may not sell the Private Placement ADSs without the Companyâ€™s approval for a period of six months following the applicable closing date for such ADSs.The BioNTech Letter Agreement terminates upon the earlier of (a) the later of (i) February 6, 2027 and (ii) such time as no securities of the Company are held by BioNTech or its affiliates and (b) the consummation of a change of control transaction involving the Company.(iv) BioNTech License and Option AgreementLicense and OptionsThe Company, through its wholly owned subsidiaries, Autolus Limited and Autolus Holdings (U.K.) Limited, entered into the BioNTech License and Option Agreement with BioNTech pursuant to which the Company granted to BioNTech:â€¸an exclusive, worldwide, sublicenseable license (the ÆBinder Licenseâ€¸) to certain binders and to exploit products that express in vivo such binders (collectively, the ÆBinder Licensed Productsâ€¸), andâ€¸several time-limited options (the ÆOptionsâ€¸) to acquire additional rights to specified clinical-stage product candidates, binders and technologies of the Company, described in more detail below:â€¸â€¸an option to obtain exclusive rights to co-fund development costs of the Companyâ€™s development-stage programs AUTO1/22 and AUTO6NG (â€¸Product Optionsâ€¸), in return for agreed upon economic terms, including an option exercise fee, milestone payments and a profit-sharing arrangement for each such product candidate, with additional options to co-promote or co-commercialize each such product candidate;â€¸â€¸an option to obtain an exclusive worldwide license to exploit products that express certain additional binders in vivo or, with respect to certain binders, in an antibody drug conjugate (the ÆBinder Optionâ€¸);â€¸â€¸an option to obtain a co-exclusive worldwide license to exploit products that express in vivo the Companyâ€™s modules for activity enhancement, with a non-exclusive right, in certain agreed instances, to exploit products that include Companyâ€™s modules for activity enhancement but do not express in vivo such modules (the ÆActivity Enhancement Optionâ€¸); andâ€¸â€¸an option to obtain a non-exclusive worldwide license to exploit products that contain the Companyâ€™s safety switches (the ÆSafety Switch Optionâ€¸ and, together with the Binder Option and the Activity Enhancement Option, the ÆTechnology Optionsâ€¸).In consideration for the Binder License and the Technology Options, BioNTech made an initial payment to the Company of \$10.0 million. In the event that all Options are fully exercised, the Company would be eligible to receive maximum aggregate payments of up to \$582.0 million pursuant to the License Agreement. This maximum amount includes the potential milestone payments for the Binder Licensed Products described below, all option exercise fees and potential milestone payments for licenses to optioned products and technologies, and additional payments that BioNTech may pay to the Company for an increased revenue interest with respect to the Companyâ€™s product candidate obe-cel as described below.The option exercise fee for each Technology Option is a low seven-digit amount. Each of the Activity Enhancement Option and the Safety Switch Option must be exercised with respect to a given biological target or combination of targets. There is a cap on the total option exercise fee if multiple options are exercised with respect to a given target.There is also a cap on milestone payments across all agreements entered into as the result of BioNTech exercising one or more of the Technology Options and a cap on the royalty rate payable on any given product for which multiple Options are exercised.12Table of contentsAUTOLUS THERAPEUTICS PLCNotes to Condensed Consolidated Financial Statements (Unaudited) - ContinuedObe-cel Product Revenue InterestBioNTech has also agreed to financially support the expansion of the clinical development program for, and planned commercialization of obe-cel. In exchange for the grant of rights to future revenues from the sales of obe-cel products, BioNTech made an upfront payment to the Company of \$40.0Â million. The Company will pay BioNTech a low single-digit percentage of annual net sales of obe-cel products, which may be increased up to a mid-single digit percentage in exchange for milestone payments of up to \$100.0Â million in the aggregate on achievement of certain regulatory events for specific new indications upon BioNTech's election.Manufacturing and Commercial Services AgreementUnder the terms of the BioNTech License and Option Agreement, the Company has agreed to grant BioNTech the option to negotiate a joint manufacturing and commercial services agreement pursuant to which the parties may access and leverage each otherâ€™s manufacturing and commercial capabilities, in addition to Autolusâ€™ commercial site network and infrastructure, with respect to certain of each partiesâ€™ CAR T products, including BioNTechâ€™s product candidate BNT211 (the ÆManufacturing and Commercial Services Agreementâ€¸ or ÆMCSAâ€¸). The MCSA, if entered into, would also grant BioNTech access to the Companyâ€™s commercial site network and infrastructure. The Company concluded there were four freestanding financial instruments arising from the execution of the BioNTech Agreements, comprising:1.the Initial ADSs representing ordinary shares purchased pursuant to the BioNTech Securities Purchase Agreement;2.the potential Subsequent ADSs representing ordinary shares that may be purchased pursuant to the BioNTech Securities Purchase Agreement;3.the BioNTech License and Option Agreement, and4.the MCSA. The Subsequent ADSs are classified as a forward instrument contingent on the MCSA being executed. As of June 30, 2024, the MCSA had not been entered into. The forward instrument has an inconsequential market value as the exercise price approximates the Companyâ€™s stock price on the last trading day prior to the signing date of the MCSA. Consequently, the initial proceeds arising from the purchase of Initial ADSs pursuant to the BioNTech Securities Purchase Agreement will not be separately allocated to this freestanding financial instrument at inception of the BioNTech Agreements. Furthermore, as the MCSA has yet to be entered into no consideration will be allocated to this freestanding financial instrument at inception of the BioNTech Agreements. Within the BioNTech License and Option Agreement, there are a number of embedded features which have each been assessed for freestanding financial instrument accounting in accordance with Accounting Standards Codification (â€¸ASCâ€¸) 480 â€¸“ Distinguishing Liabilities from Equity. Although these embedded features are separately exercisable, they lack legal detachability and, therefore, the BioNTech License and Option Agreement is accounted for as one freestanding financial instrument. However, each embedded feature is assessed for derivative accounting in accordance to ASC 815 â€¸“ Derivative and Hedging (â€¸ASC 815â€¸). The Company analyzed how it should account for the host Contract (i.e., the BioNTech License and Option Agreement) as the Binder License represents an agreement with customer for goods and services and therefore should be accounted for under ASC 606 â€¸“ Revenue from Contracts with Customers (â€¸ASC 606â€¸). However, as the other embedded features of the BioNTech License and Option Agreement fall under the scope of other topics that specify how to initially measure the contract (i.e., ASC 470 â€¸“ Debt (â€¸ASC 470â€¸)), the Company determined that the host contract should not be accounted for and initially measured pursuant to ASC 606. Furthermore, the Company determined the host contract (the BioNTech License and Option Agreement) met the scope exception of ASC 815-10-59(d) and therefore should not be accounted for as a derivative under ASC 815 but instead be accounted for as a debt financial instrument in accordance with ASC 470. 13Table of contentsAUTOLUS THERAPEUTICS PLCNotes to Condensed Consolidated Financial Statements (Unaudited) - ContinuedThe four units of accounting were recorded at fair value upon initial recognition and will not be subsequently measured at fair value. The Company allocated the total gross proceeds arising from the BioNTech Securities Purchase Agreement (i.e. the Initial ADSs representing ordinary shares), and the BioNTech License and Option Agreement among the four units of accounting on a relative fair value basis at the time of the transaction as follows:Units of AccountingGross proceeds (in millions)Initial fair value (in millions)Allocated consideration based on relative fair value (in millions)Net allocated consideration based on relative fair value after transaction costs*(in millions)Initial ADSs, representing ordinary shares\$200.0Â \$200.0Â \$200.0Â \$193.8Â Subsequent ADSs, representing ordinary shares\$â€¸Â \$â€¸Â \$â€¸Â \$â€¸Â BioNTech License and Option Agreement\$50.0Â \$50.0Â \$50.0Â \$47.9Â Liabilities related to future royalties and milestones, net (Obe-cel Product Revenue Interest)\$40.0Â \$40.0Â \$40.0Â \$38.3Â License Revenue (Binder License)\$10.0Â \$10.0Â \$10.0Â \$9.6Â MCSA\$â€¸Â \$â€¸Â \$â€¸Â \$â€¸Â Total\$250.0Â \$250.0Â \$250.0Â \$241.7Â * In addition, the total shared transaction costs of \$8.3 million, relating to the BioNTech Agreements have been allocated to the four units of accounting on a relative fair value basis.Note 2. Summary of Significant Accounting PoliciesBasis of PresentationThe accompanying unaudited condensed consolidated financial statements of the Company have been prepared in accordance with generally accepted accounting principles in the US (â€¸U.S. GAAPâ€¸) and are presented in U.S. dollars. All intercompany accounts and transactions between the Company and its subsidiaries have been eliminated upon consolidation. The significant accounting policies used in the preparation of these unaudited condensed consolidated financial statements are consistent with those discussed in Note 2, â€¸Summary of Significant Accounting Policiesâ€¸ in the Companyâ€™s Annual Report on Form 10-K for the year ended December 31, 2023 as filed with the Securities and Exchange Commission on March 21, 2024 (the ÆAnnual Reportâ€¸).Certain information and footnote disclosures have been condensed or omitted as permitted under U.S. GAAP. The information included in these unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and the related notes thereto as of and for the year ended December 31, 2023, included in the Annual Report. However, these interim financial statements include all adjustments, consisting only of normal recurring adjustments, which are, in the opinion of management, necessary to fairly state the results of the interim period. The interim results are not necessarily indicative of results to be expected for the full year ending December 31, 2024, any other interim periods, or any future year or period.Going ConcernThe Company has incurred recurring losses since its inception, including net losses of \$58.3 million and \$45.6 million for the three months ended June 30, 2024 and 2023, respectively and \$111.0 million and \$85.4 million for the six months ended June 30, 2024 and 2023, respectively. The Company had an accumulated deficit of \$989.5 million and \$878.6 million as of June 30, 2024 and December 31, 2023, respectively. The Company expects to continue to generate operating losses in the foreseeable future. The Companyâ€™s inability to raise additional capital as and when needed could have a negative impact on its financial condition and ability to pursue its business strategies. There can be no assurances, however, that the current operating plan will be achieved or that additional funding will be available on terms acceptable to the Company, or at all. The Company expects that its cash and cash equivalents at June 30, 2024 of \$705.9 million will be sufficient to fund the Companyâ€™s operations for at least twelveÂ months from the issuance date of these unaudited condensed consolidated financial statements and accordingly they have been prepared on a going concern basis. As the Company continues to incur losses, the transition to profitability is dependent upon the successful development, approval and commercialization of its product candidates and achieving a level of revenues adequate to support its cost structure. Even if the Companyâ€™s planned regulatory submissions for its products are approved, and the Company is successful in its commercialization efforts, additional funding will be needed before the Company is expected to reach cash breakeven.14Table of contentsAUTOLUS THERAPEUTICS PLCNotes to Condensed Consolidated Financial Statements (Unaudited) - ContinuedForeign Currency TranslationThe reporting currency of the Company is U.S. dollars. The Company has determined that its functional currency of the ultimate parent company, Autolus Therapeutics plc, is British Pound Sterling. The functional currency of each subsidiaryâ€™s operations is the applicable local currency. Monetary assets and liabilities denominated in currencies other than the Companyâ€™s functional currency are translated into the functional currency at rates of exchange prevailing at the balance sheet dates. Non-monetary assets and liabilities denominated in foreign currencies are translated into the functional currency at the exchange rates prevailing at the date of the transaction.The Company recorded foreign exchange gains of \$1.2 million and \$0.4 million for the three months ended June 30, 2024 and 2023, respectively, and foreign exchange losses of \$0.5 million and foreign exchange gains of \$1.3 million for the six months ended June 30, 2024 and 2023, respectively, which are included in other income (expense), net in the unaudited condensed Consolidated Statements of Operations and Comprehensive Loss.For financial reporting purposes, the financial statements of the Company have been translated into U.S. dollars. Assets and liabilities have been translated at the exchange rates at the balance sheet dates, while revenue and expenses are translated at the average exchange rates over the reporting period and shareholdersâ€™ equity amounts are translated based on historical exchange rates as of the date of each transaction. Translation adjustments are not included in determining net income (loss) but are included in foreign exchange adjustment to other comprehensive loss, a component of shareholdersâ€™ equity.Segment InformationThe Companyâ€™s chief operating decision maker (the ÆCODMâ€¸), its Chief Executive Officer, manages the Companyâ€™s operations on an integrated basis for the purpose of appropriately allocating resources. When evaluating the Companyâ€™s financial performance, the CODM reviews total revenue, total expenses and expenses by function and makes decisions using this information on a global basis. The Company and the CODM view the Companyâ€™s operations and manage its business as a single operating segment, which is the business of developing and commercializing CAR T therapies.Use of EstimatesThe preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of income and expenses during the reporting periods. Significant estimates and assumptions reflected in these consolidated financial statements include, but are not limited to, the accrual for research and development expenses, share-based compensation including assessing the probability of meeting performance conditions, income taxes, initial fair value of warrants, and interest expense on liability related to future royalties and milestones, net and related cumulative catch-up adjustment, initial lease term of the Companyâ€™s new manufacturing facility (â€¸The Nucleusâ€¸), incremental borrowing rates related to the Company's leased properties and allocation of transaction price using the relative standalone selling price. Estimates are periodically reviewed in light of changes in circumstances, facts and experience. Actual results could differ from those estimates.Allocation of transaction price using the relative standalone selling priceUpfront payments are allocated between performance obligations using the Companyâ€™s best estimate of the relative standalone selling price of the performance obligation. The relative standalone selling price is estimated by determining the market values of development and license obligations. As these inputs are not directly observable, the estimate is determined considering all reasonably available information including internal pricing objectives used in negotiating the contract, taking into account the different stage of development of each development program and consideration of adjusted-market data from comparable arrangements. Where performance obligations have been identified relating to material rights, the determination of the relative standalone selling price of these performance obligations also includes an assessment of the likelihood that the options will be exercised and any payments by the customer that are triggered upon exercising the right. This assessment involves significant judgment and could have a significant impact on the amount and timing of revenue recognition.An assessment of the allocation of transaction price using the relative standalone selling price was required for the three and six months ended June 30, 2024 and 2023 for the BioNTech License and Option Agreement and the Option and License Agreement with Cabaletta Bio Inc. (â€¸Cabalettaâ€¸), respectively. See Note 3 for additional information on the allocation of the transaction price for those agreements.15Table of contentsAUTOLUS THERAPEUTICS PLCNotes to Condensed Consolidated Financial Statements (Unaudited) - ContinuedLiability related to future royalties and milestones, net and cumulative catch-up adjustmentsThe Company accounted for each of the Blackstone Collaboration Agreement (See Note 12) (â€¸Blackstone Collaboration Agreement Liabilityâ€¸) and the BioNTech Obe-cel Product Revenue Interest (â€¸BioNTech Liabilityâ€¸) as liabilities measured at amortized cost based on an effective interest rate determined at the outset of the arrangement The Blackstone Collaboration Agreement Liability related to future royalties and milestones, net is measured based on the Companyâ€™s current estimates of the timing and amount of expected future royalties, milestone payments to be paid and the milestones receivable upon the achievement of certain specified clinical, manufacturing and regulatory milestones (each such payment, a

The Blackstone Development Payment and collectively, the BioNTech License and Option Agreement (the "BioNTech Milestone Payments") are payable upon BioNTech's election, and therefore have not been included in the determination of the effective interest rate or in the measurement of the liability. The liabilities are amortized using the effective interest rate, resulting in recognition of interest expense over the estimated term of the agreement. Each reporting period the Company assesses the estimated probability, timing and amount of the future expected royalty, milestone payments, the Blackstone Development Payment over the estimated term. If there are changes to the estimates, the Company recognizes the impact to the liability's amortization schedule and the related interest expense using the catch-up method. The Company's estimate of the probability, timing and amount of expected future royalties and milestones to be paid by the Company and the expected Blackstone Development Payment to be paid to the Company, considers significant unobservable inputs. These inputs include regulatory approval, the estimated patient population, estimated selling price, estimated sales, estimated peak sales and sales ramp, timing of the expected launch and its impact on the royalties as well as the overall probability of a success. Additionally, the transaction costs associated with the liability will be amortized to interest expense over the estimated term of the agreements. The carrying amount of the Blackstone Collaboration Agreement Liability and BioNTech Liability is based on the Company's estimate of the future royalties, milestones to be paid to Blackstone by the Company and the expected Blackstone Development Payment to be received over the life of the arrangement as discounted using the initial effective interest rate. The excess estimated present value of future royalty, milestone payments and the future Blackstone Development Payment received over the carrying amount is recognized as a cumulative catch-up adjustment within interest expense using the effective interest rate. Recent Accounting Pronouncements Not Yet Adopted In November 2023, the Financial Accounting Standards Board, (FASB), issued Accounting Standards Update, or (ASU), 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures, or (ASU 2023-07), which expanded the disclosures for reportable segments made by public entities. These amendments within ASU 2023-07 retained the existing disclosure requirements in ASC 280 - Segment Reporting and expanded upon them to require public entities to disclose significant expenses for reportable segments in both interim and annual reporting periods, as well as items that were previously disclosed only annually on an interim basis, including disclosures related to a reportable segment's profit or loss and assets. In addition, entities with a single reportable segment must provide all segment disclosures required in ASC 280, including the new disclosures for reportable segments under the amendments in ASU 2023-07. The amendments did not change the existing guidance on how a public entity identified and determined its reportable segments. A public entity should apply the amendments in ASU 2023-07 retrospectively to all prior periods presented in the financial statements. Upon transition, the segment expense categories and amounts disclosed in the prior periods should be based on the significant segment expense categories identified and disclosed in the period of adoption. The amendments in ASU 2023-07 are effective for annual periods for all public entities in fiscal years beginning after December 15, 2023, and in interim periods within fiscal years beginning after December 15, 2024. The Company will comply with any new applicable disclosures in its Annual Report on Form 10-K for the year ending December 31, 2024. The Company does not expect the adoption to have a material effect on its financial statements and related disclosures. In December 2023, the FASB issued ASU 2023-09, Improvements to Income Tax Disclosures. This ASU improves the transparency of income tax disclosure by requiring consistent categories and greater disaggregation of information in the rate reconciliation, and income taxes paid disaggregated by jurisdiction. This guidance is effective for the Company for the year beginning January 1, 2025, with early adoption permitted. The amendments should be applied on a prospective basis, with retrospective application permitted. The Company intends to adopt the guidance in the fiscal year beginning January 1, 2025. The Company does not expect the adoption of ASU 2023-09 to have a material effect on its financial statements and related disclosures. Unless otherwise discussed, the impact of recently issued standards that are not yet effective are not expected to have a material impact on the Company's consolidated financial statements and disclosures in this report and for the full year ending December 31, 2024.

Table of contents

AUTOLUS THERAPEUTICS PLC Notes to Condensed Consolidated Financial Statements (Unaudited) - Continued

Note 3. License Revenue

License revenue for the three and six months ended June 30, 2024, and 2023, is presented in the table below by geographical location (in thousands):

	Three Months Ended June 30, 2024	Six Months Ended June 30, 2024	Three Months Ended June 30, 2023	Six Months Ended June 30, 2023
Germany	\$10,091A	\$1,292A	\$10,091A	\$1,292A
Other	\$1,292A	\$1,292A	\$1,292A	\$1,292A
Total	\$11,383A	\$2,584A	\$11,383A	\$2,584A

During the six months ended June 30, 2024, and 2023, 100% of the Company's license revenues were generated from BioNTech and Cabaletta, respectively. License and Option Agreement with BioNTech See Note 1 for a description of the BioNTech License and Option Agreement, under which the Company recognized revenue during six months ended June 30, 2024. For further details on the terms and accounting treatment considerations for the BioNTech Agreement, refer to following notes to these interim condensed consolidated financial statements:

Note 1, Nature of the business

Note 2, Summary of significant accounting policies

Note 10, Shareholders' equity

Note 12, Liabilities related to future royalties and milestones, net

Note 14, Commitments and contingencies

As the BioNTech License and Option Agreement has been accounted for as one freestanding financial instrument with various embedded features, including the Binder License and related transfer of know-how, Technology Options, and Product Options, the Company is required to consider if the embedded features are required to be bifurcated from the host contract and therefore accounted for as a separate derivative. The Company concluded the Binder License and related transfer of know-how, Technology Options, and Product Options meet the scope exception set out in ASC 815-10-15-59(d) and therefore not accounted for as derivatives under ASC 815. Binder License The Company applied ASC 606 to account for the Binder License and related know-how as functional intellectual property. The Binder License and related transfer of know-how were not distinct from one another and must be combined as a performance obligation, as BioNTech requires the know-how to derive benefit from the license. Based on these determinations, the Company identified one combined distinct performance obligation at the inception of the BioNTech License and Option Agreement. The Company further determined the consideration received included in the transaction price at contract inception, is to be allocated to the one combined performance obligation. The Company determined that the performance obligation was recognized at a point-in-time, upon the delivery of the transfer of know-how and Binder License to BioNTech. The Company recognized total license revenue of \$10.1A million (net of foreign exchange differences), related to the BioNTech License and Option Agreement for the three months ended March 31, 2024. No license revenue was recognized during the three months ended June 30, 2024.

Table of contents

AUTOLUS THERAPEUTICS PLC Notes to Condensed Consolidated Financial Statements (Unaudited) - Continued

The Company is eligible to receive milestone payments of up to \$32.0A million in the aggregate upon the achievement of specified clinical development and regulatory milestones for each Binder Licensed Product that achieves such milestones. The Company is also eligible to receive a low single-digit royalty on net sales of Binder Licensed Products, subject to customary reductions, which are subject to specified limits. The royalty will be increased if BioNTech, its affiliates or sublicensees commercialize a Binder Licensed Product in an indication and country in which the Company or its affiliates or licensees also commercializes a product containing the same binders. Under the BioNTech License and Option Agreement, BioNTech is solely responsible for, and has sole decision-making authority with respect to, at its own expense, the exploitation of Binder Licensed Products. Milestone payments and royalty payments are regarded as variable consideration and will be evaluated under the most likely amount method. Milestone payments and royalty payments were not included in the transaction price, as these amounts were fully constrained as of June 30, 2024. Technology Options As the Technology Options are outside the scope of ASC 815, the Company considered other relevant accounting guidance to apply to this component of the BioNTech License and Option Agreement. The Company therefore applied ASC 606, considering particularly the accounting guidance related to any options granted to customers to purchase additional goods or services at a future date as this could provide a material right to the customer. A material right is a promise embedded in a current contract that should be accounted for as a separate performance obligation. The Company determined the Technology Options were not offered at a significant and incremental discount. Accordingly, the Technology Options granted to BioNTech do not represent a material right and, therefore, were not a performance obligation at the outset of the arrangement. The Technology Option exercise fee equates to the standalone selling price of the technologies underlying each option and consequently, the transaction price of \$10.0A million was not allocated to the Technology Options' performance obligation. No Technology Options were exercised during the three and six months ended June 30, 2024. Product Options As the Product Options are precluded from being accounted for under ASC 815 due to the scope exception, management considered the terms of the Product Options and concluded that they should be accounted for as a gain contingency under the scope of ASC 450 - Contingencies ("ASC 450"). The Product Options, unlike the Technology Options, are 1) still subject to negotiation as to the specific activities to be performed by each party, which will be determined and agreed before the Product Options can be exercised, and 2) have not been exercised upon signature of the BioNTech License and Option Agreement. As a result, Product Options are not accounted for under ASC 606, and no recognition is required under ASC 450, until the Product Options are exercised. No Product Options were exercised during the three and six months ended June 30, 2024. Option and License Agreement with Cabaletta On January 9, 2023, the Company entered into an Option and License Agreement (the "Cabaletta Agreement") with Cabaletta, pursuant to which the Company granted to Cabaletta a non-exclusive license to research, develop, manufacture, have manufactured, use, and commercialize products incorporating the Company's safety switch technology (the "RQR8 technology"). Upon the execution of the Cabaletta Agreement, the Company made available the RQR8 licensed know-how to Cabaletta for a non-refundable license fee of \$1.2A million. The Company has no further material performance obligations related to the Cabaletta Agreement. The Company further granted to Cabaletta the option to expand the rights and licenses granted under the Cabaletta Agreement to include the research, development, manufacture, use, or commercialization of licensed products up to a predetermined number of target options upon payment of an option exercise fee. The Company identified the following material promises relating to the granting of a non-exclusive license for research, development, manufacturing and commercialization activities as well as the initial transfer of know-how and information to Cabaletta. The Company determined the option exercise fee is not offered at a significant and incremental discount. Accordingly, the option granted to Cabaletta does not represent a material right and, therefore, is not a performance obligation at the outset of the arrangement. The Company determined that the granting of the research license and the initial transfer of know-how were not distinct from one another and must be combined as a performance obligation, as Cabaletta requires the know-how to derive benefit from the license. Based on these determinations, the Company identified one distinct performance obligation at the inception of the contract. The Company further determined that the license fee payable constituted the entirety of the consideration included in the transaction price at contract inception, which was allocated to the one performance obligation. The amount of the transaction price allocated to the performance obligation is recognized as or when the Company satisfies the performance obligation. The Company determined that the performance obligation was recognized at a point-in-time, upon the delivery of the transfer of know-how and research license to Cabaletta. The Company recognized total license revenue of \$1.2A million related to the Cabaletta Agreement for the six months ended June 30, 2023. No license revenue was recognized related to the Cabaletta Agreement for the three and six months ended June 30, 2024.

Table of contents

AUTOLUS THERAPEUTICS PLC Notes to Condensed Consolidated Financial Statements (Unaudited) - Continued

Upon execution of the Cabaletta Agreement, the transaction price included only the \$1.2A million non-refundable license fee payable to the Company. The Company may receive further payments upon the exercise of the options for licensed targets, the achievement of certain development and sales milestones, as well as royalty payments based on net sales of each product covered by the licensed intellectual property. The future milestones, which represent variable consideration, will be evaluated under the most likely amount method, and were not included in the transaction price, as these amounts were fully constrained as of June 30, 2024. For the three and six months ended June 30, 2024 and 2023, the Company has not recognized any variable consideration with regards to the development milestones and sales-based milestones with its customers as they are deemed not probable.

Note 4. Interest expense

Interest expense consisted of the following (in thousands):

	Three Months Ended June 30, 2024	Six Months Ended June 30, 2024	Three Months Ended June 30, 2023	Six Months Ended June 30, 2023
Basic	\$4,959A	\$18,559A	\$9,864A	\$36,411A
Diluted	\$4,959A	\$18,559A	\$9,864A	\$36,411A
Total	\$4,959A	\$18,559A	\$9,864A	\$36,411A

Cumulative catch-up adjustment arising from the liabilities related to future royalties and milestones, net (refer to Note 12)

Other interest expense

Basic and diluted net loss per ordinary share was calculated as follows (in thousands, except share and per share amounts):

	Three Months Ended June 30, 2024	Six Months Ended June 30, 2024	Three Months Ended June 30, 2023	Six Months Ended June 30, 2023
Numerator	Net loss \$(58,272)\$	\$(45,552)\$	Net loss \$(110,962)\$	\$(85,363)\$
Denominator	Weighted-average number of ordinary shares used in net loss per share - basic and diluted 266,025	783A	173,860	491A
Basic	\$0.22	\$(0.26)	\$(0.43)	\$(0.49)
Diluted	\$0.22	\$(0.26)	\$(0.43)	\$(0.49)

For all periods presented, outstanding but unvested restricted stock units and share options have been excluded from the calculation, because their effects would be anti-dilutive. Therefore, the weighted average number of ordinary shares used to calculate both basic and diluted loss per share is the same for all periods presented. The following potentially dilutive securities have been excluded from the calculation of diluted net loss per share due to their anti-dilutive effect:

	Three Months Ended June 30, 2024
--	----------------------------------

been issued. However, these vested restricted stock unit awards have been included in the calculation of the Company’s outstanding shares at June 30, 2024 as they are considered issuable for little or no cash consideration. Subsequent to June 30, 2024, all of the underlying ordinary shares were issued. February 2024 Underwritten Offering On February 12, 2024, the Company completed an underwritten offering of 58,333,336 ADSs representing 58,333,336 ordinary shares at an offering price of \$6.00 per ADS. Aggregate net proceeds to the Company, after underwriting discounts and offering expenses, were \$326.8A million. BioNTech Securities Purchase Agreement Concurrently with the execution of the BioNTech License and Option Agreement (see Note 1 and Note 3), the Company and BioNTech entered into the BioNTech Securities Purchase Agreement pursuant to which the Company sold ADSs, each representing one ordinary share, to BioNTech in a Private Placement transaction. On February 13, 2024, the Company completed the Private Placement of 33,333,333 ADSs representing 33,333,333A ordinary shares at an offering price of \$6.00 per ADS. Aggregate net proceeds to the Company, after underwriting discounts and offering expenses, were \$193.8A million. In the event that BioNTech and the Company enter into the MCSA within 18 months of the initial closing of the Private Placement, BioNTech will purchase up to 15,000,000 ADSs for an aggregate purchase price of up to \$20.0A million, subject to additional limitations and restrictions. Note 11. Share-based Compensation The following table summarizes the total share-based compensation expense included in the unaudited condensed consolidated statements of operations and comprehensive loss (in thousands): Three Months Ended June 30, Six Months Ended June 30, 2024 2023 2024 2023 Research and development \$1,048A \$1,776A \$1,498A \$3,457A General and administrative 1,887A 885A 3,723A 1,612A Capitalized 6A 7A (2) 15A Total share-based compensation expense \$2,935A \$2,668A \$5,219A \$5,084A 22 Table of contents AUTOLUS THERAPEUTICS PLC Notes to Condensed Consolidated Financial Statements (Unaudited) - Continued Share Options The table below summarizes Company’s share option activity during the six months ended June 30, 2024: Number of Options Weighted-Average Exercise Price per share Weighted-Average Remaining Contractual Term (Years) Aggregate Intrinsic Value (1) (in thousands) Outstanding as of December 31, 2023 17,956,385A \$5.64A 8.35 48,968A Granted 2,793,400A 4.33A 54A Exercised (146,310) 2.77A 369A Forfeited (797,838) 3.39A 645A Expired (246,781) 9.38A 5A Outstanding as of June 30, 2024 19,558,856A \$5.51A 8.14 11,834A Exercisable as of June 30, 2024 10,053,441A \$8.63A 6.95 3,507A Vested and expected to vest as of June 30, 2024 19,558,856A \$5.51A 8.14 \$11,834A (1) Aggregate intrinsic value is calculated as the difference between the exercise price of the underlying options and the fair value of ordinary shares for those options in the money as of June 30, 2024. During the six months ended June 30, 2024, the Company modified the exercise period of 571,352 share options resulting in the recognition of incremental share-based compensation expense of \$0.3A million. The total intrinsic value of options exercised was \$0.4 million for the six months ended June 30, 2024. The weighted average grant-date fair value of share options granted was \$3.12 per share option for the six months ended June 30, 2024. As of June 30, 2024, the total unrecognized compensation expense related to unvested share options without performance conditions was \$14.8 million, which the Company expects to recognize over a weighted average vesting period of 2.90 years. As of June 30, 2024, the total unrecognized share-based compensation expense related to unvested share options with performance conditions was \$2.9 million, which the Company expects to recognize over a weighted average vesting period of 0.38 years. Restricted Stock Units The table below summarizes Company’s restricted stock unit (RSU) awards activity during the six months ended June 30, 2024: Number of restricted units Weighted-Average grant date fair value Unvested and outstanding at December 31, 2023 116,436A \$3.43A Vested (73,604) 2.79A Forfeited (927) 7.20A Unvested and outstanding at June 30, 2024 41,905A \$4.49A As of June 30, 2024, there was less than \$0.1 million of unrecognized share-based compensation expense related to unvested RSUs without performance conditions, which is expected to be recognized over a weighted average period of 1.62 years. 23 Table of contents AUTOLUS THERAPEUTICS PLC Notes to Condensed Consolidated Financial Statements (Unaudited) - Continued Note 12. Liabilities related to future royalties and milestones, net Amount in thousands Balance at 1 January, 2023 \$125,900A Interest expense on liability related to future royalties and milestones, net 4,959A Balance at June 30, 2023 \$135,764A Interest expense on liability related to future royalties and milestones, net 5,014A Balance at September 30, 2023 \$140,778A Interest expense on liability related to future royalties and milestones, net 5,014A Cumulative catch-up adjustment 25,107A Balance at December 31, 2023 \$170,899A Initial recognition of BioNTech liability 38,335A Interest expense on liability related to future royalties and milestones, net 8,390A Cumulative catch-up adjustment 10,870A Balance at March 31, 2024 \$228,494A Interest expense on liability related to future royalties and milestones, net 10,169A Balance at June 30, 2024 \$238,663A During the three months ended June 30, 2024 and 2023, interest expense on liabilities related to future royalties and milestones, net amounted to \$10.2 million and \$5.0 million, respectively. During the six months ended June 30, 2024 and 2023, interest expense on liabilities related to future royalties and milestones, net amounted to \$18.6 million and \$9.9 million, respectively. During the three months ended June 30, 2024 and 2023 and six months ended June 30, 2023, there was no cumulative catch-up adjustment (included in interest expense). During the six months ended June 30, 2024, the cumulative catch-up adjustment amounted to \$10.9 million. Blackstone Collaboration Agreement On November 6, 2021, the Company concurrently entered into the following agreements with BXL V - Autobahn L.P. (Blackstone): (i) Strategic Collaboration Agreement (the Blackstone Collaboration Agreement), (ii) Securities Purchase Agreement (the Blackstone Securities Purchase Agreement), (iii) Warrant Agreement (the Blackstone Warrant) and (iv) a Registration Rights Agreement (the Blackstone Registration Rights Agreement). The Blackstone Collaboration Agreement, the Blackstone Securities Purchase Agreement, the Blackstone Warrant and the Blackstone Registration Rights Agreement are collectively referred to as the Blackstone Agreements. The Blackstone Agreements were entered into and in contemplation of one another and, accordingly, the Company assessed the accounting for the Blackstone Agreements in the aggregate. For further details on the terms and accounting treatment considerations for these contracts, please refer to following notes to the Company’s consolidated financial statements contained in the Company’s Annual Report: Note 2, Summary of significant accounting policies; Note 11, Liability related to future royalties and milestones; Note 12, Warrants; and Note 13, Shareholders’ equity. In November 2021, the upfront payment of \$50.0 million was paid by Blackstone upon execution of the Blackstone Collaboration Agreement. In December 2022, two Blackstone Development Payments were paid by Blackstone of \$35.0 million each as a result of (i) the joint steering committee’s review of the Company’s interim analysis of pivotal FELIX Phase 2 clinical trial of obe-cel in r/r ALL and (ii) achievement of a pre-agreed manufacturing milestone as a result of completion of planned activities demonstrating the performance and qualification of the Company’s obe-cel’s manufacturing process. The remaining \$30.0A million will be payable to the Company on the achievement of certain specified regulatory milestones. The Company considers the achievement of the specified regulatory milestone as probable when actually achieved. 24 Table of contents AUTOLUS THERAPEUTICS PLC Notes to Condensed Consolidated Financial Statements (Unaudited) - Continued BioNTech Agreements On February 6, 2024, the Company concurrently entered into the BioNTech Agreements. For further details on the terms and accounting treatment considerations for these contracts, please refer to following notes to these interim condensed consolidated financial statements: Note 1, Nature of the business; Note 2, Summary of significant accounting policies; Note 3, License Revenue; and Note 10, Shareholders’ equity. 25 Table of contents Commitment and contingencies Obe-cel Product Revenue Interest Under the BioNTech License and Option Agreement, BioNTech has agreed to financially support the expansion of the clinical development program for, and planned commercialization of obe-cel. In exchange for the grant of rights to future revenues from the sales of obe-cel products, BioNTech made an upfront payment to the Company of \$40.0A million. The Company will pay BioNTech a low single-digit percentage of annual net sales of obe-cel products, which may be increased up to a mid-single digit percentage in exchange for milestone payments of up to \$100.0A million in the aggregate on achievement of certain regulatory events for specific new indications upon BioNTech’s election. As the BioNTech License and Option Agreement has been accounted for as one freestanding financial instrument with various embedded features, (e.g. the Obe-cel Product Revenue Interest, milestone payments and royalties), the Company is required to consider if these embedded features are required to be bifurcated from the host contract and therefore accounted for as a separate derivative. The Company determined the host contract to be debt-like and therefore the embedded features were analyzed pursuant to a debt host contract. The Company concluded the BioNTech License and Option Agreement (the host contract) should not be accounted as a derivative in accordance with ASC 815-10-15-59(d) but rather as a debt instrument under ASC 470. The Company has accounted for the Obe-cel Product Revenue Interest as a liability primarily due to the Company’s significant continuing involvement in generating the royalty stream. The Company initially recognized the BioNTech Liability at \$38.3A million being the face value less debt issuance costs. If and when obe-cel is commercialized and royalties become payable, the Company will recognize the portion of royalties paid to BioNTech as a decrease to the liability with a corresponding reduction in cash. The carrying amount of the BioNTech Liability is based on the Company’s estimate of the future royalties to be paid to BioNTech to be received over the life of the arrangement as discounted using an effective interest rate. The excess or deficit of estimated present value of future royalties over the initial carrying amount, is recognized using the cumulative catch-up method within interest expense using the initial effective interest rate. The imputed rate of interest on the unamortized portion of the BioNTech Liability was approximately 28.70% as of February 6, 2024, the execution date of the BioNTech Agreements and June 30, 2024. On a quarterly basis, the Company assesses the amount and timing of expected royalty using a combination of internal projections and forecasts from external sources. To the extent the present value of such payments is greater or less than its initial estimates or the timing of such payments is materially different than its original estimates, the Company will adjust the amortization of the BioNTech Liability using the catch-up method. 25 Table of contents AUTOLUS THERAPEUTICS PLC Notes to Condensed Consolidated Financial Statements (Unaudited) - Continued Note 13. Leases Operating leases - Lessee The Company leases certain office space, laboratory space, and equipment. At the inception of an arrangement, the Company determines whether the arrangement is or contains a lease based on the unique facts and circumstances present. The Company’s costs as a lessee for the three and six months ended June 30, 2024 and 2023 were as follows (in thousands): Three Months Ended June 30, Six Months Ended June 30, 2024 2023 2024 2023 Operating lease costs \$2,087A \$1,807A \$4,185A \$3,174A Variable costs 484A 355A 1,028A 84A Short term lease costs 103A 199A 204A 242A Total lease costs \$2,674A \$2,361A \$5,417A \$3,500A Supplemental cash flow information for the three months ended June 30, 2024 and 2023 were as follows (in thousands): Six Months Ended June 30, Other information 2024 2023 Cash paid for amounts included in the measurement of lease liabilities: Operating cash outflows from operating leases \$4,485 \$2,882 The weighted average remaining lease term and weighted average discount rate of operating leases at June 30, 2024 and 2023 were as follows: Six Months Ended June 30, 2024 2023 Weighted-average remaining lease term - operating leases 15.9 years 15.8 years Weighted-average discount rate - operating leases 7.44A % 7.29A % The maturities of operating lease liabilities as of June 30, 2024 were as follows (in thousands): Remainder of 2024 \$4,235A 2025 \$626A 2026 \$623A 2027 \$648A 2028 \$764A Thereafter \$5,815A Total lease payments \$85,772A Less: imputed interest (35,751) Present value of lease liabilities \$50,021A 26 Table of contents AUTOLUS THERAPEUTICS PLC Notes to Condensed Consolidated Financial Statements (Unaudited) - Continued Operating leases - Lessor (sublease agreements) The Company subleases two manufacturing spaces in Enfield, U.K. to third parties. The annual lease payments to be received for each of the subleased units are £97,000 and £109,000, over lease terms from October 2021 to February 2029 and October 2021 to October 2026, respectively. The following table shows the sublease rental income for the three and six months ended June 30, 2024 and 2023 (in thousands): Three Months Ended June 30, Six Months Ended June 30, Sublease rental income 2024 2023 2024 2023 Sublease rental income (included in other income (expense), net) \$61A \$61A \$123A \$120A Total sublease rental income \$61A \$61A \$123A \$120A Future fixed receipts for non-cancellable operating subleases in effect as of June 30, 2024 are receivable as follows (in thousands): Remainder of 2024 \$130 2025 \$260 2026 \$203 2027 \$122 2028 \$106 Total lease payments receivable \$821 Note 14. Commitments and Contingencies License Agreements The Company has entered into an exclusive license agreement, as amended, with UCL Business Ltd (UCLB). In connection with the UCLB license agreement, the Company is required to make annual license payments and may be required to make payments to UCLB upon the achievement of specified milestones. During the three and six months ended June 30, 2024, less than \$0.1 million was paid or payable to UCLB by the Company, relating to the income allocable to the value of the sublicensed intellectual property rights. In November 2019, the Company entered into an exclusive license agreement with Noile-Immune Biotech Inc. (Noile) under which the Company will have the right to develop CAR T cell therapies incorporating Noile’s PRIME (proliferation-inducing and migration-enhancing) technology. The Company may be obligated to make additional payments to Noile upon the achievement of development milestones and receipt of regulatory approvals product sale milestones, as well as royalty payments based on possible future sales resulting from the utilization of the licensed technology. In September 2023, the Company entered into a non-exclusive sublicense agreement with Miltenyi Biotech B.V. & Co. KG (Miltenyi) under which the Company received a sublicense related to the use of certain Miltenyi products in the Company’s development, manufacture and sale of its products. Under the agreement, the Company is obligated to make specified payments to Miltenyi upon the achievement of certain regulatory and clinical milestones. The Company recognized \$0.4A million of expense in aggregate relating to an upfront license payment and milestone payments that were deemed probable during the year ended December 31, 2023. The Company did not recognize any further milestone payments during the three and six months ended June 30, 2024. Contractual obligations In July 2022, the Company renegotiated a master services agreement with Adaptive Biotechnologies Corporation (Adaptive), under which Adaptive’s assay is used to analyze patient samples from r/r B-ALL patients. Under the agreement, the Company is obligated to make specified payments to Adaptive upon the achievement and receipt of certain regulatory approvals and achievement of commercial milestones in connection with the Company’s use of the Adaptive assay. During the year ended December 31, 2023, the Company recognized all contractual milestones relating to this contract, and as a result no contractual milestones were recognized during the three and six months ended June 30, 2024. 27 Table of contents AUTOLUS THERAPEUTICS PLC Notes to Condensed Consolidated Financial Statements (Unaudited) - Continued In previous periods, the Company has entered into agreements with certain advisory firms. The Company is obligated to make specified payments upon the achievement of certain strategic transactions involving the Company. During the three and six months ended June 30, 2024, the Company paid a fee under these agreements. The Company has estimated the probability of the Company achieving each potential milestone in relation to the agreements with UCLB, Noile, Miltenyi and its agreements with certain advisory firms in accordance with ASC 450. The Company considers the regulatory approval, commercial milestones and execution of collaboration agreements probable when actually achieved. Furthermore, the Company recognizes expenses for clinical milestones when their achievement is deemed probable. The Company concluded that, as of June 30, 2024, there were no other milestones for which the likelihood of achievement was currently probable. Capital Commitments As of June 30, 2024, the Company’s unconditional purchase obligations for capital expenditures totaled \$9.7 million and included signed orders for capital equipment and capital expenditures for construction and related expenditures relating to its properties in the U.K. and the US. The Company expects to incur the full amount of these obligations within one year. Master Supply Commitments As of June 30, 2024, the Company’s unconditional purchase obligations with Miltenyi Biotech GmbH for reagents and disposables totaled \$1.1 million, which the Company expects to incur within one year. Distribution Commitments The Company entered into an Exclusive Distribution Agreement, effective as of April 25, 2024 (the Effective Date), with Cardinal Health 105, LLC (Cardinal Health). Pursuant to, and subject to the terms and conditions of, the Exclusive Distribution Agreement, the Company engaged Cardinal Health as its exclusive third-party logistics distribution agent for sales of obe-cel in the US. The Exclusive Distribution Agreement runs for an initial term of three years following commercial launch and automatically renews for additional terms of one year each, unless either party elects not to renew. In addition, the Company can terminate the Exclusive Distribution Agreement without cause, subject to the payment of termination fees if such termination occurs during the initial three-year term. Under the terms of the Exclusive Distribution Agreement, the Company must pay to Cardinal Health a one-time start-up fee, and if the Company proceeds with commercialization of obe-cel, upon its launch, a monthly account management fee, and other fees for various services, including post-launch program implementation, information systems, warehouse operations and financial services. Blackstone and BioNTech Agreements Refer to Note 12, Liabilities related to future royalties and milestones, net for further details about the BioNTech Agreements and Blackstone Agreements. BioNTech License and Option Agreement - Product Options gain contingency As the Product Options within the BioNTech License and Option Agreement were an embedded feature within a freestanding financial instrument, the Company assessed if the Product Options should be accounted for as a derivative under ASC 815. However, the Company determined the Product Options met the scope exception for derivative accounting under ASC 815 and therefore should be accounted for a gain contingency under the scope of ASC 450. As of June 30, 2024, Product Options were not exercised and therefore no amounts were recognized. Legal Proceedings From time to time, the Company may be a party to litigation or subject to claims incident to the ordinary course of business. Regardless of the outcome, litigation can have an adverse impact on the Company because of defense and settlement costs, diversion of management resources and other factors. The Company was not a party to any litigation and did not have contingency reserves established for any liabilities as of June 30, 2024 and December 31, 2023. Indemnification Agreements In the normal course of business, the Company enters into contracts and agreements that contain a variety of representations and warranties and provide for general indemnification. The Company’s exposure under these

agreements is unknown because they involve claims that may be made against the Company in the future. To date, the Company has not paid any claims or been required to defend any action related to its indemnification obligations. However, the Company may record charges in the future as a result of these indemnification obligations.28Table of contentsAUTOLUS THERAPEUTICS PLCNotes to Condensed Consolidated Financial Statements (Unaudited) - ContinuedIn accordance with the indemnification agreements entered into with relevant individuals in accordance with the Company's Articles of Association, the Company has indemnification obligations to its directors, officers and members of senior management for certain events or occurrences, subject to certain limits, while they are serving at the Company's request in such capacity. There have been no claims to date under these indemnification agreements, and the Company has director and officer insurance that may enable it to recover a portion of any amounts paid for future potential claims.Note 15. Related party transactionsBlackstone AgreementsIn November 2021, the Company concurrently entered into the Blackstone Agreements. As of the execution of the Blackstone Agreements, Blackstone became a related party of the Company, as Blackstone became the owner of more than 10% of the Company's outstanding voting securities. In addition, Blackstone received and exercised its right to nominate one director to the board of directors of the Company and is therefore considered to be one of the principal owners of the Company.As of June 30, 2024, the carrying amount of the Blackstone Collaboration Agreement Liability was \$195.9 million which included aggregated cumulative non-cash interest expense and cumulative catch-up adjustment of \$25.0 million. As of December 31, 2023, the carrying amount of the Blackstone Collaboration Agreement Liability was \$170.9 million which included aggregated cumulative non-cash interest expense (including cumulative catch-up adjustments), of \$45.0A million. Refer to Note 12, "Liabilities related to future royalties and milestones, net" for further details.BioNTech AgreementsIn February 2024, the Company concurrently entered into the BioNTech Agreements. Upon the execution of the BioNTech Agreements, BioNTech became a related party of the Company. BioNTech owns more than 10% of the Company's outstanding voting securities and is therefore one of the principal owners of the Company. In addition, BioNTech has the right to nominate one director to the board of directors of the Company which BioNTech has not yet exercised. As of June 30, 2024, the carrying amount of the BioNTech Liability was \$42.8 million which included aggregated cumulative interest expense and cumulative catch-up adjustment of \$2.7A million. Refer to Note 12, "Liabilities related to future royalties and milestones, net" for further details. Note 16. Subsequent EventsThe Company evaluated subsequent events through August 8, 2024, the date on which these unaudited condensed consolidated financial statements were issued. The Company has concluded that no subsequent event has occurred that requires disclosure.29Table of contentsItem 2. Management's Discussion and Analysis of Financial Condition and Results of OperationsThe following discussion and analysis of our financial condition and results of operations should be read together with the unaudited condensed consolidated financial statements and the related notes to those statements included in this Quarterly Report on Form 10-Q. We also recommend that you read our discussion and analysis of financial condition and results of operations together with our audited financial statements and the notes thereto, which appear in our Annual Report as filed with the SEC. We maintain our books and records in pounds sterling, our results are subsequently converted to U.S. dollars, and we prepare our consolidated financial statements in accordance with U.S. GAAP, as issued by the FASB. All references in this Quarterly Report on Form 10-Q to "pounds" are to U.S. dollars and all references to "pounds" are to pounds sterling. Our unaudited condensed Consolidated Statements of Operations and Comprehensive Loss and Cash Flows for the three months ended June 30, 2024 and 2023 have been translated from pounds sterling into U.S. dollars at the rate of A£1.00 to \$1.2616 and A£1.00 to \$1.2516, respectively. Our unaudited condensed Consolidated statements of Operations and Comprehensive Loss and Cash Flows for the six months ended June 30, 2024 and 2023 have been translated from pounds sterling into U.S. dollars at the rate of A£1.00 to \$1.2648 and A£1.00 to \$1.2330, respectively. Our unaudited condensed Consolidated Balance Sheet as of June 30, 2024 and audited Consolidated Balance Sheet as of December 31, 2023 have been translated from pounds sterling into U.S. dollars at the rate of A£1.00 to \$1.2645 and A£1.00 to \$1.2662, respectively. These translations should not be considered representations that any such amounts have been, could have been or could be converted into U.S. dollars at those or any other exchange rate as of those or any other dates.The statements in this discussion and analysis of our financial condition and results of operations regarding our expectations regarding our future performance, liquidity and capital resources and other non-historical statements are forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. These risks and uncertainties include, but are not limited to, the risks and uncertainties set forth in the "Risk Factors" section of our Annual Report, this Quarterly Report and any subsequent reports that we file with the SEC.OverviewWe are a biopharmaceutical company developing next-generation programmed T cell therapies for the treatment of cancer and autoimmune diseases. Using our broad suite of proprietary and modular T cell programming technologies, we are engineering precisely targeted, controlled and highly active T cell therapies that are designed to better recognize target cells, break down their defense mechanisms and attack and kill these cells. We believe our programmed T cell therapies have the potential to be a best-in-class and to offer patients substantial benefits over the existing standard of care, including the potential for cure in some patients.Since our inception, we have incurred significant operating losses. For the three months ended June 30, 2024 and 2023, we incurred net losses of \$58.3 million and \$45.6 million, respectively, and net losses of \$111.0 million and \$85.4 million for the six months ended June 30, 2024 and 2023, respectively, and had an accumulated deficit of \$989.5 million and \$878.6 million as of June 30, 2024 and December 31, 2023, respectively.As of June 30, 2024, we had cash and cash equivalents of \$705.9 million. Based on our current clinical development plans, we believe our existing cash and cash equivalents will be sufficient to fund our current and planned operating expenses and capital expenditure requirements through at least the next twelve months from the date of issuance of our unaudited condensed consolidated financial statements included in this report. Recent Developments Obe-cel in r/r adult B-ALL - The Felix Study: Obe-cel in relapsed / refractory (r/r) adult B-cell Acute Lymphoblastic Leukemia (B-ALL) " The FELIX StudyOur obe-cel BLA for r/r B-ALL remains on track for FDA target action date of November 16, 2024. "In April 2024, the EMA accepted our obe-cel marketing authorization application (MAA) for r/r B-ALL. In the U.K. an MAA was submitted to the U.K. Medicines and Healthcare products Regulatory Agency (MHRA) at the end of July 2024. The pooled analysis for the FELIX Phase 1b/2 study was presented at the American Society of Oncology (ASCO) and at the European Hematology Association (EHA) annual meetings in June 2024, with a median follow-up of 21 months. The data showed stabilization of event-free survival and overall survival, with 40% of patients in ongoing remission. 99 responders following treatment with obe-cel, 18 received a subsequent stem cell transplant (SCT) while in minimal residual (MRD)-negative response and did not show improved survival compared to patients without subsequent SCT. Patients with prolonged obe-cel persistence showed improved event-free survival and data indicated the bridging of high tumor burden patients with inotuzumab appears effective at reducing tumor burden, cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS) without increasing liver toxicity.30Table of contentsObe-cel in B-cell mediated autoimmune diseases "The Phase 1 dose confirmation study (CARLSLE) in refractory systemic lupus erythematosus (SLE) patients is ongoing. We continue to expect initial clinical data in late 2024.Pipeline programs in collaboration with University College LondonClinical programs AUTO8, AUTO6NG and AUTO1/22 are progressing well and we are planning data updates for all programs in 2025.Key Operational Updates during the three months ended June 30, 2024In April 2024, Autolus entered into a distribution services agreement with a subsidiary of Cardinal Health to support the ordering and distribution of obe-cel in the United States, if it receives regulatory approval. Components of Our Results of OperationsRevenueWe account for our revenue pursuant to the provisions of ASC 606, Revenue from Contracts with Customers. We have no products approved for commercial sale and have not generated any revenue from commercial product sales. The total revenue to date has been generated principally from license agreements. As of June 30, 2024, we had entered into various license agreements which included non-refundable upfront license fees, options for future commercial licenses, payments based upon achievement of clinical development and regulatory objectives, payments based upon achievement of certain levels of product sales, and royalties on licensed product sales. In determining the appropriate amount of revenue to be recognized in relation to each license agreement, we perform the following steps: (i) identify the promised goods or services in the contract; (ii) determine whether the promised goods or services are performance obligations, including whether they are distinct in the context of the contract; (iii) measure of the transaction price, including the constraint on variable consideration; (iv) allocate the transaction price to the performance obligations based on estimated selling prices; and (v) recognize of revenue when (or as) we satisfy each performance obligation.License Fees and Multiple Element ArrangementsIf a license to our intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, we recognize revenues from non-refundable, upfront fees allocated to the license at such time as the license is transferred to the licensee and the licensee is able to use, and benefit from the license. For licenses that are bundled with other promises, we utilize judgment to assess the nature of the combined performance obligations to determine whether the combined performance obligations are satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue from non-refundable, upfront fees. We evaluate the measure of progress at each reporting period and, if necessary, adjust the measure of performance and related revenue recognition.Appropriate methods of measuring progress include output methods and input methods. In determining the appropriate method for measuring progress, we consider the nature of service that we promise to transfer to the customer. When we decide on a method of measurement, we will apply that single method of measuring progress for each performance obligation satisfied over time and will apply that method consistently to similar performance obligations and in similar circumstances.Customer Options If an arrangement is determined to contain customer options that allow the customer to acquire additional goods or services, the goods and services underlying the customer options that are not determined to be material rights are not considered to be performance obligations at the outset of the arrangement, as they are contingent upon option exercise. We evaluate the customer options for material rights, or options to acquire additional goods or services for free or at a discount. If the customer options are determined to represent a material right, the material right is recognized as a separate performance obligation at the outset of the arrangement. We allocate the transaction price to material rights based on the relative standalone selling price, which is determined based on any identified discount and the probability that the customer will exercise the option. Amounts allocated to a material right are not recognized as revenue until, at the earliest, the option is exercised.31Table of contentsContingent Research Milestone PaymentsASC 606 constrains the amount of variable consideration included in the transaction price in that either all, or a portion, of an amount of variable consideration should be included in the transaction price. The variable consideration amount should be included only to the extent that it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainty associated with the variable consideration is subsequently resolved. The assessment of whether variable consideration should be constrained is largely a qualitative one that has two elements: the likelihood of a change in estimate, and the magnitude thereof. Variable consideration is not constrained if the potential reversal of cumulative revenue recognized is not significant, for example.If the consideration in a contract includes a variable amount, we will estimate the amount of consideration in exchange for transfer of promised goods or services. The consideration also can vary if our entitlement to the consideration is contingent on the occurrence or non-occurrence of a future event. We consider contingent research milestone payments to fall under the scope of variable consideration, which should be estimated for revenue recognition purposes at the inception of the contract and reassessed ongoing at the end of each reporting period.We assess whether contingent research milestones should be considered variable consideration that should be constrained and thus not part of the transaction price. This includes an assessment of the probability that all or some of the milestone revenue could be reversed when the uncertainty around whether or not the achievement of each milestone is resolved, and the amount of reversal could be significant.U.S. GAAP provides factors to consider when assessing whether variable consideration should be constrained. All of the factors should be considered, and no factor is determinative. We consider all relevant factors.Royalty RevenueFor arrangements that include sales-based royalties, including milestone payments based on the level of sales, and the license is deemed to be the predominant item to which the royalties relate, we recognize revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied).Research and Development ExpensesResearch and development expenses (R&D) consist of costs incurred in connection with the research and development of our product candidates, which are partially offset by research and development tax credits, including tax credits arising from the U.K. small and medium enterprise (SME) regime and research and development expenditure credit (RDEC) regime provided by HMRC. We expense research and development costs as incurred. These expenses include: "expenses incurred under agreements with CROs, as well as investigative sites and consultants that conduct our clinical trials, preclinical studies and other scientific development services;" manufacturing scale-up expenses and the cost of acquiring and manufacturing preclinical and clinical trial materials;" employee-related expenses, including salaries, related benefits, travel and share-based compensation expense for employees engaged in research and development functions;" expenses incurred for outsourced professional scientific development services;" costs for laboratory materials and supplies used to support our research activities;" allocated facilities costs, depreciation and other expenses, which include rent and utilities; and" upfront, milestone and management fees for maintaining licenses under our third-party licensing agreements.We recognize external development costs based on an evaluation of the progress to completion of specific tasks using information provided to us by our service providers.Our direct research and development expenses are tracked on a program-by-program basis for our product candidates and consist primarily of external costs, such as fees paid to outside consultants and CROs in connection with our preclinical development, manufacturing and clinical development activities. Our direct research and development expenses by program also include fees incurred under license agreements. We do not allocate employee costs or facility expenses, including depreciation or other indirect costs, to specific programs because these costs are deployed across multiple programs and, as such, are not separately classified. We use internal resources primarily to oversee research and development as well as for managing our preclinical development, process development, manufacturing and clinical development activities.32Table of contentsResearch and development activities are central to our business model. Product candidates in later stages of clinical development generally have higher development costs than those in earlier stages of clinical development, primarily due to the increased size and duration of later-stage clinical trials. As a result, we expect that our research and development expenses will increase substantially over the next few years as we increase personnel costs, initiate and conduct additional clinical trials and prepare regulatory filings related to our product candidates. We also expect to incur additional expenses related to milestone, royalty payments and maintenance fees payable to third parties with whom we have entered into license agreements to acquire the rights related to our product candidates.The successful development and commercialization of our product candidates is highly uncertain. At this time, we cannot reasonably estimate or know the nature, timing and costs of the efforts that will be necessary to complete the clinical development of any of our product candidates or when, if ever, material net cash inflows may commence from sales of any of our product candidates. This uncertainty is due to the numerous risks and uncertainties associated with development and commercialization activities, including the uncertainty of: "the scope, progress, outcome and costs of our clinical trials and other research and development activities, including establishing an appropriate safety profile with a IND-directed studies;" successful patient enrollment in, and the initiation and completion of, clinical trials;" the timing, receipt and terms of any marketing approvals from applicable regulatory authorities;" establishing commercial manufacturing capabilities or making arrangements with third-party manufacturers;" development and timely delivery of commercial-grade drug formulations that can be used in our clinical trials and for commercial manufacturing;" obtaining, maintaining, defending and enforcing patent claims and other intellectual property rights;" significant and changing government regulation;" launching commercial sales of our product candidates, if and when approved, whether alone or in collaboration with others;" maintaining a continued acceptable safety profile of the product candidates following approval; and" significant competition and rapidly changing technologies within the biopharmaceutical industry. We may never succeed in achieving regulatory approval for any of our product candidates. We may obtain unexpected results from our clinical trials. We may elect to discontinue, delay or modify clinical trials of some product candidates or focus on others. Any changes in the outcome of any of these variables with respect to the development of our product candidates in clinical development could mean a significant change in the costs and timing associated with the development of these product candidates. For example, if the European Medicines Agency (EMA), the FDA, or another regulatory authority were to delay our planned start of clinical trials or require us to conduct clinical trials or other testing beyond those that we currently expect or if we experience significant delays in enrollment in any of our planned clinical trials, we could be required to expend significant additional financial resources and time on the completion of clinical development of that product candidate. Commercialization of our product candidates will take several years and millions of dollars in development costs.U.K. Research and Development Tax CreditsThe U.K. operates R&D tax incentive regimes. Under these regimes qualifying R&D expenditure incurred by U.K. companies can be included within R&D claims via the corporate tax return, resulting in reimbursable tax credits from the U.K. government. As a company that carries out extensive R&D activities, we make claims under the U.K. R&D tax credit regime. This regime provides companies with tax relief at an effective rate of between 15% and 16.2% (subject to the rate of corporation tax we pay, if any) of qualifying R&D expenditure in an accounting period. The

regime’s rules are complex, and if a tax authority were to challenge or seek to disallow our claims (in whole or in part), for example by asserting that the relevant expenditure does not meet the technical conditions to be granted tax credits, then such challenge or disallowance could have a material impact on our cash-flow and financial performance. In addition, future changes to the U.K. R&D tax credit regime may mean that we no longer qualify for it or have a material impact on the extent to which we can make claims (or benefit from them).33Table of contentsThe SME program has been particularly beneficial to us, as under this program the trading losses that arise from our qualifying R&D activities can be surrendered for a cash rebate of up to 18.6% of qualifying expenditure incurred after April 1, 2023. Additionally, the U.K. Government enacted further changes to the SME regime on February 22, 2024 which include the introduction of a new rate for R&D intensive companies of 27% (which we may not qualify for) and came into effect for expenditures incurred after April 1, 2023. Qualifying expenditures largely comprise employment costs for research staff, consumables, outsourced contract research organization costs and utilities costs incurred as part of research projects for which we do not receive income. A large proportion of costs in relation to our pipeline research, clinical trials management and manufacturing development activities, all of which are being carried out by our subsidiary Autolus Limited, are eligible for inclusion within these tax credit cash rebate claims.On April 1, 2023, the headline rate under the RDEC program increased from 13% to 20% and can generate cash rebates of up to 15% (increased from 10.5%) on qualifying R&D expenditure incurred from this date.The benefit from U.K. RDEC and U.K. SME programs is recognized as income in the Consolidated Statement of Operations and Comprehensive Loss and is subject to tax at the prevailing rate. Amendments to the current SME and RDEC programs that are contained in the Finance Act 2024 which was enacted on February 22, 2024 will take effect from periods on or after April 1, 2024 and will (i) (unless limited exceptions apply) introduce restrictions on the tax relief that can be claimed for expenditure incurred on subcontracted R&D activities or externally provided workers, where such sub-contracted activities are not carried out in the U.K. or such workers are not subject to U.K. payroll taxes, and (ii) merge the SME and RDEC programs into a single scheme which would generate net cash benefit of up to 15% of the qualifying expenditure for profit making companies and up to 16.2% for loss making companies. Nevertheless, the higher rate of 27% for R&D intensive SME companies will still be in effect from periods on or after April 1, 2024.We currently meet the conditions of the SME regime, but we also can make claims under the RDEC regime to the extent that our projects are grant funded. We may not be able to continue in the future to qualify as a small or medium-sized enterprise under the SME program, based on size criteria concerning employee headcount, turnover and gross assets. If we cease to qualify under the SME regime, we may make a claim under the RDEC regime for periods ending December 31, 2024, or the merged R&D regime from the period ending December 31, 2025. It should be noted, however, that the types of qualifying expenditure in respect of which we may make claims under the RDEC regime are more restricted than under the SME regime (for example, it may be the case that certain subcontracted costs in respect of which claims may be made under the SME regime do not qualify for relief under the current RDEC regime).The subcontracted rules under the merged regime are more aligned to the current SME regime.General and Administrative ExpensesGeneral and administrative expenses consist primarily of salaries, related benefits, travel and share-based compensation expense for personnel in executive, finance, legal and other administrative functions. General and administrative expenses also include allocated facility-related costs, patent filing and prosecution costs and professional fees for marketing, insurance, legal, consulting, accounting and audit services.We anticipate that our general and administrative expenses will increase in the future as we increase our headcount to support the planned development of our product candidates. Additionally, if we believe a regulatory approval of one of our product candidates appears likely, we would anticipate an increase in salaries and related benefits as a result of our preparation for commercial operations, especially as it relates to the sales and marketing of our product candidate.We have experienced, and expect to continue to experience, increased expense with being a public company, including increased accounting, audit, legal, regulatory and compliance costs associated with maintaining compliance with Nasdaq listing rules and SEC requirements, director and officer insurance premiums, as well as higher investor and public relations costs. Additionally, should we fail to maintain our status as a foreign private issuer, we would expect to incur increased expenses to remain compliant with applicable SEC and Nasdaq requirements.Loss on disposal of property and equipmentLoss on disposal of property and equipment primarily consists of losses arising from the disposal of all categories of property and equipment.Impairment of operating lease right-of-use assets and related property and equipmentImpairment of operating lease right-of-use assets and related property and equipment consists primarily of impairment losses arising from the impairment of leased properties and leasehold improvements that are currently not be utilized by us.Other income (expense), netOther income (expense), net consists primarily of foreign currency transaction gains and losses, sublease income and gains or losses arising from the termination of leases.34Table of contentsInterest IncomeInterest income consists primarily of interest received from banks and money market funds on our cash and cash equivalents balances. We invest funds in a variety of short-term interest-bearing instruments.Interest ExpenseInterest expense consists primarily of interest expense arising from amortization of the liability related to future royalties and milestones, pursuant to our collaboration agreements with Blackstone and BioNTech, using the effective interest rate method. On a quarterly basis, we assess the expected present value of the future Blackstone and BioNTech payments under the Blackstone Collaboration Agreement and BioNTech Agreements which may be received by us and future royalties and sales milestone payments to Blackstone and BioNTech which may be paid by us. To the extent the amount or timing of such receipts or payments is materially different than our previous estimates we record a cumulative catch-up adjustment to the liability related to future royalties and milestones. The adjustment to the carrying amount is recognized as an adjustment to interest expense in the period in which the change in estimate occurred.Income Tax Benefit (Expense)We are subject to corporate taxation in the United Kingdom, United States, Germany and Switzerland. Due to the nature of our business, we have generated losses since inception. Our income tax benefit (expense) recognized represents the sum of the research and development tax credits recoverable in the U.K. and offset by income tax payable in the United States.Un-surrendered U.K. losses may be carried forward indefinitely to be offset against future taxable profits, subject to numerous utilization criteria and restrictions. The amount that can be offset each year is limited to A£5.0 million plus an incremental 50% of U.K. taxable profits.À After accounting for tax credits receivable, we had accumulated tax losses for carry forward in the U.K. of A£18.1 million at December 31, 2023. A valuation allowance has been recognized against our deferred tax asset relating to our U.K. losses. We carried aA \$3.2 millionA deferred tax asset balance related to the U.S. entity at June 30, 2024 for which there are no valuation allowance. At June 30, 2024, we recorded a full valuation allowance against the net deferred tax asset in the U.K., as the recoverability due to future taxable profits was unknown. On April 1, 2023 the main rate of the U.K. corporation tax was increased to 25% for companies with profits in excess of A£250,000, or the small profits rate of 19% for companies with profits of A£50,000 or less (with marginal relief from the main rate available to companies with profits between A£50,000 and A£250,000).In the event we generate revenues in the future, we may benefit from the U.K. ‘‘patent box’’ regime that allows profits attributable to revenues from patents or patented products to be taxed at an effective rate of 10%.Results of OperationsComparison of Three Months Ended June 30, 2024 and 2023 The following table summarizes our results of operations for the three months ended June 30, 2024, and 2023 (in thousands):Three Months Ended June 30, 2024Change20242023(in thousands)(in percentage)License revenue\$A£A \$A£A \$A£A %Operating expenses:Research and development(36,612)(33,232)(3,380)10A %General and administrative(21,903)(11,122)(10,781)97A %Loss on disposal of property and equipmentA£A (23)23A (100)%Impairment of operating lease right-of-use assets and related property and equipment(414)A£A (414)100A %Total operating expenses, net(58,929)(44,377)(14,552)33A %Other income, net1,226A 482A 744A 154A %Interest income9,656A 6,233A 184A %Interest expense(10,174)(5,020)(5,154)103A %Total other income (expense), net708A (1,135)1,843A (162)%Net loss before income tax(58,221)(45,512)(12,709)28A %Income tax expense(51)(40)(11)28A %Net loss\$(58,272)\$(45,552)\$(12,720)28A %35Table of contentsResearch and Development ExpensesThe following tables provide additional detail on our research and development expenses (in thousands):Three Months Ended June 30, 2024Change (in percentage)20242023Direct research and development expensesB cell malignancies (Obe-cel, AUTO1/22 & AUTO3)\$7,713A \$4,147A \$3,566A 86A %Other projects (AUTO4, AUTO5, AUTO6, AUTO7 & AUTO8)876A 701A 175A 25A %Total direct research and development expense\$8,589A \$4,884A \$3,741A 77A %Indirect research and development expenses and unallocated costs:Personnel related (including share-based compensation)\$18,073A \$16,659A 1,414A 8A %Indirect research and development expense*9,950A 11,725A (1,775)(15)%Total research and development expenses\$36,612A \$33,232A \$3,380A 10A %* Indirect research and development expense is net of U.K. research and development tax creditsResearch and development expenses increased by \$3.4 million to \$36.6 million for the three months ended June 30, 2024 from \$33.2 million for the three months ended June 30, 2023 primarily due to:â€¢an increase of \$4.3 million in clinical trial costs primarily relating to our research and development activities including transport costs of manufacturing consumables,â€¢an increase of \$1.4 million in salaries and other employment related costs including share-based compensation expense, which was mainly driven by an increase in the number of employees engaged in research and development activities,â€¢an increase of \$0.6 million in facilities costs related primarily to our new manufacturing facility, The Nucleus, in Stevenage, U.K. as well as increases in costs related to maintaining our current leased properties, andâ€¢an increase of \$0.4 million in depreciation and amortization related to property and equipment, offset in part by:â€¢an increase of \$1.8 million in U.K. R&D tax credits (decrease in R&D expense) due primarily to an increase in qualifying research and development expenditures related to the Small and Medium Enterprise (‘‘SME’’) scheme,â€¢a decrease of \$0.7 million in professional consulting and legal fees in relation to our research and development activities,â€¢a decrease of \$0.7 million in information technology infrastructure maintenance costs, andâ€¢a decrease of \$0.1 million in general office expenses.General and Administrative ExpensesGeneral and administrative expenses increased by \$10.8 million to \$21.9 million for the three months ended June 30, 2024 from \$11.1 million for the three months ended June 30, 2023 primarily due to: â€¢an increase of \$6.7 million in salaries and other employment related costs including share-based compensation expense, which was mainly driven by an increase in the number of employees engaged in general and administrative activities,â€¢an increase of \$2.5 million in costs related to commercial-stage readiness activities,â€¢an increase of \$1.7 million in legal and professional fees related to our general and administrative activities, andâ€¢an increase of \$0.2 million in facility costs due to the increase in space utilized for general and administrative activities and related to general office expenses, offset in part by:â€¢a decrease of \$0.3 million related to information technology infrastructure and support for information systems related to corporate and commercial operations.Impairment of Operating Lease Right-of-use Assets and Related Property and EquipmentFor the three months ended June 30, 2024, we recognized an impairment loss on operating lease right-of-use assets and related property and equipment of \$0.4 million related to a leased property in Enfield, United Kingdom. There was no similar impairment recognized for the three months ended June 30, 2023.36Table of contentsOther income (expense), netOther income (expense), net increased to \$1.2 million for the three months ended June 30, 2024 from \$0.5 million for the three months ended June 30, 2023. The increase of \$0.7 million was primarily due to the strengthening of the pound sterling exchange rate relative to the U.S. dollar between the two periods. Interest incomeInterest income increased to \$9.7 million for the three months ended June 30, 2024, as compared to \$3.4 million for the three months ended June 30, 2023. The increase in interest income of \$6.3 million primarily related to increase in yield and also higher account balances associated with our cash and cash equivalents during the three months ended June 30, 2024 as compared to the three months ended June 30, 2023.Interest expenseInterest expense increased to \$10.2 million for the three months ended June 30, 2024 as compared to \$5.0 million for the three months ended June 30, 2023. Interest expense increased by \$5.2 million primarily due to an increase in the balance of the liabilities for future royalties and milestones, net associated with our Collaboration Agreement with Blackstone and the BioNTech License and Option Agreement.Comparison of Six Months Ended June 30, 2024 and 2023The following table summarizes our results of operations for the six months ended June 30, 2024, and 2023 (in thousands):Six Months Ended June 30, 2024Change (in thousands)(in percentage)20242023License revenue\$10,091A \$1,292A \$8,799A 681A %Operating expenses:Research and development(67,283)(60,620)(6,663)11A %General and administrative(40,080)(20,406)(19,674)96A %Loss on disposal of property and equipmentA£A (3,791)3,791A (100)%Impairment of operating lease right-of-use assets and related property and equipment(414)A£A (414)100A %Total operating expenses, net(97,686)(83,525)(14,161)17A %Other (expense) income, net(3791)1,264A (1,643)(130)%Interest income16,589A 6,849A 9,740A 142A %Interest expense(29,443)(9,925)(19,518)197A %Total other expense, net(13,233)(1,812)(11,421)630A %Net loss before income tax(110,919)(85,337)(25,582)30A %Income tax expense(43)(26)(17)65A %Net loss\$(110,962)\$(85,363)\$(25,599)30A %License RevenueLicense revenue amounting to \$10.1 million for the six months ended June 30, 2024 related to license revenue recognized pursuant to the License and Option Agreement with BioNTech. License revenue of \$1.3 million for the six months ended June 30, 2023 primarily related to the execution of the Cabaletta Bio Inc. (‘‘Cabaletta’’) Option and License Agreement, which included recognition of a non-refundable license fee payable to us.37Table of contentsResearch and Development ExpensesThe following tables provide additional detail on our research and development expenses (in thousands):Six Months Ended June 30, 2024Change (in thousands)(in percentage)20242023Direct research and development expensesB cell malignancies (Obe-cel, AUTO1/22 & AUTO3)\$12,021A \$9,277A \$2,744A 30A %Other projects (AUTO4, AUTO5, AUTO6, AUTO7 & AUTO8)1,044A 1,543A (499)(32)%Total direct research and development expense\$13,065A \$10,820A \$2,245A 21A %Indirect research and development expenses and unallocated costs:Personnel related (including share-based compensation)33,475A 30,881A 2,594A 8A %Indirect research and development expense20,743A 18,919A 1,824A 10A %Total research and development expenses\$67,283A \$60,620A \$6,663A 11A %Research and development expenses increased by \$6.7 million to \$67.3 million for the six months ended June 30, 2024 from \$60.6 million for the six months ended June 30, 2023 primarily due to:â€¢an increase of \$5.2 million in clinical trial costs primarily relating to our research and development activities including transport costs of manufacturing consumables, â€¢an increase of \$2.6 million in salaries and other employment related costs, including share-based compensation expense, which was mainly driven by an increase in the number of employees engaged in research and development activities,â€¢an increase of \$2.4 million in facilities costs related primarily to our new manufacturing facility, The Nucleus, in Stevenage, U.K. as well as increases in costs related to maintaining our current leased properties, andâ€¢an increase of \$0.2 million in depreciation and amortization related to property and equipment, offset in part by:â€¢an increase of \$1.3 million in U.K. R&D tax credits (decrease in R&D expense) due primarily to an increase in qualifying research and development expenditures related to the SME scheme,â€¢a decrease of \$1.5 million in professional consulting and legal fees in relation to our research and development activities,â€¢a decrease of \$0.6 million in information technology infrastructure maintenance costs, andâ€¢a decrease of \$0.3 million in general office expenses.General and Administrative ExpensesGeneral and administrative expenses increased by \$19.7 million to \$40.1 million for the six months ended June 30, 2024 from \$20.4 million for the six months ended June 30, 2023 primarily due to: â€¢an increase of \$11.2 million in salaries and other employment related costs, including share-based compensation expense, which was mainly driven by an increase in the number of employees engaged in general and administrative activities,â€¢an increase of \$4.8 million in costs related to commercial-stage readiness activities,â€¢an increase of \$2.7 million in legal and professional fees related to our general and administrative activities,â€¢an increase of \$0.6 million related to information technology infrastructure and support for information systems related to the conduct of corporate and commercial operations, â€¢an increase of \$0.3 million in facility costs due to the increase in space utilized for general and administrative activities and related to general office expense, andâ€¢an increase of \$0.1 million in depreciation and amortization related to property and equipment.38Table of contentsLoss on disposal of property and equipmentFor the six months ended June 30, 2023, we recognized a loss on disposal of property and equipment of \$3.8 million related to fixed assets no longer being utilized in the manufacturing facility exited in Stevenage, United Kingdom. There were no such disposals for the six months ended June 30, 2024. Impairment of Operating Lease Right-of-use Assets and Related Property and EquipmentFor the six months ended June 30, 2024, we recognized an impairment loss on operating lease right-of-use assets and related property and equipment of \$0.4 million related to a leased property in Enfield, United Kingdom. There was no similar impairment recognized for the six months ended June 30, 2023.Other (expense) income, netOther (expense) income, net decreased to an expense of \$0.4 million for the six months ended June 30, 2024 from an income of \$1.3 million for the six months ended June 30, 2023. The decrease of \$1.7 million was primarily due to the strengthening of the pound sterling exchange rate relative to the U.S. dollar resulting in a net foreign exchange loss of \$1.8 million, offset by a lease termination gain of \$0.1 million for the six months ended June 30, 2024 as compared to the six months ended June 30, 2023.Interest incomeInterest income increased to \$16.6 million for the six months ended June 30, 2024, as compared to \$6.8 million for the six months ended June 30, 2023. The increase in interest income of \$9.7 million primarily related to increase in yield and also higher account balances associated with our cash and cash equivalents during the six months ended June 30, 2024 as compared to the six months ended June 30, 2023.Interest expenseInterest expense increased to \$29.4 million for the six months ended June 30, 2024 as compared to \$9.9 million for the six months ended June 30, 2023. Interest expense increased by \$19.5 million primarily due to an increase in the balance of the liabilities for future royalties and milestones, net associated with our Collaboration Agreement with Blackstone and the BioNTech License and Option Agreement.Liquidity and Capital ResourcesSince our inception, we have not generated any commercial product revenue and have incurred operating losses and negative cash flows from our operations. We expect to incur significant expenses and operating losses for the foreseeable future as we advance our product candidates through preclinical and clinical development and seek

regulatory approval and pursue commercialization of any approved product candidates. We expect that our research and development and general and administrative expenses may increase in connection with our planned research, clinical development and potential commercialization activities. As a result, we will need significant additional capital to fund our operations until such time as we can generate significant revenue from product sales. We do not currently have any approved products and have never generated any commercial revenue from product sales. We have funded our operations to date primarily with proceeds from government grants, sales of our equity securities, through public offerings and pursuant to our at-the-equity market facility, through U.K. research and development tax credits and receipts from the SME and RDEC schemes, out-licensing arrangements and strategic collaboration and financing agreements. From our inception in 2014 through June 30, 2024, we have raised an aggregate of \$1.7 billion from these capital sources. As of June 30, 2024, we had cash and cash equivalents of \$705.9 million.

Table of contents

Cash Flows

The following table summarizes our cash flows for each of the periods presented (in thousands):

Six Months Ended June 30, 2024	2023	Net cash used in operating activities
\$(91,597)	\$(80,566)	Net cash used in investing activities
1,374	(8,011)	Net cash provided by (used in) financing activities
559,362	(910)	Effect of exchange rate changes on cash, cash equivalents and restricted cash
233A	14,558A	Net increase (decrease) in cash, cash equivalents and restricted cash
\$466,624A	\$(74,929)B	Net Cash Used in Operating Activities

During the six months ended June 30, 2024, operating activities used \$91.6 million of cash, resulting from our net loss of \$111.0 million and net cash used resulting from changes in our operating assets and liabilities of \$22.6 million, partially offset by a non-cash A charges of \$42.0 million. The non-cash charges related to interest expense accrued and cumulative catch-up adjustment of \$29.4 million, share-based compensation of \$5.2 million, depreciation and amortization of \$3.7 million, non-cash operating lease expense of \$2.3 million, foreign exchange differences of \$1.2 million, and impairment of operating lease right-of-use assets and related property and equipment of \$0.4 million, which was offset by deferred income tax movement of \$0.2 million. Net cash used in operating activities resulting from changes in our operating assets and liabilities for the six months ended June 30, 2024 consisted primarily of a net increase of \$16.7 million in prepaid expenses and other current and non-current assets, a decrease in accrued expenses and other liabilities of \$4.3 million, and a decrease of \$2.6 million in our operating lease liability, offset by an increase in accounts payable of \$1.0 million. During the six months ended June 30, 2023, operating activities used \$80.6 million of cash, resulting from our net loss of \$85.4 million and net cash used resulting from changes in our operating assets and liabilities of \$12.8 million, partially offset by a non-cash A charges of \$17.6 million. The non-cash charges related to interest expense accrued and cumulative catch-up adjustment of \$9.9 million, share-based compensation of \$5.1 million, loss on disposal of property and equipment of \$3.8 million, depreciation and amortization of \$3.4 million, non-cash operating lease expense of \$1.9 million, and loss on termination of operating lease of \$0.1 million, offset by foreign exchange differences of \$6.3 million and deferred income tax movement of \$0.3 million. Net cash used in operating activities resulting from changes in our operating assets and liabilities for the six months ended June 30, 2023 consisted primarily of decreases in accrued expenses and other liabilities of \$9.6 million, a \$6.8 million decrease in right of use assets from amortization and operating lease liabilities, net, offset by an increase in accounts payable of \$3.3 million, and a net decrease of \$0.2 million in prepaid expenses and other current and non-current assets, and an increase in long-term deposits of \$0.1 million.

Net Cash Used in Investing Activities

During the six months ended June 30, 2024 and 2023, we used \$1.4 million and \$8.0 million, respectively, of cash in investing activities, all of which consisted of purchases of property and equipment. Net Cash Provided by (Used in) Financing Activities

During the six months ended June 30, 2024, net cash provided by financing activities of \$559.4 million related to net aggregate proceeds raised from the BioNTech Agreements and our underwritten offering of ADSs. During the six months ended June 30, 2023, net cash used in financing activities of \$0.9 million was primarily for payments of issuance costs relating to a prior equity financing. **Funding Requirements**

We expect our expenses to increase substantially in connection with our ongoing activities, particularly as we continue pre-commercial readiness activities for obe-cel, operate our new commercial manufacturing facility and advance the preclinical activities and clinical trials of our product candidates. Our expenses will increase as we seek regulatory approvals for obe-cel or any other product candidates that successfully complete preclinical and clinical trials; establish a sales, marketing and distribution infrastructure in anticipation of commercializing of any product candidates for which we may obtain marketing approval and intend to commercialize on our own or jointly; hire additional clinical, medical and development personnel; expand our infrastructure and facilities to accommodate our growing employee base; and maintain, expand and protect our intellectual property portfolio.

Table of contents

Our primary uses of capital are, and we expect will continue to be, compensation and related expenses, clinical costs, external research and development services, laboratory and related supplies, legal and other regulatory expenses, and administrative and overhead costs. Our future funding requirements will be heavily determined by the resources needed to support the development of our product candidates. Based on our current clinical development plans, we believe our current cash and cash equivalents will be sufficient to fund our current and planned operating expenses and capital expenditure requirements for at least the next twelve months from the date of the issuance of these unaudited condensed consolidated financial statements. We have based these estimates on assumptions that may prove to be wrong, and we could utilize our available capital resources sooner than we expect. If we receive regulatory approval for obe-cel or any of our other product candidates, we expect to incur significant commercialization expenses related to product manufacturing, sales, marketing and distribution, depending on where we choose to commercialize. We may also require additional capital to pursue A in-licenses A or acquisitions of other product candidates. Because of the numerous risks and uncertainties associated with research, development and commercialization of pharmaceutical product candidates, we are unable to estimate the exact amount of our working capital requirements. Our future funding requirements will depend on and could increase significantly as a result of many factors, including: the scope, progress, outcome and costs of our clinical trials and other research and development activities; the costs, timing, receipt and terms of any marketing approvals from applicable regulatory authorities; the costs of future activities, including product sales, medical affairs, marketing, manufacturing and distribution, for any of our product candidates for which we receive marketing approval; the revenue, if any, received from commercial sale of our products, should any of our product candidates receive marketing approval; the costs and timing of hiring new employees to support our continued growth; the costs of preparing, filing and prosecuting patent applications, maintaining and enforcing our intellectual property rights and defending intellectual property-related claims; and the extent to which we A in-licenses A or acquire additional product candidates or technologies. Until such time, if ever, that we can generate product revenue sufficient to achieve profitability, we expect to finance our cash needs through a combination of public or private equity offerings, reimbursable U.K. research and development tax credits and receipts from the SME and RDEC schemes, out-licensing arrangements, or strategic collaboration agreements. To the extent that we raise additional capital through the sale of equity, the ownership interest of existing shareholders will be diluted. If we raise additional funds through other third-party funding, collaborations agreements, strategic alliances, licensing arrangements or marketing and distribution arrangements, we may have to relinquish valuable rights to our technologies, future revenue streams, research programs or product candidates or grant licenses on terms that may not be favorable to us. If we are unable to raise additional funds when needed, we may be required to delay, limit, reduce or terminate our product development or future commercialization efforts or grant rights to develop and market products or product candidates that we would otherwise prefer to develop and market ourselves.

Critical Accounting Policies and Significant Judgments and Estimates

Our management's discussion and analysis of our financial condition and results of operations is based on our unaudited condensed consolidated financial statements, which we have prepared in accordance with U.S. GAAP. The preparation of our unaudited condensed consolidated financial statements and related disclosures requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, costs and expenses, and the disclosure of contingent assets and liabilities in our unaudited condensed consolidated financial statements. We base our estimates on historical experience, known trends and events and various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. We evaluate our estimates and assumptions on an ongoing basis. Our actual results may differ from these estimates under different assumptions or conditions. Below we have included an update to our significant judgments and accounting estimates from those included in our Annual Report.

Table of contents

Allocation of transaction price using the relative standalone selling price

Upfront payments are allocated between performance obligations using our best estimate of the relative standalone selling price of the performance obligation. The relative standalone selling price is estimated by determining the market values of development and license obligations. As these inputs are not directly observable, the estimate is determined considering all reasonably available information including internal pricing objectives used in negotiating the contract, taking into account the different stage of development of each development program and consideration of adjusted-market data from comparable arrangements. Where performance obligations have been identified relating to material rights, the determination of the relative standalone selling price of these performance obligations also includes an assessment of the likelihood that the options will be exercised and any payments by the customer that are triggered upon exercising the right. This assessment involves significant judgment and could have a significant impact on the amount and timing of revenue recognition. An assessment of the allocation of transaction price using the relative standalone selling price was required for the six months ended June 30, 2024 and 2023 for the BioNTech License and Option Agreement and Research, Option and License Agreement with Cabaletta, respectively. Liability related to future royalties and milestones, net and cumulative catch-up adjustments

We accounted for the Blackstone Collaboration Agreement and the BioNTech Obe-cel Product Revenue Interest, (A BioNTech Liability A) as liabilities measured at amortized cost based on an effective interest rate determined at the outset of the arrangement. The Blackstone Collaboration Agreement Liability related to future royalties and sales milestones, net is measured based on our current estimates of the timing and amount of expected future royalty and milestone payments to be paid and the Blackstone Development Payments expected to be received over the estimated term of the agreement. Similarly, the BioNTech Liability related to future royalties is measured based on our current estimates of the timing and amount of expected future royalty expected to be paid over the estimated term of the agreement. Milestone payments (A BioNTech Milestone Payments A) pursuant to the BioNTech License and Option Agreement are payable upon BioNTech's election, and therefore have not been included in the determination of the effective interest rate or in the measurement of the liability. The liabilities are amortized using the effective interest rate, resulting in recognition of interest expense over the estimated term of the agreement. Each reporting period we assess the estimated probability, timing and amount of the future expected royalty, milestone payments, the Blackstone Development Payment over the estimated term. If there are changes to the estimates, we recognize the impact to the liability A s amortization schedule and the related interest expense using the catch-up method. Our estimate of the probability, timing and amount of expected future royalties and milestones to be paid by us and the expected Blackstone Development Payment to be paid to us, considers significant unobservable inputs. These inputs include regulatory approval, the estimated patient population, estimated selling price, estimated sales, estimated peak sales and sales ramp, timing of the expected launch and its impact on the royalties as well as the overall probability of a success. Additionally, the transaction costs associated with the liability will be amortized to interest expense over the estimated term of the agreements. The carrying amount of the Blackstone Collaboration Agreement Liability and BioNTech Liability is based on our estimate of the future royalties, milestones to be paid to Blackstone by us and the expected Blackstone Development Payment to be received over the life of the arrangement as discounted using the initial effective interest rate. The excess or deficit of estimated present value of future royalty, milestone payments and the future Blackstone Development Payment received over the carrying amount is recognized as a cumulative catch-up adjustment within interest expense using the effective interest rate. **Contractual Obligations**

As of June 30, 2024, other than disclosed within Notes 12 to 14 to our unaudited condensed consolidated financial statements included in this report, there have been no material changes to our contractual obligations and commitments from those described under A Management A s Discussion and Analysis of Financial Condition and Results of Operations A included in our Annual Report. **Recent Accounting Pronouncements Not Yet Adopted**

A description of recently issued accounting pronouncements that may potentially impact our financial position and results of operations is disclosed in Note A 2, A Summary of Significant Accounting Policies A to our unaudited condensed consolidated financial statements included in this Quarterly Report.

Table of contents

Item 3. Quantitative and Qualitative Disclosures about Market Risk

We are exposed to market risks in the ordinary course of our business, which are principally limited to interest rate fluctuations and foreign currency exchange rate fluctuations. We maintain significant amounts of cash that are in excess of federally insured limits in various currencies, placed with one or more financial institutions for varying periods according to expected liquidity requirements. **Interest Rate Risk**

Our exposure to interest rate sensitivity is primarily impacted by changes in the underlying U.S. and U.K. bank interest rates. As of June 30, 2024 and December 31, 2023, we had cash and cash equivalents of \$705.9 million and \$239.6 million, respectively. Our surplus cash has been invested in interest-bearing savings and money market funds. We have not entered into investments for trading or speculative purposes. An immediate hypothetical one percentage point change in interest rates would have resulted in a \$2.1 million increase in interest income on our unaudited condensed Consolidated Statements of Operations and Comprehensive Loss for the year ended December 31, 2023. As of June 30, 2024 the Blackstone Collaboration Agreement Liability has a fixed effective interest rate and is not subject to any fluctuations due to interest rates. However, the effective interest rate for the BioNTech Liability may be subject to fluctuations due to the discretionary nature of certain contractual payments to us. We have no other debt outstanding that is subject to interest rate variability. **Foreign Currency Exchange Risk**

Foreign currency risk is the risk that the fair value or future cash flows of a financial instrument will fluctuate because of changes in foreign exchange rates. Our exposure to the risk of changes in foreign exchange rates relates primarily to fluctuations in value of foreign currency cash and cash equivalent balances held by our main operating subsidiary in the United Kingdom, our operating activities in the United States, and outsourced supplier agreements denominated in currencies other than pound sterling. We minimize foreign currency risk by maintaining cash and cash equivalents of each currency at levels sufficient to meet foreseeable expenditure to the extent practical. A A A As of June 30, 2024, substantially of our cash and cash equivalents were held by one of our U.K. subsidiaries, of which approximately 30% were denominated in pound sterling and approximately 70% were denominated in U.S. dollars, with immaterial amounts denominated in euros and Swiss francs. The significant remainder of our cash and cash equivalents are held by our U.S. subsidiary and denominated in U.S. dollars. Changes in exchange rates had a material impact on U.S. dollar balances held by our main operating subsidiary in the U.K., which resulted in material foreign exchange gains and losses in the Consolidated Statements of Operations and Comprehensive Loss due to the appreciation and depreciation of the subsidiary A s U.S. dollars in pounds sterling terms. Further movements in exchange rates or returns to previous exchange rate levels have caused, and may continue to cause, material fluctuations or equivalent losses in the Consolidated Statements of Operations and Comprehensive Loss. We maintain our accounting records in pounds sterling, our functional currency, and present our consolidated financial statements in U.S. dollars for financial reporting purposes. Monetary assets and liabilities denominated in currencies other than the functional currency are translated into the functional currency at rates of exchange prevailing at the balance sheet dates. Non-monetary assets and liabilities denominated in foreign currencies are translated into the functional currency at the exchange rates prevailing at the date of the transaction. Exchange gains or losses arising from foreign currency transactions are included in the determination of net income (loss) for the respective periods. We recorded foreign exchange gains of \$1.2 million for the three months ended June 30, 2024 and \$0.4 million for the three months ended June 30, 2023, respectively, and foreign exchange losses of \$0.5 million for the six months ended June 30, 2024 and foreign exchange gains of \$1.3 million for the six months ended June 30, 2023, which are included in other income (expense), net in the unaudited condensed Consolidated Statements of Operations and Comprehensive Loss. Assets and liabilities are translated at the exchange rates at the balance sheet dates and revenue and expenses are translated at the average exchange rates and shareholders A equity is translated based on historical exchange rates. Translation adjustments are not included in determining net income (loss) but are included in foreign exchange adjustment to accumulated other comprehensive income (loss), a component of shareholders A equity. We do not currently engage in currency hedging activities in order to reduce our currency exposure, but we may begin to do so in the future. These instruments may be used to selectively manage risks, but there can be no assurance that we will be fully protected against material foreign currency fluctuations.

Table of contents

Item 4. Controls and Procedures

Evaluation of Disclosure Controls and Procedures

We maintain A disclosure controls and procedures, A as defined in Rule 13a-15(e) and Rule 15d-15(e) under the Exchange Act, that are designed to ensure that information required to be disclosed by us in the reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the SEC A s rules and forms, and is accumulated and communicated to our management, including our principal executive and principal financial officers, as appropriate to allow timely decisions regarding required disclosure. In designing and evaluating our disclosure controls and procedures, management recognizes that disclosure controls and procedures, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the disclosure controls and procedures are met. Additionally, in designing disclosure controls and procedures, our management applied judgement in evaluating the cost-benefit relationship of possible disclosure controls and procedures. The design of any system of controls also is based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions; over time, controls may become inadequate because of

changes in conditions, or the degree of compliance with policies or procedures may deteriorate. Because of the inherent limitations in a control system, misstatements due to error or fraud may occur and not be detected. Our management, with the participation of our Chief Executive Officer and Chief Financial Officer, has evaluated the effectiveness of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e)) under the Exchange Act as of June 30, 2024. Based on such evaluation, our Chief Executive Officer and Chief Financial Officer have concluded that, as of June 30, 2024, our disclosure controls and procedures were not effective due to control deficiencies in our internal control over financial reporting which constituted one material weakness. The first material weakness was identified as part of the audit of our consolidated financial statements for the fiscal year ended December 31, 2023. This is described below in ["Changes in Internal Control Over Financial Reporting"](#). In connection with the review of our unaudited condensed consolidated financial statements for the quarter ended March 31, 2024, we identified a second material weakness in relation to accounting for complex transactions. The material weakness did not allow us to identify, understand and evaluate the impact of certain key aspects of the accounting for the BioNTech Agreements. Our process as designed was inadequate to deal with the complexity of the accounting for the transaction and did not allow for an effective and timely evaluation of key aspects of the agreements and their impact on the financial statements. Our remediation plan includes a redesign of the process for dealing with complex accounting transactions which will allow us to identify, understand and evaluate the impact of any key judgements, estimates or other factors which might have a material impact on the financial statements. Our plan for remediation will encompass: (i) structured project plans allowing us to manage multiple stakeholders, including any specialists we use in our work on complex accounting transactions; (ii) the use of summary outputs allowing for earlier review of key judgements, estimates and other factors which impact the financial statements; and (iii) enhancing our review process, and controls including building in more time to allow for their effective operation. Changes in Internal Control over Financial Reporting In connection with the audit of our financial statements for the fiscal year ended December 31, 2023, we identified a material weakness related to our misinterpretation and application of ASC 740 - Income Taxes (a.k.a. ASC 740), in relation to our U.K. SME tax credits, which we historically presented in income tax benefit (expense) rather than as a reduction of research and development expense. We have taken steps to remediate the material weakness by (i) enhancing the training provided to the individuals operating the income taxation controls and related financial reporting controls and (ii) improving the design of our controls related to the use of taxation subject matter experts in the determination of our U.K. SME tax credits balances. As a result, we believe this material weakness was remediated at June 30, 2024. Except for the remediation processes described above, there were no changes in our internal control over financial reporting (as defined in Rule 13a-15(f) of the Exchange Act) that occurred during the three months ended June 30, 2024 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting. [Table of contents PART II - OTHER INFORMATION](#) [Item 1. Legal Proceedings.](#) From time to time, we may become involved in legal proceedings arising in the ordinary course of our business. We are not currently a party to any material legal proceedings, and we are not aware of any pending or threatened legal proceeding against us that we believe could have an adverse effect on our business, operating results or financial condition. [Item 1A. Risk Factors.](#) Information regarding risks and uncertainties related to our business appears in Part I, [Item 1A. "Risk Factors"](#) of our Annual Report. As of the date of this Quarterly Report, there have been no material changes from the risk factors previously disclosed in the Annual Report, except as follows: We have identified material weaknesses in our internal control over financial reporting, which could continue to adversely affect our ability to report our results of operations and financial condition accurately and in a timely manner. As a public company, we are subject to the reporting requirements of the Exchange Act, as well as the requirements of the Sarbanes-Oxley Act of 2002, as amended (the "Sarbanes-Oxley Act"), and the listing standards of the Nasdaq Stock Market. The Sarbanes-Oxley Act requires, among other things, that we maintain effective disclosure controls and procedures and internal control over financial reporting. It also requires management to perform an annual assessment of the effectiveness of our internal control over financial reporting and disclosure of any material weaknesses in such controls. In connection with the audit of our financial statements for the year ended December 31, 2023, we identified a material weakness in our internal control over financial reporting in connection with the historic misinterpretation and application of ASC 740, resulting in our UK SME tax credits being incorrectly presented in income tax benefit (expense). Refer to Note 3, Restatement of Previously Issued Consolidated Financial Statements, in the Consolidated Financial Statements in Part II, [Item 8](#) of our Annual Report for additional information. We have taken steps to remediate the material weakness by (i) enhancing the training provided to the individuals operating the income taxation controls and related financial reporting controls and (ii) improving the design of our controls related to the use of taxation subject matter experts in the determination of our U.K. SME tax credits balances. We believe this material weakness was remediated at June 30, 2024, but there can be no assurance that we will not identify further control deficiencies in this area. In addition, in connection with our review procedures for the three months ended March 31, 2024, we identified an additional material weakness due to an insufficiency of controls over complex accounting transactions. The lack of controls did not allow us to identify, understand and evaluate the impact of certain key judgments that arose during the three months ended March 31, 2024 related to the BioNTech Agreements. Our process, as designed, was inadequate to deal with the complexity of the accounting for the transaction and did not allow for an effective and timely evaluation of these matters and their impact on our financial statements. Any failure to remediate the identified material weakness, or to develop or maintain effective controls, or any difficulties encountered in the implementation or improvement of such controls, could harm operating results or cause us to fail to meet our reporting obligations and may result in a restatement of our financial statements for prior periods, such as the restatement of our previously issued consolidated financial statements described in more detail in our most recent Annual Report on Form 10-K. Any failure to remediate the identified material weakness, or to implement and maintain effective internal control over financial reporting also could adversely affect the results of management evaluations and, to the extent they are required in the future, attestations of our independent registered public accounting firm with respect to our internal control over financial reporting. We can provide no assurance that the measures we are taking and plan to take in the future will remediate the material weaknesses described above, or that any additional material weaknesses or restatements of financial results will not arise in the future due to a failure to implement and maintain adequate internal control over financial reporting or circumvention of these controls. In addition, even if we are successful in strengthening our controls and procedures, in the future those controls and procedures may not be adequate to prevent or identify irregularities or errors or to facilitate the fair presentation of our financial statements. We continue to evaluate steps to remediate the material weakness identified. Any failure to maintain effective internal control over financial reporting could adversely impact our ability to report our financial position and results from operations on a timely and accurate basis. If our financial statements are not accurate, investors may not have a complete understanding of our operations. Likewise, if our financial statements are not filed on a timely basis, we could be subject to sanctions or investigations by the Nasdaq, the SEC or other regulatory authorities, or other potential claims or litigation. Ineffective internal control over financial reporting could also cause investors to lose confidence in our reported financial information, which could have a negative effect on the trading price of our ADSs. [Table of contents](#) [Ineffective disclosure controls and procedures and internal control over financial reporting could also cause investors to lose confidence in our reported financial and other information, which may have a negative effect on the trading price of our ADSs.](#) In addition, if we are unable to continue to meet these requirements, we may not be able to remain listed on the Nasdaq Global Select Market. [Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.](#) [None.](#) [Item 3. Defaults Upon Senior Securities.](#) [None.](#) [Item 4. Mine Safety Disclosures.](#) [Not applicable.](#) [Item 5. Other Information.](#) [Insider Trading Arrangements](#) During the three months ended June 30, 2024, none of our directors or officers (as defined in Rule 16a-1(f) under the Exchange Act) adopted or terminated a [Rule 10b5-1 trading arrangement](#) or [non-Rule 10b5-1 trading arrangement](#), as each term is defined in [Item 408\(a\)](#) of Regulation S-K, except as described below. On June 14, 2024, Martin Pule, our Chief Scientific Officer, adopted a [Rule 10b5-1 trading arrangement](#) as defined in [Item 408\(a\)](#) of Regulation S-K, which is intended to satisfy the affirmative defense of Rule 10b5-1(c). The sales plan has an initial term ending on March 21, 2025 and covers the sale of a total of 698,741 ADSs, each representing one ordinary share with a nominal value of \$0.000042 per share, of the Company. [Item 6. Exhibits.](#) The following exhibits are either provided with this Quarterly Report on Form 10-Q or are incorporated herein by reference: [Exhibit number](#) [Description](#) [3. Articles of Association of Autolus Therapeutics plc](#) (incorporated by reference to [Exhibit 3.1](#) to our Registration Statement on Form F-1 (file no: 333-247270)) [31.1* Certification of Principal Executive Officer Pursuant to Rules 13a-14\(a\) and 15d-14\(a\) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.](#) [31.2* Certification of Principal Financial Officer Pursuant to Rules 13a-14\(a\) and 15d-14\(a\) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.](#) [32.1* Certification of Principal Executive Officer and Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.](#) [Exhibit number](#) [Description](#) [101.INS* Inline XBRL Instance Document](#) [101.SCH* Inline XBRL Taxonomy Extension Schema With Embedded Linkbase Documents](#) [104. Cover Page Interactive Data File](#) (embedded within the Inline XBRL document) *Filed herewith**This certification is being furnished solely to accompany this Quarterly Report on Form 10-Q pursuant to 18 U.S.C. Section 1350, and is not being filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liability of that section, nor shall it be deemed incorporated by reference into any filing of the registrant under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, whether made before or after the date hereof, regardless of any general incorporation language in such filing. [Table of contents](#) [SIGNATURES](#) Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. [Autolus Therapeutics plc](#) Date: August 8, 2024 By: [/s/ Christian Itin, Ph.D.](#) [Name](#) [Christian Itin, Ph.D.](#) [Title: Chief Executive Officer](#) (On Behalf of the Registrant) Date: August 8, 2024 By: [/s/ Robert Dolski](#) [Name](#) [Robert Dolski](#) [Title: Chief Financial Officer](#) (Principal Financial Officer) [47 EX-31.1](#) 2 autolus-10qx06302024ex311.htm EX-31.1 Document [Exhibit 31.1](#) Certification by the Principal Executive Officer pursuant to Securities Exchange Act Rules 13a-14(a) and 15d-14(a) as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 I, Christian Itin, certify that: 1. I have reviewed this Quarterly Report on Form 10-Q of Autolus Therapeutics plc; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; 3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; 4. The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have: (a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; (b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; (c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and (d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and 5. The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions): (a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and (b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting. Date: August 8, 2024/s/ Robert Dolski Name: Robert Dolski Title: Chief Financial Officer (Principal Financial Officer) EX-32.1 4 autolus-10qx06302024ex311.htm EX-32.1 Document [Exhibit 32.1](#) Certification pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 Pursuant to the requirement set forth in Rule 13a-14(b) of the Securities Exchange Act of 1934, as amended, (the "Exchange Act") and Section 1350 of Chapter 63 of Title 18 of the United States Code (18 U.S.C. §1350), Christian Itin, Chief Executive Officer of Autolus Therapeutics plc (the "Company"), and Robert Dolski, Chief Financial Officer of the Company, each hereby certifies that, to the best of his or her knowledge: (1) The Company's Quarterly Report on Form 10-Q for the quarter ended June 30, 2024, to which this Certification is attached as Exhibit 32.1 (the "Periodic Report") fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and (2) The information contained in the Quarterly Report fairly presents, in all material respects, the financial condition and results of operations of the Company. [A A A A A](#)

link:presentationLink link:calculationLink link:definitionLink 9952156 - Disclosure - Nature of the Business link:presentationLink link:calculationLink link:definitionLink 9952157 - Disclosure - Summary of Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 9952158 - Disclosure - License Revenue link:presentationLink link:calculationLink link:definitionLink 9952159 - Disclosure - Interest expense link:presentationLink link:calculationLink link:definitionLink 9952160 - Disclosure - Net loss per ordinary share link:presentationLink link:calculationLink link:definitionLink 9952161 - Disclosure - Fair value measurements link:presentationLink link:calculationLink link:definitionLink 9952162 - Disclosure - Prepaid Expenses and Other Current Assets link:presentationLink link:calculationLink link:definitionLink 9952163 - Disclosure - Property and Equipment, Net link:presentationLink link:calculationLink link:definitionLink 9952164 - Disclosure - Accrued Expenses and Other Liabilities link:presentationLink link:calculationLink link:definitionLink 9952165 - Disclosure - Shareholders' Equity link:presentationLink link:calculationLink link:definitionLink 9952166 - Disclosure - Share-based Compensation link:presentationLink link:calculationLink link:definitionLink 9952167 - Disclosure - Liabilities related to future royalties and milestones, net link:presentationLink link:calculationLink link:definitionLink 9952168 - Disclosure - Leases link:presentationLink link:calculationLink link:definitionLink 9952169 - Disclosure - Commitments and Contingencies link:presentationLink link:calculationLink link:definitionLink 9952170 - Disclosure - Related party transactions link:presentationLink link:calculationLink link:definitionLink 9952171 - Disclosure - Subsequent Events link:presentationLink link:calculationLink link:definitionLink 9954471 - Disclosure - Summary of Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 9954472 - Disclosure - Nature of the Business (Tables) link:presentationLink link:calculationLink link:definitionLink 9954473 - Disclosure - License Revenue (Tables) link:presentationLink link:calculationLink link:definitionLink 9954474 - Disclosure - Interest expense (Tables) link:presentationLink link:calculationLink link:definitionLink 9954475 - Disclosure - Net loss per ordinary share (Tables) link:presentationLink link:calculationLink link:definitionLink 9954476 - Disclosure - Fair value measurements (Tables) link:presentationLink link:calculationLink link:definitionLink 9954477 - Disclosure - Prepaid Expenses and Other Current Assets (Tables) link:presentationLink link:calculationLink link:definitionLink 9954478 - Disclosure - Property and Equipment, Net (Tables) link:presentationLink link:calculationLink link:definitionLink 9954479 - Disclosure - Accrued Expenses and Other Liabilities (Tables) link:presentationLink link:calculationLink link:definitionLink 9954480 - Disclosure - Share-based Compensation (Tables) link:presentationLink link:calculationLink link:definitionLink 9954481 - Disclosure - Liabilities related to future royalties and milestones, net (Tables) link:presentationLink link:calculationLink link:definitionLink 9954482 - Disclosure - Leases (Tables) link:presentationLink link:calculationLink link:definitionLink 9954483 - Disclosure - Nature of the Business - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954484 - Disclosure - Nature of the Business - Units of Accounting (Details) link:presentationLink link:calculationLink link:definitionLink 9954485 - Disclosure - Summary of Significant Accounting Policies - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954486 - Disclosure - License Revenue - Disaggregation of Revenue (Details) link:presentationLink link:calculationLink link:definitionLink 9954487 - Disclosure - License revenue - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954488 - Disclosure - Interest expense (Details) link:presentationLink link:calculationLink link:definitionLink 9954489 - Disclosure - Net loss per ordinary share - Schedule of Net Loss Per Share (Details) link:presentationLink link:calculationLink link:definitionLink 9954490 - Disclosure - Net loss per ordinary share - Schedule of Anti-dilutive Securities (Details) link:presentationLink link:calculationLink link:definitionLink 9954491 - Disclosure - Fair value measurements (Details) link:presentationLink link:calculationLink link:definitionLink 9954492 - Disclosure - Prepaid Expenses and Other Current Assets (Details) link:presentationLink link:calculationLink link:definitionLink 9954493 - Disclosure - Property and Equipment, Net - Schedule of PPE (Details) link:presentationLink link:calculationLink link:definitionLink 9954494 - Disclosure - Property and Equipment, Net - Narratives (Details) link:presentationLink link:calculationLink link:definitionLink 9954495 - Disclosure - Accrued Expenses and Other Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 9954496 - Disclosure - Shareholders' Equity - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954497 - Disclosure - Share-based Compensation - Share-based Compensation Allocation (Details) link:presentationLink link:calculationLink link:definitionLink 9954498 - Disclosure - Share-Based Compensation - Share Options Rollforward (Details) link:presentationLink link:calculationLink link:definitionLink 9954499 - Disclosure - Share-based Compensation - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954500 - Disclosure - Share-Based Compensation - Restricted Stock Units (Details) link:presentationLink link:calculationLink link:definitionLink 9954501 - Disclosure - Liabilities related to future royalties and milestones, net - Schedule of Liability Related to Revenue (Details) link:presentationLink link:calculationLink link:definitionLink 9954502 - Disclosure - Liabilities related to future royalties and milestones, net - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954503 - Disclosure - Leases - Lease Cost (Details) link:presentationLink link:calculationLink link:definitionLink 9954504 - Disclosure - Leases - Schedule of Maturity Payments (Details) link:presentationLink link:calculationLink link:definitionLink 9954504 - Disclosure - Leases - Schedule of Maturity Payments (Details) link:presentationLink link:calculationLink link:definitionLink 9954505 - Disclosure - Leases - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954506 - Disclosure - Leases - Sublease Classification (Details) link:presentationLink link:calculationLink link:definitionLink 9954507 - Disclosure - Leases - Sublease Income Maturity (Details) link:presentationLink link:calculationLink link:definitionLink 9954508 - Disclosure - Commitments and Contingencies - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954509 - Disclosure - Related party transactions - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 6 autl-20240630 cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 7 autl-20240630 def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 8 autl-20240630 lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Weighted average contractual term vested and expected to vest Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term Adjustments to reconcile net loss to net cash used in operating activities: Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Related party transactions Related Party Transactions Disclosure [Text Block] Lease Cost Lease, Cost [Table Text Block] Assets under construction Asset under Construction [Member] Schedule of Prepaid Expenses and Other Current Assets Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Table Text Block] Interest expense Interest Income and Interest Expense Disclosure [Text Block] Cover [Abstract] Initial recognition of BioNTech liability Collaboration Agreement, Initial Recognition of Liability Collaboration Agreement, Initial Recognition of Liability Blackstone Collaboration Agreement Blackstone Collaboration Agreement [Member] Blackstone Collaboration Agreement Net increase (decrease) in cash, cash equivalents and restricted cash Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Lease Maturity Schedule Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block] Other accrued liabilities Other Liabilities, Current Trading Symbol Trading Symbol All Trading Arrangements All Trading Arrangements [Member] Units of accounting Units Of Accounting Units Of Accounting Compensation Actually Paid vs. Net Income Compensation Actually Paid vs. Net Income [Text Block] Liability Related Debt Arising Financial Agreement Liability Related Debt Arising Financial Agreement [Table Text Block] Liability Related Debt Arising Financial Agreement Non-NEOs Non-NEOs [Member] Schedule of Loss Per Share, Basic and Diluted Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] Rule 10b5-1 Arrangement Adopted Rule 10b5-1 Arrangement Adopted [Flag] Awards Close in Time to MNPI Disclosures Awards Close in Time to MNPI Disclosures [Table] Blackstone Blackstone [Member] Blackstone BioNTech License and Option Agreement BioNTech License And Options Agreement [Member] BioNTech License And Options Agreement Pay vs Performance Disclosure [Line Items] 2026 Lessor, Operating Lease, Payment to be Received, Year Two Peer Group Total Shareholder Return Amount Peer Group Total Shareholder Return Amount Decrease in operating lease liability Increase (Decrease) in Operating Lease Liability Non-Rule 10b5-1 Arrangement Adopted Non-Rule 10b5-1 Arrangement Adopted [Flag] Fair value measurements Fair Value Disclosures [Text Block] Proceeds from the exercise of share options Proceeds from Stock Options Exercised Award Timing Disclosures [Line Items] Other Performance Measure, Amount Other Performance Measure, Amount Portion at Fair Value Measurement Portion at Fair Value Measurement [Member] Leases Lessee, Operating Leases [Text Block] Shares outstanding (in shares) Beginning balance (in shares) Ending balance (in shares) Common Stock, Shares, Outstanding Operating lease costs Operating Lease, Cost Other receivables Other Receivables, Net, Current Operating lease liabilities, non-current Operating Lease, Liability, Noncurrent Loss on disposal of property and equipment Gain (Loss) on Disposition of Property Plant Equipment, Excluding Oil and Gas Property and Timber Property Segment Information Segment Reporting, Policy [Policy Text Block] Revenue from Contract with Customer [Abstract] Per share price of issuance (usd per share) Sale of Stock, Price Per Share United States UNITED STATES Collaborative arrangement, rights and obligations, maximum share purchase requirement, value Collaborative Arrangement, Rights And Obligations, Maximum Share Purchase Requirement, Value Collaborative Arrangement, Rights And Obligations, Maximum Share Purchase Requirement, Value Leases [Abstract] Leases [Abstract] Shares outstanding, including RSUs vested but not yet released (in shares) Common Stock, Shares Outstanding, Including RSUs, Vested But Not Yet Released Common Stock, Shares Outstanding, Including RSUs, Vested But Not Yet Released Antidilutive Securities, Name [Domain] Antidilutive Securities, Name [Domain] Unrecorded Unconditional Purchase Obligation by Category of Item Purchased [Axis] Unrecorded Unconditional Purchase Obligation by Category of Item Purchased [Axis] Money market funds Money Market Funds [Member] Number of directors Number of Directors Number of Directors Net cash used in operating activities Net Cash Provided by (Used in) Operating Activities Proceeds of issuance of ordinary shares, net of issuance costs Sale of Stock, Consideration Received on Transaction Cash flows from operating activities: Net Cash Provided by (Used in) Operating Activities [Abstract] Prepayments Prepaid Expense, Current License And Options License And Options [Member] License And Options Equity Components [Axis] Equity Components [Axis] Award Timing Method Award Timing Method [Text Block] Office equipment Office Equipment [Member] Options forfeited, Aggregate Intrinsic Value Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures In Period, Intrinsic Value Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures In Period, Intrinsic Value Trading Arrangements, by Individual Trading Arrangements, by Individual [Table] Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Insider Trading Policies and Procedures [Line Items] Use of Estimates Use of Estimates, Policy [Policy Text Block] Collaborative arrangement, period to enter agreement from initial closing date (in months) Collaborative Arrangement, Period To Enter Agreement From Initial Closing Date Collaborative Arrangement, Period To Enter Agreement From Initial Closing Date Adjustment to Compensation, Amount Adjustment to Compensation Amount Options outstanding, Aggregate Intrinsic Value Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value Payables and Accruals [Abstract] Payables and Accruals [Abstract] Compensation Amount Outstanding Recovery Compensation Amount Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member] Entity Small Business Entity Small Business Accrued Expenses and Other Liabilities Accounts Payable and Accrued Liabilities Disclosure [Text Block] Company Selected Measure Amount Company Selected Measure Amount Geographical [Axis] Geographical [Axis] Sublease, Lease Term 1 Sublease, Lease Term One [Member] Sublease, Lease Term One Tabular List, Table Tabular List [Table Text Block] Significant Unobservable Inputs (Level 3) Fair Value, Inputs, Level 3 [Member] Share-based Compensation Arrangement by Share-based Payment Award Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Remainder of 2024 Lessor, Operating Lease, Payment to be Received, Remainder of Fiscal Year Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member] Loss contingency accrual Loss Contingency Accrual Accrued expenses and other liabilities Accrued Liabilities, Current Total potentially dilutive securities (in shares) Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Class of Warrant or Right [Line Items] Class of Warrant or Right [Line Items] Sublease Classification Operating Lease, Lease Income [Table Text Block] Cash, cash equivalents and restricted cash, beginning of period Cash, cash equivalents and restricted cash, end of period Total cash, cash equivalents and restricted cash Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents Current assets: Assets, Current [Abstract] Number of shares modified (in shares) Share-Based Payment Arrangement, Plan Modification, Shares Modified Share-Based Payment Arrangement, Plan Modification, Shares Modified Collaborative Agreements, Debt Liability Collaborative Agreements, Debt Liability [Roll Forward] Collaborative Agreements, Debt Liability Ordinary Shares Ordinary Shares [Member] Ordinary Shares [Member] Forgone Recovery due to Disqualification of Tax Benefits, Amount Forgone Recovery due to Disqualification of Tax Benefits, Amount Product and Service [Domain] Product and Service [Domain] Short term lease costs Short-Term Lease, Cost Share options Share-Based Payment Arrangement, Option [Member] Vested (in usd per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value Depreciation expense Depreciation Fair Value Disclosures [Abstract] 2025 Lessee, Operating Lease, Liability, to be Paid, Year One License revenue License [Member] Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Antidilutive Security, Excluded EPS Calculation [Table] Total comprehensive loss Comprehensive Income (Loss), Net of Tax, Attributable to Parent Warrants Warrant [Member] Security Exchange Name Security Exchange Name Award Type [Axis] Award Type [Axis] Related Party Transaction [Domain] Related Party Transaction [Domain] Accrued interest Contract With Customer, Liability, Accrued Interest Contract With Customer, Liability, Accrued Interest Earnings Per Share Earnings Per Share, Basic [Abstract] Exercised (in usd per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price Lease Contractual Term [Domain] Lease Contractual Term [Domain] Number of restricted units Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward] Property and equipment, net Total property and equipment, net Property, Plant and Equipment, Net Total liabilities Liabilities Exercisable (in usd per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price Research and development claims receivable Research And Development Claims Receivable, Current Research and Development Claims Receivable, Current Other comprehensive income (loss): Comprehensive Income (Loss), Net of Tax, Attributable to Parent [Abstract] Stock par value (usd/gbp per share) Common Stock, Par or Stated Value Per Share Forgone Recovery, Explanation of Impracticability Forgone Recovery, Explanation of Impracticability [Text Block] Number of development payments Number Of Development Payments Number Of Development Payments Research and development Research and Development Expense Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table] Foreign Currency Translation Foreign Currency Transactions and Translations Policy [Policy Text Block] Expiration Date Trading Arrangement Expiration Date Cash flows from investing activities: Net Cash Provided by (Used in) Investing Activities [Abstract] Operating lease liabilities, current Operating Lease, Liability, Current Total Shareholder Return Amount Total Shareholder Return Amount Shares issued (in shares) Common Stock, Shares, Issued Entity [Domain] Entity [Domain] Equity Awards Adjustments, Footnote Equity Awards Adjustments, Footnote [Text Block] Concentration risk (in percent) Concentration Risk, Percentage Payments for license fees (less than) Collaborative Arrangement, Rights And Obligations, Payments Payable Collaborative Arrangement, Rights And Obligations, Payments Payable Lab equipment Equipment [Member] Insider Trading Policies and Procedures Adopted Insider Trading Policies and Procedures Adopted [Flag] Less: accumulated depreciation Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment Property and equipment, gross Property, Plant and Equipment, Gross Exercise of share options (in shares) Exercised (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period Named Executive Officers, Footnote Named Executive Officers, Footnote [Text Block] Weighted- Average Exercise Price per share Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract] Research and development Research and Development expense [Member] Shares authorized (in shares) Common Stock, Shares Authorized Class of Warrant or Right [Table] Class of Warrant or Right [Table] Technology Options Technology Options [Member] Technology Options Basis of Presentation Basis of Accounting, Policy [Policy Text Block] Weighted-average diluted ordinary shares (in shares) Weighted-average number of ordinary shares used in net loss per share - diluted (in shares) Weighted Average Number of Shares Outstanding, Diluted Vesting of restricted stock unit awards net of shares withheld to cover tax withholding Stock Vested During Period, Value, Restricted Stock Stock Vested During Period, Value, Restricted Stock MNPI Disclosure Timed for Compensation Value MNPI Disclosure Timed for Compensation Value [Flag] Collaborative agreement, period to acquire beneficial ownership from execution date Collaborative Agreement, Period To Acquire Beneficial Ownership From Execution Date Collaborative Agreement, Period To Acquire Beneficial Ownership From Execution Date Total shareholders' equity Beginning balance Ending balance Equity, Attributable to Parent Interest expense Interest Expense, Nonoperating Property and Equipment, Net Property, Plant and Equipment Disclosure [Text Block] Concentration Risk Type [Domain] Concentration Risk Type [Domain] Master Supply Commitments Master Supply Commitments [Member] Master Supply Commitments Entity Address, Country Entity Address, Country Miltenyi Biotech B.V. & Co. KG ("Miltenyi") Miltenyi Biotech B.V. & Co. KG ("Miltenyi") [Member] Miltenyi Biotech B.V. & Co. KG ("Miltenyi") Accounts receivable Accounts Receivable, after Allowance for Credit Loss,

Current BioNTech And Cabaletta BioNTech And Cabaletta [Member] BioNTech And Cabaletta Granted (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross Sale of Stock [Domain] Sale of Stock [Domain] Antidilutive Securities Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Pension Adjustments Prior Service Cost Pension Adjustments Prior Service Cost [Member] Fair Value Measurements, Recurring and Nonrecurring Fair Value Measurements, Recurring and Nonrecurring [Table Text Block] Non-cash operating lease expense Noncash Operating Lease Expense Noncash Operating Lease Expense Document Fiscal Period Focus Document Fiscal Period Focus All Executive Categories All Executive Categories [Member] Lease and lease deposit receivable Lease And Lease Deposit Receivable, Current Lease And Lease Deposit Receivable, Current Changed Peer Group, Footnote Changed Peer Group, Footnote [Text Block] Weighted average contractual term outstanding Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term Assets Assets [Abstract] Restricted cash Restricted cash Restricted Cash, Current Document Type Document Type Interest rate (in percent) Debt Instrument, Interest Rate, Effective Percentage Pension Benefits Adjustments, Footnote Pension Benefits Adjustments, Footnote [Text Block] Total Shareholder Return Vs Peer Group Total Shareholder Return Vs Peer Group [Text Block] Weighted average contractual term exercisable Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term Vested (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period Contract with customer, liability Contract with Customer, Liability Equity Valuation Assumption Difference, Footnote Equity Valuation Assumption Difference, Footnote [Text Block] Furniture and fixtures Furniture and Fixtures [Member] Increase in prepaid expenses and other current assets Increase (Decrease) In Prepaid Expense And Other Assets, Current Increase (Decrease) In Prepaid Expense And Other Assets, Current Antidilutive Securities [Axis] Antidilutive Securities [Axis] Accounts payable Accounts Payable, Current Deferred C Shares Deferred Class C Shares [Member] Deferred Class C Shares [Member] Accounting Policies [Abstract] Accounting Policies [Abstract] Leasehold improvements Leasehold Improvements [Member] Unaudited supplemental non-cash flow information Noncash or Part Noncash Acquisition, Net Nonmonetary Assets Acquired (Liabilities Assumed) [Abstract] Expired (in usd per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price Other taxes receivable Other Taxes Receivable Current Other Taxes Receivable Current Fair value measurements Fair Value Measurement, Policy [Policy Text Block] Current Fiscal Year End Date Current Fiscal Year End Date Less: imputed interest Lessee, Operating Lease, Liability, Undiscounted Excess Amount Amounts of related party transaction Related Party Transaction, Amounts of Transaction Total lease costs Lease, Cost Non-current assets: Assets, Noncurrent [Abstract] PEO Name PEO Name Non-Rule 10b5-1 Arrangement Terminated Non-Rule 10b5-1 Arrangement Terminated [Flag] Lessor, Lease, Description [Line Items] Lessor, Lease, Description [Line Items] Net loss before income tax Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Non-PEO NEO Average Total Compensation Amount Non-PEO NEO Average Total Compensation Amount Award Type [Domain] Award Type [Domain] 2025 Lessor, Operating Lease, Payment to be Received, Year One Name Outstanding Recovery, Individual Name Disaggregation of Revenue [Line Items] Disaggregation of Revenue [Line Items] Schedule of Anti-dilutive Securities Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] Compensation Actually Paid vs. Company Selected Measure Compensation Actually Paid vs. Company Selected Measure [Text Block] Deferred tax asset Deferred Income Tax Assets, Net Non-PEO NEO Non-PEO NEO [Member] Agreement term (in years) Distribution Agreement, Term Distribution Agreement, Term Total accrued expenses and other liabilities Accrued Liabilities and Other Liabilities Additional Paid in Capital Additional Paid-in Capital [Member] Award Timing Predetermined Award Timing Predetermined [Flag] Remaining performance obligation, variable consideration amount Revenue, Remaining Performance Obligation, Variable Consideration Amount Revenue, Remaining Performance Obligation, Variable Consideration Amount Class of Stock Class of Stock [Line Items] Recent Accounting Pronouncements Not Yet Adopted New Accounting Pronouncements, Policy [Policy Text Block] Diluted net loss per ordinary share (in usd per share) Net loss per share - diluted (in usd per share) Earnings Per Share, Diluted Class of Stock [Axis] Class of Stock [Axis] Counterparty Name [Domain] Counterparty Name [Domain] Name Measure Name Entity Interactive Data Current Entity Interactive Data Current Revenue, remaining performance obligation, maximum consideration, amount Revenue, Remaining Performance Obligation, Maximum Consideration, Amount Revenue, Remaining Performance Obligation, Maximum Consideration, Amount VAT receivable Value Added Tax Receivable, Current Restatement does not require Recovery Restatement Does Not Require Recovery [Text Block] Ownership [Axis] Ownership [Axis] Foreign currency gain (loss) Gain (Loss), Foreign Currency Transaction, before Tax Cash paid for income taxes Income Taxes Paid Customer [Axis] Customer [Axis] Disaggregation of Revenue [Table] Disaggregation of Revenue [Table] Foreign exchange differences Unrealized Gain (Loss), Foreign Currency Transaction, before Tax 2027 Lessor, Operating Lease, Payment to be Received, Year Three Statement of Financial Position [Abstract] Statement of Financial Position [Abstract] Cabaletta Bio Inc. (â€œCabalettaâ€) Cabaletta Bio Inc. (â€œCabalettaâ€) [Member] Cabaletta Bio Inc. (â€œCabalettaâ€) Units of Accounting from Financing Agreement Units Of Accounting From Financing Agreement [Table Text Block] Units Of Accounting From Financing Agreement Income tax expense Income Tax Expense (Benefit) Other income (expense): Nonoperating Income (Expense) [Abstract] Capitalized Capitalized Intangible Assets, Net /Property And Equipment [Member] Capitalized Fixed Assets [Member] Unaudited supplemental cash flow information Supplemental Cash Flow Information [Abstract] Share based compensation not yet recognized for unvested shares vesting period (in years) Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition Net loss - diluted Net Income (Loss) Available to Common Stockholders, Diluted Total license revenue Revenue from contract with customer Revenue from Contract with Customer, Excluding Assessed Tax Product Information [Line Items] Product Information [Line Items] Total other income (expense), net Nonoperating Income (Expense) Concentration Risk Benchmark [Domain] Concentration Risk Benchmark [Domain] Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest [Abstract] Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest [Abstract] Net cash used in investing activities Net Cash Provided by (Used in) Investing Activities Total operating expenses, net Operating Income (Loss) Total interest expense Interest Expense, Operating and Nonoperating Total liabilities and shareholders' equity Liabilities and Equity Subsequent Events Subsequent Events [Text Block] All Adjustments to Compensation All Adjustments to Compensation [Member] Rule 10b5-1 Arrangement Terminated Rule 10b5-1 Arrangement Terminated [Flag] Compensation and benefits Employee-related Liabilities, Current Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV [Axis] Decrease in prepaid expenses and other non-current assets Increase (Decrease) In Prepaid Expense and Other Assets Additional paid-in capital Additional Paid in Capital Impairment of operating lease right-of-use assets and related property and equipment Impairment of operating lease right-of-use assets and related property and equipment Operating Lease, Impairment Loss MCSA Manufacturing Commercial Services Agreement (â€œMCSAâ€) [Member] Manufacturing Commercial Services Agreement (â€œMCSAâ€) Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Disclosure [Abstract] Legal Entity [Axis] Legal Entity [Axis] Interest income Investment Income, Interest Leased assets obtained in exchange for operating lease liabilities Right-of-Use Asset Obtained in Exchange for Operating Lease Liability Payment of equity issuance costs Payment of Financing and Stock Issuance Costs Underlying Security Market Price Change Underlying Security Market Price Change, Percent Individual: Individual [Axis] Related Party Transaction [Axis] Related Party Transaction [Axis] Proceeds from liabilities related to future royalties and milestones, net Proceeds From Issuance Of Contract With Customer, Liability Proceeds From Issuance Of Contract With Customer, Liability Accumulated other comprehensive loss AOCl Attributable to Parent [Member] Lessor, operating lease, payment to be received Total lease payments receivable Lessor, Operating Lease, Payment to be Received Forfeited (in usd per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price Product and Service [Axis] Product and Service [Axis] Property, Plant and Equipment Property, Plant and Equipment [Line Items] Statement Statement [Line Items] Beginning Balance Ending Balance Carrying amount of liability Collaborative Agreements, Debt Liability Collaborative Agreements, Debt Liability Erroneous Compensation Analysis Erroneous Compensation Analysis [Text Block] Operating expenses: Operating Expenses [Abstract] Schedule of Depreciation Property, Plant and Equipment [Table Text Block] Compensation Actually Paid vs. Total Shareholder Return Compensation Actually Paid vs. Total Shareholder Return [Text Block] Total sublease rental income Sublease Income Unvested and outstanding beginning balance (in usd per share) Unvested and outstanding ending balance (in usd per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value Liabilities and shareholders' equity Liabilities and Equity [Abstract] Corporate tax receivable Corporate Tax, Current Corporate Tax, Current Number of freestanding financial instruments Number Of Freestanding Financial Instruments Number Of Freestanding Financial Instruments Restatement Determination Date Restatement Determination Date Vested and expected to vest (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number Estimate of Fair Value Measurement Estimate of Fair Value Measurement [Member] Pay vs Performance Disclosure Pay vs Performance Disclosure [Table] Adoption Date Trading Arrangement Adoption Date Related Party Transactions [Abstract] Related Party Transactions [Abstract] Decrease in accrued expenses and other liabilities Increase (Decrease) In Accrued Liabilities, Lease Liability And Other Liabilities Increase (Decrease) In Accrued Liabilities, Lease Liability And Other Liabilities Liabilities related to future royalties and milestones, net Contract with customer, liability, noncurrent Contract with Customer, Liability, Noncurrent Number of combined performance obligations Number Of Combined Performance Obligations Number Of Combined Performance Obligations Property, Plant and Equipment [Table] Property, Plant and Equipment [Table] Beginning balance (in usd per share) Ending balance (in usd per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price Operating lease right-of-use assets, net Operating Lease, Right-of-Use Asset Erroneously Awarded Compensation Recovery Erroneously Awarded Compensation Recovery [Table] Beginning balance (in shares) Ending balance (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member] Property, Plant and Equipment [Abstract] Property, Plant and Equipment [Abstract] Exercise Price Award Exercise Price Lease Contractual Term [Axis] Lease Contractual Term [Axis] Other interest expense Interest Expense, Other ADR ADR [Member] Net loss per ordinary share Earnings Per Share [Text Block] BioNTech BioNTech [Member] BioNTech Arrangement Duration Trading Arrangement Duration Exercise of share options Stock Issued During Period, Value, Stock Options Exercised Net allocated consideration based on relative fair value after transaction costs Related Party Transaction, Amounts Of Transaction, Net Of Issuance Cost. Related Party Transaction, Amounts Of Transaction, Net Of Issuance Cost. Shareholders' equity: Equity, Attributable to Parent [Abstract] Loss on termination of operating lease Gain (Loss) on Termination of Lease Thereafter Lessee, Operating Lease, Liability, To Be Paid, After Year Four Lessee, Operating Lease, Liability, To Be Paid, After Year Four Peer Group Issuers, Footnote Peer Group Issuers, Footnote [Text Block] Material Terms of Trading Arrangement Material Terms of Trading Arrangement [Text Block] All Individuals All Individuals [Member] Summary of Significant Accounting Policies Basis of Presentation and Significant Accounting Policies [Text Block] PEO PEO [Member] Name Trading Arrangement, Individual Name Other income (expense), net Other Nonoperating Income (Expense) Obe-cel Product Obe-cel Product [Member] Obe-cel Product Statement of Stockholders' Equity [Abstract] Statement of Stockholders' Equity [Abstract] Property, Plant and Equipment, Type [Axis] Long-Lived Tangible Asset [Axis] License Revenue (Binder License) License Revenue [Member] License Revenue Decrease in long-term deposits Increase (Decrease) In Other Noncurrent Assets 2028 Lessor, Operating Lease, Payment to be Received, Year Four Share based compensation not yet recognized for unvested shares other than options (less than) Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount Awards Close in Time to MNPI Disclosures, Table Awards Close in Time to MNPI Disclosures [Table Text Block] Liabilities related to future royalties and milestones, net (Obe-cel Product Revenue Interest) Liability Related To The Sale Of Future Royalties And Sales Milestones, Net [Member] Liability Related To The Sale Of Future Royalties And Sales Milestones, Net Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member] Related Party [Domain] Related and Nonrelated Parties [Domain] Deferred cost Deferred Costs, Current Cash and cash equivalents: Cash and Cash Equivalents, Fair Value Disclosure Aggregate Erroneous Compensation Amount Aggregate Erroneous Compensation Amount Additional agreement term (in years) Distribution Agreement, Additional Renewal Term Distribution Agreement, Additional Renewal Term Long-term Purchase Commitment [Line Items] Long-Term Purchase Commitment [Line Items] Local Phone Number Local Phone Number Initial ADSS, representing ordinary shares Initial ADSS, Representing Ordinary Shares [Member] Initial ADSS, Representing Ordinary Shares Aggregate Erroneous Compensation Not Yet Determined Aggregate Erroneous Compensation Not Yet Determined [Text Block] Distinct performance obligation Number Of Distinct Performance Obligations Number Of Distinct Performance Options Germany GERMANY Prepaid Expenses and Other Current Assets Other Current Assets [Text Block] Options expired, Aggregate Intrinsic Value Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations In Period, Intrinsic Value Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations In Period, Intrinsic Value Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract] Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract] Changes in operating assets and liabilities: Increase (Decrease) in Operating Capital [Abstract] Non-current liabilities: Liabilities, Noncurrent [Abstract] PEO Total Compensation Amount PEO Total Compensation Amount Collaborative arrangement, rights and obligations, maximum share purchase requirement, shares (in shares) Collaborative Arrangement, Rights And Obligations, Maximum Share Purchase Requirement, Shares Collaborative Arrangement, Rights And Obligations, Maximum Share Purchase Requirement, Shares Lessor, Lease, Description [Table] Lessor, Lease, Description [Table] Property, Plant and Equipment, Type [Domain] Long-Lived Tangible Asset [Domain] Schedule of Accrued Expenses and Other Liabilities Schedule of Accrued Liabilities [Table Text Block] Income Statement Location [Axis] Statement of Income Location, Balance [Axis] Stockholders' equity, common stock, conversion ratio Stockholders' Equity, Common Stock, Conversion Ratio Stockholders' Equity, Common Stock, Conversion Ratio Vested and expected to vest (in usd per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price No Trading Symbol Flag No Trading Symbol Flag Options granted, Aggregate Intrinsic Value Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants In Period, Intrinsic Value Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants In Period, Intrinsic Value Payments of equity issuance costs Payments of Stock Issuance Costs Commitments and Contingencies Commitments and Contingencies Disclosure [Text Block] Common shares Common Stock [Member] Measure: Measure [Axis] Martin Pule [Member] Martin Pule Forgone Recovery due to Expense of Enforcement, Amount Forgone Recovery due to Expense of Enforcement, Amount Issuance of ordinary shares, net of issuance costs (in shares) Stock Issued During Period, Shares, New Issues Entity Emerging Growth Company Entity Emerging Growth Company Entity Central Index Key Entity Central Index Key General and administrative General and Administrative Expense [Member] Non-GAAP Measure Description Non-GAAP Measure Description [Text Block] Non-PEO NEO Average Compensation Actually Paid Amount Non-PEO NEO Average Compensation Actually Paid Amount Shareholdersâ€™ Equity Equity [Text Block] Award Timing, How MNPI Considered Award Timing, How MNPI Considered [Text Block] Equity Component [Domain] Equity Component [Domain] Reconciliation of cash, cash equivalents and restricted cash reported within the unaudited condensed consolidated balance sheets: Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents [Abstract] Additional 402(v) Disclosure Additional 402(v) Disclosure [Text Block] Share-based compensation expense APIC, Share-Based Payment Arrangement, Increase for Cost Recognition Entity Shell Company Entity Shell Company Unconditional Purchase Obligation, Category of Goods or Services Acquired [Domain] Unconditional Purchase Obligation, Category of Goods or Services Acquired [Domain] Measurement Basis [Axis] Measurement Basis [Axis] Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Payments of issuance costs related to the liabilities related to the sale of future royalties and milestones, net Payment Of Contract With Customer, Liability, Issuance Costs Payment Of Contract With Customer, Liability, Issuance Costs Title Trading Arrangement, Individual Title Collaborative agreement, beneficial ownership percentage, threshold (in percent) Collaborative Agreement, Beneficial Ownership Percentage, Threshold Collaborative Agreement, Beneficial Ownership Percentage, Threshold Statement [Table] Statement [Table] Vested not issued (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Not Issued, Vested, Number Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Not Issued, Vested, Number Counterparty Name [Axis] Counterparty Name [Axis] Numerator Net Income (Loss) Available to Common Stockholders, Diluted [Abstract] City Area Code City Area Code Current liabilities: Liabilities, Current [Abstract] Insider Trading Policies and Procedures Not Adopted Insider Trading Policies and Procedures Not Adopted [Text Block] Quoted Prices in Active Markets for Identical Assets (Level 1) Fair Value, Inputs, Level 1 [Member] Concentration Risk Benchmark [Axis] Concentration Risk Benchmark [Axis] Total current assets Assets, Current Interest Income and Interest Expense Disclosure Interest Income and Interest Expense Disclosure [Table Text Block] Statement of Cash Flows [Abstract] Statement of Cash Flows [Abstract] Going Concern Going Concern,

Policy [Policy Text Block] Going Concern, Policy Exercisable (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number Document Information [Line Items] Document Information [Line Items] WeightedÅ average grant date fair value Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract] Weighted average grant date fair value (in usd per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value Unconditional purchase obligations for capital expenditures Unrecorded Unconditional Purchase Obligation 2028 Lessee, Operating Lease, Liability, to be Paid, Year Four Earnings Per Share [Abstract] Equity [Abstract] Equity [Abstract] Capital Addition Purchase Commitments Capital Addition Purchase Commitments [Member] Accumulated deficit Retained Earnings (Accumulated Deficit) Schedule of Nonvested Share Activity Schedule of Nonvested Share Activity [Table Text Block] Class of Stock [Domain] Class of Stock [Domain] Related Party Transaction Related Party Transaction [Line Items] Interest expense on liabilities related to future royalties and milestones, net Collaboration Agreement, Non-Cash Interest Expense And Cumulative Catch-Up Adjustment Collaborator Agreement, Non-Cash Interest Expense And Cumulative Catch-Up Adjustment General and administrative General and Administrative Expense Organization, Consolidation and Presentation of Financial Statements [Abstract] Organization, Consolidation and Presentation of Financial Statements [Abstract] Aggregate Available Trading Arrangement, Securities Aggregate Available Amount Liabilities related to future royalties and milestones, net Liability Related To Sales Of Future Revenue, Net [Text Block] Liability Related To Sales Of Future Revenue, Net Equity Awards Adjustments Equity Awards Adjustments [Member] Weighted-average discount rate æ” operating leases (in percent) Operating Lease, Weighted Average Discount Rate, Percent Present value of lease liabilities Operating Lease, Liability Net cash provided by (used in) financing activities Net Cash Provided by (Used in) Financing Activities Annual license fee Collaborative Arrangement, Rights And Obligations, Annual License Fee Collaborative Arrangement, Rights And Obligations, Annual License Fee Underlying Securities Award Underlying Securities Amount Performance Shares Performance Shares [Member] Prepaid expenses and other non-current assets Prepaid Expense and Other Assets, Noncurrent Amendment Flag Amendment Flag Entity Registrant Name Entity Registrant Name Loss on disposal of property and equipment Gain (Loss) on Disposition of Property Plant Equipment Adjustment to Non-PEO NEO Compensation Footnote Adjustment to Non-PEO NEO Compensation Footnote [Text Block] Stock Appreciation Rights (SARs) Stock Appreciation Rights (SARs) [Member] Depreciation and amortization Depreciation, Depletion and Amortization Foreign currency exchange translation adjustment Unrealized gain on foreign currency translation Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent Fair Value as of Grant Date Award Grant Date Fair Value Customer Concentration Risk Customer Concentration Risk [Member] Subsequent Events [Abstract] Subsequent Events [Abstract] Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract] Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract] Affiliated Entity Affiliated Entity [Member] Options vested and expected to vest Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value Significant Other Observable Inputs (Level 2) Fair Value, Inputs, Level 2 [Member] Number of shares issued in transaction (in shares) Sale of Stock, Number of Shares Issued in Transaction Leased assets terminated and obtained in exchange for operating lease liabilities, net Right-of-Use Assets Terminated and Obtained in Exchange for Operating Lease Liability, Net Right-of-Use Assets Terminated and Obtained in Exchange for Operating Lease Liability, Net Fair Value Hierarchy and NAV [Domain] Fair Value Hierarchy and NAV [Domain] Collaborative agreement, sale of stock prohibited without registrant's approval, period (in months) Collaborative Agreement, Sale of Stock Prohibited Without Registrant's Approval, Period Collaborative Agreement, Sale of Stock Prohibited Without Registrant's Approval, Period Geographical [Domain] Geographical [Domain] Variable costs Variable Lease, Cost, Net Of Reversal Variable Lease, Cost, Net Of Reversal Recovery of Erroneously Awarded Compensation Disclosure [Line Items] Issuance of ordinary shares, net of issuance costs Stock Issued During Period, Value, New Issues Entity Address, Postal Zip Code Entity Address, Postal Zip Code Schedule of Share Based Compensation Expense Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block] Restatement Determination Date: Restatement Determination Date [Axis] Title of 12(b) Security Title of 12(b) Security Long-term Purchase Commitment [Table] Long-Term Purchase Commitment [Table] Concentration Risk Type [Axis] Concentration Risk Type [Axis] Share value Common Stock, Value, Issued Share-based Payment Arrangement [Abstract] Share-Based Payment Arrangement [Abstract] Non-cash interest expense, catch-up Collaboration Agreement, Non-Cash Interest Expense, Including Cumulative Catch-Up Adjustment Collaboration Agreement, Non-Cash Interest Expense, Including Cumulative Catch-Up Adjustment Cash and cash equivalents Cash and Cash Equivalents, at Carrying Value Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member] Banking and Thrift, Interest [Abstract] Forfeited (in usd per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value Research and development costs Accrued Research And Development Cost, Current Accrued Research And Development Cost, Current BioNTech Liability BioNTech Liability [Member] BioNTech Liability Cash flows from financing activities: Net Cash Provided by (Used in) Financing Activities [Abstract] Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member] NumberA of Options Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward] Cash and Cash Equivalents [Domain] Cash and Cash Equivalents [Domain] Fair Value Measurement [Domain] Fair Value Measurement [Domain] Basic net loss per ordinary share (in usd per share) Net loss per share - basic (in usd per share) Earnings Per Share, Basic Deferred B Shares Deferred Class B Shares [Member] Deferred Class B Shares [Member] Increase in accounts payable Increase (Decrease) in Accounts Payable Deferred shares Deferred Shares Deferred Class A Shares [Member] Deferred Class A Shares [Member] Proceeds of issuance of ordinary shares Proceeds from Issuance of Common Stock Operating cash outflows from operating leases Operating Lease, Payments Long-term deposits Deposits Assets, Noncurrent Adjustment To PEO Compensation, Footnote Adjustment To PEO Compensation, Footnote [Text Block] Award Timing MNPI Disclosure Award Timing MNPI Disclosure [Text Block] Schedule of Product Information [Table] Nature of Operation, Product Information, Concentration of Risk [Table] Ownership [Domain] Ownership [Domain] Property and equipment purchases included in accounts payable or accrued expenses Capital Expenditures Incurred but Not yet Paid Aggregate Pension Adjustments Service Cost Aggregate Pension Adjustments Service Cost [Member] Contract with customer, liability gross Contract With Customer, Liability, Gross Contract With Customer, Liability, Gross Net loss - basic Net Income (Loss) Available to Common Stockholders, Basic Sublease, Lease Term 2 Sublease, Lease Term 2 [Member] Sublease, Lease Term 2 Compensation Actually Paid vs. Other Measure Compensation Actually Paid vs. Other Measure [Text Block] Schedule of Stock by Class [Table] Stock, Class of Stock [Table] Total current liabilities Liabilities, Current Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member] Share based compensation not yet recognized for unvested shares Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount Total assets Assets Incremental share-based compensation expense Share-Based Payment Arrangement, Plan Modification, Incremental Cost Purchases of property and equipment Payments to Acquire Property, Plant, and Equipment Cumulative catch-up adjustment arising from the liabilities related to future royalties and milestones, net (refer to Note 12) Cumulative catch-up adjustment Collaboration Agreement, Cumulative Catch-Up Adjustment Collaboration Agreement, Cumulative Catch-Up Adjustment Other long-term payables Other Liabilities, Noncurrent Forgone Recovery due to Violation of Home Country Law, Amount Forgone Recovery due to Violation of Home Country Law, Amount Commitments and contingencies Commitments and Contingencies Autolus Autolus [Member] Autolus Capitalized implementation costs included in accrued expenses Hosting Arrangement, Service Contract, Implementation Cost, Capitalized, after Accumulated Amortization, Current and Noncurrent Vesting of restricted stock unit awards net of shares withheld to cover tax withholding (in shares) Stock Vested During Period, Shares, Restricted Stock Stock Vested During Period, Shares, Restricted Stock Termination Date Trading Arrangement Termination Date Accrued interest income Accrued Interest Income, Current Accrued Interest Income, Current Nature of the Business Nature of Operations [Text Block] Schedule of Related Party Transactions, by Related Party [Table] Related Party Transaction [Table] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] License revenue Revenues 2026 Lessee, Operating Lease, Liability, to be Paid, Year Two Share-based Compensation Share-Based Payment Arrangement [Text Block] Interest expense on liabilities related to future royalties and milestones, net (refer to Note 12) Interest expense on liability related to future royalties and milestones, net Collaboration Agreement, Non-Cash Interest Expense Collaboration Agreement, Non-Cash Interest Expense Schedule of Revenue by Geographic Locations Revenue from External Customers by Geographic Areas [Table Text Block] Entity Address, City or Town Entity Address, City or Town Cardinal Health 105, LLC (æœCardinal Healthæ) Cardinal Health 105, LLC (æœCardinal Healthæ) [Member] Cardinal Health 105, LLC (æœCardinal Healthæ) Debt Instrument [Axis] Debt Instrument [Axis] Voting rights, votes per share Common Stock, Voting Rights, Votes Per Share Common Stock, Voting Rights, Votes Per Share Stock Option Rollforward Share-Based Payment Arrangement, Option, Activity [Table Text Block] Options exercised, Aggregate Intrinsic Value Intrinsic value of options exercised Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value Total share-based compensation expense Share-Based Payment Arrangement, Expense Net loss Net loss Net loss Net Income (Loss) Attributable to Parent Trading Arrangement: Trading Arrangement [Axis] Investments, Debt and Equity Securities [Abstract] Granted (in usd per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price Pay vs Performance Disclosure, Table Pay vs Performance [Table Text Block] Forfeited (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period Equity Awards Adjustments, Excluding Value Reported in Compensation Table Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member] Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member] Entity File Number Entity File Number Cash and Cash Equivalents [Axis] Cash and Cash Equivalents [Axis] License Revenue Revenue from Contract with Customer [Text Block] Document Fiscal Year Focus Document Fiscal Year Focus Income Statement [Abstract] Income Statement [Abstract] Entity Address, Address Line One Entity Address, Address Line One Denominator Weighted Average Number of Shares Outstanding Reconciliation [Abstract] Entity Address, Address Line Two Entity Address, Address Line Two Debt Instrument, Name [Domain] Debt Instrument, Name [Domain] Allocated consideration based on relative fair value Related Party Transaction, Amounts Of Transaction, Allocated Based On Relative Fair Value Related Party Transaction, Amounts Of Transaction, Allocated Based On Relative Fair Value Related Party Transaction, Amounts Of Transaction, Allocated Based On Relative Fair Value Effect of exchange rate changes on cash, cash equivalents and restricted cash Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations Name Forgone Recovery, Individual Name Remainder of 2024 Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year Options exercisable Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value Weighted-average remaining lease term - operating leases Operating Lease, Weighted Average Remaining Lease Term Document Period End Date Document Period End Date Sale of Stock [Axis] Sale of Stock [Axis] Number of manufacturing properties Lessor, Operating Lease, Number Of Manufacturing Properties Lessor, Operating Lease, Number Of Manufacturing Properties Deferred income tax Increase (Decrease) in Deferred Income Taxes Award Timing MNPI Considered Award Timing MNPI Considered [Flag] Total lease payments Lessee, Operating Lease, Liability, to be Paid Unvested and outstanding beginning balance (in shares) Unvested and outstanding ending balance (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number Expired (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period Insider Trading Arrangements [Line Items] Outstanding Aggregate Erroneous Compensation Amount Outstanding Aggregate Erroneous Compensation Amount 2027 Lessee, Operating Lease, Liability, to be Paid, Year Three PEO Actually Paid Compensation Amount PEO Actually Paid Compensation Amount Adjustment to Compensation: Adjustment to Compensation [Axis] Prepaid expenses and other current assets Prepaid expenses and other current assets Prepaid Expense and Other Assets, Current Capitalized share-based compensation, net of forfeitures Capitalized Share-based Compensation Capitalized Share-based Compensation Document Transition Report Document Transition Report Document Quarterly Report Document Quarterly Report Fair Value, Recurring and Nonrecurring [Table] Fair Value, Recurring and Nonrecurring [Table] Customer [Domain] Customer [Domain] Accumulated other comprehensive loss Accumulated Other Comprehensive Income (Loss), Net of Tax Entity Current Reporting Status Entity Current Reporting Status Accumulated deficit Retained Earnings [Member] Ownership percentage by noncontrolling owners (in percent) Subsidiary, Ownership Percentage, Noncontrolling Owner Pension Adjustments Service Cost Pension Adjustments Service Cost [Member] Share-based compensation net of amounts capitalized Employee Benefit and Share-Based Payment Arrangement, Noncash Investor Investor [Member] Related Party [Axis] Related and Nonrelated Parties [Axis] Weighted-average basic ordinary shares (in shares) Weighted-average number of ordinary shares used in net loss per share - basic (in shares) Weighted Average Number of Shares Outstanding, Basic Stock Price or TSR Estimation Method Stock Price or TSR Estimation Method [Text Block] Document Information [Table] Document Information [Table] Unvested restricted stock units Restricted Stock Units (RSUs) [Member] Stockholders' Equity Increase (Decrease) in Stockholders' Equity [Roll Forward] Professional fees Accrued Professional Fees, Current Executive Category: Executive Category [Axis] Name Awards Close in Time to MNPI Disclosures, Individual Name Underwriters public offering Public Stock Offering [Member] Public Stock Offering [Member] Revenue Benchmark Revenue Benchmark [Member] Forfeited (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period Entity Filer Category Entity Filer Category Income Statement Location [Domain] Statement of Income Location, Balance [Domain] Subsequent ADSs, representing ordinary shares Subsequent ADSs, Representing Ordinary Shares [Member] Subsequent ADSs, Representing Ordinary Shares Lease Receivable Maturity Schedule Lessor, Operating Lease, Payment to be Received, Maturity [Table Text Block] Company Selected Measure Name Company Selected Measure Name EX-101.PRE 9 aul-20240630_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT XML 11 R1.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Cover - shares 6 Months Ended Jun. 30, 2024 Aug. 06, 2024 Document Information [Line Items] Å Å Document Type 10-Q Å Document Quarterly Report true Å Document Period End Date Jun. 30, 2024 Å Document Transition Report false Å Entity File Number 001-38547 Å Entity Registrant Name AUTOLUS THERAPEUTICS PLC Å Entity Incorporation, State or Country Code X0 Å Entity Address, Address Line One The Mediaworks Å Entity Address, Address Line Two 191 Wood Lane Å Entity Address, City or Town London Å Entity Address, Postal Zip Code W12 7FP Å Entity Address, Country GB Å City Area Code (44) 20 Å Local Phone Number 3829 6230 Å Entity Current Reporting Status Yes Å Entity Interactive Data Current Yes Å Entity Filer Category Non-accelerated Filer Å Entity Small Business false Å Entity Emerging Growth Company false Å Entity Shell Company false Å Entity Common Stock, Shares Outstanding Å 266,094,457 Entity Central Index Key 0001730463 Å Amendment Flag false Å Document Fiscal Year Focus 2024 Å Document Fiscal Period Focus Q2 Å Current Fiscal Year End Date -12-31 Å ADR Å Å Document Information [Line Items] Å Å Title of 12(b) Security American Depositary Shares, each representing one ordinary share, par value \$0.000042 per share Å Trading Symbol AUTL Å Security Exchange Name NASDAQ Å Ordinary Shares Å Å Document Information [Line Items] Å Å Title of 12(b) Security Ordinary shares, nominal value \$0.000042 per share* Å Security Exchange Name NASDAQ Å No Trading Symbol Flag true Å X - Definition Boolean flag that is true when the XBRL content amends previously-filed or accepted submission. + ReferencesNo definition available. + Details Name: dei AmendmentFlag Namespace Prefix: dei Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionArea code of city + ReferencesNo definition available. + Details Name: dei CityAreaCode Namespace Prefix: dei Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionEnd date of current fiscal year in the format --MM-DD. + ReferencesNo definition available. + Details Name: dei CurrentFiscalYearEndDate Namespace Prefix: dei Data Type: xbrli:MonthDayItemType Balance Type: na Period Type: duration X - DefinitionFiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY. + ReferencesNo definition available. + Details Name: dei DocumentFiscalPeriodFocus Namespace Prefix: dei Data Type: dei:fiscalPeriodItemType Balance Type: na Period Type: duration X - DefinitionThis is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006. + ReferencesNo definition available. + Details Name: dei DocumentFiscalYearFocus Namespace Prefix: dei Data Type: xbrli:YearItemType Balance Type: na Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesNo definition available. + Details Name: dei DocumentInformationLineItems Namespace Prefix: dei Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionFor the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD. + ReferencesNo definition available. + Details Name:

dei_DocumentPeriodEndDate Namespace Prefix: dei_Data Type: xbrli:dateItem Type Balance Type: na Period Type: duration X - Definition Boolean flag that is true only for a form used as an quarterly report. + References Reference 1:

Section S99 - Paragraph 1B - Subparagraph (SX 210.13-02(a)(4)(i)) - Publisher FASB - URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 24: [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph \(SX 210.13-02\(a\)\(4\)\(iii\)\(A\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 25](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 25): [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph \(SX 210.13-02\(a\)\(4\)\(iii\)\(B\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 26](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 26): [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph \(SX 210.13-02\(a\)\(4\)\(iv\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 27](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 27): [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph \(SX 210.13-02\(a\)\(5\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28): [http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7Reference 29](http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7Reference 29): [http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph \(c\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 30](http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 30):

Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 25>: [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph \(SX 210.13-02\(a\)\(4\)\(iv\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 26](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 26): [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph \(SX 210.13-02\(a\)\(5\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 27](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 27): [http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7Reference 28](http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7Reference 28):

<http://www.xbrl.org/2009/role/commonPracticeRef-Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 58 -SubParagraph 28 -SubParagraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28>Reference 14: [Unaudited Condensed Consolidated Statements of Operations and Comprehensive Loss - USD \(\\$\) \\$ in Thousands 3 Months Ended 6 Months Ended Jun. 30, 2024 Jun. 30, 2023 Jun. 30, 2024 Jun. 30, 2023 Operating expenses: Æ Æ Æ Æ Research and development \\$ \(36,612\) \\$ \(33,232\) \\$ \(67,283\) \\$ \(60,620\) General and administrative \(21,903\) \(11,122\) \(40,080\) \(20,406\) Loss on disposal of property and equipment 0 \(23\) 0 \(3,791\) Impairment of operating lease right-of-use assets and related property and equipment \(414\) 0 \(414\) 0 Total operating expenses, net \(58,929\) \(44,377\) \(97,686\) \(83,525\) Other income \(expense\): Æ Æ Æ Æ Other income \(expense\), net 1,226 482 \(379\) 1,264 Interest income 9,656 3,403 16,589 6,849 Interest expense \(10,174\) \(5,020\) \(29,443\) \(9,925\) Total other income \(expense\), net 708 \(1,135\) \(13,233\) \(1,812\) Net loss before income tax \(58,221\) \(45,512\) \(110,919\) \(85,337\) Income tax expense \(51\) \(40\) \(43\) \(26\) Net loss \(58,272\) \(45,552\) \(110,962\) \(85,363\) Other comprehensive income \(loss\): Æ Æ Æ Æ Foreign currency exchange translation adjustment 1,026 5,300 1,084 1,941 Total comprehensive loss \\$ \(57,246\) \\$ \(40,252\) \\$ \(109,878\) \\$ \(74,422\) Basic net loss per ordinary share \(in usd per share\) \\$ \(0.22\) \\$ \(0.26\) \\$ \(0.43\) \\$ \(0.49\) Diluted net loss per ordinary share \(in usd per share\) \\$ \(0.22\) \\$ \(0.26\) \\$ \(0.43\) \\$ \(0.49\) Weighted-average basic ordinary shares \(in shares\) 266,025,783 173,860,491 255,131,873 173,843,249 Weighted-average diluted ordinary shares \(in shares\) 266,025,783 173,860,491 255,131,873 173,843,249 License revenue Æ Æ Æ Æ License revenue \\$ 0 \\$ 0 \\$ 10,091 \\$ 1,292 X - DefinitionAmount after tax of increase \(decrease\) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners. + ReferencesReference 1:](http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: <a href=)

220-S99-1Reference 18:

gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap NonoperatingIncomeExpenseAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap OperatingExpensesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe net result for the period of deducting operating expenses from operating revenues. + ReferencesReference 1:

Topic 718 - SubTopic 20 - Section 55 - Paragraph 2 - Publisher FASB - URI https://asc.fasb.org/1943274/2147481089/718-20-55-12 - Details Name: us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - Definition Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation. + References Reference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> - Name Accounting Standards Codification - Section 50 - Paragraph 2 - SubTopic 10 - Topic 505 - Publisher FASB - URI <https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference> 2: <http://fasb.org/us-gaap/role/ref/legacyRef> - Topic 210 - SubTopic 10 - Name Accounting Standards Codification - Section S99 - Paragraph 1 - Subparagraph (SX 210.5-02(29)) - Publisher FASB - URI <https://asc.fasb.org/1943274/2147480566/210-10-50-1Reference> 3: <http://www.xbrl.org/2003/role/disclosureRef> - Topic 946 - SubTopic 210 - Name Accounting Standards Codification - Section S99 - Paragraph 2 - Subparagraph (SX 210.6-05(4)) - Publisher FASB - URI <https://asc.fasb.org/1943274/2147479170/946-210-50-2Reference> 4: <http://www.xbrl.org/2009/role/commonPracticeRef> - Topic 946 - SubTopic 220 - Name Accounting Standards Codification - Section S99 - Paragraph 3 - Subparagraph (SX 210.6-09(4)(b)) - Publisher FASB - URI <https://asc.fasb.org/1943274/2147479134/946-220-50-3Reference> 5: <http://www.xbrl.org/2003/role/disclosureRef> - Topic 946 - SubTopic 210 - Name Accounting Standards Codification - Section S99 - Paragraph 1 - Subparagraph (SX 210.6-04(16)(a)) - Publisher FASB - URI <https://asc.fasb.org/1943274/2147479170/946-210-50-3Reference> 6: <http://www.xbrl.org/2009/role/commonPracticeRef> - Topic 946 - SubTopic 220 - Name Accounting Standards Codification - Section S99 - Paragraph 3 - Subparagraph (SX 210.6-09(7)) - Publisher FASB - URI <https://asc.fasb.org/1943274/2147479134/946-220-50-3Reference> + Details Name: us-gaap_CommonStockSharesOutstanding Namespace Prefix: us-gaap Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - Definition A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period. + References No definition available. + Details Name: us-gaap_IncreaseDecreaseInStockholdersEquityRollForward Namespace Prefix: us-gaap Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Definition The portion of profit or loss for the period, net of income taxes, which is attributable to the parent. + References Reference 1: <http://www.xbrl.org/2003/role/disclosureRef> - Topic 250 - SubTopic 10 - Name Accounting Standards Codification - Section 50 - Paragraph 6 - Publisher FASB - URI <https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference> 2: <http://www.xbrl.org/2003/role/disclosureRef> - Topic 250 - SubTopic 10 - Name Accounting Standards Codification - Section 50 - Paragraph 9 - Publisher FASB - URI <https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference> 3: <http://www.xbrl.org/2003/role/disclosureRef> - Topic 805 - SubTopic 60 - Name Accounting Standards Codification - Section 65 - Paragraph 1 - Subparagraph (g) - Publisher FASB - URI <https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference> 4: <http://www.xbrl.org/2003/role/disclosureRef> - Topic 740 - SubTopic 323 - Name Accounting Standards Codification - Section 65 - Paragraph 2 - Subparagraph (g)(3) - Publisher FASB - URI <https://asc.fasb.org/1943274/2147478667/740-323-65-2Reference> 5: <http://fasb.org/us-gaap/role/ref/legacyRef> - Topic 220 - SubTopic 10 - Name Accounting Standards Codification - Section S99 - Paragraph 2 - Subparagraph (SX 210.5-03(20)) - Publisher FASB - URI <https://asc.fasb.org/1943274/2147483621/220-10-50-3Reference> 6: <http://www.xbrl.org/2003/role/disclosureRef> - Topic 235 - SubTopic 10 - Name Accounting Standards Codification - Section S99 - Paragraph 1 - Subparagraph (SX 210.4-08(g)(1)(ii)) - Publisher FASB - URI <https://asc.fasb.org/1943274/2147480678/235-10-50-1Reference> 7: <http://www.xbrl.org/2003/role/disclosureRef> - Topic 323 - SubTopic 10 - Name Accounting Standards Codification - Section 50 - Paragraph 3 - Subparagraph (c) - Publisher FASB - URI <https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference> 8: <http://www.xbrl.org/2003/role/disclosureRef> - Topic 825 - SubTopic 10 - Name Accounting Standards Codification - Section 50 - Paragraph 28 - Subparagraph (f) - Publisher FASB - URI <https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference> 9: <http://www.xbrl.org/2003/role/disclosureRef> - Topic 220 - SubTopic 10 - Name Accounting Standards Codification - Section 50 - Paragraph 6 - Publisher FASB - URI <https://asc.fasb.org/1943274/2147482765/220-10-50-6Reference> 10: <http://www.xbrl.org/2003/role/disclosureRef> - Topic 250 - SubTopic 10 - Name Accounting Standards Codification - Section 50 - Paragraph 3 - Publisher FASB - URI <https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference> 11: <http://www.xbrl.org/2003/role/disclosureRef> - Topic 250 - SubTopic 10 - Name Accounting Standards Codification - Section 50 - Paragraph 1 - Subparagraph (b)(2) - Publisher FASB - URI <https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference> 12: <http://www.xbrl.org/2003/role/disclosureRef> - Topic 815 - SubTopic 40 - Name Accounting Standards Codification - Section 65 - Paragraph 1 - Subparagraph (f) - Publisher FASB - URI <https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference> 13: <http://www.xbrl.org/2003/role/disclosureRef> - Topic 250 - SubTopic 10 - Name Accounting Standards Codification - Section 50 - Paragraph 8 - Publisher FASB - URI <https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference> 14: <http://www.xbrl.org/2003/role/disclosureRef> - Topic 250 - SubTopic 10 - Name Accounting Standards Codification - Section 50 - Paragraph 11 - Subparagraph (a) - Publisher FASB - URI <https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference> 15: <http://www.xbrl.org/2003/role/disclosureRef> - Topic 250 - SubTopic 10 - Name Accounting Standards Codification - Section 50 - Paragraph 11 - Subparagraph (b) - Publisher FASB - URI <https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference> 16: <http://www.xbrl.org/2003/role/disclosureRef> - Topic 250 - SubTopic 10 - Name Accounting Standards Codification - Section 50 - Paragraph 4 - Publisher FASB - URI [https://asc.fasb.org/1943274/2147483443/2](https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference)

Standards Codification -Section 55 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12Reference 6:

Paragraph 2 - Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2 + Details Name: us-gaap_IncomeTaxPaid Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseInAccountsPayable Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe increase (decrease) during the reporting period in the account that represents the temporary difference that results from Income or Loss that is recognized for accounting purposes but not for tax purposes and vice versa. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseInDeferredIncomeTaxes Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_IncreaseDecreaseInOperatingCapitalAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of increase (decrease) in obligation for operating lease. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (g)(1) -SubTopic 20 -Topic 842 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4 + Details Name: us-gaap_IncreaseDecreaseInOperatingLeaseLiability Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of increase (decrease) in noncurrent assets classified as other. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseInOtherNoncurrentAssets Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of increase (decrease) in prepaid expenses, and assets classified as other. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24 + Details Name: us-gaap_NetCashProvidedByUsedInFinancingActivities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24 + Details Name: us-gaap_NetCashProvidedByUsedInInvestingActivities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25 + Details Name: us-gaap_NetCashProvidedByUsedInOperatingActivities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 17: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 32: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 37: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 + Details Name: us-gaap_NetIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of loss from impairment of right-of-use asset from operating lease. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 25 -Paragraph 6 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479365/842-20-25-6 + Details Name: us-gaap_OperatingLeaseImpairmentLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe cash outflow for cost incurred directly with the issuance of an equity security. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15 + Details Name: us-gaap_PaymentsOfStockIssuanceCosts Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 13 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13 + Details Name: us-gaap_PaymentsToAcquirePropertyPlantAndEquipment Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe cash inflow from the additional capital contribution to the entity. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14 + Details Name: us-gaap_ProceedsFromIssuanceOfCommonStock Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of cash inflow from exercise of option under share-based payment arrangement. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2A -Subparagraph (a) -SubTopic 10 -Topic 718 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2A + Details Name: us-gaap_ProceedsFromStockOptionsExercised Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8 + Details Name: us-gaap_RestrictedCashCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of increase in right-of-use asset obtained in exchange for operating lease liability. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 53 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (g)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4 + Details Name: us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_SupplementalCashFlowInformationAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 17 R7.htm IDEA: XBRL DOCUMENT v3.24.2u1 Nature of the Business 6 Months Ended Jun 30,

2024 Organization, Consolidation and Presentation of Financial Statements [Abstract] A Nature of the Business Nature of the BusinessAutolus Therapeutics plc (with its subsidiaries, collectively, theAutolus or theCompany) is a biopharmaceutical company developing next-generation programmed T cell therapies for the treatment of cancer and autoimmune diseases. Using its broad suite of proprietary and modular T cell programming technologies, the Company is engineering precisely targeted, controlled and highly active T cell therapies that are designed to better recognize target cells, break down their defense mechanisms and attack and kill these cells. The Company believes its programmed T cell therapies have the potential to be best-in-class and to offer patients substantial benefits over the existing standard of care, including the potential for cure in some patients. In November 2023, the Company submitted a Biologics License Application (theBLA) to the U.S. Food and Drug Administration (theFDA) for its lead product candidate obecabtagene autoleucel (theobe-cel) for the treatment of relapsed/refractory (the/r) adult B-cell Acute Lymphoblastic Leukemia (theB-ALL), with a Prescription Drug User Fee Act (thePDUFA) target action date of November 16, 2024.Autolus Therapeutics plc is registered in England and Wales. Its registered office is The MediaWorks, 191 Wood Lane, London, W12 7FP, United Kingdom.The Company is subject to risks and uncertainties common to companies in the biotechnology industry, including, but not limited to, development by competitors of new technological innovations, dependence on key personnel, protection of proprietary technology, compliance with government regulations and the ability to secure additional capital to fund operations. Obe-cel and the Company's other product candidates currently under development will require significant additional research and development efforts, including preclinical and clinical testing and regulatory approval, prior to commercialization. Even if obe-cel is approved by the FDA, the Company will need to incur significant additional costs to prepare for its commercialization. These efforts will require significant amounts of capital, adequate personnel and infrastructure and extensive compliance capabilities. Even if the Company's product development efforts for obe-cel and its other product candidates are successful, it is uncertain when, if ever, the Company will realize revenue from its product sales.BioNTech AgreementsOn February 6, 2024 (theExecution Date), the Company concurrently entered into a (i) Securities Purchase Agreement (theBioNTech Securities Purchase Agreement), (ii) a Registration Rights Agreement (theBioNTech Registration Rights Agreement), (iii) a Letter Agreement (theBioNTech Letter Agreement) and (iv) a License and Option Agreement (theBioNTech License and Option Agreement), collectively called theBioNTech Agreements, with BioNTech. The BioNTech Agreements were entered into and in contemplation of one another and, accordingly, the Company assessed the accounting for these agreements in the aggregate. The following descriptions of the BioNTech Agreements do not purport to be complete and are qualified in their entirety by reference to the full text of such agreements.(i) BioNTech Securities Purchase AgreementPursuant to the BioNTech Securities Purchase Agreement the Company sold to BioNTech ADSs, each representing one ordinary share with a nominal value of \$0.00042 per share, of the Company (theOrdinary Shares) in a private placement transaction (thePrivate Placement). On February 13, 2024, the Company completed the Private Placement of 33,333,333 ADSs (theInitial ADSs), representing 33,333,333 Ordinary Shares at an offering price of \$6.00 per Initial ADS. Aggregate net proceeds to the Company, after underwriting discounts and offering expenses, were \$193.8 million. In the event that BioNTech and the Company enter into a Manufacturing and Commercial Services Agreement (as defined below) within 18 months of the initial closing of the Private Placement, BioNTech will purchase additional ADSs (theSubsequent ADSs and, together with the Initial ADSs, thePrivate Placement ADSs), not to exceed 15,000,000 ADSs, for an aggregate purchase price of up to \$20.0 million. The total number of Subsequent ADSs that may be issued is subject to additional limitations and restrictions. The BioNTech Securities Purchase Agreement contains customary representations, warranties, and covenants of each of the Company and BioNTech.(ii) BioNTech Registration Rights Agreement Pursuant to the BioNTech Registration Rights Agreement the Company agreed to file a registration statement with the SEC to register the resale of the Private Placement ADSs. (iii) BioNTech Letter AgreementThe BioNTech Letter Agreement provides BioNTech with certain additional rights and subjects BioNTech's investment in the Company to certain restrictions. BioNTech received the right to nominate a director to the Company's board of directors. If BioNTech acquires beneficial ownership of at least 30% of the issued and outstanding Ordinary Shares of the Company (including in the form of ADSs) within five years of the Execution Date, BioNTech will have the right to designate an additional director who shall be independent. BioNTech's director nomination rights shall automatically terminate upon BioNTech's ownership of Ordinary Shares dropping below certain specified percentages. Additionally, BioNTech has the right to purchase equity securities sold by the Company in bona fide financing transactions in amounts that are based on BioNTech maintaining specified ownership thresholds following such financing transactions.Subject to specified exceptions, BioNTech may not sell the Private Placement ADSs without the Company's approval for a period of six months following the applicable closing date for such ADSs.The BioNTech Letter Agreement terminates upon the earlier of (a) the later of (i) February 6, 2027 and (ii) such time as no securities of the Company are held by BioNTech or its affiliates and (b) the consummation of a change of control transaction involving the Company.(iv) BioNTech License and Option AgreementLicense and OptionsThe Company, through its wholly owned subsidiaries, Autolus Limited and Autolus Holdings (U.K.) Limited, entered into the BioNTech License and Option Agreement with BioNTech pursuant to which the Company granted to BioNTech an exclusive, worldwide, sublicensable license (theBinder License) to certain binders and to exploit products that express in vivo such binders (collectively, theBinder Licensed Products), and several time-limited options (theOptions) to acquire additional rights to specified clinical-stage product candidates, binders and technologies of the Company, described in more detail below:an option to obtain exclusive rights to co-fund development costs of the Company's development-stage programs AUTO1/22 and AUTO6NG (theProduct Options), in return for agreed upon economic terms, including an option exercise fee, milestone payments and a profit-sharing arrangement for each such product candidate, with additional options to co-promote or co-commercialize each such product candidate;an option to obtain an exclusive worldwide license to exploit products that express certain additional binders in vivo or, with respect to certain binders, in an antibody drug conjugate (theBinder Option);an option to obtain a co-exclusive worldwide license to exploit products that express in vivo the Company's modules for activity enhancement, with a non-exclusive right, in certain agreed instances, to exploit products that include Company's modules for activity enhancement but do not express in vivo such modules (theActivity Enhancement Option); andan option to obtain a non-exclusive worldwide license to exploit products that contain the Company's safety switches (theSafety Switch Option) and, together with the Binder Option and the Activity Enhancement Option, theTechnology Options.In consideration for the Binder License and the Technology Options, BioNTech made an initial payment to the Company of \$10.0 million. In the event that all Options are fully exercised, the Company would be eligible to receive maximum aggregate payments of up to \$582.0 million pursuant to the License Agreement. This maximum amount includes the potential milestone payments for the Binder Licensed Products described below, all option exercise fees and potential milestone payments for licenses to optioned products and technologies, and additional payments that BioNTech may pay to the Company for an increased revenue interest with respect to the Company's product candidate obe-cel as described below.The option exercise fee for each Technology Option is a low seven-digit amount. Each of the Activity Enhancement Option and the Safety Switch Option must be exercised with respect to a given biological target or combination of targets. There is a cap on the total option exercise fee if multiple options are exercised with respect to a given target. There is also a cap on milestone payments across all agreements entered into as the result of BioNTech exercising one or more of the Technology Options and a cap on the royalty rate payable on any given product for which multiple Options are exercised.Obe-cel Product Revenue InterestBioNTech has also agreed to financially support the expansion of the clinical development program for, and planned commercialization of obe-cel. In exchange for the grant of rights to future revenues from the sales of obe-cel products, BioNTech made an upfront payment to the Company of \$40.0 million. The Company will pay BioNTech a low single-digit percentage of annual net sales of obe-cel products, which may be increased up to a mid-single digit percentage in exchange for milestone payments of up to \$100.0 million in the aggregate on achievement of certain regulatory events for specific new indications upon BioNTech's election.Manufacturing and Commercial Services AgreementUnder the terms of the BioNTech License and Option Agreement, the Company has agreed to grant BioNTech the option to negotiate a joint manufacturing and commercial services agreement pursuant to which the parties may access and leverage each other's manufacturing and commercial capabilities, in addition to Autolus' commercial site network and infrastructure, with respect to certain of each parties' CAR T products, including BioNTech's product candidate BNT211 (theManufacturing and Commercial Services Agreement or theMCSA). The MCSA, if entered into, would also grant BioNTech access to the Company's commercial site network and infrastructure. The Company concluded there were four freestanding financial instruments arising from the execution of the BioNTech Agreements, comprising:1. the Initial ADSs representing ordinary shares purchased pursuant to the BioNTech Securities Purchase Agreement;2. the potential Subsequent ADSs representing ordinary shares that may be purchased pursuant to the BioNTech Securities Purchase Agreement;3. the BioNTech License and Option Agreement, and4. the MCSA. The Subsequent ADSs are classified as a forward instrument contingent on the MCSA being executed. As of June 30, 2024, the MCSA had not been entered into. The forward instrument has an inconsequential market value as the exercise price approximates the Company's stock price on the last trading day prior to the signing date of the MCSA. Consequently, the initial proceeds arising from the purchase of Initial ADSs pursuant to the BioNTech Securities Purchase Agreement will not be separately allocated to this freestanding financial instrument at inception of the BioNTech Agreements. Furthermore, as the MCSA has yet to be entered into no consideration will be allocated to this freestanding financial instrument at inception of the BioNTech Agreements. Within the BioNTech License and Option Agreement, there are a number of embedded features which have each been assessed for freestanding financial instrument accounting in accordance with Accounting Standards Codification (theASC) 480 "Distinguishing Liabilities from Equity. Although these embedded features are separately exercisable, they lack legal detachability and, therefore, the BioNTech License and Option Agreement is accounted for as one freestanding financial instrument. However, each embedded feature is assessed for derivative accounting in accordance to ASC 815 "Derivative and Hedging (theASC 815). The Company analyzed how it should account for the host Contract (i.e., the BioNTech License and Option Agreement) as the Binder License represents an agreement with customer for goods and services and therefore should be accounted for under ASC 606 "Revenue from Contracts with Customers (theASC 606). However, as the other embedded features of the BioNTech License and Option Agreement fall under the scope of other topics that specify how to initially measure the contract (i.e., ASC 470 "Debt (theASC 470)), the Company determined that the host contract should not be accounted for and initially measured pursuant to ASC 606. Furthermore, the Company determined the host contract (theBioNTech License and Option Agreement) met the scope exception of ASC 815-10-15-59(d) and therefore should not be accounted for as a derivative under ASC 815 but instead be accounted for as a debt financial instrument in accordance with ASC 470. The four units of accounting were recorded at fair value upon initial recognition and will not be subsequently measured at fair value. The Company allocated the total gross proceeds arising from the BioNTech Securities Purchase Agreement (i.e. the Initial ADSs representing ordinary shares), and the BioNTech License and Option Agreement among the four units of accounting on a relative fair value basis at the time of the transaction as follows:Units of AccountingGross proceeds (in millions)Initial fair value (in millions)Allocated consideration based on relative fair value (in millions)Net allocated consideration based on relative fair value after transaction costs*(in millions)Initial ADSs, representing ordinary shares\$200.0A \$200.0A \$200.0A \$193.8A Subsequent ADSs, representing ordinary shares\$A \$A \$A \$A BioNTech License and Option Agreement\$50.0A \$50.0A \$50.0A \$47.9A Liabilities related to future royalties and milestones, net (Obe-cel Product Revenue Interest)\$40.0A \$40.0A \$40.0A \$38.3A License Revenue (Binder License)\$10.0A \$10.0A \$10.0A \$9.6A MCSA\$A \$A \$A \$A Total\$250.0A \$250.0A \$250.0A \$241.7A * In addition, the total shared transaction costs of \$8.3 million, relating to the BioNTech Agreements have been allocated to the four units of accounting on a relative fair value basis. X - DefinitionThe entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef-Name Accounting Standards Codification -Topic 275 -Publisher FASB -URI https://asc.fasb.org/275/tableOfContent>Reference 2:

developing and commercializing CAR T therapies. Use of Estimates The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of income and expenses during the reporting periods. Significant estimates and assumptions reflected in these consolidated financial statements include, but are not limited to, the accrual for research and development expenses, share-based compensation including assessing the probability of meeting performance conditions, income taxes, initial fair value of warrants, and interest expense on liability related to future royalties and milestones, net and related cumulative catch-up adjustment, initial lease term of the Company's new manufacturing facility (The Nucleus), incremental borrowing rates related to the Company's leased properties and allocation of transaction price using the relative standalone selling price. Estimates are periodically reviewed in light of changes in circumstances, facts and experience. Actual results could differ from those estimates. Allocation of transaction price using the relative standalone selling price Upfront payments are allocated between performance obligations using the Company's best estimate of the relative standalone selling price of the performance obligation. The relative standalone selling price is estimated by determining the market values of development and license obligations. As these inputs are not directly observable, the estimate is determined considering all reasonably available information including internal pricing objectives used in negotiating the contract, taking into account the different stage of development of each development program and consideration of adjusted-market data from comparable arrangements. Where performance obligations have been identified relating to material rights, the determination of the relative standalone selling price of these performance obligations also includes an assessment of the likelihood that the options will be exercised and any payments by the customer that are triggered upon exercising the right. This assessment involves significant judgment and could have a significant impact on the amount and timing of revenue recognition. An assessment of the allocation of transaction price using the relative standalone selling price was required for the three and six months ended June 30, 2024 and 2023 for the BioNTech License and Option Agreement and the Option and License Agreement with Cabaletta Bio Inc. (Cabaletta), respectively. See Note 3 for additional information on the allocation of the transaction price for those agreements. Liability related to future royalties and milestones, net and cumulative catch-up adjustments The Company accounted for each of the Blackstone Collaboration Agreement (See Note 12) and the Blackstone Collaboration Agreement Liability and the BioNTech Obe-cel Product Revenue Interest (BioNTech Liability) as liabilities measured at amortized cost based on an effective interest rate determined at the outset of the arrangement. The Blackstone Collaboration Agreement Liability related to future royalties and milestones, net is measured based on the Company's current estimates of the timing and amount of expected future royalties, milestone payments to be paid and the milestones receivable upon the achievement of certain specified clinical, manufacturing and regulatory milestones (each such payment, a Blackstone Development Payment and collectively, the Blackstone Development Payments) expected to be received over the estimated term of the agreement. Similarly, the BioNTech Liability related to future royalties is measured based on the Company's current estimates of the timing and amount of expected future royalty expected to be paid over the estimated term of the agreement. Milestone payments pursuant to the BioNTech License and Option Agreement (BioNTech Milestone Payments) are payable upon BioNTech's election, and therefore have not been included in the determination of the effective interest rate or in the measurement of the liability. The liabilities are amortized using the effective interest rate, resulting in recognition of interest expense over the estimated term of the agreement. Each reporting period the Company assesses the estimated probability, timing and amount of the future expected royalty, milestone payments, the Blackstone Development Payment over the estimated term. If there are changes to the estimates, the Company recognizes the impact to the liability's amortization schedule and the related interest expense using the catch-up method. The Company's estimate of the probability, timing and amount of expected future royalties and milestones to be paid by the Company and the expected Blackstone Development Payment to be paid to the Company, considers significant unobservable inputs. These inputs include regulatory approval, the estimated patient population, estimated selling price, estimated sales, estimated peak sales and sales ramp, timing of the expected launch and its impact on the royalties as well as the overall probability of a success. Additionally, the transaction costs associated with the liability will be amortized to interest expense over the estimated term of the agreements. The carrying amount of the Blackstone Collaboration Agreement Liability and BioNTech Liability is based on the Company's estimate of the future royalties, milestones to be paid to Blackstone by the Company and the expected Blackstone Development Payment to be received over the life of the arrangement as discounted using the initial effective interest rate. The excess estimated present value of future royalty, milestone payments and the future Blackstone Development Payment received over the carrying amount is recognized as a cumulative catch-up adjustment within interest expense using the effective interest rate. Recent Accounting Pronouncements Not Yet Adopted In November 2023, the Financial Accounting Standards Board, (FASB), issued Accounting Standards Update, or ASU, 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures, or ASU 2023-07, which expanded the disclosures for reportable segments made by public entities. These amendments within ASU 2023-07 retained the existing disclosure requirements in ASC 280 - Segment Reporting and expanded upon them to require public entities to disclose significant expenses for reportable segments in both interim and annual reporting periods, as well as items that were previously disclosed only annually on an interim basis, including disclosures related to a reportable segment's profit or loss and assets. In addition, entities with a single reportable segment must provide all segment disclosures required in ASC 280, including the new disclosures for reportable segments under the amendments in ASU 2023-07. The amendments did not change the existing guidance on how a public entity identified and determined its reportable segments. A public entity should apply the amendments in ASU 2023-07 retrospectively to all prior periods presented in the financial statements. Upon transition, the segment expense categories and amounts disclosed in the prior periods should be based on the significant segment expense categories identified and disclosed in the period of adoption. The amendments in ASU 2023-07 are effective for annual periods for all public entities in fiscal years beginning after December 15, 2023, and in interim periods within fiscal years beginning after December 15, 2024. The Company will comply with any new applicable disclosures in its Annual Report on Form 10-K for the year ending December 31, 2024. The Company does not expect the adoption to have a material effect on its financial statements and related disclosures. In December 2023, the FASB issued ASU 2023-09, Improvements to Income Tax Disclosures. This ASU improves the transparency of income tax disclosure by requiring consistent categories and greater disaggregation of information in the rate reconciliation, and income taxes paid disaggregated by jurisdiction. This guidance is effective for the Company for the year beginning January 1, 2025, with early adoption permitted. The amendments should be applied on a prospective basis, with retrospective application permitted. The Company intends to adopt the guidance in the fiscal year beginning January 1, 2025. The Company does not expect the adoption of ASU 2023-09 to have a material effect on its financial statements and related disclosures. Unless otherwise discussed, the impact of recently issued standards that are not yet effective are not expected to have a material impact on the Company's consolidated financial statements and disclosures in this report and for the full year ending December 31, 2024. X - References No definition available. + Details Name: us-gaap_AccountingPoliciesAbstract Namespace Prefix: us-gaap_ Data Type: xbrl:stringItemType Balance Type: na Period Type: duration X - Definition The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). Accounting policies describe all significant accounting policies of the reporting entity. + References Reference 1: <http://www.xbrl.org/2003/role/disclosureRef-Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-9> Reference 2: [http://www.xbrl.org/2003/role/disclosureRef-Topic 606 -SubTopic 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-10](http://www.xbrl.org/2003/role/disclosureRef-Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-10) Reference 3: <http://www.xbrl.org/2003/role/disclosureRef-Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-15> Reference 4: [http://www.xbrl.org/2003/role/disclosureRef-Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12](http://www.xbrl.org/2003/role/disclosureRef-Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12) Reference 5: [http://www.xbrl.org/2003/role/disclosureRef-Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Subparagraph \(b\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12](http://www.xbrl.org/2003/role/disclosureRef-Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12) Reference 6: [http://www.xbrl.org/2003/role/disclosureRef-Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Subparagraph \(c\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12](http://www.xbrl.org/2003/role/disclosureRef-Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12) Reference 7: [http://www.xbrl.org/2003/role/disclosureRef-Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Subparagraph \(d\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12](http://www.xbrl.org/2003/role/disclosureRef-Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12)

<https://asc.fasb.org/1943274/2147479806/606-10-50-12>Reference 8: [http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Subparagraph \(e\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12](http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12)Reference 9: [http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph \(b\)\(2\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-13](http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-13)Reference 10: [http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.9-04\(2\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1](http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 606 -Publisher FASB -URI https://asc.fasb.org/606/tableOfContent + Details Name: us-gaap RevenueFromContractWithCustomerTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItem Type Balance Type: na Period Type: duration XML 20 R10.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Interest expense 6 Months Ended Jun. 30, 2024 Banking and Thrift, Interest [Abstract] A Interest expense Interest expenseInterest expense consisted of the following (in thousands):Three Months Ended June 30,Six Months Ended June 30,2024202320242023Interest expense on liabilities related to future royalties and milestones, net (refer to Note 12)$10,169$4,959$18,559$9,864 Cumulative catch-up adjustment arising from the liabilities related to future royalties and milestones, net (refer to Note 12)$10,169$4,959$18,559$9,864 Total interest expense$51,174$5,020$29,443$9,925A X - ReferencesNo definition available. + Details Name: us-gaap BankingAndThriftInterestAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItem Type Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for interest income and interest expense for enterprises that derive a significant portion of their revenue from interest collected on investments, loans, and securities. + ReferencesReference 1: <a href=)Reference 2: [http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.9-04\(5\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1)Reference 3: [http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.9-04\(4\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1)Reference 4: [http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.9-04\(3\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1)Reference 5: [http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.9-04\(1\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1)Reference 6: [http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.9-04\(8\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1)Reference 7: [http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.9-04\(7\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1)Reference 8: [http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.9-04\(6\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(6)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1)Reference 9: [http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.9-04\(12\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(12)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1)Reference 10: [http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.9-04\(10\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(10)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1)Reference 11: [http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.9-04\(9\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1) + Details Name: us-gaap InterestIncomeAndInterestExpenseDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItem Type Balance Type: na Period Type: duration XML 21 R11.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Net loss per ordinary share 6 Months Ended Jun. 30, 2024 Earnings Per Share [Abstract] A Net loss per ordinary share Net loss per ordinary shareBasic and diluted net loss per ordinary share was calculated as follows (in thousands, except share and per share amounts):Three Months Ended June 30,Six Months Ended June 30,2024202320242023NumeratorNet loss\$(58,272)\$(45,552)\$(110,962)\$(85,363)Net loss - basic and diluted\$(58,272)\$(45,552)\$(110,962)\$(85,363)DenominatorWeighted-average number of ordinary shares(0.22)\$(0.26)\$(0.43)\$(0.49)For all periods presented, outstanding but unvested restricted stock units and share options have been excluded from the calculation, because their effects would be anti-dilutive. Therefore, the weighted average number of ordinary shares used to calculate both basic and diluted loss per share is the same for all periods presented. The following potentially dilutive securities have been excluded from the calculation of diluted net loss per share due to their anti-dilutive effect:Three and Six Months Ended June 30,20242023Unvested restricted stock units41,905\$ 315,460\$ Share options19,558,856\$ 14,203,439\$ Warrants3,265,306\$ 3,265,306\$ Total potentially dilutive securities22,866,067\$ 17,784,205\$ X - ReferencesNo definition available. + Details Name: us-gaap EarningsPerShareAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItem Type Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for earnings per share. + ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph \(c\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1)Reference 2: [http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph \(c\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1)Reference 3: <http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-2>Reference 4: <http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-3> + Details Name: us-gaap EarningsPerShareTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItem Type Balance Type: na Period Type: duration XML 22 R12.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Fair value measurements 6 Months Ended Jun. 30, 2024 Fair Value Disclosures [Abstract] A Fair value measurements Fair value measurementsThe Company uses valuation approaches that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible. The Company determines the fair value based on assumptions that market participants would use in pricing an asset or liability in the principal or most advantageous market. When considering market participant assumptions in fair value measurements, the following fair value hierarchy distinguishes between observable and unobservable inputs, which are categorized in of the following levels:â€¢Level 1 â€¢ Quoted prices in active markets for identical assets or liabilities.â€¢Level 2 â€¢ Inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly.â€¢Level 3 â€¢ Unobservable inputs that reflect the Companyâ€™s own assumptions about the assumptions market participants would use in pricing the asset or liability. The carrying amounts reported in the balance sheet for cash and cash equivalents, restricted cash, prepaid expenses and other assets, accounts payable and accrued expenses and other liabilities approximate their fair value because of the short-term nature of these instruments. The following tables present information about the Companyâ€™s financial assets measured at fair value on a recurring basis and indicate the level of the fair value hierarchy utilized to determine such fair values (in thousands):June 30, 2024TotalQuoted Prices in Active Markets for Identical Assets (Level 1)Significant Other Observable Inputs (Level 2)Significant Unobservable Inputs (Level 3)Financial assetsCash and cash equivalents:Money market funds\$528,910\$ 528,910\$ â€¢A â€¢A Totals\$528,910\$ 528,910\$ â€¢A â€¢A \$â€¢A December 31, 2023TotalQuoted Prices in Active Markets for Identical Assets (Level 1)Significant Other Observable Inputs (Level 2)Significant Unobservable Inputs (Level 3)Financial assetsCash and cash equivalents:Money market funds\$184,635\$ 184,635\$ â€¢A â€¢A Totals\$184,635\$ 184,635\$ â€¢A â€¢A \$â€¢A During the three and six months ended June 30, 2024 and the year ended December 31, 2023, there were no transfers between levels. X - ReferencesNo definition available. + Details Name: us-gaap FairValueDisclosuresAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItem Type Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information. + ReferencesReference 1: <http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 107 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-107>Reference 2: <http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 100 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100>Reference 3: [http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(c\)\(3\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2](http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2)Reference 4: [http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6A -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A](http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A)Reference 5: <http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2E -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2E>Reference 6: [http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6A -Subparagraph \(h\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A](http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6A -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A)Reference 7: [http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6A -Subparagraph \(f\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A](http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6A -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A)Reference 8: [http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6A -Subparagraph \(e\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A](http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6A -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A)Reference 9: [http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6A -Subparagraph \(d\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A](http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6A -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A)Reference 10: [http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(h\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2](http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2)Reference 11: [http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(g\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2](http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2)Reference 12: [http://www.xbrl.org/2003/role/disclosureRef -Topic 940 -SubTopic 820 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478119/940-820-50-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 940 -SubTopic 820 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478119/940-820-50-1) + Details Name: us-gaap FairValueDisclosuresTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItem Type Balance Type: na Period Type: duration XML 23 R13.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Prepaid Expenses and Other Current Assets 6 Months Ended Jun. 30, 2024 Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract] A Prepaid Expenses and Other Current Assets Prepaid Expenses and Other Current AssetsPrepaid expenses and other current assets consisted of the following (in thousands):June 30,December 31,20242023Research and development claims receivable\$27,750\$ 19,209\$ Prepayments\$11,865\$ 8,638\$ VAT receivable\$3,597\$ 2,771\$ Accrued interest income\$2,597\$ 999\$ Deferred cost\$1,782\$ 1,787\$ Other taxes receivable\$1,585\$ â€¢A Other receivables\$957\$ 516\$ Lease and lease deposit receivable\$938\$ 938\$ Corporate tax receivable\$570\$ â€¢A Accounts receivableâ€¢A 109\$ Total prepaid expenses and other current assets\$51,641\$ 34,967\$ X - ReferencesNo definition available. + Details Name: us-gaap DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItem Type Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for other current assets. + ReferencesNo definition available. + Details Name: us-gaap OtherCurrentAssetsTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItem Type Balance Type: na Period Type: duration XML 24 R14.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Property and Equipment, Net 6 Months Ended Jun. 30, 2024 Property, Plant and Equipment [Abstract] A Property and Equipment, Net Property and equipment, net consisted of the following (in thousands):June 30,December 31,20242023Lab equipments\$41,307\$ 332,232\$ Office equipments\$5,017\$ 3,777\$ Furniture and fixtures\$2,353\$ 2,360\$ Leasehold improvements\$14,220\$ 12,728\$ Assets under construction\$2,494\$ 12,539\$ Less: accumulated depreciation\$(32,286)\$(28,774)\$ Total property and equipment, net\$32,860\$ 34,862\$ Depreciation expense for the three months ended June 30, 2024 and 2023 was \$1.9 million and \$1.5 million, respectively, and for the six months ended June 30, 2024 and 2023 was \$3.7 million and \$3.4 million, respectively. X - ReferencesNo definition available. + Details Name: us-gaap PropertyPlantAndEquipmentAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItem Type Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef -Topic 360 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/360/tableOfContent>Reference 2: <http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 6 -SubTopic 360 -Topic 958 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477798/958-360-50-6>Reference 3: [http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph \(d\) -SubTopic 360 -Topic 958 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477798/958-360-50-1](http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -SubTopic 360 -Topic 958 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477798/958-360-50-1)Reference 4: <http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 7 -SubTopic 360 -Topic 958 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477798/958-360-50-7> + Details Name: us-gaap PropertyPlantAndEquipmentDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItem Type Balance Type: na Period Type: duration XML 25 R15.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Accrued Expenses and Other Liabilities 6 Months Ended Jun. 30, 2024 Payables and Accruals [Abstract] A Accrued Expenses and Other Liabilities Accrued Expenses and Other LiabilitiesAccrued expenses and other liabilities consisted of the following (in thousands):June 30,December 31,20242023Research and development costs\$17,930\$ 19,825\$ Compensation and benefits\$10,459\$ 14,757\$ Professional fees\$6,808\$ 4,466\$ Other accrued liabilities\$382\$ 533\$ Total accrued expenses and other liabilities\$35,579\$ 39,581\$ X - DefinitionThe entire disclosure for accounts payable and accrued liabilities at the end of the reporting period. + ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.5-02\(20\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1)Reference 2: [http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.5-02\(24\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(24)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1)Reference 3: <http://www.xbrl.org/2009/role/commonPracticeRef -Topic 720 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483384/720-30-45-1>Reference 4: [http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.5-02\(19\)\(a\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(19)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1) + Details Name: us-gaap AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItem Type Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap PayablesAndAccrualsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItem Type Balance Type: na Period Type: duration XML 26 R16.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Shareholdersâ€™ Equity 6 Months Ended Jun. 30, 2024 Equity [Abstract] A Shareholdersâ€™ Equity Shareholdersâ€™ EquityOrdinary SharesEach holder of ordinary shares is entitled to one vote per ordinary share and to receive dividends when and if such dividends are recommended by the Companyâ€™s board of directors and declared by the shareholders.Â As of June 30, 2024, the Company has not declared any dividends.Restricted Stock UnitsAt June 30, 2024, restricted stock unit awards for 100 ordinary shares had vested but the underlying shares had not been issued. However, these vested restricted stock unit awards have

been included in the calculation of the Company's outstanding shares at June 30, 2024 as they are considered issuable for little or no cash consideration. Subsequent to June 30, 2024, all of the underlying ordinary shares were issued. February 2024 Underwritten Offering On February 12, 2024, the Company completed an underwritten offering of 58,333,336 ADSs representing 58,333,336A ordinary shares at an offering price of \$6.00 per ADS. Aggregate net proceeds to the Company, after underwriting discounts and offering expenses, were \$326.8A million. BioNTech Securities Purchase Agreement Concurrently with the execution of the BioNTech License and Option Agreement (see Note 1 and Note 3), the Company and BioNTech entered into the BioNTech Securities Purchase Agreement pursuant to which the Company sold ADSs, each representing one ordinary share, to BioNTech in a Private Placement transaction. On February 13, 2024, the Company completed the Private Placement of 33,333,333 ADSs representing 33,333,333A ordinary shares at an offering price of \$6.00 per ADS. Aggregate net proceeds to the Company, after underwriting discounts and offering expenses, were \$193.8A million. In the event that BioNTech and the Company enter into the MCSA within 18 months of the initial closing of the Private Placement, BioNTech will purchase up to 15,000,000 ADSs for an aggregate purchase price of up to \$20.0A million, subject to additional limitations and restrictions. X - References No definition available. + Details Name: us-gaap_EquityAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Definition The entire disclosure for equity. + References Reference 1:

for non-cancellable operating subleases in effect as of June 30, 2024 are receivable as follows (in thousands):Remainder of 2024\$1302025\$2602026\$2032027\$1222028\$106Total lease payments receivable\$821 X - ReferencesNo definition available. + Details Name: us-gaap LeasesAbstract Namespace Prefix: us-gaap Data Type: xbrli:stringItem Type Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef-Topic 842-SubTopic 20-Name Accounting Standards Codification-Publisher FASB-URI https://asc.fasb.org/842-20/tableOfContent> + Details Name: us-gaap LesseeOperatingLeasesTextBlock Namespace Prefix: us-gaap Data Type: dtr-types:textBlockItem Type Balance Type: na Period Type: duration XML 30 R20.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Commitments and Contingencies 6 Months Ended Jun. 30, 2024 Commitments and Contingencies Disclosure [Abstract] A Commitments and Contingencies Commitments and ContingenciesLicense AgreementsThe Company has entered into an exclusive license agreement, as amended, with UCL Business Ltd (   UCLB  ). In connection with the UCLB license agreement, the Company is required to make annual license payments and may be required to make payments to UCLB upon the achievement of specified milestones. During the three and six months ended June 30, 2024, less than \$0.1 million was paid or payable to UCLB by the Company, relating to the income allocable to the value of the sublicensed intellectual property rights. In November 2019, the Company entered into an exclusive license agreement with Noile-Immune Biotech Inc. (   Noile  ) under which the Company will have the right to develop CAR T cell therapies incorporating Noile   s PRIME (proliferation-inducing and migration-enhancing) technology. The Company may be obligated to make additional payments to Noile upon the achievement of development milestones and receipt of regulatory approvals product sale milestones, as well as royalty payments based on possible future sales resulting from the utilization of the licensed technology.In September 2023, the Company entered into a non-exclusive sublicense agreement with Miltenyi Biotech B.V. & Co. KG (   Miltenyi  ) under which the Company received a sublicense related to the use of certain Miltenyi products in the Company   s development, manufacture and sale of its products. Under the agreement, the Company is obligated to make specified payments to Miltenyi upon the achievement of certain regulatory and clinical milestones. The Company recognized \$0.4   million of expense in aggregate relating to an upfront license payment and milestone payments that were deemed probable during the year ended December 31, 2023. The Company did not recognize any further milestone payments during the three and six months ended June 30, 2024.Contractual obligationsIn July 2022, the Company renegotiated a master services agreement with Adaptive Biotechnologies Corporation (   Adaptive  ), under which Adaptive  s assay is used to analyze patient samples from r/r B-ALL patients. Under the agreement, the Company is obligated to make specified payments to Adaptive upon the achievement and receipt of certain regulatory approvals and achievement of commercial milestones in connection with the Company   s use of the Adaptive assay. During the year ended December 31, 2023, the Company recognized all contractual milestones relating to this contract, and as a result no contractual milestones were recognized during the three and six months ended June 30, 2024.In previous periods, the Company has entered into agreements with certain advisory firms. The Company is obligated to make specified payments upon the achievement of certain strategic transactions involving the Company. During the three and six months ended June 30, 2024, the Company paid a fee under these agreements. The Company has estimated the probability of the Company achieving each potential milestone in relation to the agreements with UCLB, Noile, Miltenyi and its agreements with certain advisory firms in accordance with ASC 450. The Company considers the regulatory approval, commercial milestones and execution of collaboration agreements probable when actually achieved. Furthermore, the Company recognizes expenses for clinical milestones when their achievement is deemed probable. The Company concluded that, as of June 30, 2024, there were no other milestones for which the likelihood of achievement was currently probable.Capital CommitmentsAs of June 30, 2024, the Company   s unconditional purchase obligations for capital expenditures totaled \$9.7 million and included signed orders for capital equipment and capital expenditures for construction and related expenditures relating to its properties in the U.K. and the US. The Company expects to incur the full amount of these obligations within one year.Master Supply CommitmentsAs of June 30, 2024, the Company   s unconditional purchase obligations with Miltenyi Biotec GmbH for reagents and disposables totaled \$1.1 million, which the Company expects to incur within one year.Distribution CommitmentsThe Company entered into an Exclusive Distribution Agreement, effective as of April 25, 2024 (the    Effective Date  ), with Cardinal Health 105, LLC (   Cardinal Health  ). Pursuant to, and subject to the terms and conditions of, the Exclusive Distribution Agreement, the Company engaged Cardinal Health as its exclusive third-party logistics distribution agent for sales of obe-cel in the US. The Exclusive Distribution Agreement runs for an initial term of three years following commercial launch and automatically renews for additional terms of one year each, unless either party elects not to renew. In addition, the Company can terminate the Exclusive Distribution Agreement without cause, subject to the payment of termination fees if such termination occurs during the initial three-year term. Under the terms of the Exclusive Distribution Agreement, the Company must pay to Cardinal Health a one-time start-up fee, and if the Company proceeds with commercialization of obe-cel, upon its launch, a monthly account management fee, and other fees for various services, including post-launch program implementation, information systems, warehouse operations and financial services.Blackstone and BioNTech AgreementsRefer to Note 12,    Liabilities related to future royalties and milestones, net   for further details about the BioNTech Agreements and Blackstone Agreements.BioNTech License and Option Agreement - Product Options gain contingencyAs the Product Options within the BioNTech License and Option Agreement were an embedded feature within a freestanding financial instrument, the Company assessed if the Product Options should be accounted for as a derivative under ASC 815. However, the Company determined the Product Options met the scope exception for derivative accounting under ASC 815 and therefore should be accounted for a gain contingency under the scope of ASC 450. As of June 30, 2024, Product Options were not exercised and therefore no amounts were recognized.Legal ProceedingsFrom time to time, the Company may be a party to litigation or subject to claims incident to the ordinary course of business. Regardless of the outcome, litigation can have an adverse impact on the Company because of defense and settlement costs, diversion of management resources and other factors. The Company was not a party to any litigation and did not have contingency reserves established for any liabilities as of June 30, 2024 and December 31, 2023.Indemnification AgreementsIn the normal course of business, the Company enters into contracts and agreements that contain a variety of representations and warranties and provide for general indemnification. The Company   s exposure under these agreements is unknown because they involve claims that may be made against the Company in the future. To date, the Company has not paid any claims or been required to defend any action related to its indemnification obligations. However, the Company may record charges in the future as a result of these indemnification obligations.In accordance with the indemnification agreements entered into with relevant individuals in accordance with the Company   s Articles of Association, the Company has indemnification obligations to its directors, officers and members of senior management for certain events or occurrences, subject to certain limits, while they are serving at the Company   s request in such capacity. There have been no claims to date under these indemnification agreements, and the Company has director and officer insurance that may enable it to recover a portion of any amounts paid for future potential claims. X - ReferencesNo definition available. + Details Name: us-gaap CommitmentsAndContingenciesDisclosureAbstract Namespace Prefix: us-gaap Data Type: xbrli:stringItem Type Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for commitments and contingencies. + ReferencesReference 1: <http://www.xbrl.org/2009/role/commonPracticeRef-Topic 405-SubTopic 30-Name Accounting Standards Codification-Publisher FASB-URI https://asc.fasb.org/405-30/tableOfContent>Reference 2: [http://www.xbrl.org/2003/role/disclosureRef-Topic 440-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 4-Subparagraph \(a\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482648/440-10-50-4Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef-Topic 450-Name Accounting Standards Codification-Publisher FASB-URI https://asc.fasb.org/450/tableOfContent](http://www.xbrl.org/2003/role/disclosureRef-Topic 440-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 4-Subparagraph (a)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482648/440-10-50-4Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef-Topic 450-Name Accounting Standards Codification-Publisher FASB-URI https://asc.fasb.org/450/tableOfContent)Reference 4: [http://www.xbrl.org/2003/role/disclosureRef-Topic 954-SubTopic 440-Name Accounting Standards Codification-Section 50-Paragraph 1-Subparagraph \(a\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147478522/954-440-50-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef-Topic 440-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 4-Subparagraph \(c\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482648/440-10-50-4Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef-Topic 440-Name Accounting Standards Codification-Publisher FASB-URI https://asc.fasb.org/440/tableOfContent](http://www.xbrl.org/2003/role/disclosureRef-Topic 954-SubTopic 440-Name Accounting Standards Codification-Section 50-Paragraph 1-Subparagraph (a)-Publisher FASB-URI https://asc.fasb.org/1943274/2147478522/954-440-50-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef-Topic 440-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 4-Subparagraph (c)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482648/440-10-50-4Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef-Topic 440-Name Accounting Standards Codification-Publisher FASB-URI https://asc.fasb.org/440/tableOfContent) + Details Name: us-gaap CommitmentsAndContingenciesDisclosureTextBlock Namespace Prefix: us-gaap Data Type: dtr-types:textBlockItem Type Balance Type: na Period Type: duration XML 31 R21.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Related party transactions 6 Months Ended Jun. 30, 2024 Related Party Transactions [Abstract] A Related party transactions Related party transactionsBlackstone AgreementsIn November 2021, the Company concurrently entered into the Blackstone Agreements. As of the execution of the Blackstone Agreements, Blackstone became a related party of the Company, as Blackstone became the owner of more than 10% of the Company   s outstanding voting securities. In addition, Blackstone received and exercised its right to nominate one director to the board of directors of the Company and is therefore considered to be one of the principal owners of the Company.As of June 30, 2024, the carrying amount of the Blackstone Collaboration Agreement Liability was \$195.9 million which included aggregated cumulative non-cash interest expense and cumulative catch-up adjustment of \$25.0 million. As of December 31, 2023, the carrying amount of the Blackstone Collaboration Agreement Liability was \$170.9 million which included aggregated cumulative non-cash interest expense (including cumulative catch-up adjustments), of \$45.0   million. Refer to Note 12,    Liabilities related to future royalties and milestones, net   for further details.BioNTech AgreementsIn February 2024, the Company concurrently entered into the BioNTech Agreements. Upon the execution of the BioNTech Agreements, BioNTech became a related party of the Company. BioNTech owns more than 10% of the Company   s outstanding voting securities and is therefore one of the principal owners of the Company. In addition, BioNTech has the right to nominate one director to the board of directors of the Company which BioNTech has not yet exercised. As of June 30, 2024, the carrying amount of the BioNTech Liability was \$42.8 million which included aggregated cumulative interest expense and cumulative catch-up adjustment of \$2.7   million. Refer to Note 12,    Liabilities related to future royalties and milestones, net   for further details. X - ReferencesNo definition available. + Details Name: us-gaap RelatedPartyTransactionsAbstract Namespace Prefix: us-gaap Data Type: xbrli:stringItem Type Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates. + ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 20-Name Accounting Standards Codification-Section 50-Paragraph 2-Publisher FASB-URI https://asc.fasb.org/1943274/2147480990/946-20-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 20-Name Accounting Standards Codification-Section 50-Paragraph 5-Publisher FASB-URI https://asc.fasb.org/1943274/2147480990/946-20-50-5Reference 3: http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 20-Name Accounting Standards Codification-Section 50-Paragraph 6-Publisher FASB-URI https://asc.fasb.org/1943274/2147480990/946-20-50-6Reference 4: http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 235-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph \(c\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147477968/946-235-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 235-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph \(e\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147477968/946-235-50-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef-Topic 850-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 1-Subparagraph \(d\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147483326/850-10-50-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 220-Name Accounting Standards Codification-Section 50-Paragraph 1-Subparagraph \(b\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147479134/946-220-50-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 220-Name Accounting Standards Codification-Section 50-Paragraph 1-Subparagraph \(c\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147479134/946-220-50-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 220-Name Accounting Standards Codification-Section 50-Paragraph 1-Subparagraph \(e\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147479134/946-220-50-1Reference 10: http://www.xbrl.org/2003/role/disclosureRef-Topic 850-Name Accounting Standards Codification-Publisher FASB-URI https://asc.fasb.org/850/tableOfContent](http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 20-Name Accounting Standards Codification-Section 50-Paragraph 2-Publisher FASB-URI https://asc.fasb.org/1943274/2147480990/946-20-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 20-Name Accounting Standards Codification-Section 50-Paragraph 5-Publisher FASB-URI https://asc.fasb.org/1943274/2147480990/946-20-50-5Reference 3: http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 20-Name Accounting Standards Codification-Section 50-Paragraph 6-Publisher FASB-URI https://asc.fasb.org/1943274/2147480990/946-20-50-6Reference 4: http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 235-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph (c)-Publisher FASB-URI https://asc.fasb.org/1943274/2147477968/946-235-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 235-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph (e)-Publisher FASB-URI https://asc.fasb.org/1943274/2147477968/946-235-50-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef-Topic 850-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 1-Subparagraph (d)-Publisher FASB-URI https://asc.fasb.org/1943274/2147483326/850-10-50-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 220-Name Accounting Standards Codification-Section 50-Paragraph 1-Subparagraph (b)-Publisher FASB-URI https://asc.fasb.org/1943274/2147479134/946-220-50-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 220-Name Accounting Standards Codification-Section 50-Paragraph 1-Subparagraph (c)-Publisher FASB-URI https://asc.fasb.org/1943274/2147479134/946-220-50-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 220-Name Accounting Standards Codification-Section 50-Paragraph 1-Subparagraph (e)-Publisher FASB-URI https://asc.fasb.org/1943274/2147479134/946-220-50-1Reference 10: http://www.xbrl.org/2003/role/disclosureRef-Topic 850-Name Accounting Standards Codification-Publisher FASB-URI https://asc.fasb.org/850/tableOfContent)Reference 11: [http://www.xbrl.org/2003/role/disclosureRef-Topic 850-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 6-Publisher FASB-URI https://asc.fasb.org/1943274/2147483326/850-10-50-6Reference 12: http://www.xbrl.org/2003/role/disclosureRef-Topic 850-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 1-Subparagraph \(a\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147483326/850-10-50-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef-Topic 850-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 1-Subparagraph \(b\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147483326/850-10-50-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 850-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 6-Publisher FASB-URI https://asc.fasb.org/1943274/2147483326/850-10-50-6Reference 12: http://www.xbrl.org/2003/role/disclosureRef-Topic 850-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 1-Subparagraph (a)-Publisher FASB-URI https://asc.fasb.org/1943274/2147483326/850-10-50-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef-Topic 850-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 1-Subparagraph (b)-Publisher FASB-URI https://asc.fasb.org/1943274/2147483326/850-10-50-1) + Details Name: us-gaap RelatedPartyTransactionsDisclosureTextBlock Namespace Prefix: us-gaap Data Type: dtr-types:textBlockItem Type Balance Type: na Period Type: duration XML 32 R22.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Subsequent Events 6 Months Ended Jun. 30, 2024 Subsequent Events [Abstract] A Subsequent EventsSubsequent EventsThe Company evaluated subsequent events through August 8, 2024, the date on which these unaudited condensed consolidated financial statements were issued. The Company has concluded that no subsequent event has occurred that requires disclosure. X - ReferencesNo definition available. + Details Name: us-gaap SubsequentEventsAbstract Namespace Prefix: us-gaap Data Type: xbrli:stringItem Type Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef-Topic 855-Name Accounting Standards Codification-Publisher FASB-URI https://asc.fasb.org/855/tableOfContent>Reference 2: [http://www.xbrl.org/2003/role/disclosureRef-Topic 855-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph \(a\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147483399/855-10-50-2](http://www.xbrl.org/2003/role/disclosureRef-Topic 855-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph (a)-Publisher FASB-URI https://asc.fasb.org/1943274/2147483399/855-10-50-2) + Details Name: us-gaap SubsequentEventsTextBlock Namespace Prefix: us-gaap Data Type: dtr-types:textBlockItem Type Balance Type: na Period Type: duration XML 33 R23.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Pay vs Performance Disclosure - USD (\$) \$ in Thousands 3 Months Ended 6 Months Ended Jun. 30, 2024 Mar. 31, 2024 Jun. 30, 2023 Mar. 31, 2023 Jun. 30, 2024 Jun. 30, 2023 Pay vs Performance Disclosure A A A A Net loss \$ (58,272) \$ (52,690) \$ (45,552) \$ (39,811) \$ (110,962) X - ReferencesReference 1:

https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 17: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 32: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 37: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 + Details Name: us-gaap_NetIncomeLoss Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration XML 34 R24.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Insider Trading Arrangements 3 Months Ended Jun. 30, 2024 shares Jun. 30, 2024 shares Trading Arrangements, by Individual A A Non-Rule 10b5-1 Arrangement Adopted false A Rule 10b5-1 Arrangement Terminated false A Non-Rule 10b5-1 Arrangement Terminated false A Martin Pule [Member] A A Trading Arrangements, by Individual A A Material Terms of Trading Arrangement A On June 14, 2024, Martin Pule, our Chief Scientific Officer, adopted a Rule 10b5-1 trading arrangement as defined in Item 408(a) of Regulation S-K, which is intended to satisfy the affirmative defense of Rule 10b5-1(c). The sales plan has an initial term ending on March 21, 2025 and covers the sale of a total of 698,741 ADSs, each representing one ordinary share with a nominal value of \$0.000042 per share, of the Company. Name Martin Pule A Title Chief Scientific Officer A Rule 10b5-1 Arrangement Adopted true A Adoption Date June 14, 2024 A Expiration Date March 21, 2025 A Arrangement Duration 280 days A Aggregate Available 698,741 698,741 X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 1 + Details Name: ecd_MtrlTermsOfTrdArrTextBlock Namespace Prefix: ecd_Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 1 + Details Name: ecd_NonRule10b51ArrAdoptedFlag Namespace Prefix: ecd_Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 1 + Details Name: ecd_NonRule10b51ArrTrmtdFlag Namespace Prefix: ecd_Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 1 + Details Name: ecd_Rule10b51ArrAdoptedFlag Namespace Prefix: ecd_Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 1 + Details Name: ecd_Rule10b51ArrTrmtdFlag Namespace Prefix: ecd_Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 2 -Subparagraph A + Details Name: ecd_TradingArrByIndTable Namespace Prefix: ecd_Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 2 -Subparagraph B + Details Name: ecd_TrdArrAdoptionDate Namespace Prefix: ecd_Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 2 -Subparagraph C + Details Name: ecd_TrdArrDuration Namespace Prefix: ecd_Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 2 -Subparagraph C + Details Name: ecd_TrdArrExpirationDate Namespace Prefix: ecd_Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 2 -Subparagraph A + Details Name: ecd_TrdArrIndName Namespace Prefix: ecd_Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 2 -Subparagraph A + Details Name: ecd_TrdArrIndTitle Namespace Prefix: ecd_Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 2 -Subparagraph D + Details Name: ecd_TrdArrSecuritiesAggAvailAmt Namespace Prefix: ecd_Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - Details Name: ecd_IndividualAxis=autl_MartinPuleMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 35 R25.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Summary of Significant Accounting Policies (Policies) 6 Months Ended Jun. 30, 2024 Accounting Policies [Abstract] A Basis of Presentation Basis of PresentationThe accompanying unaudited condensed consolidated financial statements of the Company have been prepared in accordance with generally accepted accounting principles in the US (the "U.S. GAAP") and are presented in U.S. dollars. All intercompany accounts and transactions between the Company and its subsidiaries have been eliminated upon consolidation. The significant accounting policies used in the preparation of these unaudited condensed consolidated financial statements are consistent with those discussed in Note 2, "Summary of Significant Accounting Policies" in the Company's Annual Report on Form 10-K for the year ended December 31, 2023 as filed with the Securities and Exchange Commission on March 21, 2024 (the "Annual Report"). Certain information and footnote disclosures have been condensed or omitted as permitted under U.S. GAAP. The information included in these unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and the related notes thereto as of and for the year ended December 31, 2023, included in the Annual Report. However, these interim financial statements include all adjustments, consisting only of normal recurring adjustments, which are, in the opinion of management, necessary to fairly state the results of the interim period. The interim results are not necessarily indicative of results to be expected for the full year ending December 31, 2024, any other interim periods, or any future year or period. Going Concern Going ConcernThe Company has incurred recurring losses since its inception, including net losses of \$58.3 million and \$45.6 million for the three months ended June 30, 2024 and 2023, respectively and \$111.0 million and \$85.4 million for the six months ended June 30, 2024 and 2023, respectively. The Company had an accumulated deficit of \$989.5 million and \$878.6 million as of June 30, 2024 and December 31, 2023, respectively. The Company expects to continue to generate operating losses in the foreseeable future. The Company's inability to raise additional capital as and when needed could have a negative impact on its financial condition and ability to pursue its business strategies. There can be no assurances, however, that the current operating plan will be achieved or that additional funding will be available on terms acceptable to the Company, or at all. The Company expects that its cash and cash equivalents at June 30, 2024 of \$705.9 million will be sufficient to fund the Company's operations for at least twelve months from the issuance date of these unaudited condensed consolidated financial statements and accordingly they have been prepared on a going concern basis. As the Company continues to incur losses, the transition to profitability is dependent upon the successful development, approval and commercialization of its product candidates and achieving a level of revenues adequate to support its cost structure. Even if the Company's planned regulatory submissions for its products are approved, and the Company is successful in its commercialization efforts, additional funding will be needed before the Company is expected to reach cash breakeven. Foreign Currency Translation Foreign Currency TranslationThe reporting currency of the Company is U.S. dollars. The Company has determined that its functional currency of the ultimate parent company, Autolus Therapeutics plc, is British Pound Sterling. The functional currency of each subsidiary's operations is the applicable local currency. Monetary assets and liabilities denominated in currencies other than the Company's functional currency are translated into the functional currency at rates of exchange prevailing at the balance sheet dates. Non-monetary assets and liabilities denominated in foreign currencies are translated into the functional currency at the exchange rates prevailing at the date of the transaction. The Company recorded foreign exchange gains of \$1.2 million and \$0.4 million for the three months ended June 30, 2024 and 2023, respectively, and foreign exchange losses of \$0.5 million and foreign exchange gains of \$1.3 million for the six months ended June 30, 2024 and 2023, respectively, which are included in other income (expense), net in the unaudited condensed Consolidated Statements of Operations and Comprehensive Loss. For financial reporting purposes, the financial statements of the Company have been translated into U.S. dollars. Assets and liabilities have been translated at the exchange rates at the balance sheet dates, while revenue and expenses are translated at the average exchange rates over the reporting period and shareholders' equity amounts are translated based on historical exchange rates as of the date of each transaction. Translation adjustments are not included in determining net income (loss) but are included in foreign exchange adjustment, its other comprehensive loss, a component of shareholders' equity. Segment Information Segment InformationThe Company's chief operating decision maker (the "CODM"), its Chief Executive Officer, manages the Company's operations on an integrated basis for the purpose of appropriately allocating resources. When evaluating the Company's financial performance, the CODM reviews total revenue, total expenses and expenses by function and makes decisions using this information on a global basis. The Company and the CODM view the Company's operations and manage its business as a single operating segment, which is the business of developing and commercializing CAR T therapies. Use of Estimates Use of EstimatesThe preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of income and expenses during the reporting periods. Significant estimates and assumptions reflected in these consolidated financial statements include, but are not limited to, the accrual for research and development expenses, share-based compensation including assessing the probability of meeting performance conditions, income taxes, initial fair value of warrants, and interest expense on liability related to future royalties and milestones, net and related cumulative catch-up adjustment, initial lease term of the Company's new manufacturing facility (the "Nucleus"), incremental borrowing rates related to the Company's leased properties and allocation of transaction price using the relative standalone selling price. Estimates are periodically reviewed in light of changes in circumstances, facts and experience. Actual results could differ from those estimates. Allocation of transaction price using the relative standalone selling price Upfront payments are allocated between performance obligations using the Company's best estimate of the relative standalone selling price of the performance obligation. The relative standalone selling price is estimated by determining the market values of development and license obligations. As these inputs are not directly observable, the estimate is determined considering all reasonably available information including internal pricing objectives used in negotiating the contract, taking into account the different stage of development of each development program and consideration of adjusted-market data from comparable arrangements. Where performance obligations have been identified relating to material rights, the determination of the relative standalone selling price of these performance obligations also includes an assessment of the likelihood that the options will be exercised and any payments by the customer that are triggered upon exercising the right. This assessment involves significant judgment and could have a significant impact on the amount and timing of revenue recognition. An assessment of the allocation of transaction price using the relative standalone selling price was required for the three and six months ended June 30, 2024 and 2023 for the BioNTech License and Option Agreement and the Option and License Agreement with Cabaletta Bio Inc. (the "Cabaletta"), respectively. See Note 3 for additional information on the allocation of the transaction price for those agreements. Liability related to future royalties and milestones, net and cumulative catch-up adjustments The Company accounted for each of the Blackstone Collaboration Agreement (See Note 12) (the "Blackstone Collaboration Agreement Liability") and the BioNTech Obe-cel Product Revenue Interest (the "BioNTech Liability") as liabilities measured at amortized cost based on an effective interest rate determined at the outset of the arrangement. The Blackstone Collaboration Agreement Liability related to future royalties and milestones, net is measured based on the Company's current estimates of the timing and amount of expected future royalties, milestone payments to be paid and the milestones receivable upon the achievement of certain specified clinical, manufacturing and regulatory milestones (each such payment, a "Blackstone Development Payment") and collectively, the "Blackstone Development Payments") expected to be received over the estimated term of the agreement. Similarly, the BioNTech Liability related to future royalties is measured based on the Company's current estimates of the timing and amount of expected future royalty expected to be paid over the estimated term of the agreement. Milestone payments pursuant to the BioNTech License and Option Agreement (the "BioNTech Milestone Payments") are payable upon BioNTech's election, and therefore have not been included in the determination of the effective interest rate or in the measurement of the liability. The liabilities are amortized using the effective interest rate, resulting in recognition of interest expense over the estimated term of the agreement. Each reporting period the Company assesses the estimated probability, timing and amount of the future expected royalty, milestone payments, the Blackstone Development Payment over the estimated term. If there are changes to the estimates, the Company recognizes the impact to the liability's amortization schedule and the related interest expense using the catch-up method. The Company's estimate of the

probability, timing and amount of expected future royalties and milestones to be paid by the Company and the expected Blackstone Development Payment to be paid to the Company, considers significant unobservable inputs. These inputs include regulatory approval, the estimated patient population, estimated selling price, estimated sales, estimated peak sales and sales ramp, timing of the expected launch and its impact on the royalties as well as the overall probability of a success. Additionally, the transaction costs associated with the liability will be amortized to interest expense over the estimated term of the agreements. The carrying amount of the Blackstone Collaboration Agreement Liability and BioNTech Liability is based on the Company's estimate of the future royalties, milestones to be paid to Blackstone by the Company and the expected Blackstone Development Payment to be received over the life of the arrangement as discounted using the initial effective interest rate. The excess estimated present value of future royalty, milestone payments and the future Blackstone Development Payment received over the carrying amount is recognized as a cumulative catch-up adjustment within interest expense using the effective interest rate. Recent Accounting Pronouncements Not Yet Adopted Recent Accounting Pronouncements Not Yet Adopted In November 2023, the Financial Accounting Standards Board, (FASB), issued Accounting Standards Update, or (ASU), 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures, or (ASU 2023-07), which expanded the disclosures for reportable segments made by public entities. These amendments within ASU 2023-07 retained the existing disclosure requirements in ASC 280 - Segment Reporting (ASU 2023-07) and expanded upon them to require public entities to disclose significant expenses for reportable segments in both interim and annual reporting periods, as well as items that were previously disclosed only annually on an interim basis, including disclosures related to a reportable segment's profit or loss and assets. In addition, entities with a single reportable segment must provide all segment disclosures required in ASC 280, including the new disclosures for reportable segments under the amendments in ASU 2023-07. The amendments did not change the existing guidance on how a public entity identified and determined its reportable segments. A public entity should apply the amendments in ASU 2023-07 retrospectively to all prior periods presented in the financial statements. Upon transition, the segment expense categories and amounts disclosed in the prior periods should be based on the significant segment expense categories identified and disclosed in the period of adoption. The amendments in ASU 2023-07 are effective for annual periods for all public entities in fiscal years beginning after December 15, 2023, and in interim periods within fiscal years beginning after December 15, 2024. The Company will comply with any new applicable disclosures in its Annual Report on Form 10-K for the year ending December 31, 2024. The Company does not expect the adoption to have a material effect on its financial statements and related disclosures. In December 2023, the FASB issued ASU 2023-09, Improvements to Income Tax Disclosures. This ASU improves the transparency of income tax disclosure by requiring consistent categories and greater disaggregation of information in the rate reconciliation, and income taxes paid disaggregated by jurisdiction. This guidance is effective for the Company for the year beginning January 1, 2025, with early adoption permitted. The amendments should be applied on a prospective basis, with retrospective application permitted. The Company intends to adopt the guidance in the fiscal year beginning January 1, 2025. The Company does not expect the adoption of ASU 2023-09 to have a material effect on its financial statements and related disclosures. Unless otherwise discussed, the impact of recently issued standards that are not yet effective are not expected to have a material impact on the Company's consolidated financial statements and disclosures in this report and for the full year ending December 31, 2024. Fair value measurements The Company uses valuation approaches that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible. The Company determines the fair value based on assumptions that market participants would use in pricing an asset or liability in the principal or most advantageous market. When considering market participant assumptions in fair value measurements, the following fair value hierarchy distinguishes between observable and unobservable inputs, which are categorized in the following levels: Level 1 Quoted prices in active markets for identical assets or liabilities Level 2 Inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly Level 3 Unobservable inputs that reflect the Company's own assumptions about the assumptions market participants would use in pricing the asset or liability. The carrying amounts reported in the balance sheet for cash and cash equivalents, restricted cash, prepaid expenses and other assets, accounts payable and accrued expenses and other liabilities approximate their fair value because of the short-term nature of these instruments. X - Definition Going Concern, Policy + References No definition available. + Details Name: autl_GoingConcernPolicyPolicyTextBlock Namespace Prefix: autl_Data Type: dtr-types:1:textBlockItem Type Balance Type: na Period Type: duration X - References No definition available. + Details Name: us-gaap_AccountingPoliciesAbstract Namespace Prefix: us-gaap_Data Type: xbrli:stringItem Type Balance Type: na Period Type: duration X - Definition Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). + References No definition available. + Details Name: us-gaap_BasisOfAccountingPolicyPolicyTextBlock Namespace Prefix: us-gaap_Data Type: dtr-types:textBlockItem Type Balance Type: na Period Type: duration X - Definition Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities. + References No definition available. + Details Name: us-gaap_FairValueMeasurementPolicyPolicyTextBlock Namespace Prefix: us-gaap_Data Type: dtr-types:textBlockItem Type Balance Type: na Period Type: duration X - Definition Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/830/tableOfContent + Details Name: us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock Namespace Prefix: us-gaap_Data Type: dtr-types:textBlockItem Type Balance Type: na Period Type: duration X - Definition Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact. + References No definition available. + Details Name: us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock Namespace Prefix: us-gaap_Data Type: dtr-types:textBlockItem Type Balance Type: na Period Type: duration X - Definition Disclosure of accounting policy for segment reporting. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 47 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 29 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 54 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 36 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-36Reference 6: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 47 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 29 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 29 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 29 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 29 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 29 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 29 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29 + Details Name: us-gaap_SegmentReportingPolicyPolicyTextBlock Namespace Prefix: us-gaap_Data Type: dtr-types:textBlockItem Type Balance Type: na Period Type: duration X - Definition Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-9Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-4Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b) -SubTopic 10 -Topic 275 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c) -SubTopic 10 -Topic 275 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 11 -SubTopic 10 -Topic 275 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-11Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 12 -SubTopic 10 -Topic 275 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-12Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-8 + Details Name: us-gaap_UseOfEstimates Namespace Prefix: us-gaap_Data Type: dtr-types:textBlockItem Type Balance Type: na Period Type: duration XML 36 R26.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Nature of the Business (Tables) 6 Months Ended Jun. 30, 2024 Organization, Consolidation and Presentation of Financial Statements [Abstract] A Units of Accounting from Financing Agreement The four units of accounting were recorded at fair value upon initial recognition and will not be subsequently measured at fair value. The Company allocated the total gross proceeds arising from the BioNTech Securities Purchase Agreement (i.e. the Initial ADSs representing ordinary shares), and the BioNTech License and Option Agreement among the four units of accounting on a relative fair value basis at the time of the transaction as follows: Units of Accounting Gross proceeds (in millions) Initial fair value (in millions) Allocated consideration based on relative fair value (in millions) Net allocated consideration based on relative fair value after transaction costs* (in millions) Initial ADSs, representing ordinary shares \$200.0A \$200.0A \$200.0A \$193.8A Subsequent ADSs, representing ordinary shares \$6A \$6A \$6A \$6A BioNTech License and Option Agreement \$50.0A \$50.0A \$50.0A \$47.9A Liabilities related to future royalties and milestones, net (Obe-cel Product Revenue Interest) \$40.0A \$40.0A \$40.0A \$38.3A License Revenue (Binder License) \$10.0A \$10.0A \$10.0A \$9.6A MCSA \$6A \$6A \$6A \$6A Total \$250.0A \$250.0A \$250.0A \$241.7A * In addition, the total shared transaction costs of \$8.3 million, relating to the BioNTech Agreements have been allocated to the four units of accounting on a relative fair value basis. X - Definition Units Of Accounting From Financing Agreement + References No definition available. + Details Name: autl_UnitsOfAccountingFromFinancingAgreementTableTextBlock Namespace Prefix: autl_Data Type: dtr-types:1:textBlockItem Type Balance Type: na Period Type: duration X - References No definition available. + Details Name: us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract Namespace Prefix: us-gaap_Data Type: xbrli:stringItem Type Balance Type: na Period Type: duration XML 37 R27.htm IDEA: XBRL DOCUMENT v3.24.2.u1 License Revenue (Tables) 6 Months Ended Jun. 30, 2024 Revenue from Contract with Customer [Abstract] A Schedule of Revenue by Geographic Locations License revenue for the three and six months ended June 30, 2024, and 2023, is presented in the table below by geographical location (in thousands): Three Months Ended June 30, Six Months Ended June 30, 2024 2023 2024 2023 License revenue United States \$10,091A \$10,091A Germany \$10,091A \$10,091A Total license revenues \$6A \$6A \$10,091A \$10,091A X - References No definition available. + Details Name: us-gaap_RevenueFromContractWithCustomerAbstract Namespace Prefix: us-gaap_Data Type: xbrli:stringItem Type Balance Type: na Period Type: duration X - Definition Tabular disclosure of revenue from external customers by geographic areas attributed to the entity's country of domicile and to foreign countries from which the entity derives revenue. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41 + Details Name: us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock Namespace Prefix: us-gaap_Data Type: dtr-types:textBlockItem Type Balance Type: na Period Type: duration XML 38 R28.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Interest expense (Tables) 6 Months Ended Jun. 30, 2024 Banking and Thrift, Interest [Abstract] A Interest Income and Interest Expense Disclosure Interest expense consisted of the following (in thousands): Three Months Ended June 30, Six Months Ended June 30, 2024 2023 2024 2023 Interest expense on liabilities related to future royalties and milestones, net (refer to Note 12) \$10,169A \$4,959A \$18,559A \$9,864A Cumulative catch-up adjustment arising from the liabilities related to future royalties and milestones, net (refer to Note 12) \$6A \$6A \$10,870A \$6A Other interest expense \$61A \$61A \$14A \$61A Total interest expense \$10,174A \$5,020A \$29,443A \$9,925A X - References No definition available. + Details Name: us-gaap_BankingAndThriftInterestAbstract Namespace Prefix: us-gaap_Data Type: xbrli:stringItem Type Balance Type: na Period Type: duration X - Definition Tabular disclosure of interest income and expense, including, but not limited to, interest income and expense from investments, loans, and securities. + References No definition available. + Details Name: us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock Namespace Prefix: us-gaap_Data Type: dtr-types:textBlockItem Type Balance Type: na Period Type: duration XML 39 R29.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Net loss per ordinary share (Tables) 6 Months Ended Jun. 30, 2024 Earnings Per Share [Abstract] A Schedule of Loss Per Share, Basic and Diluted Basic and diluted net loss per ordinary share was calculated as follows (in thousands, except share and per share amounts): Three Months Ended June 30, Six Months Ended June 30, 2024 2023 2024 2023 Numerator Net loss \$(58,272) \$(45,552) \$(110,962) \$(85,363) Net loss - basic and diluted \$(58,272) \$(45,552) \$(110,962) \$(85,363) Denominator Weighted-average number of ordinary shares used in net loss per share - basic and diluted 266,025,783A 173,860,491A 255,131,873A 173,843,249A Basic and diluted net loss per ordinary shares \$(0.22) \$(0.26) \$(0.43) \$(0.49) Schedule of Anti-dilutive Securities The following potentially dilutive securities have been excluded from the calculation of diluted net loss per share due to their anti-dilutive effect: Three and Six Months Ended June 30, 2024 2023 Unvested restricted stock units 41,905A 315,460A Share options 1,558,856A 14,203,439A Warrants 3,265,306A 3,265,306A Total potentially dilutive securities 22,866,067A 17,784,205A X - References No definition available. + Details Name: us-gaap_EarningsPerShareAbstract Namespace Prefix: us-gaap_Data Type: xbrli:stringItem Type Balance Type: na Period Type: duration X - Definition Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1 + Details Name: us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTableTextBlock Namespace Prefix: us-gaap_Data Type: dtr-types:textBlockItem Type Balance Type: na Period Type: duration X - Definition Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1 + Details Name: us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock Namespace Prefix: us-gaap_Data Type: dtr-types:textBlockItem Type Balance Type: na Period Type: duration XML 40 R30.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Fair value measurements (Tables) 6 Months Ended Jun. 30, 2024 Fair Value Disclosures [Abstract] A Fair Value Measurements, Recurring and Nonrecurring The following tables present information about the Company's financial assets measured at fair value on a recurring basis and indicate the level of the fair value hierarchy utilized to determine such fair values (in thousands): June 30, 2024 Total Quoted Prices in Active Markets for Identical Assets (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) Financial assets Cash and cash equivalents: Money market funds \$528,910A \$528,910A \$6A \$6A Total \$528,910A \$528,910A \$6A \$6A December 31, 2023 Total Quoted Prices in Active Markets for Identical Assets (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) Financial assets Cash and cash

equivalents:Money market funds\$184,635\$ 184,635\$ â€”\$ â€”\$ A Total\$184,635\$ 184,635\$ â€”\$ A \$â€”\$ X - DefinitionTabular disclosure of financial instrument measured at fair value on recurring or nonrecurring basis. Includes, but is not limited to, instrument classified in shareholders' equity. + ReferencesReference 1: [http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(b\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2](http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2)Reference 2: [http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2](http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2)Reference 3: <http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 100 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100>Reference 4: [http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3](http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3) + Details Name: us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItem Type Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_FairValueDisclosuresAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItem Type Balance Type: na Period Type: duration XML 41 R31.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Prepaid Expenses and Other Current Assets (Tables) 6 Months Ended Jun. 30, 2024 Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract] A Schedule of Prepaid Expenses and Other Current Assets Prepaid expenses and other current assets consisted of the following (in thousands):June 30,December 31,20242023Research and development claims receivable\$27,750\$ 19,209\$ Prepayments\$11,865\$ 8,638\$ VAT receivable\$3,597\$ 2,771\$ Accrued interest income\$2,597\$ 999\$ Deferred cost\$1,782\$ 1,787\$ Other taxes receivable\$1,585\$ â€”\$ A Other receivables\$957\$ 516\$ Lease and lease disposal receivable\$938\$ 938\$ Corporate tax receivable\$570\$ â€”\$ A Accounts receivable\$â€”\$ 109\$ Total prepaid expenses and other current assets\$51,641\$ 34,967\$ X - ReferencesNo definition available. + Details Name: us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItem Type Balance Type: na Period Type: duration X - DefinitionTabular disclosure of the amounts paid in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event, and will be charged against earnings within one year or the normal operating cycle, if longer; the aggregate carrying amount of current assets, not separately presented elsewhere in the balance sheet; and other deferred costs. + ReferencesNo definition available. + Details Name: us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItem Type Balance Type: na Period Type: duration XML 42 R32.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Property and Equipment, Net (Tables) 6 Months Ended Jun. 30, 2024 Property, Plant and Equipment [Abstract] A Schedule of Depreciation Property and equipment, net consisted of the following (in thousands):June 30,December 31,20242023Lab equipment\$41,307\$ 32,232\$ Office equipment\$5,017\$ 3,777\$ Furniture and fixtures\$2,353\$ 2,360\$ Leasehold improvements\$14,220\$ 12,728\$ Assets under construction\$2,494\$ 12,539\$ Less: accumulated depreciation\$(32,286)\$(28,774)\$ Total property and equipment, net\$32,860\$ 34,862\$ X - ReferencesNo definition available. + Details Name: us-gaap_PropertyPlantAndEquipmentAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItem Type Balance Type: na Period Type: duration X - DefinitionTabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated depreciation. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -SubTopic 10 -Topic 360 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1> + Details Name: us-gaap_PropertyPlantAndEquipmentTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItem Type Balance Type: na Period Type: duration XML 43 R33.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Accrued Expenses and Other Liabilities (Tables) 6 Months Ended Jun. 30, 2024 Payables and Accruals [Abstract] A Schedule of Accrued Expenses and Other Liabilities Accrued expenses and other liabilities consisted of the following (in thousands):June 30,December 31,20242023Research and development costs\$17,930\$ 19,825\$ Compensation and benefits\$10,459\$ 14,757\$ Professional fees\$6,808\$ 4,466\$ Other accrued liabilities\$382\$ 533\$ Total accrued expenses and other liabilities\$35,579\$ 39,581\$ X - ReferencesNo definition available. + Details Name: us-gaap_PayablesAndAccrualsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItem Type Balance Type: na Period Type: duration X - DefinitionTabular disclosure of the components of accrued liabilities. + ReferencesNo definition available. + Details Name: us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItem Type Balance Type: na Period Type: duration XML 44 R34.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Share-based Compensation (Tables) 6 Months Ended Jun. 30, 2024 Share-Based Payment Arrangement [Abstract] A Schedule of Share Based Compensation Expense The following table summarizes the total share-based compensation expense included in the unaudited condensed consolidated statements of operations and comprehensive loss (in thousands):Three Months Ended June 30,Six Months Ended June 30,2024202320242023Research and development\$1,048\$ 1,776\$ 1,498\$ 3,457\$ General and administrative\$1,887\$ 885\$ 3,723\$ 1,612\$ Capitalized\$â€”\$ 7\$ (2)\$ 15\$ Total share-based compensation expense\$2,935\$ 2,668\$ 5,219\$ 5,084\$ Stock Option Rollforward The table below summarizes Companyâ€™s share option activity during the six months ended June 30, 2024:NumberÂ of OptionsWeighted- Average Exercise Price per shareWeighted- Average Remaining Contractual Term (Years)Aggregate Intrinsic Value (1)(in thousands)Outstanding as of December 31, 202317,956,385\$ 5.64\$ 8.35\$48,968\$ Granted\$2,793,400\$ 4.33\$ 5.4\$ Exercised(146,310)\$ 2.77\$ 369\$ Forfeited(797,838)\$ 3.39\$ 6.45\$ Expired(246,781)\$ 9.38\$ 5\$ Outstanding as of June 30, 202419,558,856\$ 5.51\$ 8.14\$11,834\$ Exercisable as of June 30, 20248,053,441\$ 8.63\$ 6.95\$3,507\$ Vested and expected to vest as of June 30, 202419,558,856\$ 5.51\$ 8.14\$11,834\$ (1) Aggregate intrinsic value is calculated as the difference between the exercise price of the underlying options and the fair value of ordinary shares for those options in the money as of June 30, 2024 Schedule of Nonvested Share Activity The table below summarizes Companyâ€™s restricted stock unit (â€œRSUâ€™s) awards activity during the six months ended June 30, 2024:NumberÂ of restricted unitsWeightedÂ average grant date fair valueUnvested and outstanding at December 31, 2023116,436\$ 3.43\$ Vested(73,604)\$ 2.79\$ Forfeited(927)6.20\$ Unvested and outstanding at June 30, 202441,905\$ 4.49\$ X - ReferencesNo definition available. + Details Name: us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItem Type Balance Type: na Period Type: duration X - DefinitionTabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement. + ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph \(h\) \(1\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (h) (1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2) + Details Name: us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItem Type Balance Type: na Period Type: duration X - DefinitionTabular disclosure of the changes in outstanding nonvested shares. + ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(c\)\(2\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://fasb.org/us-gaap/role/ref/legacyRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2) + Details Name: us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItem Type Balance Type: na Period Type: duration X - DefinitionTabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value. + ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(c\)\(1\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://fasb.org/us-gaap/role/ref/legacyRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)Reference 2: [http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(d\) -SubTopic 10 -Topic 718 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d) -SubTopic 10 -Topic 718 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)Reference 3: [http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(e\) -SubTopic 10 -Topic 718 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e) -SubTopic 10 -Topic 718 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2) + Details Name: us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItem Type Balance Type: na Period Type: duration XML 45 R35.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Liabilities related to future royalties and milestones, net (Tables) 6 Months Ended Jun. 30, 2024 Investments, Debt and Equity Securities [Abstract] A Liability Related Debt Arising Financial Agreement Amount in thousandsBalance at 1 January, 2023\$125,900\$ Interest expense on liability related to future royalties and milestones, net\$4,905\$ Balance at March 31, 2023\$130,805\$ Interest expense on liability related to future royalties and milestones, net\$4,959\$ Balance at June 30, 2023\$135,764\$ Interest expense on liability related to future royalties and milestones, net\$5,014\$ Balance at September 30, 2023\$140,778\$ Interest expense on liability related to future royalties and milestones, net\$5,014\$ Cumulative catch-up adjustment\$25,107\$ Balance at December 31, 2023\$170,899\$ Initial recognition of BioNTech liability\$38,335\$ Interest expense on liability related to future royalties and milestones, net\$8,390\$ Cumulative catch-up adjustment\$10,870\$ Balance at March 31, 2024\$228,494\$ Interest expense on liability related to future royalties and milestones, net\$10,169\$ Balance at June 30, 2024\$238,663\$ X - DefinitionLiability Related Debt Arising Financial Agreement + ReferencesNo definition available. + Details Name: autl_LiabilityRelatedDebtArisingFinancialAgreementTableTextBlock Namespace Prefix: autl_ Data Type: dtr-types1:textBlockItem Type Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItem Type Balance Type: na Period Type: duration XML 46 R36.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Leases (Tables) 6 Months Ended Jun. 30, 2024 Leases [Abstract] A Lease Cost Table The Companyâ€™s costs as a lessee for the three and six months ended June 30, 2024 and 2023 were as follows (in thousands):Three Months Ended June 30,Six Months Ended June 30,2024202320242023Operating lease costs\$2,087\$ 1,807\$ 4,185\$ 3,174\$ Variable costs\$484\$ 355\$ 1,028\$ 84\$ Short term lease costs\$103\$ 199\$ 204\$ 242\$ Total lease costs\$2,674\$ 2,361\$ 5,417\$ 3,500\$ Supplemental cash flow information for the three months ended June 30, 2024 and 2023 were as follows (in thousands):Six Months Ended June 30,Other information20242023Cash paid for amounts included in the measurement of lease liabilities:Operating cash outflows from operating leases\$4,485\$2,882\$The weighted average remaining lease term and weighted average discount rate of operating leases at June 30, 2024 and 2023 were as follows:Six Months Ended June 30,20242023Weighted-average remaining lease term - operating leases15.9 years15.8 yearsWeighted-average discount rate - operating leases7.44% 7.29% % Lease Maturity Schedule The maturities of operating lease liabilities as of June 30, 2024 were as follows (in thousands):Remainder of 2024\$4,235\$ 20256,854\$ 20266,623\$ 20276,481\$ 20285,764\$ Thereafter\$5,815\$ Total lease payments\$85,772\$ Less: imputed interest(35,751)\$ Present value of lease liabilities\$50,021\$ Sublease Classification The following table shows the sublease rental income for the three and six months ended June 30, 2024 and 2023 (in thousands): Three Months Ended June 30,Six Months Ended June 30,Sublease rental income2024202320242023Sublease rental income (included in other income (expense), net)\$61\$ 61\$ 123\$ 120\$ Total sublease rental income\$61\$ 61\$ 123\$ 120\$ Lease Receivable Maturity Schedule Future fixed receipts for non-cancellable operating subleases in effect as of June 30, 2024 are receivable as follows (in thousands):Remainder of 2024\$1302025\$2602026\$2032027\$1222028\$106Total lease payments receivable\$821 X - DefinitionTabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income. + ReferencesReference 1: <http://www.xbrl.org/2009/role/commonPracticeRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4> + Details Name: us-gaap_LeaseCostTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItem Type Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_LeasesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItem Type Balance Type: na Period Type: duration X - DefinitionTabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position. + ReferencesReference 1: <http://www.xbrl.org/2009/role/commonPracticeRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6> + Details Name: us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItem Type Balance Type: na Period Type: duration X - DefinitionTabular disclosure of maturity of undiscounted cash flows to be received by lessor on annual basis for operating lease. + ReferencesReference 1: <http://www.xbrl.org/2009/role/commonPracticeRef -Topic 842 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479773/842-30-50-12> + Details Name: us-gaap_LessorOperatingLeasePaymentsToBeReceivedMaturityTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItem Type Balance Type: na Period Type: duration X - DefinitionTabular disclosure of components of income from operating lease. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479773/842-30-50-5>Reference 2: <http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6A -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-6A> + Details Name: us-gaap_OperatingLeaseLeaseIncomeTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItem Type Balance Type: na Period Type: duration XML 47 R37.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Nature of the Business - Narrative (Details) \$ / shares in Units, \$ in Millions 1 Months Ended Feb. 13, 2024 USD (\$) \$ / shares shares Feb. 06, 2024 USD (\$) \$ / shares shares Nov. 30, 2021 USD (\$) Jun. 30, 2024 USD (\$) unit financialInstrument \$ / shares Dec. 31, 2023 \$ / shares Dec. 31, 2022 USD (\$) Nov. 06, 2021 USD (\$) (Product Information [Line Items]) A A A A A Contract with customer, liability A A A 195.9 A A Number of freestanding financial instruments [financialInstrument A A A 1 A A Units of accounting [unit A A A 4 A A BioNTech A A A A A Product Information [Line Items] A A A A A Collaborative agreement, period to acquire beneficial ownership from execution date A 5 years A A A A Ordinary Shares A A A A A Product Information [Line Items] A A A A A Stock par value (usd/gbp per share) [\$ / shares A A A \$ 0.000042 \$ 0.000042 A A Number of shares issued in transaction (in shares) [shares 33,333,333 A A A A A Per share price of issuance (usd per share) [\$ / shares \$ 6.00 A A A A A Proceeds of issuance of ordinary shares, net of issuance costs \$ 193.8 A A A A Ordinary Shares [BioNTech A A A A A Product Information [Line Items] A A A A A Collaborative arrangement, rights and obligations, maximum share purchase requirement, shares (in shares) [shares 15,000,000 A A A A A Collaborative arrangement, rights and obligations, maximum share purchase requirement, value \$ 20.0 A A A A A Collaborative agreement, beneficial ownership percentage, threshold (in percent) A 0.30 A A A Blackstone Collaboration Agreement A A A A A Product Information [Line Items] A A A A A Number of freestanding financial instruments [financialInstrument A A A 4 A A BioNTech License and Option Agreement A A A A A Product Information [Line Items] A A A A A Number of freestanding financial instruments [financialInstrument A A A 1 A A BioNTech A A A A A Product Information [Line Items] A A A A A Collaborative arrangement, period to enter agreement from initial closing date (in months) 18 months A A A A A Collaborative agreement, sale of stock prohibited without registrant's approval, period (in months) A 6 months A A A BioNTech [License And Options A A A A A Product Information [Line Items] A A A A A Contract with customer, liability A \$ 10.0 A A A A Revenue, remaining performance obligation, maximum consideration, amount A 582.0 A A A A Remaining performance obligation, variable consideration amount A \$ 32.0 A A A A BioNTech [Ordinary Shares A A A A A Product Information [Line Items] A A A A A Stockholders' equity, common stock, conversion ratio [shares 1 A A A A Stock par value (usd/gbp per share) [\$ / shares A \$ 0.000042 A A A Blackstone [Affiliated Entity [Obe-cel Product A A A A A Product Information [Line Items] A A A A A Contract with customer, liability gross A \$ 40.0 A A A Remaining performance obligation, variable consideration amount A A A A A 100.0 Blackstone [Blackstone Collaboration Agreement A A A A A Product Information [Line Items] A A A A A Contract with customer, liability A A A A A 35.0 A A Contract with customer, liability gross A \$ 50.0 A A A Remaining performance obligation, variable consideration amount A A A A 30.0 X - DefinitionCollaborative Agreement, Beneficial Ownership Percentage, Threshold + ReferencesNo definition available. + Details Name: autl_CollaborativeAgreementBeneficialOwnershipPercentageThreshold Namespace Prefix: autl_ Data Type: xbrli:pureItem Type Balance Type: na Period Type: duration X - DefinitionCollaborative Agreement, Period To Acquire Beneficial Ownership From Execution Date + ReferencesNo definition available. + Details Name: autl_CollaborativeAgreementPeriodToAcquireBeneficialOwnershipFromExecutionDate Namespace Prefix: autl_ Data Type: xbrli:durationItem Type Balance Type: na Period Type: duration X - DefinitionCollaborative Agreement, Sale of Stock Prohibited Without Registrant's Approval, Period + ReferencesNo definition available. + Details Name: autl_CollaborativeAgreementSaleOfStockProhibitedWithoutRegistrantsApprovalPeriod Namespace Prefix: autl_ Data Type: xbrli:durationItem Type Balance Type: na Period Type: duration X - DefinitionCollaborative Arrangement, Period To Enter Agreement From Initial Closing Date + ReferencesNo definition available. + Details Name: autl_CollaborativeArrangementPeriodToEnterAgreementFromInitialClosingDate Namespace Prefix: autl_ Data Type: xbrli:durationItem Type Balance Type: na Period Type: duration X -

DefinitionCollaborativeArrangement, Rights And Obligations, Maximum Share Purchase Requirement, Shares + ReferencesNo definition available. + Details Name: autl_CollaborativeArrangementRightsAndObligationsMaximumSharePurchaseRequirementShares Namespace Prefix: autl_Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionCollaborativeArrangement, Rights And Obligations, Maximum Share Purchase Requirement, Value + ReferencesNo definition available. + Details Name: autl_CollaborativeArrangementRightsAndObligationsMaximumSharePurchaseRequirementValue Namespace Prefix: autl_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionContract With Customer, Liability, Gross + ReferencesNo definition available. + Details Name: autl_ContractWithCustomerLiabilityGross Namespace Prefix: autl_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionNumber Of Freestanding Financial Instruments + ReferencesNo definition available. + Details Name: autl_NumberOfFreestandingFinancialInstruments Namespace Prefix: autl_Data Type: xbrli:integerItemType Balance Type: na Period Type: instant X - DefinitionRevenue, Remaining Performance Obligation, Maximum Consideration, Amount + ReferencesNo definition available. + Details Name: autl_RevenueRemainingPerformanceObligationMaximumConsiderationAmount Namespace Prefix: autl_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionRevenue, Remaining Performance Obligation, Variable Consideration Amount + ReferencesNo definition available. + Details Name: autl_RevenueRemainingPerformanceObligationVariableConsiderationAmount Namespace Prefix: autl_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionStockholders' Equity, Common Stock, Conversion Ratio + ReferencesNo definition available. + Details Name: autl_StockholdersEquityCommonStockConversionRatio Namespace Prefix: autl_Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionUnits Of Accounting + ReferencesNo definition available. + Details Name: autl_UnitsOfAccounting Namespace Prefix: autl_Data Type: xbrli:integerItemType Balance Type: na Period Type: instant X - DefinitionFace amount or stated value per share of common stock. + ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.5-02\(29\)\)](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.5-02(29))) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1> + Details Name: us-gaap_CommonStockParOrStatedValuePerShare Namespace Prefix: us-gaap_Data Type: dtr-types:perShareItemBalance Type: na Period Type: instant X - DefinitionAmount of obligation to transfer good or service to customer for which consideration has been received or is receivable. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef-Topic 606-SubTopic 10-Name Accounting Standards Codification-Section 45-Paragraph 1> -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479837/606-10-45-1>Reference 2: [http://www.xbrl.org/2003/role/disclosureRef-Topic 606-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 8-Subparagraph \(a\)](http://www.xbrl.org/2003/role/disclosureRef-Topic 606-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 8-Subparagraph (a)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479806/606-10-50-8>Reference 3: <http://www.xbrl.org/2003/role/disclosureRef-Topic 606-SubTopic 10-Name Accounting Standards Codification-Section 45-Paragraph 2> -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479837/606-10-45-2> + Details Name: us-gaap_ContractWithCustomerLiability Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesNo definition available. + Details Name: us-gaap_ProductInformationLineItems Namespace Prefix: us-gaap_Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionCash received on stock transaction after deduction of issuance costs. + ReferencesNo definition available. + Details Name: us-gaap_SaleOfStockConsiderationReceivedOnTransaction Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe number of shares issued or sold by the subsidiary or equity method investee per stock transaction. + ReferencesNo definition available. + Details Name: us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction Namespace Prefix: us-gaap_Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionPer share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction. + ReferencesNo definition available. + Details Name: us-gaap_SaleOfStockPricePerShare Namespace Prefix: us-gaap_Data Type: dtr-types:perShareItemBalance Type: na Period Type: instant X - Details Name: dei_LegalEntityAxis=autl_BioNTechMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementClassOfStockAxis=autl_OrdinarySharesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_RelatedPartyTransactionAxis=autl_BlackstoneCollaborationAgreementMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_RelatedPartyTransactionAxis=autl_BioNTechLicenseAndOptionsAgreementMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_CounterpartyNameAxis=autl_BioNTechMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_ProductOrServiceAxis=autl_LicenseAndOptionsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_CounterpartyNameAxis=autl_BlackstoneMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_RelatedPartyTransactionAxis=srt_AffiliatedEntityMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_ProductOrServiceAxis=autl_ObeCelProductMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 48 R38.htm IDEA: XBRL DOCUMENT V3.24.2.u1 Nature of the Business - Units of Accounting (Details) \$ in Millions 6 Months Ended Jun. 30, 2024 USD (\$) unit Class of Stock A Units of accounting | unit 4 BioNTech A Class of Stock A Payment of equity issuance costs \$ 8.3 BioNTech | Investor A Class of Stock A Amounts of related party transaction 250.0 BioNTech | Investor | Estimate of Fair Value Measurement A Class of Stock A Amounts of related party transaction 250.0 Allocated consideration based on relative fair value 250.0 Net allocated consideration based on relative fair value after transaction costs 241.7 BioNTech | Initial ADSs, representing ordinary shares | Investor A Class of Stock A Amounts of related party transaction 200.0 BioNTech | Initial ADSs, representing ordinary shares | Investor | Estimate of Fair Value Measurement A Class of Stock A Amounts of related party transaction 200.0 Allocated consideration based on relative fair value 200.0 Net allocated consideration based on relative fair value after transaction costs 193.8 BioNTech | Subsequent ADSs, representing ordinary shares | Investor A Class of Stock A Amounts of related party transaction 0.0 BioNTech | Subsequent ADSs, representing ordinary shares | Investor | Estimate of Fair Value Measurement A Class of Stock A Amounts of related party transaction 0.0 Allocated consideration based on relative fair value 0.0 Net allocated consideration based on relative fair value after transaction costs 0.0 BioNTech | BioNTech License and Option Agreement | Investor A Class of Stock A Amounts of related party transaction 50.0 BioNTech | BioNTech License and Option Agreement | Investor | Estimate of Fair Value Measurement A Class of Stock A Amounts of related party transaction 50.0 Allocated consideration based on relative fair value 50.0 Net allocated consideration based on relative fair value after transaction costs 47.9 BioNTech | Liabilities related to future royalties and milestones, net (Obe-cel Product Revenue Interest) | Investor A Class of Stock A Amounts of related party transaction 40.0 BioNTech | Liabilities related to future royalties and milestones, net (Obe-cel Product Revenue Interest) | Investor | Estimate of Fair Value Measurement A Class of Stock A Amounts of related party transaction 40.0 Allocated consideration based on relative fair value 40.0 Net allocated consideration based on relative fair value after transaction costs 38.3 BioNTech | License Revenue (Binder License) | Investor A Class of Stock A Amounts of related party transaction 10.0 BioNTech | License Revenue (Binder License) | Investor | Estimate of Fair Value Measurement A Class of Stock A Amounts of related party transaction 10.0 Allocated consideration based on relative fair value 10.0 Net allocated consideration based on relative fair value after transaction costs 9.6 BioNTech | MCSA | Investor A Class of Stock A Amounts of related party transaction 0.0 BioNTech | MCSA | Investor | Estimate of Fair Value Measurement A Class of Stock A Amounts of related party transaction 0.0 Allocated consideration based on relative fair value 0.0 Net allocated consideration based on relative fair value after transaction costs \$ 0.0 X - DefinitionRelated Party Transaction, Amounts Of Transaction, Allocated Based On Relative Fair Value + ReferencesNo definition available. + Details Name: autl_RelatedPartyTransactionAmountsOfTransactionAllocatedBasedOnRelativeFairValue Namespace Prefix: autl_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionRelated Party Transaction, Amounts Of Transaction, Net Of Issuance Cost. + ReferencesNo definition available. + Details Name: autl_RelatedPartyTransactionAmountsOfTransactionNetOfIssuanceCost Namespace Prefix: autl_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionUnits Of Accounting + ReferencesNo definition available. + Details Name: autl_UnitsOfAccounting Namespace Prefix: autl_Data Type: xbrli:integerItemType Balance Type: na Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: [http://www.xbrl.org/2003/role/exampleRef-Topic 505-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 13-Subparagraph \(d\)](http://www.xbrl.org/2003/role/exampleRef-Topic 505-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 13-Subparagraph (d)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481112/505-10-50-13>Reference 2: <http://www.xbrl.org/2003/role/recommendedDisclosureRef-Topic 272-SubTopic 10-Name Accounting Standards Codification-Section 45-Paragraph 3> -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483014/272-10-45-3>Reference 3: <http://www.xbrl.org/2003/role/disclosureRef-Topic 272-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 1> -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482987/272-10-50-1>Reference 4: [http://www.xbrl.org/2009/role/commonPracticeRef-Topic 235-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.4-08\(d\)\)](http://www.xbrl.org/2009/role/commonPracticeRef-Topic 235-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.4-08(d))) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480678/235-10-S99-1>Reference 5: [http://www.xbrl.org/2003/role/disclosureRef-Topic 505-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 13-Subparagraph \(a\)](http://www.xbrl.org/2003/role/disclosureRef-Topic 505-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 13-Subparagraph (a)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481112/505-10-50-13>Reference 6: [http://www.xbrl.org/2003/role/disclosureRef-Topic 505-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 13-Subparagraph \(b\)](http://www.xbrl.org/2003/role/disclosureRef-Topic 505-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 13-Subparagraph (b)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481112/505-10-50-13>Reference 7: [http://www.xbrl.org/2003/role/disclosureRef-Topic 505-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 13-Subparagraph \(c\)](http://www.xbrl.org/2003/role/disclosureRef-Topic 505-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 13-Subparagraph (c)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481112/505-10-50-13>Reference 8: [http://www.xbrl.org/2003/role/disclosureRef-Topic 505-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 13-Subparagraph \(h\)](http://www.xbrl.org/2003/role/disclosureRef-Topic 505-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 13-Subparagraph (h)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481112/505-10-50-13>Reference 9: [http://www.xbrl.org/2003/role/disclosureRef-Topic 505-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 14-Subparagraph \(b\)](http://www.xbrl.org/2003/role/disclosureRef-Topic 505-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 14-Subparagraph (b)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481112/505-10-50-14>Reference 10: [http://www.xbrl.org/2003/role/disclosureRef-Topic 505-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 18-Subparagraph \(c\)](http://www.xbrl.org/2003/role/disclosureRef-Topic 505-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 18-Subparagraph (c)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481112/505-10-50-18>Reference 11: [http://www.xbrl.org/2003/role/disclosureRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.5-02\(27\)\(b\)\)](http://www.xbrl.org/2003/role/disclosureRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.5-02(27)(b))) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1>Reference 12: [http://www.xbrl.org/2003/role/disclosureRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.5-02\(28\)\)](http://www.xbrl.org/2003/role/disclosureRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.5-02(28))) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1>Reference 13: <http://www.xbrl.org/2003/role/disclosureRef-Topic 505-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2> -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481112/505-10-50-2>Reference 14: [http://www.xbrl.org/2003/role/disclosureRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.5-02\(29\)\)](http://www.xbrl.org/2003/role/disclosureRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.5-02(29))) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1>Reference 15: [http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 3-Subparagraph \(SX 210.6-03\(i\)\(2\)\)](http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 3-Subparagraph (SX 210.6-03(i)(2))) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479886/946-10-S99-3>Reference 16: [http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 3-Subparagraph \(SX 210.6-03\(i\)\(1\)\)](http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 3-Subparagraph (SX 210.6-03(i)(1))) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479886/946-10-S99-3>Reference 17: [http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 3-Subparagraph \(SX 210.6-03\(i\)\(2\)\(ii\)\)](http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 3-Subparagraph (SX 210.6-03(i)(2)(ii))) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479886/946-10-S99-3> + Details Name: us-gaap_ClassOfStockLineItems Namespace Prefix: us-gaap_Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe total of the cash outflow during the period which has been paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt and the cost incurred directly for the issuance of equity securities. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification-Topic 230-SubTopic 10-Section 45-Paragraph 15> -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482740/230-10-45-15> + Details Name: us-gaap_PaymentOffFinancingAndStockIssuanceCosts Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of transactions with related party during the financial reporting period. + ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef-Topic 850-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 1-Subparagraph \(c\)](http://www.xbrl.org/2003/role/disclosureRef-Topic 850-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 1-Subparagraph (c)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483326/850-10-50-1>Reference 2: <http://www.xbrl.org/2003/role/disclosureRef-Topic 850-SubTopic 10-Section 50-Paragraph 3> -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483326/850-10-50-3> + Details Name: us-gaap_RelatedPartyTransactionAmountsOfTransaction Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - Details Name: srt_CounterpartyNameAxis=autl_BioNTechMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_InvestorMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_RelatedPartyTransactionAxis=autl_InitialADSsRepresentingOrdinarySharesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_RelatedPartyTransactionAxis=autl_SubsequentADSsRepresentingOrdinarySharesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_RelatedPartyTransactionAxis=autl_BioNTechLicenseAndOptionsAgreementMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_RelatedPartyTransactionAxis=autl_LiabilityRelatedToTheSaleOfFutureRoyaltiesAndSalesMilestonesNetMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_RelatedPartyTransactionAxis=autl_LicenseRevenueMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_RelatedPartyTransactionAxis=autl_ManufacturingCommercialServicesAgreementMCSAMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 49 R39.htm IDEA: XBRL DOCUMENT V3.24.2.u1 Summary of Significant Accounting Policies - Narrative (Details) - USD (\$) \$ in Thousands 3 Months Ended Jun. 30, 2024 Mar. 31, 2024 Mar. 31, 2024 Jun. 30, 2024 Jun. 30, 2024 Jun. 30, 2024 Dec. 31, 2023 Accounting Policies [Abstract] A A A A A A Net loss \$ (58,272) \$ (52,690) \$ (45,552) \$ (39,811) \$ (110,962) \$ (85,363) A Accumulated deficit (989,524) A A A (989,524) A \$ (878,562) Cash and cash equivalents 705,939 A 307,500 A 705,939 307,500 A 239,566 Foreign currency gain (loss) \$ 1,200 A \$ 400 A \$ (500) \$ 1,300 A X - ReferencesNo definition available. + Details Name: us-gaap_AccountingPoliciesAbstract Namespace Prefix: us-gaap_Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation. + ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.5-02\(1\)\)](http://www.xbrl.org/2003/role/disclosureRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.5-02(1))) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1>Reference 2: [http://www.xbrl.org/2003/role/exampleRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section 45-Paragraph 1-Subparagraph \(a\)](http://www.xbrl.org/2003/role/exampleRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section 45-Paragraph 1-Subparagraph (a)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483467/210-10-45-1>Reference 3: <http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification-Topic 230-SubTopic 10-Section 45-Paragraph 4> -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482740/230-10-45-4> + Details Name: us-gaap_CashAndCashEquivalentsAtCarryingValue Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount, before tax, of realized and unrealized gain (loss) from foreign currency transaction. + ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 220-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.6-07\(7\)\)](http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 220-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.6-07(7))) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479134/946-220-S99-1>Reference 2: <http://www.xbrl.org/2003/role/disclosureRef-Topic 830-SubTopic 20-Name Accounting Standards Codification-Section 35-Paragraph 1> -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482014/830-20-35-1>Reference 3: <http://www.xbrl.org/2003/role/disclosureRef-Topic 830-SubTopic 20-Name Accounting Standards Codification-Section 45-Paragraph 1> -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481956/830-20-45-1>Reference 4: <http://www.xbrl.org/2003/role/disclosureRef-Topic 830-SubTopic 20-Name Accounting Standards Codification-Section 50-Paragraph 1> -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481926/830-20-50-1>Reference 5: <http://www.xbrl.org/2003/role/disclosureRef-Topic 830-SubTopic 20-Name Accounting Standards Codification-Section 50-Paragraph 1> -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481926/830-20-50-1>Reference 5: <http://www.xbrl.org/2003/role/disclosureRef-Topic 830-SubTopic 20-Name Accounting Standards Codification-Section 50-Paragraph 1> -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481926/830-20-50-1>Reference 5: <http://www.xbrl.org/2003/role/disclosureRef-Topic 830-SubTopic 20-Name Accounting Standards Codification-Section 50-Paragraph 1> -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481926/830-20-50-1>Reference 5: <http://www.xbrl.org/2003/role/disclosureRef-Topic 830-SubTopic 20-Name Accounting Standards Codification-Section 50-Paragraph 1> -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481926/830-20-50-1>Reference 5: <http://www.xbrl.org/2003/role/disclosureRef-Topic 830-SubTopic 20-Name Accounting Standards Codification-Section 50-Paragraph 1> -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481926/830-20-50-1>Reference 5: <http://www.xbrl.org/2003/role/disclosureRef-Topic 830-SubTopic 20-Name Accounting Standards Codification-Section 50-Paragraph 1> -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481926/830-20-50-1>Reference 5: <http://www.xbrl.org/2003/role/disclosureRef-Topic 830-SubTopic 20-Name Accounting Standards Codification-Section 50-Paragraph 1> -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481926/830-20-50-1>Reference 5: <http://www.xbrl.org/2003/role/disclosureRef-Topic 830-SubTopic 20-Name Accounting Standards Codification-Section 50-Paragraph 1> -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481926/830-20-50-1>Reference 5: <http://www.xbrl.org/2003/role/disclosureRef-Topic 830-SubTopic 20-Name Accounting Standards Codification-Section 50-Paragraph 1> -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481926/830-20-50-1>Reference 5: <http://www.xbrl.org/2003/role/disclosureRef-Topic 830-SubTopic 20-Name Accounting Standards Codification-Section 50-Paragraph 1> -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481926/830-20-50-1>Reference 5: <http://www.xbrl.org/2003/role/disclosureRef-Topic 830-SubTopic 20-Name Accounting Standards Codification-Section 50-Paragraph 1> -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481926/830-20-50-1>Reference 5: <http://www.xbrl.org/2003/role/disclosureRef-Topic 830-SubTopic 20-Name Accounting Standards Codification-Section 50-Paragraph 1> -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481926/830-20-50-1>Reference 5: <http://www.xbrl.org/2003/role/disclosureRef-Topic 830-SubTopic 20-Name Accounting Standards Codification-Section 50-Paragraph 1> -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481926/830-20-50-1>Reference 5: <http://www.xbrl.org/2003/role/disclosureRef-Topic 830-SubTopic 20-Name Accounting Standards Codification-Section 50-Paragraph 1> -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481926/830-20-50-1>Reference 5: [http://www.xbrl.org/2003/role/disclosureRef-Topic 830-SubTopic 20-Name Accounting Standards Codification-Section 50-Paragraph](http://www.xbrl.org/2003/role/disclosureRef-Topic 830-SubTopic 20-Name Accounting Standards Codification-Section 50-Paragraph 1)

830 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 17 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481839/830-10-45-17 + Details Name: us-gaap ForeignCurrencyTransactionGainLossBeforeTax Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478667/740-323-65-2Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(iii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 17: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/214749168/946-830-55-10Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(ii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 32: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 37: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 + Details Name: us-gaap NetIncomeLoss Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of accumulated undistributed earnings (deficit). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)(a)(3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (h)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(23)(a)(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(17)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap RetainedEarningsAccumulatedDeficit Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant XML 50 R40.htm IDEA: XBRL DOCUMENT v3.24.2.u1 License Revenue - Disaggregation of Revenue (Details) - License revenue - USD (\$) in Thousands 3 Months Ended 6 Months Ended Jun. 30, 2024 Jun. 30, 2023 Jun. 30, 2023 Disaggregation of Revenue [Line Items] Á Á Á Total license revenue \$ 0 \$ 0 \$ 10,091 \$ 1,292 United States Á Á Á Disaggregation of Revenue [Line Items] Á Á Á Total license revenue 0 0 0 1,292 Germany Á Á Á Disaggregation of Revenue [Line Items] Á Á Á Total license revenue \$ 0 \$ 0 \$ 10,091 \$ 0 X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91Reference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91Reference 5: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91Reference 6: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91Reference 7: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91Reference 8: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91 + Details Name: us-gaap DisaggregationOfRevenueLineItems Namespace Prefix: us-gaap Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 924 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 11.L) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4 + Details Name: us-gaap RevenueFromContractWithCustomerExcludingAssessedTax Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - Details Name: srt ProductOrServiceAxis=us-gaap LicenseMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt StatementGeographicalAxis=country US Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt StatementGeographicalAxis=country DE Namespace Prefix: Data Type: na Balance Type: Period Type: XML 51 R41.htm IDEA: XBRL DOCUMENT v3.24.2.u1 License revenue - Narrative (Details) 3 Months Ended 6 Months Ended Jun. 09, 2023 USD (\$) Jun. 30, 2024 USD (\$) financialInstrument performanceObligation Mar. 31, 2024 USD (\$) Jun. 30, 2023 USD (\$) Jun. 30, 2024 USD (\$) financialInstrument performanceObligation Jun. 30, 2023 USD (\$) Feb. 06, 2024 USD (\$) Disaggregation of Revenue [Line Items] Á Á Á Á Á Number of freestanding financial instruments | financialInstrument Á Á Á Á Á Number of combined performance obligations | performanceObligation Á Á Á Á Á Á Á Distinct performance obligation | performanceObligation Á Á Á Á Á Á BioNTech And Cabaletta | Revenue Benchmark | Customer Concentration Risk Á Á Á Á Á Á Disaggregation of Revenue [Line Items] Á Á Á Á Á Concentration risk (in percent) Á Á Á Á Á 100.00% 100.00% Á License revenue Á Á Á Á Á Á Disaggregation of Revenue [Line Items] Á Á Á Á Á Revenue from contract with customer Á 0 Á 0 \$ 10,091,000 \$ 1,292,000 Á License revenue | Cabaletta Bio Inc. (á€œCabalettaá€) Á Á Á Á Á Á Disaggregation of Revenue [Line Items] Á Á Á Á Á Revenue from contract with customer \$ 1,200,000 0 Á Á 0 \$ 1,200,000 Á License revenue | BioNTech Á Á Á Á Á Á Disaggregation of Revenue [Line Items] Á Á Á Á Á Revenue from contract with customer \$ 0 \$ 10,100,000 Á Á Á License And Options | BioNTech Á Á Á Á Á Á Disaggregation of Revenue [Line Items] Á Á Á Á Á Remaining performance obligation, variable consideration amount Á Á Á Á Á \$ 32,000,000 Technology Options | BioNTech Á Á Á Á Á Á Disaggregation of Revenue [Line Items] Á Á Á Á Á Revenue from contract with customer Á Á Á Á \$ 10,000,000 Á X - DefinitionNumber Of Combined Performance Obligations + ReferencesNo definition available. + Details Name: autl_NumberOfCombinedPerformanceObligations Namespace Prefix: autl Data Type: xbrli:integerItemType Balance Type: na Period Type: instant X - DefinitionNumber Of Distinct Performance Obligations + ReferencesNo definition available. + Details Name: autl_NumberOfDistinctPerformanceObligations Namespace Prefix: autl Data Type: xbrli:integerItemType Balance Type: na Period Type: instant X - DefinitionNumber Of Freestanding Financial Instruments + ReferencesNo definition available. + Details Name: autl_NumberOfFreestandingFinancialInstruments Namespace Prefix: autl Data Type: xbrli:integerItemType Balance Type: na Period Type: instant X - DefinitionRevenue, Remaining Performance Obligation, Variable Consideration Amount + ReferencesNo definition available. + Details Name:

RevenueRemainingPerformanceObligationableConsiderationAmount Namespace Prefix: Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionFor an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42>Reference 2: [http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 825 -SubTopic 10 -Section 50 -Paragraph 21 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-21](http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 825 -SubTopic 10 -Section 50 -Paragraph 21 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-21)Reference 3: <http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 18 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-18>Reference 5: <http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 20 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-20> + Details Name: us-gaap_ConcentrationRiskPercentage1 Namespace Prefix: us-gaap_Data Type: dtr-types:percentItem Balance Type: na Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5>Reference 2: [http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph \(f\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91](http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91)Reference 3: [http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph \(b\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91](http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91)Reference 4: [http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph \(c\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91](http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91)Reference 5: [http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph \(d\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91](http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91)Reference 6: [http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph \(e\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91](http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91)Reference 7: [http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph \(f\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91](http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91)Reference 8: [http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph \(g\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91](http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91) + Details Name: us-gaap_DisaggregationOfRevenueLineItems Namespace Prefix: us-gaap_Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise. + ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41](http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41)Reference 2: [http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph \(i\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1)Reference 3: [http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph \(ee\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32](http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32)Reference 4: [http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph \(b\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32](http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32)Reference 5: [http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32](http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32)Reference 6: [http://www.xbrl.org/2003/role/disclosureRef -Topic 924 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SAB Topic 11.L\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 924 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 11.L) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1)Reference 7: <http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5>Reference 8:

https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-28Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1-Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(27)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7 + Details Name: us-gaap_EarningsPerShareDiluted Namespace Prefix: us-gaap_Data Type: dtr-types:perShareItem Type Balance Type: na Period Type: duration X - DefinitionThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(iii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1-Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 17: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 32: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 37: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 + Details Name: us-gaap_NetIncomeLoss Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItem Type Balance Type: credit Period Type: duration X - DefinitionAmount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 5 -Subparagraph (SAB Topic 6.B) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-5Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-11Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B + Details Name: us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItem Type Balance Type: credit Period Type: duration X - DefinitionAmount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) available to common shareholders. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 5 -Subparagraph (SAB Topic 6.B) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-5Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 16 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 40 -Subparagraph (b)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-40Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 40 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-40Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 40 -Subparagraph (b)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-40 + Details Name: us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItem Type Balance Type: credit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract Namespace Prefix: us-gaap_Data Type: xbrli:stringItem Type Balance Type: na Period Type: duration X - DefinitionThe average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10 + Details Name: us-gaap_WeightedAverageNumberOfSharesOutstandingBasic Namespace Prefix: us-gaap_Data Type: xbrli:sharesItem Type Balance Type: na Period Type: duration X - DefinitionNumber of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1 + Details Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount Namespace Prefix: us-gaap_Data Type: xbrli:sharesItem Type Balance Type: na Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesNo definition available. + Details Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems Namespace Prefix: us-gaap_Data

Type: xbrli:stringItem Type: na Balance Type: na Period Type: duration X - Details Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 55 R45.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Fair value measurements (Details) - USD (\$) in Thousands Jun. 30, 2024 Dec. 31, 2023 Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] A A Cash and cash equivalents: \$ 528,910 \$ 184,635 Money market funds A A Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] A A Cash and cash equivalents: 528,910 184,635 Quoted Prices in Active Markets for Identical Assets (Level 1) A A Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] A A Cash and cash equivalents: 528,910 184,635 Quoted Prices in Active Markets for Identical Assets (Level 1) | Money market funds A A Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] A A Cash and cash equivalents: 528,910 184,635 Significant Other Observable Inputs (Level 2) A A Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] A A Cash and cash equivalents: 0 0 Significant Other Observable Inputs (Level 2) | Money market funds A A Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] A A Cash and cash equivalents: 0 0 Significant Unobservable Inputs (Level 3) A A Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] A A Cash and cash equivalents: 0 0 Significant Unobservable Inputs (Level 3) | Money market funds A A Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] A A Cash and cash equivalents: \$ 0 \$ 0 X - DefinitionFair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. + ReferencesReference 1: [http://www.xbrl.org/2009/role/commonPracticeRef-Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(b\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2](http://www.xbrl.org/2009/role/commonPracticeRef-Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2)Reference 2: [http://www.xbrl.org/2009/role/commonPracticeRef-Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2](http://www.xbrl.org/2009/role/commonPracticeRef-Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2) + Details Name: us-gaap_CashAndCashEquivalentsFairValueDisclosure Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItem Type: na Balance Type: debit Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: <http://www.xbrl.org/2003/role/exampleRef-Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 100 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100>Reference 2: [http://www.xbrl.org/2003/role/disclosureRef-Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(b\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2](http://www.xbrl.org/2003/role/disclosureRef-Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2)Reference 3: [http://www.xbrl.org/2003/role/disclosureRef-Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2](http://www.xbrl.org/2003/role/disclosureRef-Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2) + Details Name: us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItem Type: na Balance Type: na Period Type: duration X - Details Name: us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member Namespace Prefix: Data Type: na Balance Type: Period Type: XML 56 R46.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Prepaid Expenses and Other Current Assets (Details) - USD (\$) Jun. 30, 2024 Dec. 31, 2023 Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract] A A Research and development claims receivable \$ 27,750,000 \$ 19,209,000 Prepayments 11,865,000 8,638,000 VAT receivable 3,597,000 2,771,000 Accrued interest income 2,597,000 999,000 Deferred cost 1,782,000 1,787,000 Other taxes receivable 1,585,000 0 Other receivables 957,000 516,000 Lease and lease deposit receivable 938,000 938,000 Corporate tax receivable 570,000 0 Accounts receivable 0 109,000 Prepaid expenses and other current assets \$ 51,641,000 \$ 34,967,000 X - DefinitionAccrued Interest Income, Current + ReferencesNo definition available. + Details Name: autl_AccruedInterestIncomeCurrent Namespace Prefix: autl_ Data Type: xbrli:monetaryItem Type: na Balance Type: debit Period Type: instant X - DefinitionCorporate Tax, Current + ReferencesNo definition available. + Details Name: autl_CorporateTaxCurrent Namespace Prefix: autl_ Data Type: xbrli:monetaryItem Type: na Balance Type: debit Period Type: instant X - DefinitionLease And Lease Deposit Receivable, Current + ReferencesNo definition available. + Details Name: autl_LeaseAndLeaseDepositReceivableCurrent Namespace Prefix: autl_ Data Type: xbrli:monetaryItem Type: na Balance Type: debit Period Type: instant X - DefinitionOther Taxes Receivable Current + ReferencesNo definition available. + Details Name: autl_OtherTaxesReceivableCurrent Namespace Prefix: autl_ Data Type: xbrli:monetaryItem Type: na Balance Type: debit Period Type: instant X - DefinitionResearch And Development Claims Receivable, Current + ReferencesNo definition available. + Details Name: autl_ResearchAndDevelopmentClaimsReceivableCurrent Namespace Prefix: autl_ Data Type: xbrli:monetaryItem Type: na Balance Type: debit Period Type: instant X - DefinitionAmount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current. + ReferencesReference 1: <http://www.xbrl.org/2009/role/commonPracticeRef-Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481990/310-10-45-2> + Details Name: us-gaap_AccountsReceivableNetCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItem Type: na Balance Type: debit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItem Type: na Balance Type: na Period Type: duration X - DefinitionSum of the carrying amounts as of the balance sheet date of deferred costs capitalized at the end of the reporting period that are expected to be charged against earnings within one year or the normal operating cycle, if longer. + ReferencesReference 1: [http://www.xbrl.org/2009/role/commonPracticeRef-Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.5-02\(8\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1](http://www.xbrl.org/2009/role/commonPracticeRef-Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1) + Details Name: us-gaap_DeferredCostsCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItem Type: na Balance Type: debit Period Type: instant X - DefinitionAmount, after allowance, of receivables classified as other, due within one year or the operating cycle, if longer. + ReferencesNo definition available. + Details Name: us-gaap_OtherReceivablesNetCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItem Type: na Balance Type: debit Period Type: instant X - DefinitionAmount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer. + ReferencesReference 1: [http://www.xbrl.org/2009/role/commonPracticeRef-Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.5-02\(9\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1](http://www.xbrl.org/2009/role/commonPracticeRef-Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1) + Details Name: us-gaap_PrepaidExpenseAndOtherAssetsCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItem Type: na Balance Type: debit Period Type: instant X - DefinitionAmount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer. + ReferencesReference 1: [http://www.xbrl.org/2003/role/exampleRef-Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph \(g\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1](http://www.xbrl.org/2003/role/exampleRef-Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1)Reference 2: [http://www.xbrl.org/2003/role/disclosureRef-Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.5-02\(7\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1)Reference 3: <http://www.xbrl.org/2003/role/disclosureRef-Topic 340 -SubTopic 10 -Name Accounting Standards Codification -Section 05 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482955/340-10-05-5>Reference 4: <http://www.xbrl.org/2003/role/disclosureRef-Topic 340 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483032/340-10-45-1> + Details Name: us-gaap_PrepaidExpenseCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItem Type: na Balance Type: debit Period Type: instant X - DefinitionCarrying amount as of the balance sheet date of value added taxes due either from customers arising from sales on credit terms, or as previously overpaid to tax authorities. For classified balance sheets, represents the current amount receivable, that is amounts expected to be collected within one year or the normal operating cycle, if longer. + ReferencesReference 1: [http://www.xbrl.org/2009/role/commonPracticeRef-Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.5-02\(3\)\(a\)\(4\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1](http://www.xbrl.org/2009/role/commonPracticeRef-Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(3)(a)(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1) + Details Name: us-gaap_ValueAddedTaxReceivableCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItem Type: na Balance Type: debit Period Type: instant X - Details Name: XBRL DOCUMENT v3.24.2.u1 Property and Equipment, Net - Schedule of PPE (Details) - USD (\$) in Thousands Jun. 30, 2024 Dec. 31, 2023 Property, Plant and Equipment A A Less: accumulated depreciation \$ (32,286) \$ (28,774) Total property and equipment, net 32,860 34,862 Lab equipment A A Property, Plant and Equipment A A Property and equipment, gross 41,307 32,232 Office equipment A A Property, Plant and Equipment A A Property and equipment, gross 5,017 3,777 Furniture and fixtures A A Property, Plant and Equipment A A Property and equipment, gross 2,353 2,360 Leasehold improvements A A Property, Plant and Equipment A A Property and equipment, gross 14,220 12,728 Assets under construction A A Property, Plant and Equipment A A Property and equipment, gross \$ 2,249 \$ 12,539 X - DefinitionAmount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services. + ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef-Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.7-03\(a\)\(8\)\(b\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(8)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1)Reference 2: [http://www.xbrl.org/2003/role/disclosureRef-Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.5-02\(14\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(14)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1)Reference 3: [http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification -Topic 360 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph \(c\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1](http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification -Topic 360 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1) + Details Name: us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItem Type: na Balance Type: credit Period Type: instant X - DefinitionAmount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures. + ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef-Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.7-03\(a\)\(8\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1)Reference 2: [http://www.xbrl.org/2003/role/disclosureRef-Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.5-02\(13\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(13)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1)Reference 3: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph \(b\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1) + Details Name: us-gaap_PropertyPlantAndEquipmentGross Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItem Type: na Balance Type: debit Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef-Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7A -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A](http://www.xbrl.org/2003/role/disclosureRef-Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A) + Details Name: us-gaap_PropertyPlantAndEquipmentLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItem Type: na Balance Type: na Period Type: duration X - DefinitionAmount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification -Section 50 -Paragraph 1 -SubTopic 10 -Topic 360 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1>Reference 2: [http://www.xbrl.org/2003/role/disclosureRef-Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7A -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A](http://www.xbrl.org/2003/role/disclosureRef-Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A)Reference 3: <http://www.xbrl.org/2003/role/exampleRef-Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10>Reference 4: [http://www.xbrl.org/2003/role/disclosureRef-Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.7-03\(a\)\(8\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1)Reference 5: <http://www.xbrl.org/2003/role/disclosureRef-Topic 942 -SubTopic 360 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1> + Details Name: us-gaap_PropertyPlantAndEquipmentNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItem Type: na Balance Type: debit Period Type: instant X - Details Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_AssetUnderConstructionMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 58 R48.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Property and Equipment, Net - Narratives (Details) - USD (\$) in Millions 3 Months Ended 6 Months Ended Jun. 30, 2024 Jun. 30, 2023 Jun. 30, 2024 Jun. 30, 2023 Property, Plant and Equipment [Abstract] A A A Depreciation expense \$ 1.9 \$ 1.5 \$ 3.7 \$ 3.4 X - DefinitionThe amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation. + ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph \(b\) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28](http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28)Reference 2: [http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification -Topic 360 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1](http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification -Topic 360 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1) + Details Name: us-gaap_Depreciation Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItem Type: na Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_PropertyPlantAndEquipmentAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItem Type: na Balance Type: na Period Type: duration XML 59 R49.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Accrued Expenses and Other Liabilities (Details) - USD (\$) in Thousands Jun. 30, 2024 Dec. 31, 2023 Payables and Accruals [Abstract] A A Research and development costs \$ 17,930 \$ 19,825 Compensation and benefits 10,459 14,757 Professional fees 6,808 4,466 Other accrued liabilities 382 533 Total accrued expenses and other liabilities \$ 35,579 \$ 39,581 X - DefinitionAccrued Research And Development Cost, Current + ReferencesNo definition available. + Details Name: autl_AccruedResearchAndDevelopmentCostCurrent Namespace Prefix: autl_ Data Type: xbrli:monetaryItem Type: na Balance Type: credit Period Type: instant X - DefinitionAmount of expenses incurred but not yet paid nor invoiced, and liabilities classified as other. + ReferencesNo definition available. + Details Name: us-gaap_AccruedLiabilitiesAndOtherLiabilities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItem Type: na Balance Type: credit Period Type: instant X - DefinitionCarrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). + ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.5-02\(20\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1) + Details Name: us-gaap_AccruedProfessionalFeesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItem Type: na Balance Type: credit Period Type: instant X - DefinitionTotal of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and

fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1> + Details Name: us-gaap_EmployeeRelatedLiabilitiesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of liabilities classified as other, due within one year or the normal operating cycle, if longer. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef> -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481372/852-10-55-10> + Details Name: us-gaap_OtherLiabilitiesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_PayablesAndAccrualsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 60 R50.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Shareholders' Equity - Narrative (Details) \$ / shares in Units, \$ in Millions Feb. 13, 2024 USD (\$) \$ / shares shares Feb. 12, 2024 USD (\$) \$ / shares shares Jun. 30, 2024 vote shares Feb. 06, 2024 shares Class of Stock A A A Voting rights, votes per share | vote A A 1 A Unvested restricted stock units A A A Class of Stock A A A Vested not issued (in shares) A A 100 A BioNTech A A A Class of Stock A A A Collaborative arrangement, period to enter agreement from initial closing date (in months) 18 months A A A Ordinary Shares A A A Class of Stock A A A Number of shares issued in transaction (in shares) 33,333,333 A A A Per share price of issuance (usd per share) | \$ / shares \$ 6.00 A A A Proceeds of issuance of ordinary shares, net of issuance costs | \$ \$ 193.8 A A A Ordinary Shares | BioNTech A A A Class of Stock A A A Collaborative arrangement, rights and obligations, maximum share purchase requirement, shares (in shares) 15,000,000 A A A Collaborative arrangement, rights and obligations, maximum share purchase requirement, value | \$ \$ 20.0 A A A Ordinary Shares | BioNTech A A A Class of Stock A A A Stockholders' equity, common stock, conversion ratio A A 1 Ordinary Shares | Underwriters public offering A A A Class of Stock A A A Number of shares issued in transaction (in shares) A 58,333,336 A A Per share price of issuance (usd per share) | \$ / shares \$ 6.00 A A A Proceeds of issuance of ordinary shares, net of issuance costs | \$ \$ 326.8 A A X - DefinitionCollaborative Arrangement, Period To Enter Agreement From Initial Closing Date + ReferencesNo definition available. + Details Name: autl_CollaborativeArrangementPeriodToEnterAgreementFromInitialClosingDate Namespace Prefix: autl_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionCollaborative Arrangement, Rights And Obligations, Maximum Share Purchase Requirement, Shares + ReferencesNo definition available. + Details Name: autl_CollaborativeArrangementRightsAndObligationsMaximumSharePurchaseRequirementShares Namespace Prefix: autl_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionCollaborative Arrangement, Rights And Obligations, Maximum Share Purchase Requirement, Value + ReferencesNo definition available. + Details Name: autl_CollaborativeArrangementRightsAndObligationsMaximumSharePurchaseRequirementValue Namespace Prefix: autl_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionCommon Stock, Voting Rights, Votes Per Share + ReferencesNo definition available. + Details Name: autl_CommonStockVotingRightsVotesPerShare Namespace Prefix: autl_ Data Type: xbrli:integerItemType Balance Type: na Period Type: instant X - DefinitionShare-based Compensation Arrangement by Share-based Payment Award, Not-Option Equity Instruments, Not Issued, Vested, Number + ReferencesNo definition available. + Details Name: autl_ShareBasedCompensationArrangementByShareBasedPaymentAwardNotOptionEquityInstrumentsNotIssuedVestedNumber Namespace Prefix: autl_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionStockholders' Equity, Common Stock, Conversion Ratio + ReferencesNo definition available. + Details Name: autl_StockholdersEquityCommonStockConversionRatio Namespace Prefix: autl_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: <http://www.xbrl.org/2003/role/exampleRef> -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (d) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef> -Topic 272 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483014/272-10-45-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef> -Topic 272 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482987/272-10-50-1Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(d)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef> -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (a) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 6: http://www.xbrl.org/2003/role/disclosureRef> -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (b) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 7: http://www.xbrl.org/2003/role/disclosureRef> -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (c) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 8: http://www.xbrl.org/2003/role/disclosureRef> -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (h) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 9: http://www.xbrl.org/2003/role/disclosureRef> -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 14 -Subparagraph (b) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481112/505-10-50-14Reference 10: http://www.xbrl.org/2003/role/disclosureRef> -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph (c) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481112/505-10-50-18Reference 11: http://www.xbrl.org/2003/role/disclosureRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(27)(b)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 12: http://www.xbrl.org/2003/role/disclosureRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 14: http://www.xbrl.org/2003/role/disclosureRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 15: http://www.xbrl.org/2003/role/disclosureRef> -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(2)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479886/946-10-S99-3Reference 16: http://www.xbrl.org/2003/role/disclosureRef> -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(1)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479886/946-10-S99-3Reference 17: http://www.xbrl.org/2003/role/disclosureRef> -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(2)(i)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479886/946-10-S99-3Reference 18: http://www.xbrl.org/2003/role/disclosureRef> -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(2)(ii)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479886/946-10-S99-3> + Details Name: us-gaap_ClassOfStockLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionCash received on stock transaction after deduction of issuance costs. + ReferencesNo definition available. + Details Name: us-gaap_SaleOfStockConsiderationReceivedOnTransaction Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe number of shares issued or sold by the subsidiary or equity method investee per stock transaction. + ReferencesNo definition available. + Details Name: us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionPer share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction. + ReferencesNo definition available. + Details Name: us-gaap_SaleOfStockPricePerShare Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - Details Name: us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_CounterpartyNameAxis=autl_BioNTechMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: dei_LegalEntityAxis=autl_BioNTechMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_SubsidarySaleOfStockAxis=autl_PublicStockOfferingMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 61 R51.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Share-based Compensation - Share-based Compensation Allocation (Details) - USD (\$) \$ in Thousands 3 Months Ended 6 Months Ended Jun. 30, 2024 Jun. 30, 2023 Jun. 30, 2024 Jun. 30, 2023 Share-based Compensation Arrangement by Share-based Payment Award A A A Total share-based compensation expense 2,935 \$ 5,219 \$ 5,084 Research and development A A A Share-based Compensation Arrangement by Share-based Payment Award A A A Total share-based compensation expense 1,048 1,776 1,498 3,457 General and administrative A A A Share-based Compensation Arrangement by Share-based Payment Award A A A Total share-based compensation expense 1,887 885 3,723 1,612 Capitalized A A A Share-based Compensation Arrangement by Share-based Payment Award A A A Total share-based compensation expense \$ 0 \$ 7 (2) \$ 15 X - DefinitionAmount of expense for award under share-based payment arrangement. Excludes amount capitalized. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 14.F) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479830/718-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef> -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (h)(1)(i) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480429/718-10-50-2> + Details Name: us-gaap_AllocatedShareBasedCompensationExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 1D -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480483/718-10-35-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef> -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 3 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480483/718-10-35-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef> -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef> -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(2) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef> -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(3) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef> -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(i) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 7: http://www.xbrl.org/2003/role/disclosureRef> -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(01) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 8: http://www.xbrl.org/2003/role/disclosureRef> -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(02) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 9: http://www.xbrl.org/2003/role/disclosureRef> -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(03) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 10: http://www.xbrl.org/2003/role/disclosureRef> -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(04) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 11: http://www.xbrl.org/2003/role/disclosureRef> -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(i) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 12: http://www.xbrl.org/2003/role/disclosureRef> -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(03) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 13: http://www.xbrl.org/2003/role/disclosureRef> -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(04) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 14: http://www.xbrl.org/2003/role/disclosureRef> -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(i) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 15: http://www.xbrl.org/2003/role/disclosureRef> -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(ii) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 16: http://www.xbrl.org/2003/role/disclosureRef> -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 17: http://www.xbrl.org/2003/role/disclosureRef> -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(01) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 18: http://www.xbrl.org/2003/role/disclosureRef> -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(02) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 19: http://www.xbrl.org/2003/role/disclosureRef> -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(03) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 20: http://www.xbrl.org/2003/role/disclosureRef> -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(1) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 21: http://www.xbrl.org/2003/role/disclosureRef> -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(2) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 22: http://www.xbrl.org/2003/role/disclosureRef> -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(1) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 23: http://www.xbrl.org/2003/role/disclosureRef> -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(2) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 24: http://www.xbrl.org/2003/role/disclosureRef> -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(i) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 25: http://www.xbrl.org/2003/role/disclosureRef> -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(ii) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 26: http://www.xbrl.org/2003/role/disclosureRef> -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iii) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 27: http://www.xbrl.org/2003/role/disclosureRef> -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iv) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480429/718-10-50-2> + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_IncomeStatementLocationAxis=autl_CapitalizedIntangibleAssetsNetPropertyAndEquipmentMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 62 R52.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Share-Based Compensation - Share Options Rollover (Details) \$ / shares in Units, \$ in Thousands 6 Months Ended 12 Months Ended Jun. 30, 2024 USD (\$) \$ / shares shares Dec. 31, 2023 USD (\$) \$ / shares shares NumberA of Options A A Beginning balance (in shares) | shares 17,956,385 A Granted (in shares) | shares 2,793,400 A Exercised (in shares) | shares (146,310) A Forfeited (in shares) | shares (797,838) A Expired (in shares) | shares (246,781) A Ending balance (in shares) | shares 19,558,856 17,956,385 Exercisable (in

shares) | shares 8,053,441 Å Vested and expected to vest (in shares) | shares 19,558,856 Å Weighted- Average Exercise Price per share Å Å Beginning balance (in usd per share) | \$ / shares \$ 5.64 Å Granted (in usd per share) | \$ / shares 4.33 Å Exercised (in usd per share) | \$ / shares 2.77 Å Forfeited (in usd per share) | \$ / shares 3.39 Å Expired (in usd per share) | \$ / shares 9.38 Å Ending balance (in usd per share) | \$ / shares 5.51 Å 5.64 Exercisable (in usd per share) | \$ / shares 8.63 Å Vested and expected to vest (in usd per share) | \$ / shares 5.51 Å Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract] Å Å Weighted average contractual term outstanding 8 years 1 month 20 days 8 years 4 months 6 days Weighted average contractual term exercisable 6 years 11 months 12 days Å Weighted average contractual term vested and expected to vest 8 years 1 month 20 days Å Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest [Abstract] Å Å Options outstanding, Aggregate Intrinsic Value | \$ \$ 11,834 \$ 48,968 Options granted, Aggregate Intrinsic Value | \$ 54 Å Options exercised, Aggregate Intrinsic Value | \$ 369 Å Options forfeited, Aggregate Intrinsic Value | \$ 645 Å Options expired, Aggregate Intrinsic Value | \$ 5 Å Options exercisable | \$ 3,507 Å Options vested and expected to vest | \$ \$ 11,834 Å X - DefinitionShare-based Compensation Arrangement by Share-based Payment Award, Options, Expirations In Period, Intrinsic Value + ReferencesNo definition available. + Details Name: autl_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriodIntrinsicValue Namespace Prefix: autl_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionShare-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures In Period, Intrinsic Value + ReferencesNo definition available. + Details Name: autl_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriodIntrinsicValue Namespace Prefix: autl_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionShare-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants In Period, Intrinsic Value + ReferencesNo definition available. + Details Name: autl_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodIntrinsicValue Namespace Prefix: autl_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract Namespace Prefix: us-gaap_Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iii) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480429/718-10-50-2> + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber Namespace Prefix: us-gaap_Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionThe weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iii) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480429/718-10-50-2> + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice Namespace Prefix: us-gaap_Data Type: dtr-types:perShareItemtype Balance Type: na Period Type: instant X - DefinitionAmount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(2) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480429/718-10-50-2> + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemtype Balance Type: debit Period Type: duration X - DefinitionNumber of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(04) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480429/718-10-50-2> + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod Namespace Prefix: us-gaap_Data Type: xbrli:sharesItemtype Balance Type: na Period Type: duration X - DefinitionThe number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(03) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480429/718-10-50-2> + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod Namespace Prefix: us-gaap_Data Type: xbrli:sharesItemtype Balance Type: na Period Type: duration X - DefinitionGross number of share options (or share units) granted during the period. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(01) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480429/718-10-50-2> + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross Namespace Prefix: us-gaap_Data Type: xbrli:sharesItemtype Balance Type: na Period Type: duration X - DefinitionAmount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480429/718-10-50-2> + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemtype Balance Type: debit Period Type: instant X - DefinitionNumber of options outstanding, including both vested and non-vested options. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(i) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480429/718-10-50-2>Reference 2: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(ii) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480429/718-10-50-2> + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber Namespace Prefix: us-gaap_Data Type: xbrli:sharesItemtype Balance Type: na Period Type: instant X - DefinitionA roll forward is a reconciliation of a concept from the beginning of a period to the end of a period. + ReferencesNo definition available. + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward Namespace Prefix: us-gaap_Data Type: xbrli:stringItemtype Balance Type: na Period Type: duration X - DefinitionWeighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(i) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480429/718-10-50-2>Reference 2: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(ii) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480429/718-10-50-2> + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice Namespace Prefix: us-gaap_Data Type: dtr-types:perShareItemtype Balance Type: na Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward Namespace Prefix: us-gaap_Data Type: xbrli:stringItemtype Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract Namespace Prefix: us-gaap_Data Type: xbrli:stringItemtype Balance Type: na Period Type: duration X - DefinitionAmount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(1) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480429/718-10-50-2> + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemtype Balance Type: debit Period Type: instant X - DefinitionNumber of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(1) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480429/718-10-50-2> + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber Namespace Prefix: us-gaap_Data Type: xbrli:sharesItemtype Balance Type: na Period Type: instant X - DefinitionWeighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(1) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480429/718-10-50-2> + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice Namespace Prefix: us-gaap_Data Type: dtr-types:perShareItemtype Balance Type: na Period Type: instant X - DefinitionWeighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(04) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480429/718-10-50-2> + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice Namespace Prefix: us-gaap_Data Type: dtr-types:perShareItemtype Balance Type: na Period Type: duration X - DefinitionWeighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(03) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480429/718-10-50-2> + Details Name: us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice Namespace Prefix: us-gaap_Data Type: dtr-types:perShareItemtype Balance Type: na Period Type: duration X - DefinitionWeighted average per share amount at which grantees can acquire shares of common stock by exercise of options. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(01) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480429/718-10-50-2> + Details Name: us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice Namespace Prefix: us-gaap_Data Type: dtr-types:perShareItemtype Balance Type: na Period Type: duration X - DefinitionAmount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480429/718-10-50-2> + Details Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1 Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemtype Balance Type: debit Period Type: instant X - DefinitionWeighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480429/718-10-50-2> + Details Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 Namespace Prefix: us-gaap_Data Type: xbrli:durationItemtype Balance Type: na Period Type: duration X - DefinitionWeighted average remaining contractual term for option awards outstanding, in 'PnYnMnDnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 718 -SubTopic 10 -Subparagraph (e)(1) -Name Accounting Standards Codification -Paragraph 2 -Section 50 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480429/718-10-50-2> + Details Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 Namespace Prefix: us-gaap_Data Type: xbrli:durationItemtype Balance Type: na Period Type: duration X - DefinitionWeighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(1) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480429/718-10-50-2> + Details Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1 Namespace Prefix: us-gaap_Data Type: xbrli:durationItemtype Balance Type: na Period Type: duration X - DefinitionNumber of share options (or share units) exercised during the current period. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481112/505-10-50-2>Reference 2: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1>Reference 3: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1>Reference 4: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(02) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480429/718-10-50-2>Reference 5: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480008/505-10-S99-1> + Details Name: us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised Namespace Prefix: us-gaap_Data Type: xbrli:sharesItemtype Balance Type: na Period Type: duration XML 63 R53.htm IDEA: XBRL DOCUMENT V3.24.2.u1 Share-based Compensation - Narrative (Details) \$ / shares in Units, \$ in Thousands 6 Months Ended Jun. 30, 2024 USD (\$) \$ / shares shares Share-based Compensation Arrangement by Share-based Payment Award Å Number of shares modified (in shares) | shares 571,352 Incremental share-based compensation expense \$ 300 Intrinsic value of options exercised \$ 369 Share options Å Share-based Compensation Arrangement by Share-based Payment Award Å Weighted average grant date fair value (in usd per share) | \$ / shares 3.12 Share based compensation not yet recognized for unvested shares \$ 14,800 Share based compensation not yet recognized for unvested shares vesting period (in years) 2 years 10 months 24 days

Performance Shares $\bar{A}$ Share-based Compensation Arrangement by Share-based Payment Award $\bar{A}$ Share based compensation not yet recognized for unvested shares \$ 2,900 Share based compensation not yet recognized for unvested shares vesting period (in years) 4 months 17 days Unvested restricted stock units $\bar{A}$ Share-based Compensation Arrangement by Share-based Payment Award $\bar{A}$ Share based compensation not yet recognized for unvested shares vesting period (in years) 1 year 7 months 13 days Share based compensation not yet recognized for unvested shares other than options (less than) \$ 100 X - DefinitionShare-Based Payment Arrangement, Plan Modification, Shares Modified + ReferencesNo definition available. + Details Name: autl_ShareBasedPaymentArrangementPlanModificationSharesModified Namespace Prefix: autl_Data Type: xbrli:sharesItem Type Balance Type: na Period Type: duration X - DefinitionWeighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMdTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. + ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(i\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2) + Details Name: us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 Namespace Prefix: us-gaap_Data Type: xbrli:durationItem Type Balance Type: na Period Type: duration X - DefinitionAmount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options. + ReferencesReference 1: [http://www.xbrl.org/2009/role/commonPracticeRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(i\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2009/role/commonPracticeRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2) + Details Name: us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItem Type Balance Type: debit Period Type: instant X - DefinitionAmount of cost to be recognized for option under share-based payment arrangement. + ReferencesReference 1: [http://www.xbrl.org/2009/role/commonPracticeRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(i\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2009/role/commonPracticeRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2) + Details Name: us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItem Type Balance Type: debit Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 1D -Publisher FASB -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D>Reference 2: <http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3>Reference 3: [http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(a\)\(1\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)Reference 4: [http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(a\)\(2\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)Reference 5: [http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(a\)\(3\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)Reference 6: [http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(c\)\(1\)\(i\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)Reference 7: [http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(c\)\(1\)\(ii\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)Reference 8: [http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(c\)\(1\)\(iii\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)Reference 9: [http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(c\)\(1\)\(iv\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)Reference 10: [http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(c\)\(1\)\(iv\)\(01\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)Reference 11: [http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(c\)\(1\)\(iv\)\(02\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)Reference 12: [http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(c\)\(1\)\(iv\)\(03\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)Reference 13: [http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(c\)\(1\)\(iv\)\(04\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)Reference 14: [http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(c\)\(2\)\(i\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)Reference 15: [http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(c\)\(2\)\(ii\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)Reference 16: [http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(c\)\(2\)\(iii\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)Reference 17: [http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(c\)\(2\)\(iii\)\(01\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)Reference 18: [http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(c\)\(2\)\(iii\)\(02\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)Reference 19: [http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(c\)\(2\)\(iii\)\(03\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)Reference 20: [http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(d\)\(1\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)Reference 21: [http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(d\)\(2\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)Reference 22: [http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(e\)\(1\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)Reference 23: [http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(f\)\(2\)\(i\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)Reference 24: [http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(f\)\(2\)\(ii\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)Reference 25: [http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(f\)\(2\)\(iii\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)Reference 26: [http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(f\)\(2\)\(iv\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)Reference 27: [http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(f\)\(2\)\(v\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(v) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2) + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems Namespace Prefix: us-gaap_Data Type: xbrli:stringItem Type Balance Type: na Period Type: duration X - DefinitionAmount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares. + ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(d\)\(2\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2) + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItem Type Balance Type: debit Period Type: duration X - DefinitionThe weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology. + ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(d\)\(1\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2) + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue Namespace Prefix: us-gaap_Data Type: dtr-types:perShareItem Type Balance Type: na Period Type: duration X - DefinitionAn excess of the fair value of the modified award over the fair value of the award immediately before the modification. + ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(h\)\(2\)\(iii\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (h)(2)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2) + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItem Type Balance Type: debit Period Type: duration X - Details Name: us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 64 R54.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Share-Based Compensation - Restricted Stock Units (Details) - Unvested restricted stock units 6 Months Ended Jun. 30, 2024 \$ / shares shares NumberA of restricted units $\bar{A}$ Unvested and outstanding beginning balance (in shares) | shares 116,436 Vested (in shares) | shares (73,604) Forfeited (in shares) | shares (927) Unvested and outstanding ending balance (in shares) | shares 41,905 WeightedA average grant date fair value $\bar{A}$ Unvested and outstanding beginning balance (in usd per share) | \$ / shares \$ 3.43 Vested (in usd per share) | \$ / shares 2.79 Forfeited (in usd per share) | \$ / shares 6.20 Unvested and outstanding ending balance (in usd per share) | \$ / shares \$ 4.49 X - DefinitionThe number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period. + ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(c\)\(2\)\(iii\)\(03\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2) + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod Namespace Prefix: us-gaap_Data Type: xbrli:sharesItem Type Balance Type: na Period Type: duration X - DefinitionWeighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event. + ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(c\)\(2\)\(iii\)\(03\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2) + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue Namespace Prefix: us-gaap_Data Type: dtr-types:perShareItem Type Balance Type: na Period Type: duration X - DefinitionThe number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date. + ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(c\)\(2\)\(i\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)Reference 2: [http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(c\)\(2\)\(ii\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2) + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber Namespace Prefix: us-gaap_Data Type: xbrli:sharesItem Type Balance Type: na Period Type: instant X - DefinitionA roll forward is a reconciliation of a concept from the beginning of a period to the end of a period. + ReferencesNo definition available. + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward Namespace Prefix: us-gaap_Data Type: xbrli:stringItem Type Balance Type: na Period Type: duration X - DefinitionPer share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options. + ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(c\)\(2\)\(i\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)Reference 2: [http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(c\)\(2\)\(ii\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2) + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue Namespace Prefix: us-gaap_Data Type: dtr-types:perShareItem Type Balance Type: na Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward Namespace Prefix: us-gaap_Data Type: xbrli:stringItem Type Balance Type: na Period Type: duration X - DefinitionThe number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period. + ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(c\)\(2\)\(iii\)\(02\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2) + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod Namespace Prefix: us-gaap_Data Type: xbrli:sharesItem Type Balance Type: na Period Type: duration X - DefinitionThe weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement. + ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(c\)\(2\)\(iii\)\(02\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2) + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue Namespace Prefix: us-gaap_Data Type: dtr-types:perShareItem Type Balance Type: na Period Type: duration X - Details Name: us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 65 R55.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Liabilities related to future royalties and milestones, net - Schedule of Liability Related to Revenue (Details) - USD (\$) 3 Months Ended 6 Months Ended Jun. 30, 2024 Mar. 31, 2024 Dec. 31, 2023 Sep. 30, 2023 Jun. 30, 2023 Mar. 31, 2023 Jun. 30, 2023 Jun. 30, 2023 Jun. 30, 2023 Collaborative Agreements, Debt Liability $\bar{A}$ $\bar{A}$ $\bar{A}$ $\bar{A}$ $\bar{A}$ Beginning Balance \$ 228,494,000 \$ 170,899,000 \$ 140,778,000 $\bar{A}$ \$ 125,900,000 \$ 170,899,000 \$ 125,900,000 Initial recognition of BioNTech liability $\bar{A}$ 38,335,000 $\bar{A}$ $\bar{A}$ $\bar{A}$ $\bar{A}$ $\bar{A}$ Interest expense on liability related to future royalties and milestones, net 10,169,000 8,390,000 5,014,000 \$ 5,014,000 \$ 4,959,000 \$ 4,905,000 18,559,000 9,864,000 Cumulative catch-up adjustment $\bar{A}$ 0 10,870,000 25,107,000 $\bar{A}$ $\bar{A}$ $\bar{A}$ 0 10,870,000 \$ 0 Ending Balance \$ 238,663,000 \$ 228,494,000 \$ 170,899,000 \$ 140,778,000 $\bar{A}$ $\bar{A}$ \$ 238,663,000 $\bar{A}$ X - DefinitionCollaboration Agreement, Cumulative Catch-Up Adjustment + ReferencesNo definition available. + Details Name: autl_CollaborationAgreementCumulativeCatchUpAdjustment Namespace Prefix: autl_Data Type: xbrli:monetaryItem Type Balance Type: credit Period Type: duration X - DefinitionCollaboration Agreement, Initial Recognition of Liability + ReferencesNo definition available. + Details Name: autl_CollaborationAgreementInitialRecognitionOfLiability Namespace Prefix: autl_Data Type: xbrli:monetaryItem Type Balance Type: credit Period Type: duration X - DefinitionCollaboration Agreement, Non-Cash Interest Expense + ReferencesNo definition available. + Details Name: autl_CollaborationAgreementNonCashInterestExpense Namespace Prefix: autl_Data Type: xbrli:monetaryItem Type Balance Type: debit Period Type: duration X - DefinitionCollaborative Agreements, Debt Liability + ReferencesNo definition available. + Details Name: autl_CollaborativeAgreementsDebtLiability Namespace Prefix: autl_Data Type: xbrli:monetaryItem Type Balance Type: credit Period Type: instant X - DefinitionCollaborative Agreements, Debt Liability + ReferencesNo definition available. + Details Name:

CollaborativeAgreementsDebtLiabilityRollForward Namespace Prefix: autl_ **Data Type:** xbrli:stringItemType **Balance Type:** na **Period Type:** duration XML 68 R55.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Liabilities related to future royalties and milestones, net - Narrative (Details) 1 Months Ended 3 Months Ended 6 Months Ended Dec. 31, 2022 USD (\$) payment Nov. 30, 2021 USD (\$) Jun. 30, 2024 USD (\$) financialInstrument Mar. 31, 2023 USD (\$) Sep. 30, 2023 USD (\$) Jun. 30, 2023 USD (\$) Mar. 31, 2023 USD (\$) Jun. 30, 2024 USD (\$) financialInstrument Jun. 30, 2023 USD (\$) Feb. 06, 2024 Nov. 06, 2021 USD (\$) Class of Warrant or Right [Line Items] A A A A A A A A A A Interest expense on liability related to future royalties and milestones, net A \$ 10,169,000 \$ 8,390,000 \$ 5,014,000 \$ 5,014,000 \$ 4,959,000 \$ 4,905,000 \$ 18,559,000 \$ 9,864,000 A Cumulative catch-up adjustment A 0 \$ 10,870,000 25,107,000 A 0 \$ 10,870,000 0 A Number of development payments | payment 2 A A A A A A A A A A Contract with customer, liability A \$ 195,900,000 A A A A \$ 195,900,000 A A A A Number of freestanding financial instruments | financialInstrument A 1 A A A A 1 A A A Contract with customer, liability, noncurrent A \$ 238,663,000 A A \$ 170,899,000 A A A \$ 238,663,000 A A BioNTech Liability A A A A A A A A A A Class of Warrant or Right [Line Items] A A A A A A A A A A Interest rate (in percent) A A 28.70% A A A A 28.70% A A Blackstone Collaboration Agreement A A A A A A A A A A Class of Warrant or Right [Line Items] A A A A A A A A A A Number of freestanding financial instruments | financialInstrument A 4 A A A A 4 A A A Blackstone | Blackstone Collaboration Agreement A A A A A A A A A A Class of Warrant or Right [Line Items] A A A A A A A A A A Contract with customer, liability gross A \$ 50,000,000.0 A A A A A A A A A A Remaining performance obligation, variable consideration amount \$ 30,000,000 A A A A A A A A A A Contract with customer, liability \$ 35,000,000.0 A A A A A A A A A A Blackstone | Affiliated Entity | Obe-cel Product A A A A A A A A A A Class of Warrant or Right [Line Items] A A A A A A A A A A Contract with customer, liability gross A \$ 40,000,000 A A A A A A A A A A Remaining performance obligation, variable consideration amount A A A A A A A A A A \$ 100,000,000 BioNTech A A A A A A A A A A Class of Warrant or Right [Line Items] A A A A A A A A A A Contract with customer, liability, noncurrent A \$ 38,300,000 A A A A \$ 38,300,000 A A X - DefinitionCollaboration Agreement, Cumulative Catch-Up Adjustment + ReferencesNo definition available. + Details Name: autl_CollaborationAgreementCumulativeCatchUpAdjustment Namespace Prefix: autl_ **Data Type:** xbrli:monetaryItemType **Balance Type:** credit **Period Type:** duration X - DefinitionCollaboration Agreement, Non-Cash Interest Expense + ReferencesNo definition available. + Details Name: autl_CollaborationAgreementNonCashInterestExpense Namespace Prefix: autl_ **Data Type:** xbrli:monetaryItemType **Balance Type:** debit **Period Type:** duration X - DefinitionContract With Customer, Liability, Gross + ReferencesNo definition available. + Details Name: autl_ContractWithCustomerLiabilityGross Namespace Prefix: autl_ **Data Type:** xbrli:monetaryItemType **Balance Type:** credit **Period Type:** duration X - DefinitionNumber Of Development Payments + ReferencesNo definition available. + Details Name: autl_NumberOfDevelopmentPayments Namespace Prefix: autl_ **Data Type:** xbrli:integerItemType **Balance Type:** na **Period Type:** duration X - DefinitionNumber Of Freestanding Financial Instruments + ReferencesNo definition available. + Details Name: autl_NumberOfFreestandingFinancialInstruments Namespace Prefix: autl_ **Data Type:** xbrli:integerItemType **Balance Type:** na **Period Type:** instant X - DefinitionRevenue, Remaining Performance Obligation, Variable Consideration Amount + ReferencesNo definition available. + Details Name: autl_RevenueRemainingPerformanceObligationVariableConsiderationAmount Namespace Prefix: autl_ **Data Type:** xbrli:monetaryItemType **Balance Type:** credit **Period Type:** instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesNo definition available. + Details Name: us-gaap_ClassOfWarrantOrRightLineItems Namespace Prefix: us-gaap_ **Data Type:** xbrli:stringItemType **Balance Type:** na **Period Type:** duration X - DefinitionAmount of obligation to transfer good or service to customer for which consideration has been received or is receivable. + ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef-Topic 606-SubTopic 10-Name Accounting Standards Codification-Section 45-Paragraph 1-Publisher FASB-URI](http://www.xbrl.org/2003/role/disclosureRef-Topic 606-SubTopic 10-Name Accounting Standards Codification-Section 45-Paragraph 1-Publisher FASB-URI https://asc.fasb.org/1943274/2147479837/606-10-45-1) <https://asc.fasb.org/1943274/2147479837/606-10-45-1>-Reference 2: [http://www.xbrl.org/2003/role/disclosureRef-Topic 606-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 8-Subparagraph \(a\)-Publisher FASB-URI](http://www.xbrl.org/2003/role/disclosureRef-Topic 606-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 8-Subparagraph (a)-Publisher FASB-URI https://asc.fasb.org/1943274/2147479806/606-10-50-8) <https://asc.fasb.org/1943274/2147479806/606-10-50-8>-Reference 3: [http://www.xbrl.org/2003/role/disclosureRef-Topic 606-SubTopic 10-Name Accounting Standards Codification-Section 45-Paragraph 2-Publisher FASB-URI](http://www.xbrl.org/2003/role/disclosureRef-Topic 606-SubTopic 10-Name Accounting Standards Codification-Section 45-Paragraph 2-Publisher FASB-URI https://asc.fasb.org/1943274/2147479837/606-10-45-2) <https://asc.fasb.org/1943274/2147479837/606-10-45-2> + Details Name: us-gaap_ContractWithCustomerLiability Namespace Prefix: us-gaap_ **Data Type:** xbrli:monetaryItemType **Balance Type:** credit **Period Type:** instant X - DefinitionAmount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent. + ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef-Topic 606-SubTopic 10-Name Accounting Standards Codification-Section 45-Paragraph 1-Publisher FASB-URI](http://www.xbrl.org/2003/role/disclosureRef-Topic 606-SubTopic 10-Name Accounting Standards Codification-Section 45-Paragraph 1-Publisher FASB-URI https://asc.fasb.org/1943274/2147479837/606-10-45-1) <https://asc.fasb.org/1943274/2147479837/606-10-45-1>-Reference 2: [http://www.xbrl.org/2003/role/disclosureRef-Topic 606-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 8-Subparagraph \(a\)-Publisher FASB-URI](http://www.xbrl.org/2003/role/disclosureRef-Topic 606-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 8-Subparagraph (a)-Publisher FASB-URI https://asc.fasb.org/1943274/2147479806/606-10-50-8) <https://asc.fasb.org/1943274/2147479806/606-10-50-8>-Reference 3: [http://www.xbrl.org/2003/role/disclosureRef-Topic 606-SubTopic 10-Name Accounting Standards Codification-Section 45-Paragraph 2-Publisher FASB-URI](http://www.xbrl.org/2003/role/disclosureRef-Topic 606-SubTopic 10-Name Accounting Standards Codification-Section 45-Paragraph 2-Publisher FASB-URI https://asc.fasb.org/1943274/2147479837/606-10-45-2) <https://asc.fasb.org/1943274/2147479837/606-10-45-2> + Details Name: us-gaap_ContractWithCustomerLiabilityNoncurrent Namespace Prefix: us-gaap_ **Data Type:** xbrli:monetaryItemType **Balance Type:** credit **Period Type:** instant X - DefinitionEffective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium. + ReferencesReference 1: [http://www.xbrl.org/2003/role/exampleRef-Topic 835-SubTopic 30-Name Accounting Standards Codification-Section 55-Paragraph 8-Publisher FASB-URI](http://www.xbrl.org/2003/role/exampleRef-Topic 835-SubTopic 30-Name Accounting Standards Codification-Section 55-Paragraph 8-Publisher FASB-URI https://asc.fasb.org/1943274/2147482949/835-30-55-8) <https://asc.fasb.org/1943274/2147482949/835-30-55-8>-Reference 2: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.5-02\(2\)\(a\)\(1\)\)-Publisher FASB-URI](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.5-02(2)(a)(1))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1) <https://asc.fasb.org/1943274/2147480566/210-10-S99-1>-Reference 3: [http://www.xbrl.org/2003/role/disclosureRef-Topic 835-SubTopic 30-Name Accounting Standards Codification-Section 50-Paragraph 1-Publisher FASB-URI](http://www.xbrl.org/2003/role/disclosureRef-Topic 835-SubTopic 30-Name Accounting Standards Codification-Section 50-Paragraph 1-Publisher FASB-URI https://asc.fasb.org/1943274/2147482900/835-30-50-1) <https://asc.fasb.org/1943274/2147482900/835-30-50-1>-Reference 4: [http://www.xbrl.org/2003/role/disclosureRef-Topic 835-SubTopic 30-Name Accounting Standards Codification-Section 45-Paragraph 2-Publisher FASB-URI](http://www.xbrl.org/2003/role/disclosureRef-Topic 835-SubTopic 30-Name Accounting Standards Codification-Section 45-Paragraph 2-Publisher FASB-URI https://asc.fasb.org/1943274/2147482925/835-30-45-2) <https://asc.fasb.org/1943274/2147482925/835-30-45-2>-Reference

[illegible]

[illegible]

MPGVB|XBKJ|9W*KT|K*BO|OAMOA&=PN10.G1%1M MJ1|!MI N\$3=->[-9-H,Q,011|@T(0|/|@+<*> 9*FM;80Z19RV11|;MM\$P+V+*7N*W|)%C\$=M5G;:MT9
NVRG|IBV3|<=RD|66G-IVV3|L1:CM6J|JML|T4T\$V|BC4|1=-. *161PM)/KX MT-3V9Q04&L1P720WISX6*JWP;QE6*+*E4F=I= MB(O|P+V|/|<X.OX08?
J=Q>~>D|NR4721WU41=O1#<@S-E9QW|6Z@9FX*FY7B&P<@ MONJW|?K\$KS8J|K6U= &V*ACB(P\$88AKQ,^KFT: MQ.? %8U#I%G\4,J|L|^9F7O@ 6
M\$OY*YU=W|A7:O+>X7|?7.3B|PJ09&|J|<@Q9TVZ?BK6G^E89F7=AS,3P| MP=UA186U&O,4BD:8SDIPT<@Q|G|C.SM4QYUN<_H3W3^DH7O|O2|1%#B>3>0U;|^!V21|@)55E
M-Y1P<@>2>:1\$G\$C9U,0|N2&1<=|>P|BQ|V?%,QHOL3^B,5M+&X,|OOCV|J%AMSZODJ30|J+|@B<@("17 M 5 0MBDTCA<_||@SJA 8;HE#W6N6WAHB= K1I+K9I-
W+|F+&+,-8P5KOSIN^ZDL6|R*UH">KIS^_I%G|PM MM 16+2A&=-\$#|)UANDN5%69|J>|A29;+|0B3Z,L1^D^FZ;6,R+G'3';V>|/^-5W81DN?9'M ? G=-,MNT?5^L;(%? 956P5K?<
C|B.E00Q<J2|J| (5&H M7+> G>|(4;U-E1N5580QFS317%6MM44G|L^T|D<+&DfNYHCBDBVRBK;|?3DQ M17N4)?
&X9:3:B>2AB 3|)Q|J?7SA+^G2420&M03#4A^C&S^ZHRCT@WMPN,K2| M"B%6^FCA Y*XU^OFE<5|J0,?A91%2OM4|W|O=3NC(=%YBL+ _1XH^7D|JL.BRDKTP^1A*6?,
V|36@51L,X(4<9S)?&#;7? MZD D M^MP<@<C^N^JN*=3%B^3K^W|R?W A6^8?X*|I4Y9N<5^7|J|F>TG0) ME+#+#< C|J|6^D^HC=V?+*#8;G|OTPV+
S_9CY8.S&9Q|OQ539~<@.1^Q|PG8M M2Q(AJ6|-K|,|B6H2\$S=^THTB?W+& IP0^Q=|<A/|@Y51&4Y2 'SWF|?W<0=|<X\$S#G MHV|!< NM28NBCT:|@6|IHN_
I<2A|<H>M2O|1F?|51G=99|DDMLP|L\$S: G7 M<G|I, (T+~>70^R&C.(1QEP M?WOF>6X~>JYVS3^QRT374ME0^PC\$W L+Y+G|&LZZCE(SFU&X&C|?2G M8O|U5V|1|>FAK^|/K^T &-
=|N2|Z4(X(N,+@+O+3)_5J_A+<C7Y|+W+&V0 MCI|^56F^KZ2?|QT?Q^GNO|_VYC<@&^/YS19R^Q^<X^21^|<X^1+Y+G| M UI+ P04 ~|^I@X^AWB?;0H\$ #Z#@<
@^AL+W=O|Y|TTW7V\$S; M?|2F5G46<|59 M^M>M>8,G14%>HZ,E2FY|YCN6KV&8&61Z<2AFG27|UNC9T^W01&?W=XB5)Z|^+<QK<6,
MNE<Z>|U|OU^M^T\$Y;F;Q4LN 1.2^670:08Y+5DMWHJ|> 8:OGR<C+6WXA75C M.R9C7ENGR|9&|1^? LOHU^S^<T>+<8A;1W2P+MY46#YGCVDVGQJ|!M^M^:
C^QZLBE6W^+|^|#[|4|P<90|JDDP-XXT|L|_~_?7L M=1&|L2<6_K|(+&GG|I|JNAO8R7YBWS=GMF<(9Q^UAD5SA|)^S:O1<7@|<2D M(STYA/Z&83|M9_IR^<
A63|EFG(SRL#<?)UH|P|4&=5L0R,<S,Q^Q M N=5DQM0&M^<_<4N5?|?60|A|.1VL|B|X<~>78#0S=>AX9M# 9Z#K^K^?&6 M(C<G^TEK7+P+|^|G^R^G^GJM2
F9|EKK\$Z9G@/STR|_J|T=|>|&MG^5 Y4 M^NXT|1|<6|LA1-(2B<X+,<^&5|^|#TB|FCYD|L7|;BP(C 43^<G|U^<A^8. MP7@?|>1|>DX>|^?7.69R3VPK^P|YB&6|^|644@ @60;NM46&&X
M|ALY^&6VZ;\$.6A|^|6FP2S9DQ&R^E;I6;D^>:S1^EFG#@AZ|K,\$?QF5^~^L^K- MFI+Q>O3N;B.A|J4WFQ=^%YOH7|9Y\$Y^*W;A473RN|JL10|BI|ZRYGU=KZP
MK^<0TO?&8A?<3,^>|M75\$R_J4I&EY/1@G1-D|JMQO>4FE#XU.O.7YI MG2?|R^G|N?T0+|>|M;|@N+>CNQ^7&|(HJ2M=39+!<+>1L|)4Q5T2C=VR M=C65DM\$;L,S^VB^PQ
^D1%FI|<?&51Y&E+&|J|E|T3\$CJB(705^O<_~. MD^8^9KV@&YE?>|>(>BHW^A5A7; _AJ/GX^|9T\$= S6)?8\$X|<=4?;S|P|6|?|<3L3E|Z6T44ALU|JTEWBUV M^T^V^#>;(6?
F^D)|K\$G\$|DEPY.C|J&XO7&Z^M-M-IAMW2M&R&H.44C3>@YTM- MA=|I=|^T=Z^|VUI+ P04 ~|^I@A9E;=|G|< 310 &0^AL+W=O MP|
MJ9UK+|>144H;9D>Z144H;VT:YNAH|JM2V|ED908U|,RP|2QFL5%+&HNW&#%/M MG10^<PQBWS3^|_U1ZFZ<C)=X594MOM&M)BUK,|(-=>|&T.G=& I18^*JW
MX^J+>87RVGPCPX^|9V;PADY76?|P|P9G61|^\$SKD+&^(R6&5ZBE|&(9#Q1 M.9A9 _M^W^LWG+NE,N^*6;S4|Z^X\$;?X^J|?2QBJT M^<G|<@/N^K=|<?DP^&|Z^E3UN_>X^<Q1 9!0
7G4W0>~^<C|RXQJ9T17BXSUL M81-3C6@2|U0HRITS=|L^YX|H|+<X^X\$Y^N-KOUYU21|3A.N5;BF5;D|J|<0? M6GK|JW4|L7R.3TG.H^G2;5K61F^P<C6^278>?99C|_!
AAPGD6_RVASAUV)E MG:\$7?M0NCW;|#|;Z|<+VS^<X3:P^+98%^|?3,^<RSX+1?^*5(\$+JZ|JLKV.ZNE^&.(M5|<,<D\$6>)&D;IT^ (2_Q^&W^35C;,<
M|N%Q?>D4@GSE0^A=|>T4US|HW9>1FZ%UO;^?7EAEMO<2H&E-EHS1H|J<C|.ODRO M^7-S@W68.(N^T?ZJ|^JFIE^* 12P3>1N|.5\$#|J|<@/3K>Q>54|1?;4U3 M\$TUPH|NUUFYW"
&\$.5S 514 P04 ~|^I@<A9C^U|HK0 ~^#0 &0 M^E+W=O> H@ MT&N^1\$SXT4B@*66R.(4^RM; 1%6Q1056,|@6Y|9 3#16U25A6818X(T84 MZK4YBT)?B3P<,&|<
(5T6V|<L|<Q:Q67C(E|E0^V84EGC|R<R^C3|,1-5 M2|('';H00P60|&^&LP|9^>?6PYEMC|?)YI013\$;XEO^<2&X<(-8|S4L RL MX|;R7 G|;?Q1-(W610^WQOQUJ8Y=QO^,=S2_>6B^1H|
V4P|JN7B|ZSSMH MXO&57DQ\$K 1NK;U0?0%1>T>T^&YQ(RC1|_~MJA|_|J 4X#;N= P|P&^|J M^?>P^L5|UO|G&H^&4SWT&|G^DU5_7V19;18X^A&E=Z|L1NH:Z/QJ6F8D
M|(ZH2^P63;S|)B6B.W|^HSDP7<4D|C3>_>Q37^C E^C<C=8U^P^77Q&^R@CZ&=^M^XY|PD-32|^P8B;Z/C|KW/ CXON^\$1\$11Q.2YD+13X SP1>^E#&W@3N;P\$?<
M4<O^E^K04;9>C=SS>G|CAYG\$|8^X^30;@<^<=|U|S|J|OAG|J|3BK< MM@9=K>~>IP:|2Jv6|K|E|U-DX^6.86C(PYD+6X\$1?P@?!|7KCR?4VQ|3K^| M.
<6F9Q2;G4ELLU|JME|8^K1#|F=96ETGDS^6A2|>15=.GWC93R^FJOME^?>9 M.<@U6VLGV|C#5?_2^YMTFT+G7?>O>9MV^FV=1WLR^?>?T|D;?>B< MY^|0KJRKGNQMK&
|J4340G<>9RID |J=5-Z2@>D^#>?7Y|J=A|(E/VWA7|J51+ M P04 ~|^I@A9^NFK^H\$ I\$&@<0^AL+W=OG M:1%Q=QE1|)C3T4Z;15Y|J54ADL05E|1%6= /&,<|<|=
<^NY|CH2AURG. MDZ^#&+&R>8JIV(R^T^MY<|?7B3B|&P8^M|UO<22|J|98|YAKKC(O|>R MY\$W^RUGB^P^J2?<C|J|B-E+LOW&|^*E_9

```

@OQHL8PR2 K /?ID% O+?K +PL6QG&:ISFL[ @H1B'P63Z&8XW M.9@U+=I-F*7.B7TGJ1[1P'XPM* _[672-0]_X'X7=2.U 8 M(G,-DVMMB.=@!O'~!:#UIGQ>&\
[170?5+~+RV;102P,$% @J8((622?9 MUH+ M P $@D ID IX;[!WJ;W)K&ULE59M;JLV M$XKJZT8D?W4F14PTD38MM:(N@312+7410)14A0G<+SV MBW2D> ?.$1[TWRC]+V!S2T-
D0:A5=>NJT( E/AV#ISKK8H4DE=,==,1#?4F M#N.R-K&&'889+>#?/26[Z1N1N]G'O6'BJ1H-IFX;I]U[ M'J;V');S+=O=>[MNV]8VFC13'B=EQ\;B2H+>=>?>
1Q57FUG<+> N'X,WLVNS6C M2MVP1J EP@L=1(1886? Z/6 U[IS[!TOT ATPO7+V]YA0Z?J[ &+G6;,'X'LE M[GAI2X4W-]#SBK7?E6G'WW&(IR-
&S&Z?> SZM66N0=&S;YKJF1[?/177OJC MD8-<IA&KIAS \<<<[WZAC+1X1(=RLJ' LK)SRZ ,MT+D+900L472)9-T+JLJA';ME;HJF=IY9V#ET!S;,&M5':TXOX+;6B' $ M
G34V1WUBC~^~^6P#V2?>M+M+VZIF67D)?T.3K*!T B4V>FF9IEO1E%#H3 + M>WN~4F5-G#YIG;D?Y6G0T?Z1JFH4CLN=IVM@.49>RIV&P39-FN7U.I57@VNT MAC.B%Y(Y?
I'00Y3B7/?#-;GTP2B2>)/A1/9Q'6>9'2>1/-)FOAQ.H? V M.V4'? SR/-(K ID186<CL+,%O=EM/RLHT+W~RP:#6W';TA/1) M/5R,MS4.0J6RAZVR2/LQ;[!V#<'9JX2C@O6B-
*16+1.7)56#E] ~Y4?D3MW^0#&K<9A64U+YQ);'XAU9R M.R'~ #F801)E2J1P[VFMHJZ]@6A;JWZTRR'~7C;/ 39 W93&NB9H14D1. MPWS/NE66B?1-5AR3$B, $80$1WITXID
PUZ>H6C==>Z:KQ-T&?>M? GJWN?>E = "928W9G(26)%K<#XA3>B - <#J19=UULKZ2SVT,V0Z:4 M#M#M#W M2E#8P1M/X&+?7#45K!#1!0 ( *F*W%FFUA A1@, #T( 9 >6PO
M=VJR.W-H965TJW1[!CGN#2M,3@E,Z4>W0>1(X0'3' L0&T6>O " M'~B';C'~#HCG61@_O'YK63EADS>+*#Y1P;I,D @QY6P4U5K&5=2^<^@XO
M4<+X7UC6MOTX@~0R5A4K9V)0<%E_V=,J#BV?02.0[QRBW#50B#A/119-AEI MM03MK G-#;Q4[TWDN'27ABDWB51.M8&2TYFQFK+DUSK-610+2;K6$1684+C
M@<#K#H#Y@,-G'T#F(CC80)[C6$>Y00VX006G>T!]>85%IS.O5QHV7Q67$V1;1HPMH MF4[R9Z@L' M PWP5M#U61E4][@O3E)WK*G _.;2,%1E2 BS.P1#&Z5)<+?
M*V4JZKSA$5(8>J$>A+M' L$1(2EPGE(HB) ~2UOYZNVG-F%KSZ7';BJM4E M=5P.7-Q=5&C@!V/G;@UK<5'8760/ZRW&Y5GT5B[D6,1+7Z?CX?>_2_S
M~4&0;V#;KU>B]~U[ XNBJ?>2R)L>D%ZKE07 8254E;O~1-M;IW5+>6M &MR&N>@ZEH@KR#7:/~P'H.MF54~L'G'V#?!"E+!<B/<~KOJ)T!6]>*
[G$U<0&LUC55M;JLV$XKJ14H6D'(WBS+2T?F#CM.A&U8T++N MPJ [M'2VB#~B1E)QNE ?(R6K#N 8.64#Y2[-=]P+CN(C5Y)U6AC@N1:7GFS M,;>UUS.BBPIK?1EB0R=
[J61F~*D.@6X5LM(OU2*(PW >+U(PWWGKI)N[4>BD[ M(WB#M=PTI5)=?;M1(8K+>_)& ?41F($:R7+30@ YL_VJCMQ#J[V#T40C;@&UE M
M335F1M[~M5'U4$'6#FRJD63@B42BRL[6]SDJG$;7G4~*U@;7R J;6KS M641' O/S>0>G;CJ8C'U<$-:=L31'679_/N^ YL^O'W0UJ 1#X0@=>~.JG3L
MR32(RE/35+^8^4X61K1N&.VEHM#JOHK<@,E56@1Y4YK2P_/KN/X.4$!L!!0 M ( *F""E/>=&PQ=VJR.W-H965T7/HD?P13HW-K1$=W~2V7E4J _.;D)06-
3;Y'NS2D)3N44C2HK- *#%;SZ'PPOI920BR<1^#TN<_W*4'(AJW6)QH%I([ILLZ?O>_M,D,5ZAJ0T&;K';G'(6G76ZV3JLW@C5 M? _GJJAIV'1,PYLZ[ [SY08'G)'5_C-Z
]=:SYH60@O F3JWPET9J.SD>10'U2>Q%O>E3V#.H( M/FOE:@005(GE4 _&#&_YHL@=>?>PHX,=G4&6QLI2EA _RW919PS0^>_1,2PE M5_CJ10J1?>6&=H8+Y
M\W/HBVMJRK'3'+J'2ZO A~"~N@;Q(ITT.+3:~L'E14#68F3K0.UJ_0UB5 MEM320JWA1'[C.T9TE-WLZ7J7HM#~J]UB04V~$20#ZJ?GTLT&G YJ]0U=0CZ(LW1,
M019BEC'X6E6BP#V389P.QI#%S_ $8&KJCJA.L;I'P$N>@R119GP.ROHQ0' (751 MK64)HFF.O0_/8F&0QXRE,&#QF$W@W#JDS8XJU(3DG.GZ24$DM;?>J)B)BQK MIS0B)J(I)?
IEWOW#B>>=>[!T'B=LO03R4_BN'9?0'KG)D>.>#>?ODI#&4&4M+M-TW=H9(T66);==7M74+T6RR M8DN\1_MJ=-!_P@~( [Y~Y);0ZM#-/I?3 M'D;4&A;O.CUQ->H1'.B&S[V7
&_TD'W]JOV3_ZW'F713-XI<1/7MIZ@P# M*+&MK;IW:OT- _GDCJJOPO@GK+08G12+UEC5;_T;[CLWNQYX$4L?7OL(W9R~)~1P/PXFM#/#RZ61BKZ90Y?
2CECC$[S.#C]&Q6K,HO(5B4)M1_O_KM>J/QSQF~W9L8 M9 =4EVAK$5%0%;[N]JOQPK6HW"8Y""E&N>=-05/H 5%*K'C[N(PRT?P0)<_H]'Y5A4_U04 M@<K 3YH.1&XS'?>B#
M0CUI)M?>#>?J]EU3N%MINW+>K>Z:X47? _Z'=YWTENDEEP85@2-SP-Y +KK M3MW$J?10 MEJ;_X84T~4+H/U""N;_<_<=+V+V)U! P08 " !@&A9 M#&PGP<?>_S
&0 _AL+V=02CZ0.V.~][*2X7D2G.O<~69S; M60B~MQCDDDG-XAG-F2)UEM/YFEH6@I[NZ>+>16;K6D$ES$MIAFK#;8T,U>Z MS9;<~C$Q'XVB9) M$ P>/_IS(Q=+RA[GT;46>
(OV~I.TVBR0ZED@ZV1J@6~/_117/RF?)ZM~^+ MQ(WZP-L,EJ/P>_5^<#GPEAC:5E1$->J'PKAF('S78+YV6I+AP?O\1_3?G M._DR$P:O5/U55G9Y/L@/4.%<=+6]490?
<>M/PGBEJHW[IA4V _DX&4';&JF9K M3 P:V?;MN->?>PYY!|CJCS&X~OL>[W@BQ"?_LF)YIM0'_JPF-_Y59TWD9,M!
MN;6:9B79V>GM4FA(S7Y5<4;BK41[KB=&V)6HQF=32QMPKLGY1;RLH<G,VX% MX8-J+V[ ];Z'GJ[CA.M.C';" _#X!;=.T8M(JC'~T'_C(WC1SN?'X45'?>YT
M/E~+1'9A0NM1(M _U _S8F/LK)MW= MV2[ LBBV&ZS 1.6.61JVRH@;SIZIRGP_Z'X$=V9=V1[CCJ+V6]=6T;CDI1_T M6Z160C~";PU"1' E=(T@10&43+30NN33RL$6IE#
P=L-LH,S901'=PM->(3 M.0) '9V4;N7]L,S,OZ)IGHW=I]'ET'NWT1>+&D0P158231.ML~7K(MW MPR _A0R&XOB'1.Y~![:P@N+54+~&4RB1+&A601(8C0DQVODR.1]&J]AM
M6KEJ;T@>=#ULA'X-B>XXNSNK516;XA;]&J1?0@CB$J~WC1;Y55;1Z2D M]91.(' 'VO1'Q9'>@?>(PNV&L7U55K$61QJ2X6'TX+DAR;UAU&EG%UW M M'~
@!]"JP?>.DCS;BK<63I]OL$0'P5>KYH@XHD];*<OY&,TQCRL0M+G'L% MQ>4>E1S6>>AE!1Q$D;4PZE)R@=(=I3 B/X)PG&401070;31'ES'?> MK,BV,I'(SVC
M(XX>27F)= "LLMR(EH,QHRZ X2?CXHO)3)O3Q>=DD(+@] MS(F4H8)2BY2A~QSSST _B3@<DWR<1T'.B3E0>G\ 4~$'8T)66/+>_UO3Y
M]/ABR(EI$)>~WB)0V4HBZ[V141T5>I2LJG+&S66EV@] A7I(=P>~;RT+&U M1[G6M3A;1;X,J]1=87'9Z;'ZFW+W!5TG2B)KJ6FHF5&J6B<=&W;;;D2[QX9'O
M1U(1QW65C'LO7PD?P5K00[~B^<(BVV?>_K,HZC/7P>_F*YD0VS1'KT.Y;K184 M5M?>Z1$;[_JH M4;##+>J2/W;9JR3BC;D<1# _@V374=IU[AN_P?Q?7'CS9>@<UJ]TNN4IB
M5EUKU$?>[NON17$1P+>_+?TQ?>?7E1.O45,07^8
```

[illegible]

```

and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection.
U.S.C. 105. var Show=1; Show.LastAR=null; Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var
e=a;while(e&&e.nodeName!="TABLE")e=e.nextSibling;if(!e||e.nodeName!="TABLE"){var ref=(window)?w.document.document.getElementById(r):if(ref)
{e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e);} if(e.e.style.display='block';Show.LastAR=e}; Show.hideAR=function()
{Show.LastAR.style.display='none';} Show.toggleNext=function(a){var e=a;while(e.nodeName!="DIV")e=e.nextSibling;if(!e.style){} else if(!e.style.display){} else {var
d,p;if(e.style.display=="none"){d='block';p='';} else {d='none';p='*';} e.e.style.display=d;if(a.textContent)
v2.2.0.24 */% DefRef Styles */.report table.authRefData { background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } .report
table.authRefData a { display: block; font-weight: bold; } .report table.authRefData p { margin-top: 0px; } .report table.authRefData .hide { background-color: #2F4497;
padding: 1px 3px 0px 0px; text-align: right; } .report table.authRefData .hide a:hover { background-color: #2F4497; } .report table.authRefData .body { height: 150px;
overflow: auto; width: 400px; } .report table.authRefData table { font-size: 1em; } .Report Styles */.pl a, .pl a:visited { color: black; text-decoration: none; } * table */
.report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } .report hr { border:
1px solid #acf; } /* Top labels */.report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } .report th, void { background-color: transparent;
color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } .report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space:
normal; } /* word-wrap: break-word; */ } .report td.pl a a { cursor: pointer; display: block; width: 200px; overflow: hidden; } .report td.pl div a { width: 200px; } .report td.pl
a:hover { background-color: #ffc; } /* Header rows... */.report tr, tr { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */.report rc { background-
color: #f0f0f0; } /* Even rows... */.report re, .report reu { background-color: #def; } .report reu td { border-bottom: 1px solid black; } /* Odd rows... */.report ro, .report
rou { background-color: white; } .report rou td { border-bottom: 1px solid black; } .report rou table td { border-bottom: 0px solid black; } /* styles
for footnote marker */.report .fn { white-space: nowrap; } /* styles for numeric types */.report .num, .report .num p { text-align: right; white-space: nowrap; } .report
.num p { padding-left: 2em; } .report .num p { padding: 0px 4em 0px 2em; } /* styles for text types */.report .text { text-align: left; white-space: normal; } .report .text
big { margin-bottom: 1em; width: 17em; } .report .text more { display: none; } .report .text type { font-style: italic; font-weight: bold; } .report .text .small { width:

```

10cm; }-report-sup {font-style: italic; }-report-outerFootnotes {font-size: 1em; }XML 78 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.2.u1.html 216 296 1 false 62 0 false 13 false false R1.htm 00000001 - Document - Cover Sheet http://www.autolus.com/role/Cover Cover Cover 1 false false R2.htm 9952151 - Statement - Unaudited Condensed Consolidated Balance Sheets Sheet http://www.autolus.com/role/UnauditedCondensedConsolidatedBalanceSheets Unaudited Condensed Consolidated Balance Sheets Statements 2 false false R3.htm 9952152 - Statement - Unaudited Condensed Consolidated Balance Sheets (Parentheticals) Sheet http://www.autolus.com/role/UnauditedCondensedConsolidatedBalanceSheetsParentheticals Unaudited Condensed Consolidated Balance Sheets (Parentheticals) Statements 3 false false R4.htm 9952153 - Statement - Unaudited Condensed Consolidated Statements of Operations and Comprehensive Loss Sheet http://www.autolus.com/role/UnauditedCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss Unaudited Condensed Consolidated Statements of Operations and Comprehensive Loss Statements 4 false false R5.htm 9952154 - Statement - Unaudited Condensed Consolidated Statements of Shareholders' Equity Sheet http://www.autolus.com/role/UnauditedCondensedConsolidatedStatementsOfShareholdersEquity Unaudited Condensed Consolidated Statements of Shareholders' Equity Statements 5 false false R6.htm 9952155 - Statement - Unaudited Condensed Consolidated Statements of Cash Flows Sheet http://www.autolus.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows Unaudited Condensed Consolidated Statements of Cash Flows Statements 6 false false R7.htm 9952156 - Disclosure - Nature of the Business Sheet http://www.autolus.com/role/NatureOfTheBusiness Nature of the Business Notes 7 false false R8.htm 9952157 - Disclosure - Summary of Significant Accounting Policies Sheet http://www.autolus.com/role/SummaryOfSignificantAccountingPolicies Summary of Significant Accounting Policies Notes 8 false false R9.htm 9952158 - Disclosure - License Revenue Sheet http://www.autolus.com/role/LicenseRevenue License Revenue Notes 9 false false R10.htm 9952159 - Disclosure - Interest expense Sheet http://www.autolus.com/role/InterestExpense Interest expense Notes 10 false false R11.htm 9952160 - Disclosure - Net loss per ordinary share Sheet http://www.autolus.com/role/NetLossPerOrdinaryShare Net loss per ordinary share Notes 11 false false R12.htm 9952161 - Disclosure - Fair value measurements Sheet http://www.autolus.com/role/FairValueMeasurements Fair value measurements Notes 12 false false R13.htm 9952162 - Disclosure - Prepaid Expenses and Other Current Assets Sheet http://www.autolus.com/role/PrepaidExpensesAndOtherCurrentAssets Prepaid Expenses and Other Current Assets Notes 13 false false R14.htm 9952163 - Disclosure - Property and Equipment, Net Sheet http://www.autolus.com/role/PropertyAndEquipmentNet Property and Equipment, Net Notes 14 false false R15.htm 9952164 - Disclosure - Accrued Expenses and Other Liabilities Sheet http://www.autolus.com/role/AccruedExpensesAndOtherLiabilities Accrued Expenses and Other Liabilities Notes 15 false false R16.htm 9952165 - Disclosure - Shareholders' Equity Sheet http://www.autolus.com/role/ShareholdersEquity Shareholders' Equity Notes 16 false false R17.htm 9952166 - Disclosure - Share-based Compensation Sheet http://www.autolus.com/role/ShareBasedCompensation Share-based Compensation Notes 17 false false R18.htm 9952167 - Disclosure - Liabilities related to future royalties and milestones, net Sheet http://www.autolus.com/role/LiabilitiesRelatedToFutureRoyaltiesAndMilestonesNet Liabilities related to future royalties and milestones, net Notes 18 false false R19.htm 9952168 - Disclosure - Leases Sheet http://www.autolus.com/role/Leases Leases Notes 19 false false R20.htm 9952169 - Disclosure - Commitments and Contingencies Sheet http://www.autolus.com/role/CommitmentsAndContingencies Commitments and Contingencies Notes 20 false false R21.htm 9952170 - Disclosure - Related party transactions Sheet http://www.autolus.com/role/RelatedPartyTransactions Related party transactions Notes 21 false false R22.htm 9952171 - Disclosure - Subsequent Events Sheet http://www.autolus.com/role/SubsequentEvents Subsequent Events Notes 22 false false R23.htm 995410 - Disclosure - Pay vs Performance Disclosure Sheet http://xbrl.sec.gov/ecd/role/PvpDisclosure Pay vs Performance Disclosure Notes 23 false false R24.htm 995445 - Disclosure - Insider Trading Arrangements Sheet http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements Insider Trading Arrangements Notes 24 false false R25.htm 995447 - Disclosure - Summary of Significant Accounting Policies (Policies) Sheet http://www.autolus.com/role/SummaryOfSignificantAccountingPoliciesPolicies Summary of Significant Accounting Policies (Policies) Policies 25 false false R26.htm 9954472 - Disclosure - Nature of the Business (Tables) Sheet http://www.autolus.com/role/NatureOfTheBusinessTables Nature of the Business (Tables) Tables http://www.autolus.com/role/NatureOfTheBusiness 26 false false R27.htm 9954473 - Disclosure - License Revenue (Tables) Sheet http://www.autolus.com/role/LicenseRevenueTables License Revenue (Tables) Tables http://www.autolus.com/role/LicenseRevenue 27 false false R28.htm 9954474 - Disclosure - Interest expense (Tables) Sheet http://www.autolus.com/role/InterestExpenseTables Interest expense (Tables) Tables http://www.autolus.com/role/InterestExpense 28 false false R29.htm 9954475 - Disclosure - Net loss per ordinary share (Tables) Sheet http://www.autolus.com/role/NetLossPerOrdinaryShareTables Net loss per ordinary share (Tables) Tables http://www.autolus.com/role/NetLossPerOrdinaryShare 29 false false R30.htm 9954476 - Disclosure - Fair value measurements (Tables) Sheet http://www.autolus.com/role/FairValueMeasurementsTables Fair value measurements (Tables) Tables http://www.autolus.com/role/FairValueMeasurements 30 false false R31.htm 9954477 - Disclosure - Prepaid Expenses and Other Current Assets (Tables) Sheet http://www.autolus.com/role/PrepaidExpensesAndOtherCurrentAssetsTables Prepaid Expenses and Other Current Assets (Tables) Tables http://www.autolus.com/role/PrepaidExpensesAndOtherCurrentAssets 31 false false R32.htm 9954478 - Disclosure - Property and Equipment, Net (Tables) Sheet http://www.autolus.com/role/PropertyAndEquipmentNetTables Property and Equipment, Net (Tables) Tables http://www.autolus.com/role/PropertyAndEquipmentNet 32 false false R33.htm 9954479 - Disclosure - Accrued Expenses and Other Liabilities (Tables) Sheet http://www.autolus.com/role/AccruedExpensesAndOtherLiabilitiesTables Accrued Expenses and Other Liabilities (Tables) Tables http://www.autolus.com/role/AccruedExpensesAndOtherLiabilities 33 false false R34.htm 9954480 - Disclosure - Share-based Compensation (Tables) Sheet http://www.autolus.com/role/ShareBasedCompensationTables Share-based Compensation (Tables) Tables http://www.autolus.com/role/ShareBasedCompensation 34 false false R35.htm 9954481 - Disclosure - Liabilities related to future royalties and milestones, net (Tables) Sheet http://www.autolus.com/role/LiabilitiesRelatedToFutureRoyaltiesAndMilestonesNetTables Liabilities related to future royalties and milestones, net (Tables) Tables http://www.autolus.com/role/LiabilitiesRelatedToFutureRoyaltiesAndMilestonesNet 35 false false R36.htm 9954482 - Disclosure - Leases (Tables) Sheet http://www.autolus.com/role/LeasesTables Leases (Tables) Tables http://www.autolus.com/role/Leases 36 false false R37.htm 9954483 - Disclosure - Nature of the Business - Narrative (Details) Sheet http://www.autolus.com/role/NatureOfTheBusinessNarrativeDetails Nature of the Business - Narrative (Details) Details 37 false false R38.htm 9954484 - Disclosure - Nature of the Business - Units of Accounting (Details) Sheet http://www.autolus.com/role/NatureOfTheBusinessUnitsOfAccountingDetails Nature of the Business - Units of Accounting (Details) Details 38 false false R39.htm 9954485 - Disclosure - Summary of Significant Accounting Policies - Narrative (Details) Sheet http://www.autolus.com/role/SummaryOfSignificantAccountingPoliciesNarrativeDetails Summary of Significant Accounting Policies - Narrative (Details) Details 39 false false R40.htm 9954486 - Disclosure - License Revenue - Disaggregation of Revenue (Details) Sheet http://www.autolus.com/role/LicenseRevenueDisaggregationOfRevenueDetails License Revenue - Disaggregation of Revenue (Details) Details 40 false false R41.htm 9954487 - Disclosure - License revenue - Narrative (Details) Sheet http://www.autolus.com/role/LicenseRevenueNarrativeDetails License revenue - Narrative (Details) Details 41 false false R42.htm 9954488 - Disclosure - Interest expense (Details) Sheet http://www.autolus.com/role/InterestExpenseDetails Interest expense (Details) Details 42 false false R43.htm 9954489 - Disclosure - Net loss per ordinary share - Schedule of Net Loss Per Share (Details) Sheet http://www.autolus.com/role/NetLossPerOrdinaryShareScheduleOfNetLossPerShareDetails Net loss per ordinary share - Schedule of Net Loss Per Share (Details) Details 43 false false R44.htm 9954490 - Disclosure - Net loss per ordinary share - Schedule of Anti-dilutive Securities (Details) Sheet http://www.autolus.com/role/NetLossPerOrdinaryShareScheduleOfAntiDilutiveSecuritiesDetails Net loss per ordinary share - Schedule of Anti-dilutive Securities (Details) Details 44 false false R45.htm 9954491 - Disclosure - Fair value measurements (Details) Sheet http://www.autolus.com/role/FairValueMeasurementsDetails Fair value measurements (Details) Details 45 false false R46.htm 9954492 - Disclosure - Prepaid Expenses and Other Current Assets (Details) Sheet http://www.autolus.com/role/PrepaidExpensesAndOtherCurrentAssetsDetails Prepaid Expenses and Other Current Assets (Details) Details 46 false false R47.htm 9954493 - Disclosure - Property and Equipment, Net - Schedule of PPE (Details) Sheet http://www.autolus.com/role/PropertyAndEquipmentNetScheduleOfPPEDetails Property and Equipment, Net - Schedule of PPE (Details) Details 47 false false R48.htm 9954494 - Disclosure - Property and Equipment, Net - Narratives (Details) Sheet http://www.autolus.com/role/PropertyAndEquipmentNetNarrativesDetails Property and Equipment, Net - Narratives (Details) Details 48 false false R49.htm 9954495 - Disclosure - Accrued Expenses and Other Liabilities (Details) Sheet http://www.autolus.com/role/AccruedExpensesAndOtherLiabilitiesDetails Accrued Expenses and Other Liabilities (Details) Details 49 false false R50.htm 9954496 - Disclosure - Shareholders' Equity - Narrative (Details) Sheet http://www.autolus.com/role/ShareholdersEquityNarrativeDetails Shareholders' Equity - Narrative (Details) Details 50 false false R51.htm 9954497 - Disclosure - Share-based Compensation - Share-based Compensation Allocation (Details) Sheet http://www.autolus.com/role/ShareBasedCompensationShareBasedCompensationAllocationDetails Share-based Compensation - Share-based Compensation Allocation (Details) Details 51 false false R52.htm 9954498 - Disclosure - Share-based Compensation - Share Options Rollforward (Details) Sheet http://www.autolus.com/role/ShareBasedCompensationShareOptionsRollforwardDetails Share-based Compensation - Share Options Rollforward (Details) Details 52 false false R53.htm 9954499 - Disclosure - Share-based Compensation - Narrative (Details) Sheet http://www.autolus.com/role/ShareBasedCompensationNarrativeDetails Share-based Compensation - Narrative (Details) Details 53 false false R54.htm 9954500 - Disclosure - Share-based Compensation - Restricted Stock Units (Details) Sheet http://www.autolus.com/role/ShareBasedCompensationRestrictedStockUnitsDetails Share-based Compensation - Restricted Stock Units (Details) Details 54 false false R55.htm 9954501 - Disclosure - Liabilities related to future royalties and milestones, net - Schedule of Liability Related to Revenue (Details) Sheet http://www.autolus.com/role/LiabilitiesRelatedToFutureRoyaltiesAndMilestonesNetScheduleOfLiabilityRelatedToRevenueDetails Liabilities related to future royalties and milestones, net - Schedule of Liability Related to Revenue (Details) Details 55 false false R56.htm 9954502 - Disclosure - Liabilities related to future royalties and milestones, net - Narrative (Details) Sheet http://www.autolus.com/role/LiabilitiesRelatedToFutureRoyaltiesAndMilestonesNetNarrativeDetails Liabilities related to future royalties and milestones, net - Narrative (Details) Details 56 false false R57.htm 9954503 - Disclosure - Leases - Lease Cost (Details) Sheet http://www.autolus.com/role/LeasesLeaseCostDetails Leases - Lease Cost (Details) Details 57 false false R58.htm 9954504 - Disclosure - Leases - Schedule of Maturity Payments (Details) Sheet http://www.autolus.com/role/LeasesScheduleOfMaturityPaymentsDetails Leases - Schedule of Maturity Payments (Details) Details 58 false false R59.htm 9954505 - Disclosure - Leases - Narrative (Details) Sheet http://www.autolus.com/role/LeasesNarrativeDetails Leases - Narrative (Details) Details 59 false false R60.htm 9954506 - Disclosure - Leases - Sublease Classification (Details) Sheet http://www.autolus.com/role/LeasesSubleaseClassificationDetails Leases - Sublease Classification (Details) Details 60 false false R61.htm 9954507 - Disclosure - Leases - Sublease Income Maturity (Details) Sheet http://www.autolus.com/role/LeasesSubleaseIncomeMaturityDetails Leases - Sublease Income Maturity (Details) Details 61 false false R62.htm 9954508 - Disclosure - Commitments and Contingencies - Narrative (Details) Sheet http://www.autolus.com/role/CommitmentsAndContingenciesNarrativeDetails Commitments and Contingencies - Narrative (Details) Details 62 false false R63.htm 9954509 - Disclosure - Related party transactions - Narrative (Details) Sheet http://www.autolus.com/role/RelatedPartyTransactionsNarrativeDetails Related party transactions - Narrative (Details) Details 63 false false All Reports Book All Reports autl-20240630.htm autl-20240630.xsd autl-20240630_cal.xml autl-20240630_def.xml autl-20240630_lab.xml autl-20240630_pre.xml http://fasb.org/us-gaap/2024 http://xbrl.sec.gov/dei/2024 http://xbrl.sec.gov/ecd/2024 true true JSON 81 MetaLinks.json IDEA: XBRL DOCUMENT {"version": "2.2", "instance": {"autl-20240630.htm"}, {"nsPrefix": "autl", "nsuri": "http://www.autolus.com/20240630", "dts": {"inline": {"local": {"autl-20240630.htm"}, {"schema": {"local": {"autl-20240630.xsd"}, {"remote": {"http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"}, {"http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"}, {"http://www.xbrl.org/2003/xl-2003-12-31.xsd"}, {"http://www.xbrl.org/2003/xlink-2003-12-31.xsd"}, {"http://www.xbrl.org/2005/xbrldt-2005.xsd"}, {"http://www.xbrl.org/2006/ref-2006-02-27.xsd"}, {"http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd"}, {"http://www.xbrl.org/lrr/role/net-2009-12-16.xsd"}, {"http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd"}, {"https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd"}, {"https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"}, {"https://www.xbrl.org/dtr/type/2022-03-31/types.xsd"}, {"https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd"}, {"https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd"}, {"https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024/elts/us-gaap-2024.xsd"}, {"https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd"}, {"https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd"}, {"https://xbrl.sec.gov/country/2024/country-2024.xsd"}, {"https://xbrl.sec.gov/dei/2024/dei-2024.xsd"}, {"https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd"}, {"https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd"}, {"calculationLink": {"local": {"autl-20240630_cal.xml"}, {"definitionLink": {"local": {"autl-20240630_def.xml"}, {"labelLink": {"local": {"autl-20240630_lab.xml"}, {"presentationLink": {"local": {"autl-20240630_pre.xml"}, {"keyStandard": "237", "keyCustom": "59", "axisStandard": "24", "axisCustom": "0", "memberStandard": "29", "memberCustom": "28", "hidden": {"total": "7", "http://xbrl.sec.gov/dei/2024": "6", "http://xbrl.sec.gov/ecd/2024": "1"}, "contextCount": "216", "entityCount": "1", "segmentCount": "62", "elementCount": "570", "unitCount": "13", "baseTaxonomies": {"http://fasb.org/us-gaap/2024": "641", "http://xbrl.sec.gov/dei/2024": "32", "http://xbrl.sec.gov/ecd/2024": "11"}, "report": {"R1": {"role": {"http://www.autolus.com/role/Cover"}, {"longName": "00000001 - Document - Cover"}, {"shortName": "Cover"}, {"isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": {"contextRef": "c-1", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": {"span": "1", "div": "body", "html": "1", "reportCount": "1", "baseRef": "autl-20240630.htm", "first": "true", "unique": "true"}, {"uniqueAnchor": {"contextRef": "c-1", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": {"span": "1", "div": "body", "html": "1", "reportCount": "1", "baseRef": "autl-20240630.htm", "first": "true", "unique": "true"}, {"R2": {"role": {"http://www.autolus.com/role/UnauditedCondensedConsolidatedBalanceSheets"}, {"longName": "9952151 - Statement - Unaudited Condensed Consolidated Balance Sheets"}}

"shortName": "Unaudited Condensed Consolidated Balance Sheets", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "2", "firstAnchor": { "contextRef": "c-5", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "3", "ancestors": { "span": "td", "tr": "table", "div": "body", "html": "1", "reportCount": "1", "baseRef": "autl-20240630.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-5", "name": "us-gaap:AssetsCurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "3", "ancestors": { "span": "td", "tr": "table", "div": "body", "html": "1", "reportCount": "1", "baseRef": "autl-20240630.htm", "unique": true } }, "R3": { "role": "http://www.autolus.com/role/UnauditedCondensedConsolidatedBalanceSheetsParentheticals", "longName": "9952152 - Statement - Unaudited Condensed Consolidated Balance Sheets (Parentheticals)", "shortName": "Unaudited Condensed Consolidated Balance Sheets (Parentheticals)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "3", "firstAnchor": { "contextRef": "c-7", "name": "us-gaap:CommonStockParOrStatedValuePerShare", "unitRef": "usdPerShare", "xsiNil": "false", "lang": "en-US", "decimals": "6", "ancestors": { "span": "div", "td": "tr", "table": "div", "body": "html", "1", "reportCount": "1", "baseRef": "autl-20240630.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-10", "name": "us-gaap:CommonStockParOrStatedValuePerShare", "unitRef": "gbpPerShare", "xsiNil": "false", "lang": "en-US", "decimals": "5", "ancestors": { "span": "div", "td": "tr", "table": "div", "body": "html", "1", "reportCount": "1", "baseRef": "autl-20240630.htm", "unique": true } }, "R4": { "role": "http://www.autolus.com/role/UnauditedCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss", "longName": "9952153 - Statement - Unaudited Condensed Consolidated Statements of Operations and Comprehensive Loss", "shortName": "Unaudited Condensed Consolidated Statements of Operations and Comprehensive Loss", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "4", "firstAnchor": { "contextRef": "c-19", "name": "us-gaap:ResearchAndDevelopmentExpense", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "3", "ancestors": { "span": "td", "tr": "table", "div": "body", "html": "1", "reportCount": "1", "baseRef": "autl-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-19", "name": "us-gaap:ResearchAndDevelopmentExpense", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "3", "ancestors": { "span": "td", "tr": "table", "div": "body", "html": "1", "reportCount": "1", "baseRef": "autl-20240630.htm", "first": true, "unique": true } }, "R5": { "role": "http://www.autolus.com/role/UnauditedCondensedConsolidatedStatementsOfShareholdersEquity", "longName": "9952154 - Statement - Unaudited Condensed Consolidated Statements of Shareholders'2019 Equity", "shortName": "Unaudited Condensed Consolidated Statements of Shareholders'2019 Equity", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "5", "firstAnchor": { "contextRef": "c-53", "name": "us-gaap:CommonStockSharesOutstanding", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": { "span": "td", "tr": "table", "div": "body", "html": "1", "reportCount": "1", "baseRef": "autl-20240630.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-62", "name": "us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "3", "ancestors": { "span": "td", "tr": "table", "div": "body", "html": "1", "reportCount": "1", "baseRef": "autl-20240630.htm", "unique": true } }, "R6": { "role": "http://www.autolus.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows", "longName": "9952155 - Statement - Unaudited Condensed Consolidated Statements of Cash Flows", "shortName": "Unaudited Condensed Consolidated Statements of Cash Flows", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "6", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:NetIncomeLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "3", "ancestors": { "span": "td", "tr": "table", "div": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "ix:continuation", "body", "html": "1", "reportCount": "1", "baseRef": "autl-20240630.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:DepreciationDepletionAndAmortization", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "3", "ancestors": { "span": "td", "tr": "table", "div": "body", "html": "1", "reportCount": "1", "baseRef": "autl-20240630.htm", "unique": true } }, "R7": { "role": "http://www.autolus.com/role/NatureOfTheBusiness", "longName": "9952156 - Disclosure - Nature of the Business", "shortName": "Nature of the Business", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "7", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:NatureOfOperations", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "span": "div", "body", "html": "1", "reportCount": "1", "baseRef": "autl-20240630.htm", "first": true, "unique": true } }, "R8": { "role": "http://www.autolus.com/role/SummaryOfSignificantAccountingPolicies", "longName": "9952157 - Disclosure - Summary of Significant Accounting Policies", "shortName": "Summary of Significant Accounting Policies", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "8", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "span": "div", "body", "html": "1", "reportCount": "1", "baseRef": "autl-20240630.htm", "first": true, "unique": true } }, "R9": { "role": "http://www.autolus.com/role/LicenseRevenue", "longName": "9952158 - Disclosure - License Revenue", "shortName": "License Revenue", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "9", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "span": "div", "body", "html": "1", "reportCount": "1", "baseRef": "autl-20240630.htm", "first": true, "unique": true } }, "R10": { "role": "http://www.autolus.com/role/InterestExpense", "longName": "9952159 - Disclosure - Interest expense", "shortName": "Interest expense", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "10", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:InterestIncomeAndInterestExpenseDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "span": "div", "body", "html": "1", "reportCount": "1", "baseRef": "autl-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:InterestIncomeAndInterestExpenseDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "span": "div", "body", "html": "1", "reportCount": "1", "baseRef": "autl-20240630.htm", "first": true, "unique": true } }, "R11": { "role": "http://www.autolus.com/role/Netlossperordinaryshare", "longName": "9952160 - Disclosure - Net loss per ordinary share", "shortName": "Net loss per ordinary share", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "11", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:EarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "span": "div", "body", "html": "1", "reportCount": "1", "baseRef": "autl-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:EarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "span": "div", "body", "html": "1", "reportCount": "1", "baseRef": "autl-20240630.htm", "first": true, "unique": true } }, "R12": { "role": "http://www.autolus.com/role/Fairvaluemeasurements", "longName": "9952161 - Disclosure - Fair value measurements", "shortName": "Fair value measurements", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "12", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:FairValueDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "span": "div", "body", "html": "1", "reportCount": "1", "baseRef": "autl-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:FairValueDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "span": "div", "body", "html": "1", "reportCount": "1", "baseRef": "autl-20240630.htm", "first": true, "unique": true } }, "R13": { "role": "http://www.autolus.com/role/PrepaidExpensesandOtherCurrentAssets", "longName": "9952162 - Disclosure - Prepaid Expenses and Other Current Assets", "shortName": "Prepaid Expenses and Other Current Assets", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "13", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:OtherCurrentAssetsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "span": "div", "body", "html": "1", "reportCount": "1", "baseRef": "autl-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:OtherCurrentAssetsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "span": "div", "body", "html": "1", "reportCount": "1", "baseRef": "autl-20240630.htm", "first": true, "unique": true } }, "R14": { "role": "http://www.autolus.com/role/PropertyandEquipmentNet", "longName": "9952163 - Disclosure - Property and Equipment, Net", "shortName": "Property and Equipment, Net", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "14", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "span": "div", "body", "html": "1", "reportCount": "1", "baseRef": "autl-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "span": "div", "body", "html": "1", "reportCount": "1", "baseRef": "autl-20240630.htm", "first": true, "unique": true } }, "R15": { "role": "http://www.autolus.com/role/AccruedExpensesandOtherLiabilities", "longName": "9952164 - Disclosure - Accrued Expenses and Other Liabilities", "shortName": "Accrued Expenses and Other Liabilities", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "15", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "span": "div", "body", "html": "1", "reportCount": "1", "baseRef": "autl-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "span": "div", "body", "html": "1", "reportCount": "1", "baseRef": "autl-20240630.htm", "first": true, "unique": true } }, "R16": { "role": "http://www.autolus.com/role/ShareholdersEquity", "longName": "9952165 - Disclosure - Shareholders'2019 Equity", "shortName": "Shareholders'2019 Equity", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "16", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "span": "div", "body", "html": "1", "reportCount": "1", "baseRef": "autl-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "span": "div", "body", "html": "1", "reportCount": "1", "baseRef": "autl-20240630.htm", "first": true, "unique": true } }, "R17": { "role": "http://www.autolus.com/role/SharebasedCompensation", "longName": "9952166 - Disclosure - Share-based Compensation", "shortName": "Share-based Compensation", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "17", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "span": "div", "body", "html": "1", "reportCount": "1", "baseRef": "autl-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "span": "div", "body", "html": "1", "reportCount": "1", "baseRef": "autl-20240630.htm", "first": true, "unique": true } }, "R18": { "role": "http://www.autolus.com/role/Liabilitiesrelatedtofutureroyaltiesandmilestonesnet", "longName": "9952167 - Disclosure - Liabilities related to future royalties and milestones, net", "shortName": "Liabilities related to future royalties and milestones, net", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "18", "firstAnchor": { "contextRef": "c-1", "name": "autl:LiabilityRelatedToSalesOfFutureRevenueNetTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "span": "div", "body", "html": "1", "reportCount": "1", "baseRef": "autl-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "autl:LiabilityRelatedToSalesOfFutureRevenueNetTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "span": "div", "body", "html": "1", "reportCount": "1", "baseRef": "autl-20240630.htm", "first": true, "unique": true } }, "R19": { "role": "http://www.autolus.com/role/Leases", "longName": "9952168 - Disclosure - Leases", "shortName": "Leases", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "19", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "span": "div", "body", "html": "1", "reportCount": "1", "baseRef": "autl-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "span": "div", "body", "html": "1", "reportCount": "1", "baseRef": "autl-20240630.htm", "first": true, "unique": true } }, "R20": { "role": "http://www.autolus.com/role/CommitmentsandContingencies", "longName": "9952169 - Disclosure - Commitments and Contingencies", "shortName": "Commitments and Contingencies", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "20", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "span": "div", "body", "html": "1", "reportCount": "1", "baseRef": "autl-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "span": "div", "body", "html": "1", "reportCount": "1", "baseRef": "autl-20240630.htm", "first": true, "unique": true } }, "R21": { "role": "http://www.autolus.com/role/Relatedpartytransactions", "longName": "9952170 - Disclosure - Related party transactions", "shortName": "Related party transactions", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "21", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "span": "div", "body", "html": "1", "reportCount": "1", "baseRef": "autl-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "span": "div", "body", "html": "1", "reportCount": "1", "baseRef": "autl-20240630.htm", "first": true, "unique": true } }, "R22": { "role": "http://www.autolus.com/role/SubsequentEvents", "longName": "9952171 - Disclosure - Subsequent events", "shortName": "Subsequent events", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "22", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:SubsequentEventsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "span": "div", "body", "html": "1", "reportCount": "1", "baseRef": "autl-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:SubsequentEventsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "span": "div", "body", "html": "1", "reportCount": "1", "baseRef": "autl-20240630.htm", "first": true, "unique": true } } }

"9952171 - Disclosure - Subsequent Events", "shortName": "Subsequent Events", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "22", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:SubsequentEventsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "span": "div", "body": "html" }, "reportCount": 1, "baseRef": "autl-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:SubsequentEventsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "span": "div", "body": "html" }, "reportCount": 1, "baseRef": "autl-20240630.htm", "first": true, "unique": true }, "R23": { "role": "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "longName": "995410 - Disclosure - Pay vs Performance Disclosure", "shortName": "Pay vs Performance Disclosure", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "23", "firstAnchor": { "contextRef": "c-19", "name": "us-gaap:NetIncomeLoss", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "span": "div", "body": "html" }, "reportCount": 1, "baseRef": "autl-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-19", "name": "us-gaap:NetIncomeLoss", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "span": "div", "body": "html" }, "reportCount": 1, "baseRef": "autl-20240630.htm", "first": true, "unique": true }, "R24": { "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "longName": "995445 - Disclosure - Insider Trading Arrangements", "shortName": "Insider Trading Arrangements", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "24", "firstAnchor": { "contextRef": "c-19", "name": "ecd:NonRule10b51ArrAdoptedFlag", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "span": "div", "body": "html" }, "reportCount": 1, "baseRef": "autl-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-19", "name": "ecd:NonRule10b51ArrAdoptedFlag", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "span": "div", "body": "html" }, "reportCount": 1, "baseRef": "autl-20240630.htm", "first": true, "unique": true }, "R25": { "role": "http://www.autolus.com/role/SummaryofSignificantAccountingPoliciesPolicies", "longName": "9954471 - Disclosure - Summary of Significant Accounting Policies (Policies)", "shortName": "Summary of Significant Accounting Policies (Policies)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "policies", "menuCat": "Policies", "order": "25", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:BasisOfAccountingPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "ix:continuation": "body", "html" }, "reportCount": 1, "baseRef": "autl-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:BasisOfAccountingPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "ix:continuation": "body", "html" }, "reportCount": 1, "baseRef": "autl-20240630.htm", "first": true, "unique": true }, "R26": { "role": "http://www.autolus.com/role/NatureoftheBusinessTables", "longName": "9954472 - Disclosure - Nature of the Business (Tables)", "shortName": "Nature of the Business (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "26", "firstAnchor": { "contextRef": "c-1", "name": "autl:UnitsOfAccountingFromFinancingAgreementTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "body": "html" }, "reportCount": 1, "baseRef": "autl-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "autl:UnitsOfAccountingFromFinancingAgreementTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "body": "html" }, "reportCount": 1, "baseRef": "autl-20240630.htm", "first": true, "unique": true }, "R27": { "role": "http://www.autolus.com/role/LicenseRevenueTables", "longName": "9954473 - Disclosure - License Revenue (Tables)", "shortName": "License Revenue (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "27", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "ix:continuation": "body", "html" }, "reportCount": 1, "baseRef": "autl-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "ix:continuation": "body", "html" }, "reportCount": 1, "baseRef": "autl-20240630.htm", "first": true, "unique": true }, "R28": { "role": "http://www.autolus.com/role/InterestexpenseTables", "longName": "9954474 - Disclosure - Interest expense (Tables)", "shortName": "Interest expense (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "28", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:InterestIncomeAndInterestExpenseDisclosureTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "body": "html" }, "reportCount": 1, "baseRef": "autl-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:InterestIncomeAndInterestExpenseDisclosureTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "body": "html" }, "reportCount": 1, "baseRef": "autl-20240630.htm", "first": true, "unique": true }, "R29": { "role": "http://www.autolus.com/role/NetlossperordinaryshareTables", "longName": "9954475 - Disclosure - Net loss per ordinary share (Tables)", "shortName": "Net loss per ordinary share (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "29", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "ix:continuation": "body", "html" }, "reportCount": 1, "baseRef": "autl-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "ix:continuation": "body", "html" }, "reportCount": 1, "baseRef": "autl-20240630.htm", "first": true, "unique": true }, "R30": { "role": "http://www.autolus.com/role/FairvaluemeasurementsTables", "longName": "9954476 - Disclosure - Fair value measurements (Tables)", "shortName": "Fair value measurements (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "30", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "ix:continuation": "body", "html" }, "reportCount": 1, "baseRef": "autl-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "ix:continuation": "body", "html" }, "reportCount": 1, "baseRef": "autl-20240630.htm", "first": true, "unique": true }, "R31": { "role": "http://www.autolus.com/role/PrepaidExpensesandOtherCurrentAssetsTables", "longName": "9954477 - Disclosure - Prepaid Expenses and Other Current Assets (Tables)", "shortName": "Prepaid Expenses and Other Current Assets (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "31", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "ix:continuation": "body", "html" }, "reportCount": 1, "baseRef": "autl-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "ix:continuation": "body", "html" }, "reportCount": 1, "baseRef": "autl-20240630.htm", "first": true, "unique": true }, "R32": { "role": "http://www.autolus.com/role/PropertyandEquipmentNetTables", "longName": "9954478 - Disclosure - Property and Equipment, Net (Tables)", "shortName": "Property and Equipment, Net (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "32", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:PropertyPlantAndEquipmentTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "ix:continuation": "body", "html" }, "reportCount": 1, "baseRef": "autl-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:PropertyPlantAndEquipmentTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "ix:continuation": "body", "html" }, "reportCount": 1, "baseRef": "autl-20240630.htm", "first": true, "unique": true }, "R33": { "role": "http://www.autolus.com/role/AccruedExpensesandOtherLiabilitiesTables", "longName": "9954479 - Disclosure - Accrued Expenses and Other Liabilities (Tables)", "shortName": "Accrued Expenses and Other Liabilities (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "33", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "body": "html" }, "reportCount": 1, "baseRef": "autl-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "body": "html" }, "reportCount": 1, "baseRef": "autl-20240630.htm", "first": true, "unique": true }, "R34": { "role": "http://www.autolus.com/role/SharebasedCompensationTables", "longName": "9954480 - Disclosure - Share-based Compensation (Tables)", "shortName": "Share-based Compensation (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "34", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "body": "html" }, "reportCount": 1, "baseRef": "autl-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "body": "html" }, "reportCount": 1, "baseRef": "autl-20240630.htm", "first": true, "unique": true }, "R35": { "role": "http://www.autolus.com/role/LiabilitiesrelatedtofutureroyaltiesandmilestonesnetTables", "longName": "9954481 - Disclosure - Liabilities related to future royalties and milestones, net (Tables)", "shortName": "Liabilities related to future royalties and milestones, net (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "35", "firstAnchor": { "contextRef": "c-1", "name": "autl:LiabilityRelatedDebtArisingFinancialAgreementTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "ix:continuation": "body", "html" }, "reportCount": 1, "baseRef": "autl-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "autl:LiabilityRelatedDebtArisingFinancialAgreementTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "ix:continuation": "body", "html" }, "reportCount": 1, "baseRef": "autl-20240630.htm", "first": true, "unique": true }, "R36": { "role": "http://www.autolus.com/role/LeasesTables", "longName": "9954482 - Disclosure - Leases (Tables)", "shortName": "Leases (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "36", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:LeaseCostTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "ix:continuation": "body", "html" }, "reportCount": 1, "baseRef": "autl-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:LeaseCostTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "ix:continuation": "body", "html" }, "reportCount": 1, "baseRef": "autl-20240630.htm", "first": true, "unique": true }, "R37": { "role": "http://www.autolus.com/role/NatureoftheBusinessNarrativeDetails", "longName": "9954483 - Disclosure - Nature of the Business - Narrative (Details)", "shortName": "Nature of the Business - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "37", "firstAnchor": { "contextRef": "c-5", "name": "us-gaap:ContractWithCustomerLiability", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "5", "ancestors": { "span": "div", "ix:continuation": "body", "html" }, "reportCount": 1, "baseRef": "autl-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-92", "name": "autl:CollaborativeAgreementPeriodToAcquireBeneficialOwnershipFromExecutionDate", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "span": "div", "ix:continuation": "body", "html" }, "reportCount": 1, "baseRef": "autl-20240630.htm", "first": true, "unique": true }, "R38": { "role": "http://www.autolus.com/role/NatureoftheBusinessUnitsOfAccountingDetails", "longName": "9954484 - Disclosure - Nature of the Business - Units of Accounting (Details)", "shortName": "Nature of the Business - Units of Accounting (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "38", "firstAnchor": { "contextRef": "c-5", "name": "autl:UnitsOfAccounting", "unitRef": "unit", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": { "span": "div", "td": "tr", "table": "div", "ix:continuation": "autl:UnitsOfAccountingFromFinancingAgreementTableTextBlock", "body": "html" }, "reportCount": 1, "baseRef": "autl-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-114", "name": "us-gaap:PaymentOffFinancingAndStockIssuanceCosts", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "5", "ancestors": { "span": "div", "td": "tr", "table": "div", "ix:continuation": "autl:UnitsOfAccountingFromFinancingAgreementTableTextBlock", "body": "html" }, "reportCount": 1, "baseRef": "autl-20240630.htm", "first": true, "unique": true }, "R39": { "role": "http://www.autolus.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails", "longName": "9954485 - Disclosure - Summary of Significant Accounting Policies - Narrative (Details)", "shortName": "Summary of Significant Accounting Policies - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "39", "firstAnchor": { "contextRef": "c-19", "name": "us-gaap:NetIncomeLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "3", "ancestors": { "span": "div", "td": "tr", "table": "div", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "ix:continuation": "body", "html" }, "reportCount": 1, "baseRef": "autl-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-19", "name": "us-gaap:ForeignCurrencyTransactionGainLossBeforeTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "5", "ancestors": { "span": "div", "us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock", "ix:continuation": "body", "html" }, "reportCount": 1, "baseRef": "autl-20240630.htm", "first": true, "unique": true }, "R40": { "role": "http://www.autolus.com/role/LicenseRevenueDisaggregationofRevenueDetails", "longName": "9954486 - Disclosure - License Revenue - Disaggregation of Revenue (Details)", "shortName": "License Revenue - Disaggregation of Revenue (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "40", "firstAnchor": { "contextRef": "c-15", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "3", "ancestors": { "span": "td", "tr", "table": "div", "us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock", "ix:continuation": "body", "html" }, "reportCount": 1, "baseRef": "autl-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-115", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "3", "ancestors": { "span": "td", "tr", "table": "div", "us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock", "ix:continuation": "body", "html" }, "reportCount": 1, "baseRef": "autl-20240630.htm", "first": true, "unique": true }, "R41": { "role": "http://www.autolus.com/role/LicenseRevenueNarrativeDetails", "longName": "9954487 - Disclosure - License revenue - Narrative

"name": "shortName", "License revenue - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "41", "firstAnchor": { "contextRef": "c-5", "name": "autl: Number Of Free Standing Financial Instruments", "unitRef": "financialInstrument", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": { "span": "div", "ix: continuation": "body", "html": "1", "reportCount": 1, "baseRef": "autl-20240630.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-123", "name": "us-gaap: Concentration Risk Percentage", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": { "span": "div", "ix: continuation": "body", "html": "1", "reportCount": 1, "baseRef": "autl-20240630.htm", "unique": true }, "R42": { "role": "http://www.autolus.com/role/InterestExpenseDetails", "longName": "9954488 - Disclosure - Interest expense (Details)", "shortName": "Interest expense (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "42", "firstAnchor": { "contextRef": "c-19", "name": "autl: Collaboration Agreement Non Cash Interest Expense", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "3", "ancestors": { "span": "td", "tr": "table", "div": "us-gaap: Interest Income And Interest Expense Disclosure Table Text Block", "body": "html", "reportCount": 1, "baseRef": "autl-20240630.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-19", "name": "us-gaap: Interest Expense Other", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "3", "ancestors": { "span": "td", "tr": "table", "div": "us-gaap: Interest Income And Interest Expense Disclosure Table Text Block", "body": "html", "reportCount": 1, "baseRef": "autl-20240630.htm", "unique": true }, "R43": { "role": "http://www.autolus.com/role/NetLossPerOrdinaryShareScheduleOfNetLossPerShareDetails", "longName": "9954489 - Disclosure - Net loss per ordinary share - Schedule of Net Loss Per Share (Details)", "shortName": "Net loss per ordinary share - Schedule of Net Loss Per Share (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "43", "firstAnchor": { "contextRef": "c-19", "name": "us-gaap: Net Income Loss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "3", "ancestors": { "span": "td", "tr": "table", "div": "us-gaap: Schedule Of Earnings Per Share Basic And Diluted Table Text Block", "ix: continuation": "body", "html": "1", "reportCount": 1, "baseRef": "autl-20240630.htm", "unique": true }, "R44": { "role": "http://www.autolus.com/role/NetLossPerOrdinaryShareScheduleOfAntidilutiveSecuritiesDetails", "longName": "9954490 - Disclosure - Net loss per ordinary share - Schedule of Anti-dilutive Securities (Details)", "shortName": "Net loss per ordinary share - Schedule of Anti-dilutive Securities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "44", "firstAnchor": { "contextRef": "c-19", "name": "us-gaap: Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "0", "ancestors": { "span": "td", "tr": "table", "div": "us-gaap: Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share Text Block", "ix: continuation": "body", "html": "1", "reportCount": 1, "baseRef": "autl-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-19", "name": "us-gaap: Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "0", "ancestors": { "span": "td", "tr": "table", "div": "us-gaap: Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share Text Block", "ix: continuation": "body", "html": "1", "reportCount": 1, "baseRef": "autl-20240630.htm", "first": true, "unique": true }, "R45": { "role": "http://www.autolus.com/role/FairValueMeasurementsDetails", "longName": "9954491 - Disclosure - Fair value measurements (Details)", "shortName": "Fair value measurements (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "45", "firstAnchor": { "contextRef": "c-5", "name": "us-gaap: Cash And Cash Equivalents Fair Value Disclosure", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "3", "ancestors": { "span": "td", "tr": "table", "div": "us-gaap: Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Table Text Block", "ix: continuation": "body", "html": "1", "reportCount": 1, "baseRef": "autl-20240630.htm", "first": true, "unique": true }, "R46": { "role": "http://www.autolus.com/role/PrepaidExpensesAndOtherCurrentAssetsDetails", "longName": "9954492 - Disclosure - Prepaid Expenses and Other Current Assets (Details)", "shortName": "Prepaid Expenses and Other Current Assets (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "46", "firstAnchor": { "contextRef": "c-5", "name": "autl: Research And Development Claims Receivable Current", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "3", "ancestors": { "span": "td", "tr": "table", "div": "us-gaap: Deferred Costs Capitalized Prepaid And Other Assets Disclosure Table Text Block", "body": "html", "reportCount": 1, "baseRef": "autl-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-5", "name": "autl: Research And Development Claims Receivable Current", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "3", "ancestors": { "span": "td", "tr": "table", "div": "us-gaap: Deferred Costs Capitalized Prepaid And Other Assets Disclosure Table Text Block", "body": "html", "reportCount": 1, "baseRef": "autl-20240630.htm", "first": true, "unique": true }, "R47": { "role": "http://www.autolus.com/role/PropertyAndEquipmentNetScheduleOfPPEDetails", "longName": "9954493 - Disclosure - Property and Equipment, Net - Schedule of PPE (Details)", "shortName": "Property and Equipment, Net - Schedule of PPE (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "47", "firstAnchor": { "contextRef": "c-5", "name": "us-gaap: Accumulated Depreciation Depletion And Amortization Property Plant And Equipment", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "3", "ancestors": { "span": "td", "tr": "table", "div": "us-gaap: Property Plant And Equipment Text Block", "ix: continuation": "body", "html": "1", "reportCount": 1, "baseRef": "autl-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-5", "name": "us-gaap: Accumulated Depreciation Depletion And Amortization Property Plant And Equipment", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "3", "ancestors": { "span": "td", "tr": "table", "div": "us-gaap: Property Plant And Equipment Text Block", "ix: continuation": "body", "html": "1", "reportCount": 1, "baseRef": "autl-20240630.htm", "first": true, "unique": true }, "R48": { "role": "http://www.autolus.com/role/PropertyAndEquipmentNetNarrativesDetails", "longName": "9954494 - Disclosure - Property and Equipment, Net - Narratives (Details)", "shortName": "Property and Equipment, Net - Narratives (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "48", "firstAnchor": { "contextRef": "c-19", "name": "us-gaap: Depreciation", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "5", "ancestors": { "span": "div", "ix: continuation": "body", "html": "1", "reportCount": 1, "baseRef": "autl-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-19", "name": "us-gaap: Depreciation", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "5", "ancestors": { "span": "div", "ix: continuation": "body", "html": "1", "reportCount": 1, "baseRef": "autl-20240630.htm", "first": true, "unique": true }, "R49": { "role": "http://www.autolus.com/role/AccruedExpensesAndOtherLiabilitiesDetails", "longName": "9954495 - Disclosure - Accrued Expenses and Other Liabilities (Details)", "shortName": "Accrued Expenses and Other Liabilities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "49", "firstAnchor": { "contextRef": "c-5", "name": "autl: Accrued Research And Development Cost Current", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "3", "ancestors": { "span": "td", "tr": "table", "div": "us-gaap: Accrued Research And Development Cost Current", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "3", "ancestors": { "span": "td", "tr": "table", "div": "us-gaap: Accrued Research And Development Cost Current", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "3", "ancestors": { "span": "td", "tr": "table", "div": "us-gaap: Common Stock Voting Rights Votes Per Share", "unitRef": "vote", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": { "span": "div", "ix: continuation": "body", "html": "1", "reportCount": 1, "baseRef": "autl-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-5", "name": "autl: Common Stock Voting Rights Votes Per Share", "unitRef": "vote", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": { "span": "div", "ix: continuation": "body", "html": "1", "reportCount": 1, "baseRef": "autl-20240630.htm", "first": true, "unique": true }, "R51": { "role": "http://www.autolus.com/role/ShareBasedCompensationShareBasedCompensationAllocationDetails", "longName": "9954497 - Disclosure - Share-based Compensation - Share-based Compensation Allocation (Details)", "shortName": "Share-based Compensation - Share-based Compensation Allocation (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "51", "firstAnchor": { "contextRef": "c-19", "name": "us-gaap: Allocated Share Based Compensation Expense", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "3", "ancestors": { "span": "td", "tr": "table", "div": "us-gaap: Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs Text Block", "body": "html", "reportCount": 1, "baseRef": "autl-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-19", "name": "us-gaap: Allocated Share Based Compensation Expense", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "3", "ancestors": { "span": "td", "tr": "table", "div": "us-gaap: Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs Text Block", "body": "html", "reportCount": 1, "baseRef": "autl-20240630.htm", "first": true, "unique": true }, "R52": { "role": "http://www.autolus.com/role/ShareBasedCompensationShareOptionsRollforwardDetails", "longName": "9954498 - Disclosure - Share-based Compensation - Share Options Rollforward (Details)", "shortName": "Share-based Compensation - Share Options Rollforward (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "52", "firstAnchor": { "contextRef": "c-6", "name": "us-gaap: Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": { "span": "td", "tr": "table", "div": "us-gaap: Schedule Of Nonvested Share Activity Table Text Block", "ix: continuation": "body", "html": "1", "reportCount": 1, "baseRef": "autl-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-188", "name": "us-gaap: Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": { "span": "td", "tr": "table", "div": "us-gaap: Schedule Of Share Based

}, "uniqueAnchor": { "contextRef": "c-196", "name": "autl:NumberOfDevelopmentPayments", "unitRef": "payment", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": { "span": "div", "ix:continuation": "body", "html": "1", "reportCount": 1, "baseRef": "autl-20240630.htm", "unique": "true" }, "R57": { "role": "http://www.autolus.com/role/LeasesLeaseCostDetails", "longName": "9954503 - Disclosure - Leases - Lease Cost (Details)", "shortName": "Leases - Lease Cost (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "57", "firstAnchor": { "contextRef": "c-19", "name": "us-gaap:OperatingLeaseCost", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": { "span": "td", "tr": "table", "div": "us-gaap:LeaseCostTableTextBlock", "ix:continuation": "body", "html": "1", "reportCount": 1, "baseRef": "autl-20240630.htm", "first": true, "unique": "true" }, "uniqueAnchor": { "contextRef": "c-19", "name": "us-gaap:OperatingLeaseCost", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": { "span": "td", "tr": "table", "div": "us-gaap:LeaseCostTableTextBlock", "ix:continuation": "body", "html": "1", "reportCount": 1, "baseRef": "autl-20240630.htm", "first": true, "unique": "true" }, "R58": { "role": "http://www.autolus.com/role/LeasesScheduleOfMaturityPaymentsDetails", "longName": "9954504 - Disclosure - Leases - Schedule of Maturity Payments (Details)", "shortName": "Leases - Schedule of Maturity Payments (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "58", "firstAnchor": { "contextRef": "c-5", "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": { "span": "td", "tr": "table", "div": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "ix:continuation": "body", "html": "1", "reportCount": 1, "baseRef": "autl-20240630.htm", "first": true, "unique": "true" }, "R59": { "role": "http://www.autolus.com/role/LeasesNarrativeDetails", "longName": "9954505 - Disclosure - Leases - Narrative (Details)", "shortName": "Leases - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "59", "firstAnchor": { "contextRef": "c-1", "name": "autl:LessorOperatingLeaseNumberOfManufacturingProperties", "unitRef": "contract", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": { "span": "div", "ix:continuation": "body", "html": "1", "reportCount": 1, "baseRef": "autl-20240630.htm", "first": true, "unique": "true" }, "uniqueAnchor": { "contextRef": "c-1", "name": "autl:LessorOperatingLeaseNumberOfManufacturingProperties", "unitRef": "contract", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": { "span": "div", "ix:continuation": "body", "html": "1", "reportCount": 1, "baseRef": "autl-20240630.htm", "first": true, "unique": "true" }, "R60": { "role": "http://www.autolus.com/role/LeasesSubleaseClassificationDetails", "longName": "9954506 - Disclosure - Leases - Sublease Classification (Details)", "shortName": "Leases - Sublease Classification (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "60", "firstAnchor": { "contextRef": "c-19", "name": "us-gaap:SubleaseIncome", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": { "span": "td", "tr": "table", "div": "us-gaap:OperatingLeaseLeaseIncomeTableTextBlock", "ix:continuation": "body", "html": "1", "reportCount": 1, "baseRef": "autl-20240630.htm", "first": true, "unique": "true" }, "uniqueAnchor": { "contextRef": "c-19", "name": "us-gaap:SubleaseIncome", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": { "span": "td", "tr": "table", "div": "us-gaap:OperatingLeaseLeaseIncomeTableTextBlock", "ix:continuation": "body", "html": "1", "reportCount": 1, "baseRef": "autl-20240630.htm", "first": true, "unique": "true" }, "R61": { "role": "http://www.autolus.com/role/LeasesSubleaseIncomeMaturityDetails", "longName": "9954507 - Disclosure - Leases - Sublease Income Maturity (Details)", "shortName": "Leases - Sublease Income Maturity (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "61", "firstAnchor": { "contextRef": "c-5", "name": "us-gaap:LessorOperatingLeasePaymentsToBeReceivedRemainderOfFiscalYear", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": { "span": "td", "tr": "table", "div": "us-gaap:LessorOperatingLeasePaymentsToBeReceivedMaturityTableTextBlock", "ix:continuation": "body", "html": "1", "reportCount": 1, "baseRef": "autl-20240630.htm", "first": true, "unique": "true" }, "uniqueAnchor": { "contextRef": "c-5", "name": "us-gaap:LessorOperatingLeasePaymentsToBeReceivedRemainderOfFiscalYear", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": { "span": "td", "tr": "table", "div": "us-gaap:LessorOperatingLeasePaymentsToBeReceivedMaturityTableTextBlock", "ix:continuation": "body", "html": "1", "reportCount": 1, "baseRef": "autl-20240630.htm", "first": true, "unique": "true" }, "R62": { "role": "http://www.autolus.com/role/CommitmentsandContingenciesNarrativeDetails", "longName": "9954508 - Disclosure - Commitments and Contingencies - Narrative (Details)", "shortName": "Commitments and Contingencies - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "62", "firstAnchor": { "contextRef": "c-19", "name": "autl:CollaborativeArrangementRightsAndObligationsPaymentsPayable", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": { "span": "div", "ix:continuation": "body", "html": "1", "reportCount": 1, "baseRef": "autl-20240630.htm", "first": true, "unique": "true" }, "uniqueAnchor": { "contextRef": "c-19", "name": "autl:CollaborativeArrangementRightsAndObligationsPaymentsPayable", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": { "span": "div", "ix:continuation": "body", "html": "1", "reportCount": 1, "baseRef": "autl-20240630.htm", "first": true, "unique": "true" }, "R63": { "role": "http://www.autolus.com/role/RelatedpartytransactionsNarrativeDetails", "longName": "9954509 - Disclosure - Related party transactions - Narrative (Details)", "shortName": "Related party transactions - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "63", "firstAnchor": { "contextRef": "c-211", "name": "autl:NumberOfDirectors", "unitRef": "director", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": { "span": "div", "ix:continuation": "body", "html": "1", "reportCount": 1, "baseRef": "autl-20240630.htm", "first": true, "unique": "true" }, "uniqueAnchor": { "contextRef": "c-211", "name": "autl:NumberOfDirectors", "unitRef": "director", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": { "span": "div", "ix:continuation": "body", "html": "1", "reportCount": 1, "baseRef": "autl-20240630.htm", "first": true, "unique": "true" }, "tag": { "us-gaap:AccountingPoliciesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountingPoliciesAbstract", "lang": "en-us", "role": "terseLabel", "label": "Accounting Policies Abstract", "label": "Accounting Policies Abstract", "auth_ref": {} }, "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "presentation": {} }, "http://www.autolus.com/role/AccruedExpensesandOtherLiabilities": { "lang": "en-us", "role": "terseLabel", "label": "Accrued Expenses and Other Liabilities", "label": "Accounts Payable and Accrued Liabilities Disclosure [Text Block]", "documentation": "The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period." }, "auth_ref": { "r45": "r47", "r51": "r823" }, "us-gaap:AccountsPayableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsPayableCurrent", "crdr": "credit", "calculation": { "http://www.autolus.com/role/UnauditedCondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap:LiabilitiesCurrent", "weight": 1.0, "order": 1.0 }, "presentation": { "http://www.autolus.com/role/UnauditedCondensedConsolidatedBalanceSheets": { "lang": "en-us", "role": "terseLabel", "label": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." }, "auth_ref": { "r45": "r655" }, "us-gaap:AccountsReceivableNetCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsReceivableNetCurrent", "crdr": "debit", "calculation": { "http://www.autolus.com/role/PrepaidExpensesandOtherCurrentAssetsDetails": { "parentTag": "us-gaap:PrepaidExpenseAndOtherAssetsCurrent", "weight": 1.0, "order": 8.0 }, "presentation": { "http://www.autolus.com/role/PrepaidExpensesandOtherCurrentAssetsDetails": { "lang": "en-us", "role": "terseLabel", "label": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current." }, "auth_ref": { "r805" }, "autl:AccruedInterestIncomeCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.autolus.com/20240630", "localname": "AccruedInterestIncomeCurrent", "crdr": "debit", "calculation": { "http://www.autolus.com/role/PrepaidExpensesandOtherCurrentAssetsDetails": { "parentTag": "us-gaap:PrepaidExpenseAndOtherAssetsCurrent", "weight": 1.0, "order": 4.0 }, "presentation": { "http://www.autolus.com/role/PrepaidExpensesandOtherCurrentAssetsDetails": { "lang": "en-us", "role": "terseLabel", "label": "Accrued interest income", "label": "Accrued Interest Income, Current", "documentation": "Accrued Interest Income, Current" }, "auth_ref": { "us-gaap:AccruedLiabilitiesAndOtherLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccruedLiabilitiesAndOtherLiabilities", "crdr": "credit", "calculation": { "http://www.autolus.com/role/AccruedExpensesandOtherLiabilitiesDetails": { "parentTag": null, "weight": null, "order": null, "root": true }, "presentation": { "http://www.autolus.com/role/AccruedExpensesandOtherLiabilitiesDetails": { "lang": "en-us", "role": "terseLabel", "label": "Total accrued expenses and other liabilities", "label": "Accrued Liabilities and Other Liabilities", "documentation": "Amount of expenses incurred but not yet paid nor invoiced, and liabilities classified as other." }, "auth_ref": { "us-gaap:AccruedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccruedLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.autolus.com/role/UnauditedCondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap:LiabilitiesCurrent", "weight": 1.0, "order": 2.0 }, "presentation": { "http://www.autolus.com/role/UnauditedCondensedConsolidatedBalanceSheets": { "lang": "en-us", "role": "terseLabel", "label": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." }, "auth_ref": { "r47": "r47", "us-gaap:AccruedProfessionalFeesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccruedProfessionalFeesCurrent", "crdr": "credit", "calculation": { "http://www.autolus.com/role/AccruedExpensesandOtherLiabilitiesDetails": { "parentTag": "us-gaap:AccruedLiabilitiesAndOtherLiabilities", "weight": 1.0, "order": 3.0 }, "presentation": { "http://www.autolus.com/role/AccruedExpensesandOtherLiabilitiesDetails": { "lang": "en-us", "role": "terseLabel", "label": "Professional fees", "label": "Accrued Professional Fees, Current", "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." }, "auth_ref": { "r47": "r47", "autl:AccruedResearchAndDevelopmentCostCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.autolus.com/20240630", "localname": "AccruedResearchAndDevelopmentCostCurrent", "crdr": "credit", "calculation": { "http://www.autolus.com/role/AccruedExpensesandOtherLiabilitiesDetails": { "parentTag": "us-gaap:AccruedLiabilitiesAndOtherLiabilities", "weight": 1.0, "order": 4.0 }, "presentation": { "http://www.autolus.com/role/AccruedExpensesandOtherLiabilitiesDetails": { "lang": "en-us", "role": "terseLabel", "label": "Research and development costs", "label": "Accrued Research And Development Cost, Current", "documentation": "Accrued Research And Development Cost, Current" }, "auth_ref": { "us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "crdr": "credit", "calculation": { "http://www.autolus.com/role/PropertyandEquipmentNetScheduleofPPEDetails": { "parentTag": "us-gaap:PropertyPlantAndEquipmentNet", "weight": 1.0, "order": 2.0 }, "presentation": { "http://www.autolus.com/role/PropertyandEquipmentNetScheduleofPPEDetails": { "lang": "en-us", "role": "negatedTerseLabel", "label": "Less: accumulated depreciation", "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment", "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services." }, "auth_ref": { "r29": "r131", "r482" }, "us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "crdr": "credit", "calculation": { "http://www.autolus.com/role/UnauditedCondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap:StockholdersEquity", "weight": 1.0, "order": 3.0 }, "presentation": { "http://www.autolus.com/role/UnauditedCondensedConsolidatedBalanceSheets": { "lang": "en-us", "role": "terseLabel", "label": "Accumulated other comprehensive loss", "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax", "documentation": "Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source." }, "auth_ref": { "r13": "r14", "r61": "r136", "r478": "r504", "r505" }, "us-gaap:AccumulatedOtherComprehensiveIncomeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccumulatedOtherComprehensiveIncomeMember", "presentation": { "http://www.autolus.com/role/UnauditedCondensedConsolidatedStatementsOfShareholdersEquity": { "lang": "en-us", "role": "terseLabel", "label": "Accumulated other comprehensive loss", "label": "AOGI Attributable to Parent [Member]", "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners." }, "auth_ref": { "r1": "r7", "r14", "r356": "r359", "r423": "r500", "r501": "r782", "r783": "r784", "r794": "r795", "r796": "r797" }, "ecd:Additional402vDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "Additional402vDisclosureTextBlock", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure": { "lang": "en-us", "role": "terseLabel", "label": "Additional 402(v) Disclosure", "label": "Additional 402(v) Disclosure [Text Block]", "auth_ref": { "r720" }, "us-gaap:AdditionalPaidInCapital": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdditionalPaidInCapital", "crdr": "credit", "calculation": { "http://www.autolus.com/role/UnauditedCondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap:StockholdersEquity", "weight": 1.0, "order": 2.0 }, "presentation": { "http://www.autolus.com/role/UnauditedCondensedConsolidatedBalanceSheets": { "lang": "en-us", "role": "terseLabel", "label": "Additional paid-in capital", "label": "Additional Paid in Capital", "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or

stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock." } }, "auth_ref": { "r56", "r655", "r877" } }, "us-gaap-AdditionalPaidInCapitalMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdditionalPaidInCapitalMember", "presentation": { "http://www.autolus.com/role/UnauditedCondensedConsolidatedStatementsOfShareholdersEquity", "lang": { "en-us": { "role": { "terseLabel": "Additional Paid in Capital", "label": "Additional Paid in Capital [Member]", "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders." } } }, "auth_ref": { "r516", "r794", "r795", "r796", "r797", "r826", "r879" } }, "ecd-AdjToCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToCompAmt", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "lang": { "en-us": { "role": { "terseLabel": "Adjustment to Compensation Amount", "label": "Adjustment to Compensation Amount", "auth_ref": { "r733" } }, "ecd-AdjToCompAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToCompAxis", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "lang": { "en-us": { "role": { "terseLabel": "Adjustment to Compensation", "label": "Adjustment to Compensation [Axis]", "auth_ref": { "r733" } }, "ecd-AdjToNonPeoNeoCompFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToNonPeoNeoCompFnTextBlock", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "lang": { "en-us": { "role": { "terseLabel": "Adjustment to Non-PEO-NEO Compensation Footnote", "label": "Adjustment to Non-PEO-NEO Compensation Footnote [Text Block]", "auth_ref": { "r733" } }, "ecd-AdjToPeoCompFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToPeoCompFnTextBlock", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "lang": { "en-us": { "role": { "terseLabel": "Adjustment to PEO Compensation, Footnote [Text Block]", "auth_ref": { "r733" } }, "us-gaap-AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "crdr": "credit", "presentation": { "http://www.autolus.com/role/UnauditedCondensedConsolidatedStatementsOfShareholdersEquity", "lang": { "en-us": { "role": { "terseLabel": "Share-based compensation expense", "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition", "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement." } } }, "auth_ref": { "r39", "r40", "r300" } }, "us-gaap-AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": { "http://www.autolus.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows", "lang": { "en-us": { "role": { "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities", "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]", "auth_ref": { "dei-AdrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AdrMember", "presentation": { "http://www.autolus.com/role/Cover", "lang": { "en-us": { "role": { "terseLabel": "ADR", "label": "ADR [Member]", "documentation": "American Depositary Receipt (or American Depositary Share, ADS)", "auth_ref": { "r686" } }, "srt-AffiliatedEntityMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "AffiliatedEntityMember", "presentation": { "http://www.autolus.com/role/LiabilitiesrelatedtofutureroyaltiesandmilestonesetNarrativeDetails", "lang": { "en-us": { "role": { "terseLabel": "Affiliated Entity [Member]", "auth_ref": { "r558", "r609", "r675", "r821", "r840", "r841", "r842" } }, "ecd-AggtChngPnsnValInSummryCompstnTblForApblYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtChngPnsnValInSummryCompstnTblForApblYrMember", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "lang": { "en-us": { "role": { "terseLabel": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table", "label": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member]", "auth_ref": { "r766" } }, "ecd-AggtErrCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtErrCompAmt", "presentation": { "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "lang": { "en-us": { "role": { "terseLabel": "Aggregate Erroneous Compensation Amount", "label": "Aggregate Erroneous Compensation Amount", "auth_ref": { "r692", "r702", "r712", "r744" } }, "ecd-AggtErrCompNotYetDeterminedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtErrCompNotYetDeterminedTextBlock", "presentation": { "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "lang": { "en-us": { "role": { "terseLabel": "Aggregate Erroneous Compensation Not Yet Determined", "label": "Aggregate Erroneous Compensation Not Yet Determined [Text Block]", "auth_ref": { "r695", "r705", "r715", "r747" } }, "ecd-AggtPnsnAdjsSvcCstMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtPnsnAdjsSvcCstMember", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "lang": { "en-us": { "role": { "terseLabel": "Aggregate Pension Adjustments Service Cost", "label": "Aggregate Pension Adjustments Service Cost [Member]", "auth_ref": { "r767" } }, "ecd-AllAdjToCompMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllAdjToCompMember", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "lang": { "en-us": { "role": { "terseLabel": "All Adjustments to Compensation", "label": "All Adjustments to Compensation [Member]", "auth_ref": { "r733" } }, "ecd-AllExecutiveCategoriesMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllExecutiveCategoriesMember", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "lang": { "en-us": { "role": { "terseLabel": "All Executive Categories", "label": "All Executive Categories [Member]", "auth_ref": { "r740" } }, "ecd-AllIndividualsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllIndividualsMember", "presentation": { "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "lang": { "en-us": { "role": { "terseLabel": "All Individuals", "label": "All Individuals [Member]", "auth_ref": { "r696", "r706", "r716", "r740", "r748", "r752", "r760" } }, "ecd-AllTradingArrangementsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllTradingArrangementsMember", "presentation": { "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "lang": { "en-us": { "role": { "terseLabel": "All Trading Arrangements", "label": "All Trading Arrangements [Member]", "auth_ref": { "r758" } }, "us-gaap-AllocatedShareBasedCompensationExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AllocatedShareBasedCompensationExpense", "crdr": "debit", "presentation": { "http://www.autolus.com/role/SharebasedCompensationSharebasedCompensationAllocationDetails", "lang": { "en-us": { "role": { "terseLabel": "Total share-based compensation expense", "label": "Share-Based Payment Arrangement, Expense", "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized." } } }, "auth_ref": { "r329", "r335" } }, "dei-AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AmendmentFlag", "presentation": { "http://www.autolus.com/role/Cover", "lang": { "en-us": { "role": { "terseLabel": "Amendment Flag", "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously filed or accepted submission." } } }, "auth_ref": { "us-gaap-AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "presentation": { "http://www.autolus.com/role/NetlossperordinaryshareScheduleofAntidilutiveSecuritiesDetails", "lang": { "en-us": { "role": { "terseLabel": "Total potentially dilutive securities (in shares)", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount", "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented." } } }, "auth_ref": { "r186" } }, "us-gaap-AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis", "presentation": { "http://www.autolus.com/role/NetlossperordinaryshareScheduleofAntidilutiveSecuritiesDetails", "lang": { "en-us": { "role": { "terseLabel": "Antidilutive Securities [Axis]", "label": "Antidilutive Securities [Axis]", "documentation": "Information by type of antidilutive security." } } }, "auth_ref": { "r22" } }, "us-gaap-AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems", "presentation": { "http://www.autolus.com/role/NetlossperordinaryshareScheduleofAntidilutiveSecuritiesDetails", "lang": { "en-us": { "role": { "terseLabel": "Antidilutive Securities", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": { "us-gaap-AntidilutiveSecuritiesNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesNameDomain", "presentation": { "http://www.autolus.com/role/NetlossperordinaryshareScheduleofAntidilutiveSecuritiesDetails", "lang": { "en-us": { "role": { "terseLabel": "Antidilutive Securities, Name [Domain]", "label": "Antidilutive Securities, Name [Domain]", "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented." } } }, "auth_ref": { "r22" } }, "us-gaap-AssetUnderConstructionMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetUnderConstructionMember", "presentation": { "http://www.autolus.com/role/PropertyandEquipmentNetScheduleofPPEDetails", "lang": { "en-us": { "role": { "terseLabel": "Assets under construction", "label": "Asset under Construction [Member]", "documentation": "Asset in process of being built." } } }, "auth_ref": { "us-gaap-Assets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Assets", "crdr": "debit", "calculation": { "http://www.autolus.com/role/UnauditedCondensedConsolidatedBalanceSheets", "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": { "http://www.autolus.com/role/UnauditedCondensedConsolidatedBalanceSheets", "lang": { "en-us": { "role": { "totalLabel": "Total assets", "label": "Assets", "documentation": "Amount of asset recognized for present right to economic benefit." } } }, "auth_ref": { "r89", "r111", "r132", "r153", "r190", "r195", "r211", "r212", "r219", "r234", "r235", "r236", "r237", "r238", "r239", "r240", "r241", "r242", "r351", "r353", "r386", "r474", "r551", "r628", "r629", "r655", "r682", "r816", "r817", "r843" } }, "us-gaap-AssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsAbstract", "presentation": { "http://www.autolus.com/role/UnauditedCondensedConsolidatedBalanceSheets", "lang": { "en-us": { "role": { "terseLabel": "Assets", "label": "Assets [Abstract]", "auth_ref": { "us-gaap-AssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsCurrent", "crdr": "debit", "calculation": { "http://www.autolus.com/role/UnauditedCondensedConsolidatedBalanceSheets", "parentTag": "us-gaap-Assets", "weight": 1.0, "order": 1.0 } }, "presentation": { "http://www.autolus.com/role/UnauditedCondensedConsolidatedBalanceSheets", "lang": { "en-us": { "role": { "totalLabel": "Total current assets", "label": "Assets, Current", "documentation": "Amount of asset recognized for present right to economic benefit, classified as current." } } }, "auth_ref": { "r127", "r138", "r153", "r219", "r234", "r235", "r236", "r237", "r238", "r239", "r240", "r241", "r242", "r351", "r353", "r386", "r655", "r816", "r817", "r843" } }, "us-gaap-AssetsCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsCurrentAbstract", "presentation": { "http://www.autolus.com/role/UnauditedCondensedConsolidatedBalanceSheets", "lang": { "en-us": { "role": { "terseLabel": "Current assets", "label": "Assets, Current [Abstract]", "auth_ref": { "us-gaap-AssetsNoncurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsNoncurrentAbstract", "presentation": { "http://www.autolus.com/role/UnauditedCondensedConsolidatedBalanceSheets", "lang": { "en-us": { "role": { "terseLabel": "Non-current assets", "label": "Assets, Noncurrent [Abstract]", "auth_ref": { "autl-AutolusMember": { "xbrltype": "domainItemType", "nsuri": "http://www.autolus.com/20240630", "localname": "AutolusMember", "presentation": { "http://www.autolus.com/role/RelatedpartytransactionsNarrativeDetails", "lang": { "en-us": { "role": { "terseLabel": "Autolus", "label": "Autolus [Member]", "documentation": "Autolus", "auth_ref": { "ecd-AwardExcPrice": { "xbrltype": "perShareItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardExcPrice", "presentation": { "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "lang": { "en-us": { "role": { "terseLabel": "Award Exercise Price", "label": "Award Exercise Price", "auth_ref": { "r755" } }, "ecd-AwardGrantDateFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardGrantDateFairValue", "presentation": { "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "lang": { "en-us": { "role": { "terseLabel": "Fair Value as of Grant Date", "label": "Award Grant Date Fair Value", "auth_ref": { "r756" } }, "ecd-AwardTmgDisclLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgDisclLineItems", "lang": { "en-us": { "role": { "label": "Award Timing Disclosures [Line Items]", "auth_ref": { "r751" } }, "ecd-AwardTmgHowMnpiCnsdrdTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgHowMnpiCnsdrdTextBlock", "presentation": { "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "lang": { "en-us": { "role": { "terseLabel": "Award Timing, How MNPI Considered", "label": "Award Timing, How MNPI Considered [Text Block]", "auth_ref": { "r751" } }, "ecd-AwardTmgMethodTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgMethodTextBlock", "presentation": { "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "lang": { "en-us": { "role": { "terseLabel": "Award Timing Method", "label": "Award Timing Method [Text Block]", "auth_ref": { "r751" } }, "ecd-AwardTmgMnpiCnsdrdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgMnpiCnsdrdFlag", "presentation": { "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "lang": { "en-us": { "role": { "terseLabel": "Award Timing MNPI Considered", "label": "Award Timing MNPI

Considered [Flag]] } } } , "auth_ref": { "r751" } } } , "ecd_AwardTmgMnpiDiscTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgMnpiDiscTextBlock", "presentation": { "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure": { "lang": { "en-us": { "role": { "terseLabel": "Award Timing MNPI Disclosure", "label": "Award Timing MNPI Disclosure [Text Block]" } } } } , "auth_ref": { "r751" } } } , "ecd_AwardTmgPredtrmndFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgPredtrmndFlag", "presentation": { "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure": { "lang": { "en-us": { "role": { "terseLabel": "Award Timing Predetermined", "label": "Award Timing Predetermined [Flag]" } } } } , "auth_ref": { "r751" } } } , "us-gaap_AwardTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AwardTypeAxis", "presentation": { "http://www.autolus.com/role/ShareBasedCompensationRestrictedStockUnitsDetails": { "http://www.autolus.com/role/ShareBasedCompensationNarrativeDetails": { "http://www.autolus.com/role/ShareholdersEquityNarrativeDetails": { "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure": { "lang": { "en-us": { "role": { "terseLabel": "Award Type [Axis]", "label": "Award Type [Axis]", "documentation": "Information by type of award under share-based payment arrangement." } } } } , "auth_ref": { "r303", "r304", "r305", "r306", "r307", "r308", "r309", "r310", "r311", "r312", "r313", "r314", "r315", "r316", "r317", "r318", "r319", "r320", "r321", "r322", "r323", "r324", "r325", "r326", "r327", "r328" } } } , "ecd_AwardUndrlygSecuritiesAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardUndrlygSecuritiesAmt", "presentation": { "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure": { "lang": { "en-us": { "role": { "terseLabel": "Underlying Securities", "label": "Award Underlying Securities Amount" } } } } , "auth_ref": { "r754" } } } , "ecd_AwardsCloseToMnpiDiscIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardsCloseToMnpiDiscIndName", "presentation": { "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure": { "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Awards Close in Time to MNPI Disclosures, Individual Name" } } } } , "auth_ref": { "r753" } } } , "ecd_AwardsCloseToMnpiDiscTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardsCloseToMnpiDiscTable", "presentation": { "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure": { "lang": { "en-us": { "role": { "terseLabel": "Awards Close in Time to MNPI Disclosures", "label": "Awards Close in Time to MNPI Disclosures [Table]" } } } } , "auth_ref": { "r752" } } } , "ecd_AwardsCloseToMnpiDiscTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardsCloseToMnpiDiscTableTextBlock", "presentation": { "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure": { "lang": { "en-us": { "role": { "terseLabel": "Awards Close in Time to MNPI Disclosures, Table", "label": "Awards Close in Time to MNPI Disclosures [Table Text Block]" } } } } , "auth_ref": { "r752" } } } , "us-gaap_BankingAndThriftInterestAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BankingAndThriftInterestAbstract", "lang": { "en-us": { "role": { "label": "Banking and Thrift, Interest [Abstract]" } } } , "auth_ref": { "r752" } } } , "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BasisOfAccountingPolicyPolicyTextBlock", "presentation": { "http://www.autolus.com/role/SummaryofSignificantAccountingPoliciesPolicies": { "lang": { "en-us": { "role": { "terseLabel": "Basis of Presentation", "label": "Basis of Accounting, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)." } } } } , "auth_ref": { "r752" } } } , "us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "presentation": { "http://www.autolus.com/role/SummaryofSignificantAccountingPolicies": { "lang": { "en-us": { "role": { "terseLabel": "Summary of Significant Accounting Policies", "label": "Basis of Presentation and Significant Accounting Policies [Text Block]", "documentation": "The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). Accounting policies describe all significant accounting policies of the reporting entity." } } } } , "auth_ref": { "r72" } } } , "autl_BioNTechAndCabalettaMember": { "xbrltype": "domainItemType", "nsuri": "http://www.autolus.com/20240630", "localname": "BioNTechAndCabalettaMember", "presentation": { "http://www.autolus.com/role/LicenseRevenueNarrativeDetails": { "lang": { "en-us": { "role": { "terseLabel": "BioNTech And Cabaletta", "label": "BioNTech And Cabaletta [Member]", "documentation": "BioNTech And Cabaletta" } } } } , "auth_ref": { "r72" } } } , "autl_BioNTechLiabilityMember": { "xbrltype": "domainItemType", "nsuri": "http://www.autolus.com/20240630", "localname": "BioNTechLiabilityMember", "presentation": { "http://www.autolus.com/role/LiabilitiesrelatedtofutureroyaltiesandmilestonesnetNarrativeDetails": { "lang": { "en-us": { "role": { "terseLabel": "BioNTech Liability", "label": "BioNTech Liability [Member]", "documentation": "BioNTech Liability" } } } } , "auth_ref": { "r72" } } } , "autl_BioNTechLicenseAndOptionsAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.autolus.com/20240630", "localname": "BioNTechLicenseAndOptionsAgreementMember", "presentation": { "http://www.autolus.com/role/NatureoftheBusinessNarrativeDetails": { "http://www.autolus.com/role/NatureoftheBusinessUnitsofAccountingDetails": { "lang": { "en-us": { "role": { "terseLabel": "BioNTech License and Option Agreement", "label": "BioNTech License and Options Agreement [Member]", "documentation": "BioNTech License and Options Agreement" } } } } , "auth_ref": { "r72" } } } , "autl_BioNTechMember": { "xbrltype": "domainItemType", "nsuri": "http://www.autolus.com/20240630", "localname": "BioNTechMember", "presentation": { "http://www.autolus.com/role/LiabilitiesrelatedtofutureroyaltiesandmilestonesnetNarrativeDetails": { "http://www.autolus.com/role/LicenseRevenueNarrativeDetails": { "http://www.autolus.com/role/NatureoftheBusinessNarrativeDetails": { "http://www.autolus.com/role/NatureoftheBusinessUnitsofAccountingDetails": { "http://www.autolus.com/role/ShareholdersEquityNarrativeDetails": { "lang": { "en-us": { "role": { "terseLabel": "BioNTech", "label": "BioNTech [Member]", "documentation": "BioNTech" } } } } } , "auth_ref": { "r72" } } } , "autl_BlackstoneCollaborationAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.autolus.com/20240630", "localname": "BlackstoneCollaborationAgreementMember", "presentation": { "http://www.autolus.com/role/LiabilitiesrelatedtofutureroyaltiesandmilestonesnetNarrativeDetails": { "http://www.autolus.com/role/NatureoftheBusinessNarrativeDetails": { "http://www.autolus.com/role/RelatedpartytransactionsNarrativeDetails": { "lang": { "en-us": { "role": { "terseLabel": "Blackstone Collaboration Agreement", "label": "Blackstone Collaboration Agreement [Member]", "documentation": "Blackstone Collaboration Agreement" } } } } } , "auth_ref": { "r72" } } } , "autl_BlackstoneMember": { "xbrltype": "domainItemType", "nsuri": "http://www.autolus.com/20240630", "localname": "BlackstoneMember", "presentation": { "http://www.autolus.com/role/LiabilitiesrelatedtofutureroyaltiesandmilestonesnetNarrativeDetails": { "http://www.autolus.com/role/NatureoftheBusinessNarrativeDetails": { "http://www.autolus.com/role/RelatedpartytransactionsNarrativeDetails": { "lang": { "en-us": { "role": { "terseLabel": "Blackstone", "label": "Blackstone [Member]", "documentation": "Blackstone" } } } } } , "auth_ref": { "r72" } } } , "autl_CabalettaBioIncCabalettaMember": { "xbrltype": "domainItemType", "nsuri": "http://www.autolus.com/20240630", "localname": "CabalettaBioIncCabalettaMember", "presentation": { "http://www.autolus.com/role/LicenseRevenueNarrativeDetails": { "lang": { "en-us": { "role": { "terseLabel": "Cabaletta Bio Inc. (u201cCabaletta u201d)", "label": "Cabaletta Bio Inc. (u201cCabaletta u201d) [Member]", "documentation": "Cabaletta Bio Inc. (u201cCabaletta u201d)" } } } } , "auth_ref": { "r72" } } } , "us-gaap_CapitalAdditionsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CapitalAdditionsMember", "presentation": { "http://www.autolus.com/role/CommitmentsandContingenciesNarrativeDetails": { "lang": { "en-us": { "role": { "terseLabel": "Capital Addition Purchase Commitments", "label": "Capital Addition Purchase Commitments [Member]", "documentation": "Contractual obligation to increase property, plant and equipment either through construction or future purchases." } } } } , "auth_ref": { "r19", "r20", "r21" } } } , "us-gaap_CapitalExpendituresIncurredButNotYetPaid": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CapitalExpendituresIncurredButNotYetPaid", "crdr": "credit", "presentation": { "http://www.autolus.com/role/UnauditedCondensedConsolidatedStatementsofCashFlows": { "lang": { "en-us": { "role": { "terseLabel": "Property and equipment purchases included in accounts payable or accrued expenses", "label": "Capital Expenditures Incurred but Not yet Paid", "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred." } } } } , "auth_ref": { "r19", "r20", "r21" } } } , "autl_CapitalizedIntangibleAssetsNetPropertyAndEquipmentMember": { "xbrltype": "domainItemType", "nsuri": "http://www.autolus.com/20240630", "localname": "CapitalizedIntangibleAssetsNetPropertyAndEquipmentMember", "presentation": { "http://www.autolus.com/role/ShareBasedCompensationShareBasedCompensationAllocationDetails": { "lang": { "en-us": { "role": { "terseLabel": "Capitalized", "label": "Capitalized Intangible Assets, Net [Property And Equipment [Member]", "documentation": "Capitalized Fixed Assets [Member]" } } } } , "auth_ref": { "r72" } } } , "autl_CapitalizedShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://www.autolus.com/20240630", "localname": "CapitalizedShareBasedCompensation", "crdr": "debit", "presentation": { "http://www.autolus.com/role/UnauditedCondensedConsolidatedStatementsofCashFlows": { "lang": { "en-us": { "role": { "terseLabel": "Capitalized share-based compensation, net of forfeitures", "label": "Capitalized Share-based Compensation", "documentation": "Capitalized Share-based Compensation" } } } } , "auth_ref": { "r72" } } } , "autl_CardinalHealth105LLCCardinalHealthMember": { "xbrltype": "domainItemType", "nsuri": "http://www.autolus.com/20240630", "localname": "CardinalHealth105LLCCardinalHealthMember", "presentation": { "http://www.autolus.com/role/CommitmentsandContingenciesNarrativeDetails": { "lang": { "en-us": { "role": { "terseLabel": "Cardinal Health 105, LLC (u201cCardinal Health u201d)", "label": "Cardinal Health 105, LLC (u201cCardinal Health u201d) [Member]", "documentation": "Cardinal Health 105, LLC (u201cCardinal Health u201d)" } } } } , "auth_ref": { "r72" } } } , "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashAndCashEquivalentsAtCarryingValue", "crdr": "debit", "calculation": { "http://www.autolus.com/role/UnauditedCondensedConsolidatedBalanceSheets": { "parentTag": { "us-gaap_AssetsCurrent", "weight": 1.0, "order": 1.0 }, "http://www.autolus.com/role/UnauditedCondensedConsolidatedStatementsofCashFlows": { "parentTag": { "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "weight": 1.0, "order": 1.0 } } } , "presentation": { "http://www.autolus.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails": { "http://www.autolus.com/role/UnauditedCondensedConsolidatedBalanceSheets": { "http://www.autolus.com/role/UnauditedCondensedConsolidatedStatementsofCashFlows": { "lang": { "en-us": { "role": { "terseLabel": "Cash and cash equivalents", "label": "Cash and Cash Equivalents, at Carrying Value", "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } } } , "auth_ref": { "r17", "r19", "r20", "r21" } } } , "us-gaap_CashAndCashEquivalentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashAndCashEquivalentsAxis", "presentation": { "http://www.autolus.com/role/FairValueMeasurementsDetails": { "lang": { "en-us": { "role": { "terseLabel": "Cash and Cash Equivalents [Axis]", "label": "Cash and Cash Equivalents [Axis]", "documentation": "Information by type of cash and cash equivalent balance." } } } } , "auth_ref": { "r129" } } } , "us-gaap_CashAndCashEquivalentsFairValueDisclosure": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashAndCashEquivalentsFairValueDisclosure", "crdr": "debit", "presentation": { "http://www.autolus.com/role/FairValueMeasurementsDetails": { "lang": { "en-us": { "role": { "terseLabel": "Cash and cash equivalents", "label": "Cash and Cash Equivalents, Fair Value Disclosure", "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } } } , "auth_ref": { "r827", "r828" } } } , "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "crdr": "debit", "calculation": { "http://www.autolus.com/role/UnauditedCondensedConsolidatedStatementsofCashFlows": { "parentTag": { "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract", "weight": null, "order": null, "root": true } } } , "presentation": { "http://www.autolus.com/role/UnauditedCondensedConsolidatedStatementsofCashFlows": { "lang": { "en-us": { "role": { "terseLabel": "Cash, cash equivalents and restricted cash, beginning of period", "label": "Cash, cash equivalents and restricted cash, end of period", "totalLabel": "Total cash, cash equivalents and restricted cash", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents", "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } } } , "auth_ref": { "r17", "r68", "r151" } } } , "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract", "presentation": { "http://www.autolus.com/role/UnauditedCondensedConsolidatedStatementsofCashFlows": { "lang": { "en-us": { "role": { "terseLabel": "Reconciliation of cash, cash equivalents and restricted cash reported within the unaudited condensed consolidated balance sheets", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents [Abstract]" } } } } , "auth_ref": { "r72" } } } , "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "crdr": "debit", "calculation": { "http://www.autolus.com/role/UnauditedCondensedConsolidatedStatementsofCashFlows": { "parentTag": { "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract", "weight": null, "order": null, "root": true } } } , "presentation": { "http://www.autolus.com/role/UnauditedCondensedConsolidatedStatementsofCashFlows": { "lang": { "en-us": { "role": { "totalLabel": "Net increase (decrease) in cash,

cash equivalents and restricted cash,"label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage, including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": { "r0": "r68" } } }, "ecd_ChangedPeerGroupFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ChangedPeerGroupFnTextBlock", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure": { "lang": { "en-us": { "role": { "terseLabel": "Changed Peer Group, Footnote", "label": "Changed Peer Group, Footnote [Text Block] } } }, "auth_ref": { "r731" } } }, "ecd_ChngInFrValAsOfVstngDtOfPrYrEqtyAwrdsVstdInCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ChngInFrValAsOfVstngDtOfPrYrEqtyAwrdsVstdInCvrdYrMember", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure": { "lang": { "en-us": { "role": { "terseLabel": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year", "label": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member] } } }, "auth_ref": { "r728" } } }, "ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrYrsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrYrsMember", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure": { "lang": { "en-us": { "role": { "terseLabel": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested", "label": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member] } } }, "auth_ref": { "r726" } } }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CityAreaCode", "presentation": { "http://www.autolus.com/role/Cover": { "lang": { "en-us": { "role": { "verboseLabel": "City Area Code", "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": { "us-gaap_ClassOfStockDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfStockDomain", "presentation": { "http://www.autolus.com/role/Cover", "http://www.autolus.com/role/NatureoftheBusinessNarrativeDetails", "http://www.autolus.com/role/ShareholdersEquityNarrativeDetails", "http://www.autolus.com/role/UnauditedCondensedConsolidatedBalanceSheets", "http://www.autolus.com/role/UnauditedCondensedConsolidatedBalanceSheetsParentheticals", "http://www.autolus.com/role/UnauditedCondensedConsolidatedStatementsOfShareholdersEquity": { "lang": { "en-us": { "role": { "terseLabel": "Class of Stock [Domain]", "label": "Class of Stock [Domain]", "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock." } } }, "auth_ref": { "r124": "r133": "r134": "r135": "r153": "r175": "r176": "r183": "r185": "r193": "r194": "r219": "r234": "r236": "r237": "r238": "r241": "r242": "r261": "r262": "r265": "r268": "r275": "r386": "r508": "r509": "r510": "r511": "r516": "r517": "r518": "r519": "r520": "r521": "r522": "r523": "r524": "r525": "r526": "r527": "r539": "r561": "r584": "r596": "r597": "r598": "r599": "r600": "r770": "r791": "r798" } } }, "us-gaap_ClassOfStockLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfStockLineItems", "presentation": { "http://www.autolus.com/role/NatureoftheBusinessUnitsofAccountingDetails": "http://www.autolus.com/role/ShareholdersEquityNarrativeDetails": { "lang": { "en-us": { "role": { "terseLabel": "Class of Stock", "label": "Class of Stock [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": { "r133": "r134": "r135": "r193": "r261": "r262": "r263": "r265": "r268": "r273": "r275": "r508": "r509": "r510": "r511": "r636": "r770": "r791" } } }, "us-gaap_ClassOfWarrantOrRightLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfWarrantOrRightLineItems", "presentation": { "http://www.autolus.com/role/LiabilitiesrelatedtofutureroyaltiesandmilestonesnetNarrativeDetails": { "lang": { "en-us": { "role": { "terseLabel": "Class of Warrant or Right [Table]", "label": "Class of Warrant or Right [Table]", "documentation": "Disclosure of information about warrant or right issued that give holder right to purchase security from issuer at specific price within certain time frame." } } }, "auth_ref": { "r36" } } }, "ecd_CoSelectedMeasureAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CoSelectedMeasureAmt", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure": { "lang": { "en-us": { "role": { "terseLabel": "Company Selected Measure Amount", "label": "Company Selected Measure Amount" } } }, "auth_ref": { "r732" } } }, "ecd_CoSelectedMeasureName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CoSelectedMeasureName", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure": { "lang": { "en-us": { "role": { "terseLabel": "Company Selected Measure Name", "label": "Company Selected Measure Name" } } }, "auth_ref": { "r732" } } }, "autl_CollaborationAgreementCumulativeCatchUpAdjustment": { "xbrltype": "monetaryItemType", "nsuri": "http://www.autolus.com/20240630", "localname": "CollaborationAgreementCumulativeCatchUpAdjustment", "crdr": "credit", "calculation": { "http://www.autolus.com/role/InterestExpenseDetails": { "parentTag": "us-gaap-InterestExpense", "weight": -1.0, "order": 3.0 } }, "presentation": { "http://www.autolus.com/role/InterestExpenseDetails": "http://www.autolus.com/role/LiabilitiesrelatedtofutureroyaltiesandmilestonesnetNarrativeDetails", "http://www.autolus.com/role/LiabilitiesrelatedtofutureroyaltiesandmilestonesnetScheduleofLiabilityRelatedtoRevenueDetails": { "lang": { "en-us": { "role": { "negatedTerseLabel": "Cumulative catch-up adjustment arising from the liabilities related to future royalties and milestones, net (refer to Note 12)", "negatedLabel": "Cumulative catch-up adjustment", "label": "Collaboration Agreement, Cumulative Catch-Up Adjustment", "documentation": "Collaboration Agreement, Cumulative Catch-Up Adjustment" } } }, "auth_ref": { "autl_CollaborationAgreementInitialRecognitionOfLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://www.autolus.com/20240630", "localname": "CollaborationAgreementInitialRecognitionOfLiability", "crdr": "credit", "presentation": { "http://www.autolus.com/role/LiabilitiesrelatedtofutureroyaltiesandmilestonesnetScheduleofLiabilityRelatedtoRevenueDetails": { "lang": { "en-us": { "role": { "terseLabel": "Initial recognition of BioNTech liability", "label": "Collaboration Agreement, Initial Recognition of Liability", "documentation": "Collaboration Agreement, Initial Recognition of Liability" } } }, "auth_ref": { "autl_CollaborationAgreementNonCashInterestExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://www.autolus.com/20240630", "localname": "CollaborationAgreementNonCashInterestExpense", "crdr": "debit", "calculation": { "http://www.autolus.com/role/InterestExpenseDetails": { "parentTag": "us-gaap-InterestExpense", "weight": -1.0, "order": 2.0 } }, "presentation": { "http://www.autolus.com/role/InterestExpenseDetails": "http://www.autolus.com/role/LiabilitiesrelatedtofutureroyaltiesandmilestonesnetNarrativeDetails", "http://www.autolus.com/role/LiabilitiesrelatedtofutureroyaltiesandmilestonesnetScheduleofLiabilityRelatedtoRevenueDetails": { "lang": { "en-us": { "role": { "verboseLabel": "Interest expense on liabilities related to future royalties and milestones, net (refer to Note 12)", "terseLabel": "Interest expense on liability related to future royalties and milestones, net", "label": "Collaboration Agreement, Non-Cash Interest Expense", "documentation": "Collaboration Agreement, Non-Cash Interest Expense" } } }, "auth_ref": { "autl_CollaborationAgreementNonCashInterestExpenseAndCumulativeCatchUpAdjustment": { "xbrltype": "monetaryItemType", "nsuri": "http://www.autolus.com/20240630", "localname": "CollaborationAgreementNonCashInterestExpenseAndCumulativeCatchUpAdjustment", "crdr": "debit", "calculation": { "http://www.autolus.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap-NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 16.0 } }, "presentation": { "http://www.autolus.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows": { "lang": { "en-us": { "role": { "terseLabel": "Interest expense on liabilities related to future royalties and milestones, net", "label": "Collaboration Agreement, Non-Cash Interest Expense And Cumulative Catch-Up Adjustment", "documentation": "Collaboration Agreement, Non-Cash Interest Expense And Cumulative Catch-Up Adjustment" } } }, "auth_ref": { "autl_CollaborationAgreementNonCashInterestExpenseIncludingCumulativeCatchUpAdjustment": { "xbrltype": "monetaryItemType", "nsuri": "http://www.autolus.com/20240630", "localname": "CollaborationAgreementNonCashInterestExpenseIncludingCumulativeCatchUpAdjustment", "crdr": "debit", "presentation": { "http://www.autolus.com/role/RelatedpartytransactionsNarrativeDetails": { "lang": { "en-us": { "role": { "terseLabel": "Non-cash interest expense, catch-up", "label": "Collaboration Agreement, Non-Cash Interest Expense, Including Cumulative Catch-Up Adjustment", "documentation": "Collaboration Agreement, Non-Cash Interest Expense, Including Cumulative Catch-Up Adjustment" } } }, "auth_ref": { "autl_CollaborativeAgreementBeneficialOwnershipPercentageThreshold": { "xbrltype": "pureItemType", "nsuri": "http://www.autolus.com/20240630", "localname": "CollaborativeAgreementBeneficialOwnershipPercentageThreshold", "presentation": { "http://www.autolus.com/role/NatureoftheBusinessNarrativeDetails": { "lang": { "en-us": { "role": { "terseLabel": "Collaborative agreement, beneficial ownership percentage, threshold (in percent)", "label": "Collaborative Agreement, Beneficial Ownership Percentage, Threshold", "documentation": "Collaborative Agreement, Beneficial Ownership Percentage, Threshold" } } }, "auth_ref": { "autl_CollaborativeAgreementPeriodToAcquireBeneficialOwnershipFromExecutionDate": { "xbrltype": "durationItemType", "nsuri": "http://www.autolus.com/20240630", "localname": "CollaborativeAgreementPeriodToAcquireBeneficialOwnershipFromExecutionDate", "presentation": { "http://www.autolus.com/role/NatureoftheBusinessNarrativeDetails": { "lang": { "en-us": { "role": { "terseLabel": "Collaborative arrangement, period to enter agreement from execution date", "label": "Collaborative Agreement, Period To Acquire Beneficial Ownership From Execution Date", "documentation": "Collaborative Agreement, Period To Acquire Beneficial Ownership From Execution Date" } } }, "auth_ref": { "autl_CollaborativeAgreementSaleOfStockProhibitedWithoutRegistrantsApprovalPeriod": { "xbrltype": "durationItemType", "nsuri": "http://www.autolus.com/20240630", "localname": "CollaborativeAgreementSaleOfStockProhibitedWithoutRegistrantsApprovalPeriod", "presentation": { "http://www.autolus.com/role/NatureoftheBusinessNarrativeDetails": { "lang": { "en-us": { "role": { "terseLabel": "Collaborative agreement, sale of stock prohibited without registrant's approval, period (in months)", "label": "Collaborative Agreement, Sale of Stock Prohibited Without Registrant's Approval, Period", "documentation": "Collaborative Agreement, Sale of Stock Prohibited Without Registrant's Approval, Period" } } }, "auth_ref": { "autl_CollaborativeAgreementsDebtLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://www.autolus.com/20240630", "localname": "CollaborativeAgreementsDebtLiability", "crdr": "credit", "presentation": { "http://www.autolus.com/role/LiabilitiesrelatedtofutureroyaltiesandmilestonesnetScheduleofLiabilityRelatedtoRevenueDetails": { "http://www.autolus.com/role/RelatedpartytransactionsNarrativeDetails": { "lang": { "en-us": { "role": { "periodStartLabel": "Beginning Balance", "periodEndLabel": "Ending Balance", "terseLabel": "Carrying amount of liability", "label": "Collaborative Agreements, Debt Liability", "documentation": "Collaborative Agreements, Debt Liability" } } }, "auth_ref": { "autl_CollaborativeAgreementsDebtLiabilityRollForward": { "xbrltype": "stringItemType", "nsuri": "http://www.autolus.com/20240630", "localname": "CollaborativeAgreementsDebtLiabilityRollForward", "presentation": { "http://www.autolus.com/role/LiabilitiesrelatedtofutureroyaltiesandmilestonesnetScheduleofLiabilityRelatedtoRevenueDetails": { "lang": { "en-us": { "role": { "terseLabel": "Collaborative Agreements, Debt Liability", "label": "Collaborative Agreements, Debt Liability Roll Forward", "documentation": "Collaborative Agreements, Debt Liability" } } }, "auth_ref": { "autl_CollaborativeArrangementPeriodToEnterAgreementFromInitialClosingDate": { "xbrltype": "durationItemType", "nsuri": "http://www.autolus.com/20240630", "localname": "CollaborativeArrangementPeriodToEnterAgreementFromInitialClosingDate", "presentation": { "http://www.autolus.com/role/NatureoftheBusinessNarrativeDetails": { "lang": { "en-us": { "role": { "terseLabel": "Collaborative arrangement, period to enter agreement from initial closing date (in months)", "label": "Collaborative Arrangement, Period To Enter Agreement From Initial Closing Date", "documentation": "Collaborative Arrangement, Period To Enter Agreement From Initial Closing Date" } } }, "auth_ref": { "autl_CollaborativeArrangementRightsAndObligationsAnnualLicenseFee": { "xbrltype": "monetaryItemType", "nsuri": "http://www.autolus.com/20240630", "localname": "CollaborativeArrangementRightsAndObligationsAnnualLicenseFee", "crdr": "debit", "presentation": { "http://www.autolus.com/role/CommitmentsandContingenciesNarrativeDetails": { "lang": { "en-us": { "role": { "terseLabel": "Annual license fee", "label": "Collaborative Arrangement, Rights And Obligations, Annual License Fee", "documentation": "Collaborative Arrangement, Rights And Obligations, Annual License Fee" } } }, "auth_ref": { "autl_CollaborativeArrangementRightsAndObligationsMaximumSharePurchaseRequirementShares": { "xbrltype": "sharesItemType", "nsuri": "http://www.autolus.com/20240630", "localname": "CollaborativeArrangementRightsAndObligationsMaximumSharePurchaseRequirementShares", "presentation": { "http://www.autolus.com/role/NatureoftheBusinessNarrativeDetails": "http://www.autolus.com/role/ShareholdersEquityNarrativeDetails": { "lang": { "en-us": { "role": { "terseLabel": "Collaborative arrangement, rights and obligations, maximum share purchase requirement, shares (in shares)", "label": "Collaborative Arrangement, Rights And Obligations, Maximum Share Purchase Requirement, Shares", "documentation": "Collaborative Arrangement, Rights And Obligations, Maximum Share Purchase Requirement, Shares" } } }, "auth_ref": { "autl_CollaborativeArrangementRightsAndObligationsMaximumSharePurchaseRequirementValue": { "xbrltype": "monetaryItemType", "nsuri": "http://www.autolus.com/20240630", "localname": "CollaborativeArrangementRightsAndObligationsMaximumSharePurchaseRequirementValue", "crdr": "debit", "presentation": { "http://www.autolus.com/role/NatureoftheBusinessNarrativeDetails": "http://www.autolus.com/role/ShareholdersEquityNarrativeDetails": { "lang": { "en-us": { "role": { "terseLabel": "Collaborative arrangement, rights and obligations, maximum share purchase requirement, value", "label": "Collaborative Arrangement, Rights And Obligations, Maximum Share Purchase Requirement, Value", "documentation": "Collaborative Arrangement, Rights And Obligations, Maximum Share Purchase Requirement, Value" } } }, "auth_ref": { "autl_CollaborativeArrangementRightsAndObligationsPaymentsPayable": { "xbrltype": "monetaryItemType", "nsuri":

"http://www.autolus.com/20240630", "localname": "CollaborativeArrangementRightsAndObligationsPaymentsPayable", "crdr": "credit", "presentation": {
"http://www.autolus.com/role/CommitmentsAndContingenciesNarrativeDetails": { "lang": { "en-us": { "terseLabel": "Payments for license fees (less than)", "label":
"Collaborative Arrangement, Rights And Obligations, Payments Payable", "documentation": "Collaborative Arrangement, Rights And Obligations, Payments Payable" } } },
"auth_ref": { "us-gaap_CommitmentsAndContingencies": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"CommitmentsAndContingencies", "crdr": "credit", "calculation": { "http://www.autolus.com/role/UnauditedCondensedConsolidatedBalanceSheets": { "parentTag": "us-
gaap_StockholdersEquity", "weight": 1.0, "order": 5.0 } }, "presentation": { "http://www.autolus.com/role/UnauditedCondensedConsolidatedBalanceSheets": { "lang": { "en-
us": { "role": { "terseLabel": "Commitments and contingencies", "label": "Commitments and Contingencies", "documentation": "Represents the caption on the face of the
balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms
thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under
contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur
do occur or fail to occur." } } }, "auth_ref": { "r52", "r92", "r476", "r538" } }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "xbrltype": "stringItemType",
"nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommitmentsAndContingenciesDisclosureAbstract", "lang": { "en-us": { "role": { "terseLabel": "Commitments and
Contingencies Disclosure [Abstract]", "label": "Commitments and Contingencies Disclosure [Abstract]" } } }, "auth_ref": { "us-
gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"CommitmentsAndContingenciesDisclosureTextBlock", "presentation": { "http://www.autolus.com/role/CommitmentsandContingencies": { "lang": { "en-us": { "role": {
"terseLabel": "Commitments and Contingencies", "label": "Commitments and Contingencies Disclosure [Text Block]", "documentation": "The entire disclosure for
commitments and contingencies." } } }, "auth_ref": { "r78", "r228", "r230", "r604", "r809", "r813" } }, "us-gaap_CommonStockMember": { "xbrltype": "domainItemType",
"nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockMember", "presentation": {
"http://www.autolus.com/role/UnauditedCondensedConsolidatedStatementsofShareholdersEquity": { "lang": { "en-us": { "role": { "terseLabel": "Common shares", "label":
"Common Stock [Member]", "documentation": "Stock that is subordinate to all other stock of the issuer." } } }, "auth_ref": { "r672", "r673", "r674", "r676", "r677", "r678",
"r679", "r794", "r795", "r797", "r826", "r876", "r879" } }, "us-gaap_CommonStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "CommonStockParOrStatedValuePerShare", "presentation": {
"http://www.autolus.com/role/NatureoftheBusinessNarrativeDetails": { "http://www.autolus.com/role/UnauditedCondensedConsolidatedBalanceSheetsParenteticals": {
"lang": { "en-us": { "role": { "terseLabel": "Stock par value (usd/gbp per share)", "label": "Common Stock, Par or Stated Value Per Share", "documentation": "Face amount
or stated value per share of common stock." } } }, "auth_ref": { "r55" } }, "us-gaap_CommonStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesAuthorized", "presentation": {
"http://www.autolus.com/role/UnauditedCondensedConsolidatedBalanceSheets":
"http://www.autolus.com/role/UnauditedCondensedConsolidatedBalanceSheetsParenteticals": { "lang": { "en-us": { "role": { "terseLabel": "Shares authorized (in shares)",
"label": "Common Stock, Shares Authorized", "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws." } } },
"auth_ref": { "r55", "r539" } }, "us-gaap_CommonStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"CommonStockSharesIssued", "presentation": { "http://www.autolus.com/role/UnauditedCondensedConsolidatedBalanceSheetsParenteticals": { "lang": { "en-us": { "role":
"terseLabel": "Shares issued (in shares)", "label": "Common Stock, Shares, Issued", "documentation": "Total number of common shares of an entity that have been sold
or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's
shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury."
} } }, "auth_ref": { "r55" } }, "us-gaap_CommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"CommonStockSharesOutstanding", "presentation": { "http://www.autolus.com/role/UnauditedCondensedConsolidatedBalanceSheetsParenteticals":
"http://www.autolus.com/role/UnauditedCondensedConsolidatedStatementsofShareholdersEquity": { "lang": { "en-us": { "role": { "terseLabel": "Shares outstanding (in
shares)", "periodStartLabel": "Beginning balance (in shares)", "periodEndLabel": "Ending balance (in shares)", "label": "Common Stock, Shares, Outstanding",
"documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation." } } }, "auth_ref": { "r8", "r55",
"r539", "r557", "r879", "r880" } }, "autl_CommonStockSharesOutstandingIncludingRSUsVestedButNotYetReleased": { "xbrltype": "sharesItemType", "nsuri":
"http://www.autolus.com/20240630", "localname": "CommonStockSharesOutstandingIncludingRSUsVestedButNotYetReleased", "presentation": {
"http://www.autolus.com/role/UnauditedCondensedConsolidatedBalanceSheetsParenteticals": { "lang": { "en-us": { "role": { "terseLabel": "Shares outstanding, including
RSUs vested but not yet released (in shares)", "label": "Common Stock, Shares Outstanding, Including RSUs, Vested But Not Yet Released", "documentation": "Common
Stock, Shares Outstanding, Including RSUs, Vested But Not Yet Released" } } }, "auth_ref": { "us-gaap_CommonStockValue": { "xbrltype": "monetaryItemType",
"nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockValue", "crdr": "credit", "calculation": {
"http://www.autolus.com/role/UnauditedCondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 1.0 } },
"presentation": { "http://www.autolus.com/role/UnauditedCondensedConsolidatedBalanceSheets": { "lang": { "en-us": { "role": { "terseLabel": "Share value", "label":
"Common Stock, Value, Issued", "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the
option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other
disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": { "r55", "r477", "r655" } }, "autl_CommonStockVotingRightsVotesPerShare": {
"xbrltype": "integerItemType", "nsuri": "http://www.autolus.com/20240630", "localname": "CommonStockVotingRightsVotesPerShare", "presentation": {
"http://www.autolus.com/role/ShareholdersEquityNarrativeDetails": { "lang": { "en-us": { "role": { "terseLabel": "Voting rights, votes per share", "label": "Common Stock,
Voting Rights, Votes Per Share", "documentation": "Common Stock, Voting Rights, Votes Per Share" } } }, "auth_ref": {
"ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname":
"CompActuallyPaidVsCoSelectedMeasureTextBlock", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure": { "lang": { "en-us": { "role": { "terseLabel":
"Compensation Actually Paid vs. Company Selected Measure", "label": "Compensation Actually Paid vs. Company Selected Measure [Text Block]" } } }, "auth_ref": { "r737"
} }, "ecd_CompActuallyPaidVsNetIncomeTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname":
"CompActuallyPaidVsNetIncomeTextBlock", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure": { "lang": { "en-us": { "role": { "terseLabel": "Compensation
Actually Paid vs. Net Income", "label": "Compensation Actually Paid vs. Net Income [Text Block]" } } }, "auth_ref": { "r736" } },
"ecd_CompActuallyPaidVsOtherMeasureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname":
"CompActuallyPaidVsOtherMeasureTextBlock", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure": { "lang": { "en-us": { "role": { "terseLabel": "Compensation
Actually Paid vs. Other Measure", "label": "Compensation Actually Paid vs. Other Measure [Text Block]" } } }, "auth_ref": { "r738" } },
"ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname":
"CompActuallyPaidVsTotalShareholderRtnTextBlock", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure": { "lang": { "en-us": { "role": { "terseLabel":
"Compensation Actually Paid vs. Total Shareholder Return", "label": "Compensation Actually Paid vs. Total Shareholder Return [Text Block]" } } }, "auth_ref": { "r735" } },
"us-gaap_ComprehensiveIncomeNetOffTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ComprehensiveIncomeNetOffTax",
"crdr": "credit", "calculation": { "http://www.autolus.com/role/UnauditedCondensedConsolidatedStatementsofOperationsandComprehensiveLoss": { "parentTag": null,
"weight": null, "order": null, "root": true } }, "presentation": {
"http://www.autolus.com/role/UnauditedCondensedConsolidatedStatementsofOperationsandComprehensiveLoss": { "lang": { "en-us": { "role": { "totalLabel": "Total
comprehensive loss", "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent", "documentation": "Amount after tax of increase (decrease) in equity
from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity
resulting from investments by owners and distributions to owners." } } }, "auth_ref": { "r15", "r140", "r142", "r147", "r469", "r487", "r488" } }, "us-
gaap_ComprehensiveIncomeNetOffTaxAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ComprehensiveIncomeNetOffTaxAbstract", "presentation": {
"http://www.autolus.com/role/UnauditedCondensedConsolidatedStatementsofOperationsandComprehensiveLoss": { "lang": { "en-us": { "role": { "terseLabel": "Other
comprehensive income (loss)", "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent [Abstract]" } } }, "auth_ref": { "us-
gaap_ConcentrationRiskBenchmarkDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ConcentrationRiskBenchmarkDomain", "presentation": { "http://www.autolus.com/role/LicenserevenueNarrativeDetails": { "lang": { "en-us": { "role": { "terseLabel":
"Concentration Risk Benchmark [Domain]", "label": "Concentration Risk Benchmark [Domain]", "documentation": "The denominator in a calculation of a disclosed
concentration risk percentage." } } }, "auth_ref": { "r23", "r24", "r41", "r42", "r217", "r603" } }, "us-gaap_ConcentrationRiskByBenchmarkAxis": { "xbrltype":
"stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConcentrationRiskByBenchmarkAxis", "presentation": {
"http://www.autolus.com/role/LicenserevenueNarrativeDetails": { "lang": { "en-us": { "role": { "terseLabel": "Concentration Risk Benchmark [Axis]", "label":
"Concentration Risk Benchmark [Axis]", "documentation": "Information by benchmark of concentration risk." } } }, "auth_ref": { "r23", "r24", "r41", "r42", "r217", "r506",
"r603" } }, "us-gaap_ConcentrationRiskByTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConcentrationRiskByTypeAxis",
"presentation": { "http://www.autolus.com/role/LicenserevenueNarrativeDetails": { "lang": { "en-us": { "role": { "terseLabel": "Concentration Risk Type [Axis]", "label":
"Concentration Risk Type [Axis]", "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic,
customer, employees, supplier, lender." } } }, "auth_ref": { "r23", "r24", "r41", "r42", "r217", "r603", "r773" } }, "us-gaap_ConcentrationRiskPercentage1": { "xbrltype":
"percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConcentrationRiskPercentage1", "presentation": {
"http://www.autolus.com/role/LicenserevenueNarrativeDetails": { "lang": { "en-us": { "role": { "terseLabel": "Concentration risk (in percent)", "label": "Concentration Risk,
Percentage", "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator)
in the equation, this concept represents the concentration percentage derived from the division." } } }, "auth_ref": { "r23", "r24", "r41", "r42", "r217" } }, "us-
gaap_ConcentrationRiskTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConcentrationRiskTypeDomain",
"presentation": { "http://www.autolus.com/role/LicenserevenueNarrativeDetails": { "lang": { "en-us": { "role": { "terseLabel": "Concentration Risk Type [Domain]", "label":
"Concentration Risk Type [Domain]", "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark,
identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration." } } }, "auth_ref": { "r23", "r24",
"r41", "r42", "r217", "r603" } }, "us-gaap_ContractWithCustomerLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ContractWithCustomerLiability", "crdr": "credit", "presentation": { "http://www.autolus.com/role/LiabilitiesrelatedtofutureroyaltiesandmilestonesnetNarrativeDetails":
"http://www.autolus.com/role/NatureoftheBusinessNarrativeDetails": { "http://www.autolus.com/role/RelatedpartytransactionsNarrativeDetails": { "lang": { "en-us": { "role":
"terseLabel": "Contract with customer, liability", "label": "Contract with Customer, Liability", "documentation": "Amount of obligation to transfer good or service to
customer for which consideration has been received or is receivable." } } }, "auth_ref": { "r277", "r278", "r289" } }, "autl_ContractWithCustomerLiabilityAccruedInterest": {
"xbrltype": "monetaryItemType", "nsuri": "http://www.autolus.com/20240630", "localname": "ContractWithCustomerLiabilityAccruedInterest", "crdr": "debit",
"presentation": { "http://www.autolus.com/role/RelatedpartytransactionsNarrativeDetails": { "lang": { "en-us": { "role": { "terseLabel": "Accrued interest", "label":
"Contract With Customer, Liability, Accrued Interest", "documentation": "Contract With Customer, Liability, Accrued Interest" } } }, "auth_ref": { "us-
gaap_ContractWithCustomerLiabilityGross": { "xbrltype": "monetaryItemType", "nsuri": "http://www.autolus.com/20240630", "localname":
"ContractWithCustomerLiabilityGross", "crdr": "credit", "presentation": {
"http://www.autolus.com/role/UnauditedCondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 1.0 } }, "presentation": {
"http://www.autolus.com/role/LiabilitiesrelatedtofutureroyaltiesandmilestonesnetNarrativeDetails": { "http://www.autolus.com/role/NatureoftheBusinessNarrativeDetails": {
"lang": { "en-us": { "role": { "terseLabel": "Contract with customer, liability, gross", "label": "Contract With Customer, Liability, Gross", "documentation": "Contract With
Customer, Liability, Gross" } } }, "auth_ref": { "us-gaap_ContractWithCustomerLiabilityNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-
gaap/2024", "localname": "ContractWithCustomerLiabilityNoncurrent", "crdr": "credit", "calculation": {
"http://www.autolus.com/role/UnauditedCondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 1.0 } }, "presentation": {
"http://www.autolus.com/role/UnauditedCondensedConsolidatedBalanceSheets": { "lang": { "en-us": { "role": { "verboseLabel": "Liabilities related to future royalties and
milestones, net", "terseLabel": "Contract with customer, liability, noncurrent", "label": "Contract with Customer, Liability, Noncurrent", "documentation": "Amount of
obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent." } } }, "auth_ref": { "r277", "r278",

```

"2022", "autl:CorporateTaxCurrent", {"xbrltype": "monetaryItemType", "nsuri": "http://www.autolus.com/20240630", "localname": "CorporateTaxCurrent", "crdr": "debit", "calculation": {"http://www.autolus.com/role/PrepaidExpensesandOtherCurrentAssetsDetails": {"parentTag": "us-gaap:PrepaidExpenseAndOtherAssetsCurrent", "weight": 1.0, "order": 7.0 }}, "presentation": {"http://www.autolus.com/role/PrepaidExpensesandOtherCurrentAssetsDetails": {"lang": {"en-us": {"role": {"terseLabel": "Corporate tax receivable", "label": "Corporate Tax Current", "documentation": "Corporate Tax Current"} }}, "auth_ref": {}}, "srt_CounterpartyNameAxis": {"xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "CounterpartyNameAxis", "presentation": {"http://www.autolus.com/role/CommitmentsandContingenciesNarrativeDetails": {"http://www.autolus.com/role/LiabilitiesrelatedtofuturoyaltiesandmilestonesnetNarrativeDetails": {"http://www.autolus.com/role/LicenserevenueNarrativeDetails": {"http://www.autolus.com/role/NatureoftheBusinessNarrativeDetails": {"http://www.autolus.com/role/NatureoftheBusinessUnitofAccountingDetails": {"http://www.autolus.com/role/RelatedpartytransactionsNarrativeDetails": {"http://www.autolus.com/role/ShareholdersEquityNarrativeDetails": {"lang": {"en-us": {"role": {"terseLabel": "Counterparty Name [Axis]", "label": "Counterparty Name [Axis]"} }}, "auth_ref": {"r154", "r155", "r246", "r263", "r429", "r436", "r473", "r620", "r622"} }}, "dei_CoverAbstract": {"xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CoverAbstract", "lang": {"en-us": {"role": {"label": "Cover Abstract", "documentation": "Cover page." }}, "auth_ref": {}}, "dei_CurrentFiscalYearEndDate": {"xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CurrentFiscalYearEndDate", "presentation": {"http://www.autolus.com/role/Cover": {"lang": {"en-us": {"role": {"terseLabel": "Current Fiscal Year End Date", "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format -MM-DD." }}, "auth_ref": {}}, "us-gaap_CustomerConcentrationRiskMember": {"xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CustomerConcentrationRiskMember", "presentation": {"http://www.autolus.com/role/LicenserevenueNarrativeDetails": {"lang": {"en-us": {"role": {"terseLabel": "Customer Concentration Risk", "label": "Customer Concentration Risk [Member]", "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer." }}, "auth_ref": {"r73", "r217"}}, "country_DE": {"xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/country/2024", "localname": "DE", "presentation": {"http://www.autolus.com/role/LicenseRevenueDisaggregationofRevenueDetails": {"lang": {"en-us": {"role": {"terseLabel": "Germany", "label": "GERMANY"} }}, "auth_ref": {}}, "us-gaap_DebtInstrumentAxis": {"xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentAxis", "presentation": {"http://www.autolus.com/role/LiabilitiesrelatedtofuturoyaltiesandmilestonesnetNarrativeDetails": {"http://www.autolus.com/role/RelatedpartytransactionsNarrativeDetails": {"lang": {"en-us": {"role": {"terseLabel": "Debt Instrument [Axis]", "label": "Debt Instrument [Axis]", "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities." }}, "auth_ref": {"r12", "r46", "r47", "r90", "r91", "r156", "r243", "r244", "r245", "r246", "r247", "r248", "r249", "r250", "r251", "r252", "r253", "r254", "r255", "r256", "r257", "r258", "r631", "r632", "r633", "r634", "r635", "r653", "r792", "r810", "r811", "r812", "r833", "r834"} }}, "us-gaap_DebtInstrumentInterestRateEffectivePercentage": {"xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentInterestRateEffectivePercentage", "presentation": {"http://www.autolus.com/role/LiabilitiesrelatedtofuturoyaltiesandmilestonesnetNarrativeDetails": {"lang": {"en-us": {"role": {"terseLabel": "Interest rate (in percent)", "label": "Debt Instrument, Interest Rate, Effective Percentage", "documentation": "Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium." }}, "auth_ref": {"r49", "r259", "r400", "r401", "r653"} }}, "us-gaap_DebtInstrumentNameDomain": {"xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentNameDomain", "presentation": {"http://www.autolus.com/role/LiabilitiesrelatedtofuturoyaltiesandmilestonesnetNarrativeDetails": {"http://www.autolus.com/role/RelatedpartytransactionsNarrativeDetails": {"lang": {"en-us": {"role": {"terseLabel": "Debt Instrument, Name [Domain]", "label": "Debt Instrument, Name [Domain]", "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities." }}, "auth_ref": {"r12", "r156", "r243", "r244", "r245", "r246", "r247", "r248", "r249", "r250", "r251", "r252", "r253", "r254", "r255", "r256", "r257", "r258", "r631", "r632", "r633", "r634", "r635", "r653", "r792", "r810", "r811", "r812", "r833", "r834"} }}, "autl_DeferredClassASharesMember": {"xbrltype": "domainItemType", "nsuri": "http://www.autolus.com/20240630", "localname": "DeferredClassASharesMember", "presentation": {"http://www.autolus.com/role/UnauditedCondensedConsolidatedBalanceSheets": {"http://www.autolus.com/role/UnauditedCondensedConsolidatedBalanceSheetsParentheticals": {"http://www.autolus.com/role/UnauditedCondensedConsolidatedStatementsofShareholdersEquity": {"lang": {"en-us": {"role": {"verboseLabel": "Deferred shares", "terseLabel": "Deferred Shares", "label": "Deferred Class A Shares [Member]", "documentation": "Deferred Class A Shares [Member]"} }}, "auth_ref": {}}, "autl_DeferredClassBSharesMember": {"xbrltype": "domainItemType", "nsuri": "http://www.autolus.com/20240630", "localname": "DeferredClassBSharesMember", "presentation": {"http://www.autolus.com/role/UnauditedCondensedConsolidatedBalanceSheets": {"http://www.autolus.com/role/UnauditedCondensedConsolidatedBalanceSheetsParentheticals": {"http://www.autolus.com/role/UnauditedCondensedConsolidatedStatementsofShareholdersEquity": {"lang": {"en-us": {"role": {"terseLabel": "Deferred B Shares", "label": "Deferred Class B Shares [Member]", "documentation": "Deferred Class B Shares [Member]"} }}, "auth_ref": {}}, "autl_DeferredClassCSharesMember": {"xbrltype": "domainItemType", "nsuri": "http://www.autolus.com/20240630", "localname": "DeferredClassCSharesMember", "presentation": {"http://www.autolus.com/role/UnauditedCondensedConsolidatedBalanceSheets": {"http://www.autolus.com/role/UnauditedCondensedConsolidatedBalanceSheetsParentheticals": {"http://www.autolus.com/role/UnauditedCondensedConsolidatedStatementsofShareholdersEquity": {"lang": {"en-us": {"role": {"terseLabel": "Deferred C Shares", "label": "Deferred Class C Shares [Member]", "documentation": "Deferred Class C Shares [Member]"} }}, "auth_ref": {}}, "us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract": {"xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract", "lang": {"en-us": {"role": {"terseLabel": "Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]", "label": "Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure TextBlock", "documentation": "Sum of the carrying amounts as of the balance sheet date of deferred costs capitalized at the end of the reporting period that are expected to be charged against earnings within one year or the normal operating cycle, if longer." }}, "auth_ref": {"r780"} }}, "us-gaap_DeferredIncomeTaxAssetsNet": {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredIncomeTaxAssetsNet", "crdr": "debit", "calculation": {"http://www.autolus.com/role/UnauditedCondensedConsolidatedBalanceSheets": {"parentTag": "us-gaap:Assets", "weight": 1.0, "order": 5.0 }}, "presentation": {"http://www.autolus.com/role/UnauditedCondensedConsolidatedBalanceSheets": {"lang": {"en-us": {"role": {"terseLabel": "Deferred tax asset", "label": "Deferred Income Tax Assets, Net", "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting." }}, "auth_ref": {"r337", "r338"} }}, "us-gaap_DepositsAssetsNoncurrent": {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DepositsAssetsNoncurrent", "crdr": "debit", "calculation": {"http://www.autolus.com/role/UnauditedCondensedConsolidatedBalanceSheets": {"parentTag": "us-gaap:Assets", "weight": 1.0, "order": 3.0 }}, "presentation": {"http://www.autolus.com/role/UnauditedCondensedConsolidatedBalanceSheets": {"lang": {"en-us": {"role": {"terseLabel": "Long-term deposits", "label": "Deposits Assets, Noncurrent", "documentation": "Carrying value of amounts transferred to third parties for security purposes that are expected to be returned or applied towards payment after one year or beyond the operating cycle, if longer." }}, "auth_ref": {"r777"} }}, "us-gaap_Depreciation": {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Depreciation", "crdr": "debit", "presentation": {"http://www.autolus.com/role/PropertyandEquipmentNetNarrativesDetails": {"lang": {"en-us": {"role": {"terseLabel": "Depreciation expense", "label": "Depreciation", "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation." }}, "auth_ref": {"r5", "r28"} }}, "us-gaap_DepreciationDepletionAndAmortization": {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DepreciationDepletionAndAmortization", "crdr": "debit", "calculation": {"http://www.autolus.com/role/UnauditedCondensedConsolidatedStatementsofCashFlows": {"parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 5.0 }}, "presentation": {"http://www.autolus.com/role/UnauditedCondensedConsolidatedStatementsofCashFlows": {"lang": {"en-us": {"role": {"terseLabel": "Depreciation and amortization", "label": "Depreciation, Depletion and Amortization", "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets." }}, "auth_ref": {"r5", "r190", "r200", "r212", "r628", "r629"} }}, "us-gaap_DisaggregationOfRevenueLineItems": {"xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisaggregationOfRevenueLineItems", "presentation": {"http://www.autolus.com/role/LicenseRevenueDisaggregationofRevenueDetails": {"http://www.autolus.com/role/LicenserevenueNarrativeDetails": {"lang": {"en-us": {"role": {"terseLabel": "Disaggregation of Revenue [Line Items]", "label": "Disaggregation of Revenue [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." }}, "auth_ref": {"r288", "r637", "r638", "r639", "r640", "r641", "r642", "r643"} }}, "us-gaap_DisaggregationOfRevenueTable": {"xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisaggregationOfRevenueTable", "presentation": {"http://www.autolus.com/role/LicenseRevenueDisaggregationofRevenueDetails": {"http://www.autolus.com/role/LicenserevenueNarrativeDetails": {"lang": {"en-us": {"role": {"terseLabel": "Disaggregation of Revenue [Table]", "label": "Disaggregation of Revenue [Table]", "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor." }}, "auth_ref": {"r288", "r637", "r638", "r639", "r640", "r641", "r642", "r643"} }}, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {"xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "presentation": {"http://www.autolus.com/role/SharebasedCompensation": {"lang": {"en-us": {"role": {"terseLabel": "Share-based Compensation", "label": "Share-Based Payment Arrangement [Text Block]", "documentation": "The entire disclosure for share-based payment arrangement." }}, "auth_ref": {"r298",
```

{ "terseLabel": "Document Information [Line Items]", "label": "Document Information [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." }, { "auth_ref": "I", "dei_DocumentInformationTable": { "xbrlType": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentInformationTable", "presentation": { "http://www.autolus.com/role/Cover": { "lang": { "en-us": { "role": { "terseLabel": "Document Information [Table]", "label": "Document Information [Table]", "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package." } } }, "auth_ref": "I", "dei_DocumentPeriodEndDate": { "xbrlType": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentPeriodEndDate", "presentation": { "http://www.autolus.com/role/Cover": { "lang": { "en-us": { "role": { "terseLabel": "Document Period End Date", "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": "I", "dei_DocumentQuarterlyReport": { "xbrlType": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentQuarterlyReport", "presentation": { "http://www.autolus.com/role/Cover": { "lang": { "en-us": { "role": { "terseLabel": "Document Quarterly Report", "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as a quarterly report." } } }, "auth_ref": { "r687" }, "dei_DocumentTransitionReport": { "xbrlType": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentTransitionReport", "presentation": { "http://www.autolus.com/role/Cover": { "lang": { "en-us": { "role": { "terseLabel": "Document Transition Report", "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": { "r719" }, "dei_DocumentType": { "xbrlType": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentType", "presentation": { "http://www.autolus.com/role/Cover": { "lang": { "en-us": { "role": { "terseLabel": "Document Type", "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": "I", "ecd_DvddsOrOtherErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtCompForCvrdYrMember": { "xbrlType": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "DvddsOrOtherErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtCompForCvrdYrMember", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure": { "lang": { "en-us": { "role": { "terseLabel": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year", "label": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member]", "documentation": { "http://www.autolus.com/role/UnauditedCondensedConsolidatedStatementsOfOperationsandComprehensiveLoss": { "lang": { "en-us": { "role": { "terseLabel": "Basic net loss per ordinary share (in usd per share)", "label": "Basic net loss per ordinary share", "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period." } } }, "auth_ref": { "r148", "r162", "r163", "r164", "r165", "r166", "r167", "r172", "r175", "r183", "r184", "r185", "r189", "r347", "r350", "r363", "r364", "r470", "r489", "r623" }, "us-gaap_EarningsPerShareBasicAbstract": { "xbrlType": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareBasicAbstract", "presentation": { "http://www.autolus.com/role/NetLossperOrdinaryShareScheduleofNetLossPerShareDetails": { "lang": { "en-us": { "role": { "terseLabel": "Earnings Per Share", "label": "Earnings Per Share, Basic [Abstract]", "documentation": { "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareBasic", "presentation": { "http://www.autolus.com/role/NetLossperOrdinaryShareScheduleofNetLossPerShareDetails": { "lang": { "en-us": { "role": { "terseLabel": "Earnings Per Share", "label": "Earnings Per Share, Basic [Abstract]", "documentation": { "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareDiluted", "presentation": { "http://www.autolus.com/role/NetLossperOrdinaryShareScheduleofNetLossPerShareDetails": { "lang": { "en-us": { "role": { "terseLabel": "Diluted net loss per ordinary share (in usd per share)", "label": "Diluted net loss per ordinary share", "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period." } } }, "auth_ref": { "r148", "r162", "r163", "r164", "r165", "r166", "r167", "r175", "r183", "r184", "r185", "r189", "r347", "r350", "r363", "r364", "r470", "r489", "r623" }, "us-gaap_EarningsPerShareTextBlock": { "xbrlType": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareTextBlock", "presentation": { "http://www.autolus.com/role/NetLossperOrdinaryShare": { "lang": { "en-us": { "role": { "terseLabel": "Net loss per ordinary share", "label": "Earnings Per Share [Text Block]", "documentation": "The entire disclosure for earnings per share." } } }, "auth_ref": { "r171", "r186", "r187", "r188" }, "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "xbrlType": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "crdr": "debit", "calculation": { "http://www.autolus.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 1.0 }, "presentation": { "http://www.autolus.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows": { "lang": { "en-us": { "role": { "terseLabel": "Effect of exchange rate changes on cash, cash equivalents and restricted cash", "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations", "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": { "r392" }, "us-gaap_EmployeeBenefitsAndShareBasedCompensationNoncash": { "xbrlType": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeBenefitsAndShareBasedCompensationNoncash", "crdr": "debit", "calculation": { "http://www.autolus.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 9.0 }, "presentation": { "http://www.autolus.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows": { "lang": { "en-us": { "role": { "terseLabel": "Share-based compensation net of amounts capitalized", "label": "Employee Benefit and Share-Based Payment Arrangement, Noncash", "documentation": "Amount of non-cash expense (reversal of expense) for employee benefits and share-based payment arrangement. Includes, but is not limited to, pension, other postretirement, postemployment and termination benefits." } } }, "auth_ref": { "r5" }, "us-gaap_EmployeeRelatedLiabilitiesCurrent": { "xbrlType": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeRelatedLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.autolus.com/role/AccruedExpensesandOtherLiabilitiesDetails": { "parentTag": "us-gaap_AccruedLiabilitiesAndOtherLiabilities", "weight": 1.0, "order": 2.0 }, "presentation": { "http://www.autolus.com/role/AccruedExpensesandOtherLiabilitiesDetails": { "lang": { "en-us": { "role": { "terseLabel": "Compensation and benefits", "label": "Employee-related Liabilities, Current", "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": { "r47" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": { "xbrlType": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "presentation": { "http://www.autolus.com/role/SharebasedCompensationNarrativeDetails": { "lang": { "en-us": { "role": { "terseLabel": "Share based compensation not yet recognized for unvested shares vesting period (in years)", "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition", "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in PnYnMnDtnHnMnS format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": { "r333" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions": { "xbrlType": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions", "crdr": "debit", "presentation": { "http://www.autolus.com/role/SharebasedCompensationNarrativeDetails": { "lang": { "en-us": { "role": { "terseLabel": "Share based compensation not yet recognized for unvested shares other than options (less than)", "label": "Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount", "documentation": "Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options." } } }, "auth_ref": { "r822" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": { "xbrlType": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions", "crdr": "debit", "presentation": { "http://www.autolus.com/role/SharebasedCompensationNarrativeDetails": { "lang": { "en-us": { "role": { "terseLabel": "Share based compensation not yet recognized for unvested shares", "label": "Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount", "documentation": "Amount of cost to be recognized for option under share-based payment arrangement." } } }, "auth_ref": { "r822" }, "us-gaap_EmployeeStockOptionMember": { "xbrlType": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeStockOptionMember", "presentation": { "http://www.autolus.com/role/NetLossperOrdinaryShareScheduleofAntidilutiveSecuritiesDetails": { "http://www.autolus.com/role/SharebasedCompensationNarrativeDetails": { "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure": { "lang": { "en-us": { "role": { "terseLabel": "Share options", "label": "Share-Based Payment Arrangement, Option [Member]", "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time." } } }, "auth_ref": "I", "dei_EntityAddressAddressLine1": { "xbrlType": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine1", "presentation": { "http://www.autolus.com/role/Cover": { "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Address Line One", "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": "I", "dei_EntityAddressAddressLine2": { "xbrlType": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine2", "presentation": { "http://www.autolus.com/role/Cover": { "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Address Line Two", "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": "I", "dei_EntityAddressCityOrTown": { "xbrlType": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressCityOrTown", "presentation": { "http://www.autolus.com/role/Cover": { "lang": { "en-us": { "role": { "terseLabel": "Entity Address, City or Town", "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": "I", "dei_EntityAddressCountry": { "xbrlType": "countryCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressCountry", "presentation": { "http://www.autolus.com/role/Cover": { "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Country", "label": "Entity Address, Country", "documentation": "ISO 3166-1 alpha-2 country code." } } }, "auth_ref": "I", "dei_EntityAddressPostalZipCode": { "xbrlType": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressPostalZipCode", "presentation": { "http://www.autolus.com/role/Cover": { "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Postal Zip Code", "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": "I", "dei_EntityCentralIndexKey": { "xbrlType": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCentralIndexKey", "presentation": { "http://www.autolus.com/role/Cover": { "lang": { "en-us": { "role": { "terseLabel": "Entity Central Index Key", "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": { "r684" }, "dei_EntityCommonStockSharesOutstanding": { "xbrlType": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCommonStockSharesOutstanding", "presentation": { "http://www.autolus.com/role/Cover": { "lang": { "en-us": { "role": { "terseLabel": "Entity Common Stock, Shares Outstanding", "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": "I", "dei_EntityCurrentReportingStatus": { "xbrlType": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCurrentReportingStatus", "presentation": { "http://www.autolus.com/role/Cover": { "lang": { "en-us": { "role": { "terseLabel": "Entity Current Reporting Status", "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants

were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityDomain", "presentation": { "http://www.autolus.com/role/NatureoftheBusinessNarrativeDetails", "http://www.autolus.com/role/ShareholdersEquityNarrativeDetails", "lang": { "en-us": { "role": { "terseLabel": "Entity {Domain}", "label": "Entity {Domain}" }, "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains." } } }, "auth_ref": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityEmergingGrowthCompany", "presentation": { "http://www.autolus.com/role/Cover", "lang": { "en-us": { "role": { "terseLabel": "Entity Emerging Growth Company", "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": { "r684" }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFileNumber", "presentation": { "http://www.autolus.com/role/Cover", "lang": { "en-us": { "role": { "terseLabel": "Entity File Number", "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": { "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFilerCategory", "presentation": { "http://www.autolus.com/role/Cover", "lang": { "en-us": { "role": { "terseLabel": "Entity Filer Category", "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": { "r684" }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityIncorporationStateCountryCode", "presentation": { "http://www.autolus.com/role/Cover", "lang": { "en-us": { "role": { "terseLabel": "Entity Incorporation, State or Country Code", "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": { "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityInteractiveDataCurrent", "presentation": { "http://www.autolus.com/role/Cover", "lang": { "en-us": { "role": { "terseLabel": "Entity Interactive Data Current", "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": { "r769" }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityRegistrantName", "presentation": { "http://www.autolus.com/role/Cover", "lang": { "en-us": { "role": { "terseLabel": "Entity Registrant Name", "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": { "r684" }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityShellCompany", "presentation": { "http://www.autolus.com/role/Cover", "lang": { "en-us": { "role": { "terseLabel": "Entity Shell Company", "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": { "r684" }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntitySmallBusiness", "presentation": { "http://www.autolus.com/role/Cover", "lang": { "en-us": { "role": { "terseLabel": "Entity Small Business", "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": { "r684" }, "ecd_EqtyAwrdsAdjFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsAdjFnTextBlock", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "lang": { "en-us": { "role": { "terseLabel": "Equity Awards Adjustments, Footnote", "label": "Equity Awards Adjustments, Footnote {Text Block}" } } }, "auth_ref": { "r724" }, "ecd_EqtyAwrdsAdjExclgValRptdInSummryCompstnTblMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsAdjExclgValRptdInSummryCompstnTblMember", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "lang": { "en-us": { "role": { "terseLabel": "Equity Awards Adjustments, Excluding Value Reported in Compensation Table", "label": "Equity Awards Adjustments, Excluding Value Reported in the Compensation Table {Member}" } } }, "auth_ref": { "r765" }, "ecd_EqtyAwrdsAdjExclgValRptdInSummryCompstnTblMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsAdjExclgValRptdInSummryCompstnTblMember", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "lang": { "en-us": { "role": { "terseLabel": "Equity Awards Adjustments", "label": "Equity Awards Adjustments {Member}" } } }, "auth_ref": { "r765" }, "ecd_EqtyAwrdsInSummryCompstnTblForApblYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsInSummryCompstnTblForApblYrMember", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "lang": { "en-us": { "role": { "terseLabel": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table", "label": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table {Member}" } } }, "auth_ref": { "r765" }, "us-gaap_EquipmentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquipmentMember", "presentation": { "http://www.autolus.com/role/PropertyandEquipmentNetScheduleofPPEDetails", "lang": { "en-us": { "role": { "terseLabel": "Lab equipment", "label": "Equipment {Member}", "documentation": "Tangible personal property used to produce goods and services." } } }, "auth_ref": { "us-gaap_EquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquityAbstract", "lang": { "en-us": { "role": { "terseLabel": "Equity {Abstract}", "label": "Equity {Abstract}" } } }, "auth_ref": { "us-gaap_EquityComponentDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquityComponentDomain", "presentation": { "http://www.autolus.com/role/UnauditedCondensedConsolidatedStatementsofShareholdersEquity", "lang": { "en-us": { "role": { "terseLabel": "Equity Component {Domain}", "label": "Equity Component {Domain}", "documentation": "Components of equity are the parts of the total equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc." } } }, "auth_ref": { "r8", "r125", "r143", "r144", "r145", "r157", "r158", "r159", "r161", "r166", "r168", "r170", "r192", "r220", "r221", "r224", "r276", "r341", "r342", "r344", "r345", "r346", "r348", "r349", "r349", "r350", "r355", "r356", "r357", "r358", "r359", "r360", "r362", "r393", "r394", "r395", "r396", "r397", "r398", "r402", "r404", "r423", "r486", "r500", "r501", "r502", "r516", "r584" }, "ecd_EquityValuationAssumptionDifferenceFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EquityValuationAssumptionDifferenceFnTextBlock", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "lang": { "en-us": { "role": { "terseLabel": "Equity Valuation Assumption Difference, Footnote", "label": "Equity Valuation Assumption Difference, Footnote {Text Block}" } } }, "auth_ref": { "r734" }, "ecd_ErrCompAnalysisTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ErrCompAnalysisTextBlock", "presentation": { "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "lang": { "en-us": { "role": { "terseLabel": "Erroneous Compensation Analysis", "label": "Erroneous Compensation Analysis {Text Block}" } } }, "auth_ref": { "r692", "r702", "r712", "r744" }, "ecd_ErrCompRecoveryTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ErrCompRecoveryTable", "presentation": { "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "lang": { "en-us": { "role": { "terseLabel": "Erroneously Awarded Compensation Recovery", "label": "Erroneously Awarded Compensation Recovery {Table}" } } }, "auth_ref": { "r689", "r699", "r709", "r741" }, "us-gaap_EstimateOffFairValueFairValueDisclosureMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EstimateOffFairValueFairValueDisclosureMember", "presentation": { "http://www.autolus.com/role/NatureoftheBusinessUnitsofAccountingDetails", "lang": { "en-us": { "role": { "terseLabel": "Estimate of Fair Value Measurement", "label": "Estimate of Fair Value Measurement {Member}", "documentation": "Measured as an estimate of fair value." } } }, "auth_ref": { "r251", "r385", "r632", "r633" }, "ecd_ExecutiveCategoryAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ExecutiveCategoryAxis", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "lang": { "en-us": { "role": { "terseLabel": "Executive Category", "label": "Executive Category {Axis}" } } }, "auth_ref": { "r740" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems", "presentation": { "http://www.autolus.com/role/FairvaluemeasurementsDetails", "lang": { "en-us": { "role": { "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis {Line Items}", "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis {Line Items}", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": { "r366", "r367", "r377", "r649" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable", "presentation": { "http://www.autolus.com/role/FairvaluemeasurementsDetails", "lang": { "en-us": { "role": { "terseLabel": "Fair Value, Recurring and Nonrecurring {Table}", "label": "Fair Value, Recurring and Nonrecurring {Table}", "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis." } } }, "auth_ref": { "r366", "r367", "r377", "r649" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock", "presentation": { "http://www.autolus.com/role/FairvaluemeasurementsTables", "lang": { "en-us": { "role": { "terseLabel": "Fair Value Measurements, Recurring and Nonrecurring", "label": "Fair Value Measurements, Recurring and Nonrecurring {Table Text Block}", "documentation": "Tabular disclosure of financial instrument measured at fair value on recurring or nonrecurring basis. Includes, but is not limited to, instrument classified in shareholders' equity." } } }, "auth_ref": { "r649", "r827", "r828", "r829" }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueByFairValueHierarchyLevelAxis", "presentation": { "http://www.autolus.com/role/FairvaluemeasurementsDetails", "lang": { "en-us": { "role": { "terseLabel": "Fair Value Hierarchy and NAV {Axis}", "label": "Fair Value Hierarchy and NAV {Axis}", "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient." } } }, "auth_ref": { "r251", "r291", "r292", "r293", "r294", "r295", "r296", "r365", "r367", "r368", "r369", "r370", "r376", "r377", "r379", "r433", "r434", "r435", "r632", "r633", "r644", "r645", "r646", "r649", "r651" }, "us-gaap_FairValueByMeasurementBasisAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueByMeasurementBasisAxis", "presentation": { "http://www.autolus.com/role/NatureoftheBusinessUnitsofAccountingDetails", "lang": { "en-us": { "role": { "terseLabel": "Measurement Basis {Axis}", "label": "Measurement Basis {Axis}", "documentation": "Information by measurement basis." } } }, "auth_ref": { "r251", "r632", "r633" }, "us-gaap_FairValueDisclosureItemAmountsDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueDisclosureItemAmountsDomain", "presentation": { "http://www.autolus.com/role/NatureoftheBusinessUnitsofAccountingDetails", "lang": { "en-us": { "role": { "terseLabel": "Fair Value Measurement {Domain}", "label": "Fair Value Measurement {Domain}", "documentation": "Measurement basis, for example, but not limited to, reported value, fair value, portion at fair value, portion at other than fair value." } } }, "auth_ref": { "r251", "r632", "r633" }, "us-gaap_FairValueDisclosuresAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueDisclosuresAbstract", "lang": { "en-us": { "role": { "label": "Fair Value Disclosures {Abstract}" } } }, "auth_ref": { "us-gaap_FairValueDisclosuresTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueDisclosuresTextBlock", "presentation": { "http://www.autolus.com/role/Fairvaluemeasurements", "lang": { "en-us": { "role": { "terseLabel": "Fair value measurements", "label": "Fair Value Disclosures {Text Block}", "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information." } } }, "auth_ref": { "r372", "r374", "r375", "r376", "r379", "r380", "r381", "r382", "r383", "r468", "r649", "r652" }, "us-gaap_FairValueInputsLevel1Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueInputsLevel1Member", "presentation": { "http://www.autolus.com/role/FairvaluemeasurementsDetails", "lang": { "en-us": { "role": { "terseLabel": "Quoted Prices in Active Markets for Identical Assets {Level 1}", "label": "Fair Value, Inputs, Level 1 {Member}", "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date." } } }, "auth_ref": { "r251", "r291", "r296", "r367", "r377", "r433", "r644", "r645", "r646", "r649" }, "us-gaap_FairValueInputsLevel2Member": {

"xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueInputsLevel2Member", "presentation": {
"http://www.autolus.com/role/FairValueMeasurementsDetails": {
"lang": {
"en-us": {
"role": {
"terseLabel": "Significant Other Observable Inputs (Level 2)",
"label": "Fair Value, Inputs, Level 2 [Member]",
"documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets." } } }
"auth_ref": {
"r251", "r291", "r296", "r367", "r368", "r377", "r434", "r632", "r633", "r644", "r645", "r646", "r649" } }
"us-gaap_FairValueInputsLevel3Member": {
"xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueInputsLevel3Member",
"presentation": {
"http://www.autolus.com/role/FairValueMeasurementsDetails": {
"lang": {
"en-us": {
"role": {
"terseLabel": "Significant Unobservable Inputs (Level 3)",
"label": "Fair Value, Inputs, Level 3 [Member]",
"documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing." } } }
"auth_ref": {
"r251", "r291", "r292", "r293", "r294", "r295", "r296", "r367", "r368", "r369", "r370", "r377", "r435", "r632", "r633", "r644", "r645", "r646", "r649", "r651" } }
"us-gaap_FairValueMeasurementPolicyPolicyTextBlock": {
"xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueMeasurementPolicyPolicyTextBlock", "presentation": {
"http://www.autolus.com/role/SummaryOfSignificantAccountingPoliciesPolicies": {
"lang": {
"en-us": {
"role": {
"terseLabel": "Fair value measurements",
"label": "Fair Value Measurement, Policy [Policy Text Block]",
"documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities." } } }
"auth_ref": {
"r251", "r291", "r292", "r293", "r294", "r295", "r296", "r367", "r368", "r369", "r370", "r377", "r435", "r632", "r633", "r644", "r645", "r646", "r649", "r651" } }
"us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
"xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueMeasurementsFairValueHierarchyDomain", "presentation": {
"http://www.autolus.com/role/FairValueMeasurementsDetails": {
"lang": {
"en-us": {
"role": {
"terseLabel": "Fair Value Hierarchy and NAV [Domain]",
"label": "Fair Value Hierarchy and NAV [Domain]",
"documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value." } } }
"auth_ref": {
"r251", "r291", "r292", "r293", "r294", "r295", "r296", "r367", "r368", "r369", "r370", "r377", "r435", "r632", "r633", "r644", "r645", "r646", "r649", "r651" } }
"us-gaap_ForeignCurrencyTransactionGainLossBeforeTax": {
"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ForeignCurrencyTransactionGainLossBeforeTax", "crdr": "credit", "presentation": {
"http://www.autolus.com/role/SummaryOfSignificantAccountingPoliciesNarrativeDetails": {
"lang": {
"en-us": {
"role": {
"terseLabel": "Foreign currency gain (loss)",
"label": "Gain (loss), Foreign Currency Transaction, before Tax",
"documentation": "Amount, before tax, of realized and unrealized gain (loss) from foreign currency transaction." } } }
"auth_ref": {
"r388", "r389", "r390", "r391", "r581" } }
"us-gaap_ForeignCurrencyTransactionGainLossUnrealized": {
"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ForeignCurrencyTransactionGainLossUnrealized", "crdr": "credit", "calculation": {
"http://www.autolus.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows": {
"parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
"weight": -1.0, "order": 6.0 } }
"presentation": {
"http://www.autolus.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows": {
"lang": {
"en-us": {
"role": {
"negatedTerseLabel": "Foreign exchange differences",
"label": "Unrealized Gain (loss), Foreign Currency Transaction, before Tax",
"documentation": "Amount, before tax, of unrealized gain (loss) from foreign currency transaction." } } }
"auth_ref": {
"r71", "r559", "r680", "r831", "r832", "r878" } }
"us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock": {
"xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock", "presentation": {
"http://www.autolus.com/role/SummaryOfSignificantAccountingPoliciesPolicies": {
"lang": {
"en-us": {
"role": {
"terseLabel": "Foreign Currency Translation",
"label": "Foreign Currency Transactions and Translations Policy [Policy Text Block]",
"documentation": "Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy." } } }
"auth_ref": {
"r387" } }
"ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": {
"xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt", "presentation": {
"http://xbrl.sec.gov/ecd/role/ErrCompDisclosure": {
"lang": {
"en-us": {
"role": {
"terseLabel": "Forgone Recovery due to Disqualification of Tax Benefits, Amount",
"label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount" } } }
"auth_ref": {
"r696", "r786", "r716", "r748" } }
"ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": {
"xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt", "presentation": {
"http://xbrl.sec.gov/ecd/role/ErrCompDisclosure": {
"lang": {
"en-us": {
"role": {
"terseLabel": "Forgone Recovery due to Expense of Enforcement, Amount",
"label": "Forgone Recovery due to Expense of Enforcement, Amount" } } }
"auth_ref": {
"r696", "r706", "r716", "r748" } }
"ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": {
"xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt", "presentation": {
"http://xbrl.sec.gov/ecd/role/ErrCompDisclosure": {
"lang": {
"en-us": {
"role": {
"terseLabel": "Forgone Recovery due to Violation of Home Country Law, Amount",
"label": "Forgone Recovery due to Violation of Home Country Law, Amount" } } }
"auth_ref": {
"r696", "r706", "r716", "r748" } }
"ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": {
"xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock", "presentation": {
"http://xbrl.sec.gov/ecd/role/ErrCompDisclosure": {
"lang": {
"en-us": {
"role": {
"terseLabel": "Forgone Recovery, Explanation of Impracticability",
"label": "Forgone Recovery, Explanation of Impracticability [Text Block]" } } }
"auth_ref": {
"r696", "r706", "r716", "r748" } }
"ecd_ForgoneRecoveryIndName": {
"xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryIndName", "presentation": {
"http://xbrl.sec.gov/ecd/role/ErrCompDisclosure": {
"lang": {
"en-us": {
"role": {
"terseLabel": "Name",
"label": "Forgone Recovery, Individual Name" } } }
"auth_ref": {
"r696", "r706", "r716", "r748" } }
"ecd_FrValAsOfPrYrEndOfEqtyAwrdsGrntdInPrYrFldVstngCondsDrngCvrdYrMember": {
"xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "FrValAsOfPrYrEndOfEqtyAwrdsGrntdInPrYrFldVstngCondsDrngCvrdYrMember", "presentation": {
"http://xbrl.sec.gov/ecd/role/PvpDisclosure": {
"lang": {
"en-us": {
"role": {
"terseLabel": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year",
"label": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member]" } } }
"auth_ref": {
"r729" } }
"us-gaap_FurnitureAndFixturesMember": {
"xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FurnitureAndFixturesMember", "presentation": {
"http://www.autolus.com/role/PropertyAndEquipmentNetSchedulePPPEDetails": {
"lang": {
"en-us": {
"role": {
"terseLabel": "Furniture and fixtures",
"label": "Furniture and Fixtures [Member]",
"documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases." } } }
"auth_ref": {
"r696", "r706", "r716", "r748" } }
"us-gaap_GainLossOnDispositionOfAssets": {
"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GainLossOnDispositionOfAssets", "crdr": "credit", "calculation": {
"http://www.autolus.com/role/UnauditedCondensedConsolidatedStatementsOfOperationsandComprehensiveLoss": {
"parentTag": "us-gaap_OperatingIncomeLoss",
"weight": 1.0, "order": 2.0 } }
"presentation": {
"http://www.autolus.com/role/UnauditedCondensedConsolidatedStatementsOfOperationsandComprehensiveLoss": {
"lang": {
"en-us": {
"role": {
"terseLabel": "Loss on disposal of property and equipment",
"label": "Gain (Loss) on Disposition of Property Plant Equipment, Excluding Oil and Gas Property and Timber Property",
"documentation": "Amount of gain (loss) on sale or disposal of property, plant and equipment assets, excluding oil and gas property and timber property." } } }
"auth_ref": {
"r788", "r807", "r808" } }
"us-gaap_GainLossOnSaleOfPropertyPlantEquipment": {
"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GainLossOnSaleOfPropertyPlantEquipment", "crdr": "credit", "calculation": {
"http://www.autolus.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows": {
"parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
"weight": -1.0, "order": 8.0 } }
"presentation": {
"http://www.autolus.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows": {
"lang": {
"en-us": {
"role": {
"negatedTerseLabel": "Loss on disposal of property and equipment",
"label": "Gain (Loss) on Disposition of Property Plant Equipment",
"documentation": "Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property." } } }
"auth_ref": {
"r51", "r511", "r512", "r513", "r514", "r515", "r516", "r517", "r518", "r519", "r520", "r521", "r522", "r523", "r524", "r525", "r526", "r527", "r528", "r529", "r530", "r531", "r532", "r533", "r534", "r535", "r536", "r537", "r538", "r539", "r540", "r541", "r542", "r543", "r544", "r545", "r546", "r547", "r548", "r549", "r550", "r551", "r552", "r553", "r554", "r555", "r556", "r557", "r558", "r559", "r560", "r561", "r562", "r563", "r564", "r565", "r566", "r567", "r568", "r569", "r570", "r571", "r572", "r573", "r574", "r575", "r576", "r577", "r578", "r579", "r580", "r581", "r582", "r583", "r584", "r585", "r586", "r587", "r588", "r589", "r590", "r591", "r592", "r593", "r594", "r595", "r596", "r597", "r598", "r599", "r600", "r601", "r602", "r603", "r604", "r605", "r606", "r607", "r608", "r609", "r610", "r611", "r612", "r613", "r614", "r615", "r616", "r617", "r618", "r619", "r620", "r621", "r622", "r623", "r624", "r625", "r626", "r627", "r628", "r629", "r630", "r631", "r632", "r633", "r634", "r635", "r636", "r637", "r638", "r639", "r640", "r641", "r642", "r643", "r644", "r645", "r646", "r647", "r648", "r649", "r650", "r651", "r652", "r653", "r654", "r655", "r656", "r657", "r658", "r659", "r660", "r661", "r662", "r663", "r664", "r665", "r666", "r667", "r668", "r669", "r670", "r671", "r672", "r673", "r674", "r675", "r676", "r677", "r678", "r679", "r680", "r681", "r682", "r683", "r684", "r685", "r686", "r687", "r688", "r689", "r690", "r691", "r692", "r693", "r694", "r695", "r696", "r697", "r698", "r699", "r700", "r701", "r702", "r703", "r704", "r705", "r706", "r707", "r708", "r709", "r710", "r711", "r712", "r713", "r714", "r715", "r716", "r717", "r718", "r719", "r720", "r721", "r722", "r723", "r724", "r725", "r726", "r727", "r728", "r729", "r730", "r731", "r732", "r733", "r734", "r735", "r736", "r737", "r738", "r739", "r740", "r741", "r742", "r743", "r744", "r745", "r746", "r747", "r748", "r749", "r750", "r751", "r752", "r753", "r754", "r755", "r756", "r757", "r758", "r759", "r760", "r761", "r762", "r763", "r764", "r765", "r766", "r767", "r768", "r769", "r770", "r771", "r772", "r773", "r774", "r775", "r776", "r777", "r778", "r779", "r780", "r781", "r782", "r783", "r784", "r785", "r786", "r787", "r788", "r789", "r790", "r791", "r792", "r793", "r794", "r795", "r796", "r797", "r798", "r799", "r800", "r801", "r802", "r803", "r804", "r805", "r806", "r807", "r808", "r809", "r810", "r811", "r812", "r813", "r814", "r815", "r816", "r817", "r818", "r819", "r820", "r821", "r822", "r823", "r824", "r825", "r826", "r827", "r828", "r829", "r830", "r831", "r832", "r833", "r834", "r835", "r836", "r837", "r838", "r839", "r840", "r841", "r842", "r843", "r844", "r845", "r846", "r847", "r848", "r849", "r850", "r851", "r852", "r853", "r854", "r855", "r856", "r857", "r858", "r859", "r860", "r861", "r862", "r863", "r864", "r865", "r866", "r867", "r868", "r869", "r870", "r871", "r872", "r873", "r874", "r875", "r876", "r877", "r878", "r879", "r880", "r881", "r882", "r883", "r884", "r885", "r886", "r887", "r888", "r889", "r890", "r891", "r892", "r893", "r894", "r895", "r896", "r897", "r898", "r899", "r900", "r901", "r902", "r903", "r904", "r905", "r906", "r907", "r908", "r909", "r910", "r911", "r912", "r913", "r914", "r915", "r916", "r917", "r918", "r919", "r920", "r921", "r922", "r923", "r924", "r925", "r926", "r927", "r928", "r929", "r930", "r931", "r932", "r933", "r934", "r935", "r936", "r937", "r938", "r939", "r940", "r941", "r942", "r943", "r944", "r945", "r946", "r947", "r948", "r949", "r950", "r951", "r952", "r953", "r954", "r955", "r956", "r957", "r958", "r959", "r960", "r961", "r962", "r963", "r964", "r965", "r966", "r967", "r968", "r969", "r970", "r971", "r972", "r973", "r974", "r975", "r976", "r977", "r978", "r979", "r980", "r981", "r982", "r983", "r984", "r985", "r986", "r987", "r988", "r989", "r990", "r991", "r992", "r993", "r994", "r995", "r996", "r997", "r998", "r999" } }
"us-gaap_GainLossOnTerminationOfLease": {
"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GainLossOnTerminationOfLease", "crdr": "credit", "calculation": {
"http://www.autolus.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows": {
"parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
"weight": -1.0, "order": 2.0 } }
"presentation": {
"http://www.autolus.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows": {
"lang": {
"en-us": {
"role": {
"negatedTerseLabel": "Loss on termination of operating lease",
"label": "Gain (Loss) on Termination of Lease",
"documentation": "Amount of gain (loss) on termination of lease before expiration of lease term." } } }
"auth_ref": {
"r405" } }
"us-gaap_GeneralAndAdministrativeExpense": {
"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GeneralAndAdministrativeExpense", "crdr": "debit", "calculation": {
"http://www.autolus.com/role/UnauditedCondensedConsolidatedStatementsOfOperationsandComprehensiveLoss": {
"parentTag": "us-gaap_OperatingIncomeLoss",
"weight": -1.0, "order": 4.0 } }
"presentation": {
"http://www.autolus.com/role/UnauditedCondensedConsolidatedStatementsOfOperationsandComprehensiveLoss": {
"lang": {
"en-us": {
"role": {
"negatedTerseLabel": "General and administrative",
"label": "General and Administrative Expense",
"documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line." } } }
"auth_ref": {
"r64", "r563" } }
"us-gaap_GeneralAndAdministrativeExpenseMember": {
"xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GeneralAndAdministrativeExpenseMember", "presentation": {
"http://www.autolus.com/role/SharebasedCompensationSharebasedCompensationAllocationDetails": {
"lang": {
"en-us": {
"role": {
"terseLabel": "General and administrative",
"label": "General and Administrative Expense [Member]",
"documentation": "Primary financial statement caption encompassing general and administrative expense." } } }
"auth_ref": {
"r64" } }
"autl_GoingConcernPolicyPolicyTextBlock": {
"xbrltype": "textBlockItemType", "nsuri": "http://www.autolus.com/20240630", "localname": "GoingConcernPolicyPolicyTextBlock", "presentation": {
"http://www.autolus.com/role/SummaryOfSignificantAccountingPoliciesPolicies": {
"lang": {
"en-us": {
"role": {
"terseLabel": "Going Concern",
"label": "Going Concern, Policy [Policy Text Block]",
"documentation": "Going Concern, Policy" } } }
"auth_ref": {
"r64" } }
"autl_HostingArrangementServiceContractImplementationCostCapitalizedAfterAccumulatedAmortizationCurrentAndNoncurrent": {
"xbrltype": "monetaryItemType", "nsuri": "http://www.autolus.com/20240630", "localname": "HostingArrangementServiceContractImplementationCostCapitalizedAfterAccumulatedAmortizationCurrentAndNoncurrent", "crdr": "debit", "presentation": {
"http://www.autolus.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows": {
"lang": {
"en-us": {
"role": {
"terseLabel": "Capitalized implementation costs included in accrued expenses",
"label": "Hosting Arrangement, Service Contract, Implementation Cost, Capitalized, after Accumulated Amortization, Current and Noncurrent",
"documentation": "Hosting Arrangement, Service Contract, Implementation Cost, Capitalized, after Accumulated Amortization, Current and Noncurrent" } } }
"auth_ref": {
"r64" } }
"us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "crdr": "credit", "calculation": {
"http://www.autolus.com/role/UnauditedCondensedConsolidatedStatementsOfOperationsandComprehensiveLoss": {
"parentTag": "us-gaap_NetIncomeLoss",
"weight": 1.0, "order": 1.0 } }
"presentation": {
"http://www.autolus.com/role/UnauditedCondensedConsolidatedStatementsOfOperationsandComprehensiveLoss": {
"lang": {
"en-us": {
"role": {
"totalLabel": "Net loss before income tax",
"label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
"documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest." } } }
"auth_ref": {
"r62", "r98", "r110", "r471", "r484", "r625", "r628", "r800", "r801", "r802", "r803", "r804" } }
"us-gaap_IncomeStatementAbstract": {
"xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementAbstract", "lang": {
"en-us": {
"role": {
"terseLabel": "Income Statement [Abstract]",
"label": "Income Statement [Abstract]" } } }
"auth_ref": {
"r64" } }
"us-gaap_IncomeStatementLocationAxis": {
"xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementLocationAxis", "presentation": {
"http://www.autolus.com/role/SharebasedCompensationSharebasedCompensationAllocationDetails": {
"lang": {
"en-us": {
"role": {
"terseLabel": "Income Statement Location [Axis]",
"label": "Statement of Income Location, Balance [Axis]",
"documentation": "Information by location in statement of income where disaggregated amount has been reported." } } }
"auth_ref": {
"r225", "r226", "r227", "r371", "r373", "r378", "r498", "r499", "r568", "r615", "r650", "r847" } }
"us-gaap_IncomeStatementLocationDomain": {
"xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementLocationDomain", "presentation": {
"http://www.autolus.com/role/SharebasedCompensationSharebasedCompensationAllocationDetails": {
"lang": {
"en-us": {
"role": {
"terseLabel": "Income Statement Location [Domain]",
"label": "Statement of Income Location, Balance [Domain]",
"documentation": "Location in statement of income where disaggregated amount has been reported." } } }
"auth_ref": {
"r226", "r227", "r371", "r373", "r378", "r498", "r499", "r568", "r615", "r650", "r847" } }
"us-gaap_IncomeTaxExpenseBenefit": {
"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxExpenseBenefit", "crdr": "debit", "calculation": {
"http://www.autolus.com/role/UnauditedCondensedConsolidatedStatementsOfOperationsandComprehensiveLoss": {
"parentTag": "us-

gaap_NetIncomeLoss", "weight": -1.0, "order": 2.0 }, "presentation": {
"http://www.autolus.com/role/UnauditedCondensedConsolidatedStatementsOfOperationsandComprehensiveLoss", "lang": { "en-us": { "role": { "negatedTerseLabel":
"Income tax expense", "label": "Income Tax Expense (Benefit)", "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense
(benefit) pertaining to continuing operations." } } }, "auth_ref": { "r112", "r121", "r169", "r170", "r190", "r201", "r212", "r339", "r340", "r343", "r490", "r648" }, "us-
gaap_IncomeTaxesPaid": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxesPaid", "crdr": "credit", "presentation": {
"http://www.autolus.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows", "lang": { "en-us": { "role": { "verboseLabel": "Cash paid for income taxes",
"label": "Income Taxes Paid", "documentation": "Amount, before refund, of cash paid to foreign, federal, state, and local jurisdictions as income tax." } } }, "auth_ref": {
"r18", "r70", "r789", "r824", "r825" } }, "us-gaap_IncreaseDecreaseInAccountsPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "IncreaseDecreaseInAccountsPayable", "crdr": "debit", "calculation": {
"http://www.autolus.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
"weight": 1.0, "order": 1.0 }, "presentation": { "http://www.autolus.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows": { "lang": { "en-us": { "role": {
"terseLabel": "Increase in accounts payable", "label": "Increase (Decrease) in Accounts Payable", "documentation": "The increase (decrease) during the reporting period
in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used
in an entity's business." } } }, "auth_ref": { "r4" } }, "autl_IncreaseDecreaseInAccruedLiabilitiesLeaseLiabilityAndOtherLiabilities": { "xbrltype": "monetaryItemType",
"nsuri": "http://www.autolus.com/20240630", "localname": "IncreaseDecreaseInAccruedLiabilitiesLeaseLiabilityAndOtherLiabilities", "crdr": "debit", "calculation": {
"http://www.autolus.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
"weight": 1.0, "order": 1.0 }, "presentation": { "http://www.autolus.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows": { "lang": { "en-us": { "role": {
"terseLabel": "Decrease in accrued expenses and other liabilities", "label": "Increase (Decrease) in Accrued Liabilities, Lease Liability And Other Liabilities",
"documentation": "Increase (Decrease) In Accrued Liabilities, Lease Liability And Other Liabilities" } } }, "auth_ref": { "r4" } }, "us-
gaap_IncreaseDecreaseInDeferredIncomeTaxes": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"IncreaseDecreaseInDeferredIncomeTaxes", "crdr": "credit", "calculation": { "http://www.autolus.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows": {
"parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 7.0 }, "presentation": {
"http://www.autolus.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows": { "lang": { "en-us": { "role": { "negatedTerseLabel": "Deferred income tax",
"label": "Increase (Decrease) in Deferred Income Taxes", "documentation": "The increase (decrease) during the reporting period in the account that represents the
temporary difference that results from Income or Loss that is recognized for accounting purposes but not for tax purposes and vice versa." } } }, "auth_ref": { "r4" } }, "us-
gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"IncreaseDecreaseInOperatingCapitalAbstract", "presentation": { "http://www.autolus.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows": { "lang": { "en-
us": { "role": { "terseLabel": "Changes in operating assets and liabilities", "label": "Increase (Decrease) in Operating Capital [Abstract]" } } }, "auth_ref": { "r4" } }, "us-
gaap_IncreaseDecreaseInOperatingLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"IncreaseDecreaseInOperatingLeaseLiability", "crdr": "debit", "calculation": { "http://www.autolus.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows": {
"parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 1.0 }, "presentation": {
"http://www.autolus.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows": { "lang": { "en-us": { "role": { "terseLabel": "Decrease in operating lease
liability", "label": "Increase (Decrease) in Operating Lease Liability", "documentation": "Amount of increase (decrease) in obligation for operating lease." } } }, "auth_ref": {
"r75", "r787" } }, "us-gaap_IncreaseDecreaseInOtherNoncurrentAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"IncreaseDecreaseInOtherNoncurrentAssets", "crdr": "credit", "calculation": { "http://www.autolus.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows": {
"parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 1.0 }, "presentation": {
"http://www.autolus.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows": { "lang": { "en-us": { "role": { "negatedTerseLabel": "Decrease in long-term
deposits", "label": "Increase (Decrease) in Other Noncurrent Assets", "documentation": "Amount of increase (decrease) in noncurrent assets classified as other." } } },
"auth_ref": { "r787" } }, "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "crdr": "credit", "calculation": {
"http://www.autolus.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
"weight": 1.0, "order": 1.0 }, "presentation": { "http://www.autolus.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows": { "lang": { "en-us": { "role": {
"negatedTerseLabel": "Decrease in prepaid expenses and other non-current assets", "label": "Increase (Decrease) in Prepaid Expense and Other Assets", "documentation":
"Amount of increase (decrease) in prepaid expenses and assets classified as other." } } }, "auth_ref": { "r4" } }, "autl_IncreaseDecreaseInPrepaidExpenseAndOtherAssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.autolus.com/20240630", "localname":
"IncreaseDecreaseInPrepaidExpenseAndOtherAssetsCurrent", "crdr": "credit", "calculation": {
"http://www.autolus.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
"weight": 1.0, "order": 1.0 }, "presentation": { "http://www.autolus.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows": { "lang": { "en-us": { "role": {
"negatedLabel": "Increase in prepaid expenses and other current assets", "label": "Increase (Decrease) in Prepaid Expense And Other Assets, Current", "documentation":
"Increase (Decrease) In Prepaid Expense And Other Assets, Current" } } }, "auth_ref": { "r4" } }, "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": { "xbrltype":
"stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInStockholdersEquityRollForward", "presentation": {
"http://www.autolus.com/role/UnauditedCondensedConsolidatedStatementsOfShareholdersEquity": { "lang": { "en-us": { "role": { "terseLabel": "Stockholders' Equity",
"label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to
the end of a period." } } }, "auth_ref": { "r4" } }, "ecd_IndividualAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "IndividualAxis",
"presentation": { "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
"http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "lang": { "en-us": { "role": { "terseLabel": "Individual", "label":
"Individual [Axis]" } } }, "auth_ref": { "r696", "r706", "r716", "r740", "r748", "r752", "r760" } }, "autl_InitialADSSRepresentingOrdinarySharesMember": { "xbrltype":
"domainItemType", "nsuri": "http://www.autolus.com/20240630", "localname": "InitialADSSRepresentingOrdinarySharesMember", "presentation": {
"http://www.autolus.com/role/NatureoftheBusinessUnitsofAccountingDetails": { "lang": { "en-us": { "role": { "verboseLabel": "Initial ADSS, representing ordinary shares",
"label": "Initial ADSS, Representing Ordinary Shares [Member]", "documentation": "Initial ADSS, Representing Ordinary Shares" } } }, "auth_ref": { "r4" } }, "ecd_InsiderTradingArrLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTradingArrLineItems", "lang": { "en-us": { "role": { "label": "Insider Trading Arrangements [Line Items]", "documentation": "Insider Trading Arrangements [Line Items]", "auth_ref": { "r758" } }, "ecd_InsiderTradingPoliciesProcLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTradingPoliciesProcLineItems", "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures
[Line Items]" } } }, "auth_ref": { "r688", "r764" } }, "ecd_InsiderTrdPoliciesProcAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024",
"localname": "InsiderTrdPoliciesProcAdoptedFlag", "presentation": { "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc", "lang": { "en-us": { "role": { "terseLabel":
"Insider Trading Policies and Procedures Adopted", "label": "Insider Trading Policies and Procedures Adopted [Flag]" } } }, "auth_ref": { "r688", "r764" } }, "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname":
"InsiderTrdPoliciesProcNotAdoptedTextBlock", "presentation": { "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc", "lang": { "en-us": { "role": { "terseLabel":
"Insider Trading Policies and Procedures Not Adopted", "label": "Insider Trading Policies and Procedures Not Adopted [Text Block]" } } }, "auth_ref": { "r688", "r764" } }, "us-gaap_InterestExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InterestExpense", "crdr": "debit", "calculation": {
"http://www.autolus.com/role/InterestExpenseDetails": { "parentTag": null, "weight": null, "order": null, "root": true }, "presentation": {
"http://www.autolus.com/role/InterestExpenseDetails": { "lang": { "en-us": { "role": { "totalLabel": "Total interest expense", "label": "Interest Expense, Operating and
Nonoperating", "documentation": "Amount of interest expense classified as operating and nonoperating. Includes, but is not limited to, cost of borrowing accounted for as
interest expense." } } }, "auth_ref": { "r190", "r195", "r199", "r202", "r212", "r399", "r628", "r629" } }, "us-gaap_InterestExpenseNonoperating": { "xbrltype":
"monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InterestExpenseNonoperating", "crdr": "debit", "calculation": {
"http://www.autolus.com/role/UnauditedCondensedConsolidatedStatementsOfOperationsandComprehensiveLoss": { "parentTag": "us-gaap_NonoperatingIncomeExpense",
"weight": 1.0, "order": 3.0 }, "presentation": { "http://www.autolus.com/role/UnauditedCondensedConsolidatedStatementsOfOperationsandComprehensiveLoss": { "lang": {
"en-us": { "role": { "negatedLabel": "Interest expense", "label": "Interest Expense, Nonoperating", "documentation": "Amount of interest expense classified as
nonoperating." } } }, "auth_ref": { "r199", "r786" } }, "us-gaap_InterestExpenseOther": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "InterestExpenseOther", "crdr": "debit", "calculation": { "http://www.autolus.com/role/InterestExpenseDetails": { "parentTag": "us-gaap_InterestExpense",
"weight": 1.0, "order": 1.0 }, "presentation": { "http://www.autolus.com/role/InterestExpenseDetails": { "lang": { "en-us": { "role": { "terseLabel": "Other interest
expense", "label": "Interest Expense, Other", "documentation": "Amount of interest expense classified as other." } } }, "auth_ref": { "r4" } }, "us-
gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"InterestIncomeAndInterestExpenseDisclosureTableTextBlock", "presentation": { "http://www.autolus.com/role/InterestExpenseTables": { "lang": { "en-us": { "role": {
"terseLabel": "Interest Income and Interest Expense Disclosure", "label": "Interest Income and Interest Expense Disclosure [Table Text Block]", "documentation":
"Tabular disclosure of interest income and expense, including, but not limited to, interest income and expense from investments, loans, and securities." } } }, "auth_ref": {
"r4" } }, "us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"InterestIncomeAndInterestExpenseDisclosureTableTextBlock", "presentation": { "http://www.autolus.com/role/InterestExpenseTables": { "lang": { "en-us": { "role": { "terseLabel":
"Interest expense", "label": "Interest Income and Interest Expense Disclosure [Text Block]", "documentation": "The entire disclosure for interest income and interest
expense for enterprises that derive a significant portion of their revenue from interest collected on investments, loans, and securities." } } }, "auth_ref": { "r94", "r95",
"r96", "r97", "r99", "r101", "r102", "r103", "r104", "r105", "r106", "r107" } }, "us-gaap_InvestmentIncomeInterest": { "xbrltype": "monetaryItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "InvestmentIncomeInterest", "crdr": "credit", "calculation": {
"http://www.autolus.com/role/UnauditedCondensedConsolidatedStatementsOfOperationsandComprehensiveLoss": { "parentTag": "us-gaap_NonoperatingIncomeExpense",
"weight": 1.0, "order": 1.0 }, "presentation": { "http://www.autolus.com/role/UnauditedCondensedConsolidatedStatementsOfOperationsandComprehensiveLoss": { "lang": {
"en-us": { "role": { "terseLabel": "Interest income", "label": "Investment Income, Interest", "documentation": "Amount before accretion (amortization) of purchase
discount (premium) of interest income on nonoperating securities." } } }, "auth_ref": { "r190", "r198", "r212", "r628", "r785" } }, "us-
gaap_InvestmentsDebtAndEquitySecuritiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"InvestmentsDebtAndEquitySecuritiesAbstract", "lang": { "en-us": { "role": { "label": "Investments, Debt and Equity Securities [Abstract]" } } }, "auth_ref": { "r4" } }, "us-
gaap_InvestorMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InvestorMember", "presentation": {
"http://www.autolus.com/role/NatureoftheBusinessUnitsofAccountingDetails": { "lang": { "en-us": { "role": { "terseLabel": "Investor", "label": "Investor [Member]",
"documentation": "Business entity or individual that puts money, by purchase or expenditure, in something offering potential profitable returns, such as interest income
or appreciation in value." } } }, "auth_ref": { "r840", "r841" } }, "autl_LeaseAndLeaseDepositReceivableCurrent": { "xbrltype": "monetaryItemType", "nsuri":
"http://www.autolus.com/20240630", "localname": "LeaseAndLeaseDepositReceivableCurrent", "crdr": "debit", "calculation": {
"http://www.autolus.com/role/PrepaidExpensesAndOtherCurrentAssetsDetails": { "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent", "weight": 1.0, "order":
6.0 }, "presentation": { "http://www.autolus.com/role/PrepaidExpensesAndOtherCurrentAssetsDetails": { "lang": { "en-us": { "role": { "terseLabel": "Lease and lease
deposit receivable", "label": "Lease And Lease Deposit Receivable, Current", "documentation": "Lease And Lease Deposit Receivable, Current", "auth_ref": { "r4" } }, "us-
gaap_LeaseContractualTermAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LeaseContractualTermAxis", "presentation": {
"http://www.autolus.com/role/LeasesNarrativeDetails": { "lang": { "en-us": { "role": { "terseLabel": "Lease Contractual Term [Axis]", "label": "Lease Contractual Term
[Axis]", "documentation": "Information by contractual term of lease arrangement." } } }, "auth_ref": { "r419", "r774" } }, "us-gaap_LeaseContractualTermDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LeaseContractualTermDomain", "presentation": {
"http://www.autolus.com/role/LeasesNarrativeDetails": { "lang": { "en-us": { "role": { "terseLabel": "Lease Contractual Term [Domain]", "label": "Lease Contractual Term
[Domain]", "documentation": "Contractual term of lease arrangement." } } }, "auth_ref": { "r419", "r774" } }, "us-gaap_LeaseCost": { "xbrltype": "monetaryItemType",
"nsuri": "http://fasb.org/us-gaap/2024", "localname": "LeaseCost", "crdr": "debit", "calculation": { "http://www.autolus.com/role/LeasesLeaseCostDetails": { "parentTag":
null, "weight": null, "order": null, "root": true }, "presentation": { "http://www.autolus.com/role/LeasesLeaseCostDetails": { "lang": { "en-us": { "role": { "totalLabel":

```

Total-lease-costs,"label":"Lease,Cost","documentation":"Amount of lease cost recognized by lessee for lease contract." } },"auth_ref":{"r409","r654"},"us-gaap-LeaseCostTableTextBlock":{"xbrltype":"TextBlockItemType","nsuri":"http://fasb.org/us-gaap/2024","localname":"LeaseCostTableTextBlock","presentation":{"http://www.autolus.com/role/LeasesTables"},"lang":{"en-us":{"role":{"terseLabel":"Lease,Cost","label":"Lease,Cost [Table Text Block]","documentation":"Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income." } },"auth_ref":{"r837"},"us-gaap-LeaseholdImprovementsMember":{"xbrltype":"domainItemType","nsuri":"http://fasb.org/us-gaap/2024","localname":"LeaseholdImprovementsMember","presentation":{"http://www.autolus.com/role/PropertyandEquipmentNetScheduleofPPEDetails"},"lang":{"en-us":{"role":{"terseLabel":"Leasehold improvements","label":"Leasehold Improvements [Member]","documentation":"Additions or improvements to assets held under a lease arrangement." } },"auth_ref":{"r77","r418"},"us-gaap-LeasesAbstract":{"xbrltype":"stringItemType","nsuri":"http://fasb.org/us-gaap/2024","localname":"LeasesAbstract","lang":{"en-us":{"role":{"terseLabel":"Leases [Abstract]","label":"Leases [Abstract]"} },"auth_ref":{"deiLegalEntityAxis":{"xbrltype":"stringItemType","nsuri":"http://xbrl.sec.gov/dei/2024","localname":"LegalEntityAxis","presentation":{"http://www.autolus.com/role/NatureoftheBusinessNarrativeDetails"},"lang":{"en-us":{"role":{"terseLabel":"Legal Entity [Axis]","label":"Legal Entity [Axis]","documentation":"The set of legal entities associated with a report." } },"auth_ref":{"us-gaap-LesseeOperatingLeaseLiabilityMaturityTableTextBlock":{"xbrltype":"TextBlockItemType","nsuri":"http://fasb.org/us-gaap/2024","localname":"LesseeOperatingLeaseLiabilityMaturityTableTextBlock","presentation":{"http://www.autolus.com/role/LeasesTables"},"lang":{"en-us":{"role":{"terseLabel":"Lease Maturity Schedule","label":"Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]","documentation":"Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position." } },"auth_ref":{"r838"},"us-gaap-LesseeOperatingLeaseLiabilityPaymentsDue":{"xbrltype":"monetaryItemType","nsuri":"http://fasb.org/us-gaap/2024","localname":"LesseeOperatingLeaseLiabilityPaymentsDue","crdr":"credit","calculation":{"http://www.autolus.com/role/LeasesScheduleofMaturityPaymentsDetails":{"parentTag":null,"weight":null,"order":null,"root":true},"http://www.autolus.com/role/LeasesScheduleofMaturityPaymentsDetails"},"parentTag":null,"weight":null,"order":null,"root":true},"presentation":{"http://www.autolus.com/role/LeasesScheduleofMaturityPaymentsDetails"},"lang":{"en-us":{"role":{"totalLabel":"Total lease payments","label":"Lessee, Operating Lease, Liability, to be Paid","documentation":"Amount of lessee's undiscounted obligation for lease payment for operating lease." } },"auth_ref":{"r417"},"us-gaap-LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths":{"xbrltype":"monetaryItemType","nsuri":"http://fasb.org/us-gaap/2024","localname":"LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths","crdr":"credit","calculation":{"http://www.autolus.com/role/LeasesScheduleofMaturityPaymentsDetails"},"parentTag":"us-gaap-LesseeOperatingLeaseLiabilityPaymentsDue","weight":1.0,"order":3.0},"presentation":{"http://www.autolus.com/role/LeasesScheduleofMaturityPaymentsDetails"},"lang":{"en-us":{"role":{"terseLabel":"2025","label":"Lessee, Operating Lease, Liability, to be Paid, Year One","documentation":"Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."} },"auth_ref":{"r417"},"us-gaap-LesseeOperatingLeaseLiabilityPaymentsDueYearFour":{"xbrltype":"monetaryItemType","nsuri":"http://fasb.org/us-gaap/2024","localname":"LesseeOperatingLeaseLiabilityPaymentsDueYearFour","crdr":"credit","calculation":{"http://www.autolus.com/role/LeasesScheduleofMaturityPaymentsDetails"},"parentTag":"us-gaap-LesseeOperatingLeaseLiabilityPaymentsDue","weight":1.0,"order":1.0},"presentation":{"http://www.autolus.com/role/LeasesScheduleofMaturityPaymentsDetails"},"lang":{"en-us":{"role":{"terseLabel":"2028","label":"Lessee, Operating Lease, Liability, to be Paid, Year Four","documentation":"Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."} },"auth_ref":{"r417"},"us-gaap-LesseeOperatingLeaseLiabilityPaymentsDueYearThree":{"xbrltype":"monetaryItemType","nsuri":"http://fasb.org/us-gaap/2024","localname":"LesseeOperatingLeaseLiabilityPaymentsDueYearThree","crdr":"credit","calculation":{"http://www.autolus.com/role/LeasesScheduleofMaturityPaymentsDetails"},"parentTag":"us-gaap-LesseeOperatingLeaseLiabilityPaymentsDue","weight":1.0,"order":6.0},"presentation":{"http://www.autolus.com/role/LeasesScheduleofMaturityPaymentsDetails"},"lang":{"en-us":{"role":{"terseLabel":"2027","label":"Lessee, Operating Lease, Liability, to be Paid, Year Three","documentation":"Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."} },"auth_ref":{"r417"},"us-gaap-LesseeOperatingLeaseLiabilityPaymentsDueYearTwo":{"xbrltype":"monetaryItemType","nsuri":"http://fasb.org/us-gaap/2024","localname":"LesseeOperatingLeaseLiabilityPaymentsDueYearTwo","crdr":"credit","calculation":{"http://www.autolus.com/role/LeasesScheduleofMaturityPaymentsDetails"},"parentTag":"us-gaap-LesseeOperatingLeaseLiabilityPaymentsDue","weight":1.0,"order":5.0},"presentation":{"http://www.autolus.com/role/LeasesScheduleofMaturityPaymentsDetails"},"lang":{"en-us":{"role":{"terseLabel":"2026","label":"Lessee, Operating Lease, Liability, to be Paid, Year Two","documentation":"Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."} },"auth_ref":{"r417"},"us-gaap-LesseeOperatingLeaseLiabilityPaymentsRemainderOffFiscalYear":{"xbrltype":"monetaryItemType","nsuri":"http://fasb.org/us-gaap/2024","localname":"LesseeOperatingLeaseLiabilityPaymentsRemainderOffFiscalYear","crdr":"credit","calculation":{"http://www.autolus.com/role/LeasesScheduleofMaturityPaymentsDetails"},"parentTag":"us-gaap-LesseeOperatingLeaseLiabilityPaymentsDue","weight":1.0,"order":2.0},"presentation":{"http://www.autolus.com/role/LeasesScheduleofMaturityPaymentsDetails"},"lang":{"en-us":{"role":{"terseLabel":"Remainder of 2024","label":"Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year","documentation":"Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year." } },"auth_ref":{"r838"},"autl-LesseeOperatingLeaseLiabilityToBePaidAfterYearFour":{"xbrltype":"monetaryItemType","nsuri":"http://www.autolus.com/20240630","localname":"LesseeOperatingLeaseLiabilityToBePaidAfterYearFour","crdr":"credit","calculation":{"http://www.autolus.com/role/LeasesScheduleofMaturityPaymentsDetails"},"parentTag":"us-gaap-LesseeOperatingLeaseLiabilityPaymentsDue","weight":1.0,"order":4.0},"presentation":{"http://www.autolus.com/role/LeasesScheduleofMaturityPaymentsDetails"},"lang":{"en-us":{"role":{"terseLabel":"Thereafter","label":"Lessee, Operating Lease, Liability, To Be Paid, After Year Four","documentation":"Lessee, Operating Lease, Liability, To Be Paid, After Year Four"} },"auth_ref":{"us-gaap-LesseeOperatingLeaseLiabilityUndiscountedExcessAmount":{"xbrltype":"monetaryItemType","nsuri":"http://fasb.org/us-gaap/2024","localname":"LesseeOperatingLeaseLiabilityUndiscountedExcessAmount","crdr":"credit","calculation":{"http://www.autolus.com/role/LeasesScheduleofMaturityPaymentsDetails"},"parentTag":"us-gaap-LesseeOperatingLeaseLiabilityPaymentsDue","weight":1.0,"order":2.0},"presentation":{"http://www.autolus.com/role/LeasesScheduleofMaturityPaymentsDetails"},"lang":{"en-us":{"role":{"negatedLabel":"Less: imputed interest","label":"Lessee, Operating Lease, Liability, Undiscounted Excess Amount","documentation":"Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease." } },"auth_ref":{"r417"},"us-gaap-LesseeOperatingLeasesTextBlock":{"xbrltype":"TextBlockItemType","nsuri":"http://fasb.org/us-gaap/2024","localname":"LesseeOperatingLeasesTextBlock","presentation":{"http://www.autolus.com/role/Leases"},"lang":{"en-us":{"role":{"terseLabel":"Leases","label":"Lessee, Operating Leases [Text Block]","documentation":"The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability." } },"auth_ref":{"r403"},"us-gaap-LessorLeaseDescriptionLineItems":{"xbrltype":"stringItemType","nsuri":"http://fasb.org/us-gaap/2024","localname":"LessorLeaseDescriptionLineItems","presentation":{"http://www.autolus.com/role/LeasesNarrativeDetails"},"lang":{"en-us":{"role":{"terseLabel":"Lessor, Lease, Description [Line Items]","label":"Lessor, Lease, Description [Line Items]","documentation":"Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } },"auth_ref":{"r421"},"us-gaap-LessorLeaseDescriptionTable":{"xbrltype":"stringItemType","nsuri":"http://fasb.org/us-gaap/2024","localname":"LessorLeaseDescriptionTable","presentation":{"http://www.autolus.com/role/LeasesNarrativeDetails"},"lang":{"en-us":{"role":{"terseLabel":"Lessor, Lease, Description [Table]","label":"Lessor, Lease, Description [Table]","documentation":"Disclosure of information about lessor's leases." } },"auth_ref":{"r421"},"autl-LessorOperatingLeaseNumberOfManufacturingProperties":{"xbrltype":"integerItemType","nsuri":"http://www.autolus.com/20240630","localname":"LessorOperatingLeaseNumberOfManufacturingProperties","presentation":{"http://www.autolus.com/role/LeasesNarrativeDetails"},"lang":{"en-us":{"role":{"terseLabel":"Number of manufacturing properties","label":"Lessor, Operating Lease, Number Of Manufacturing Properties","documentation":"Lessor, Operating Lease, Number Of Manufacturing Properties"} },"auth_ref":{"us-gaap-LessorOperatingLeasePaymentsToBeReceived":{"xbrltype":"monetaryItemType","nsuri":"http://fasb.org/us-gaap/2024","localname":"LessorOperatingLeasePaymentsToBeReceived","crdr":"debit","calculation":{"http://www.autolus.com/role/LeasesSubleaseIncomeMaturityDetails":{"parentTag":null,"weight":null,"order":null,"root":true},"presentation":{"http://www.autolus.com/role/LeasesNarrativeDetails"},"http://www.autolus.com/role/LeasesSubleaseIncomeMaturityDetails"},"lang":{"en-us":{"role":{"terseLabel":"Lessor, operating lease, payment to be received","totalLabel":"Total lease payments receivable","label":"Lessor, Operating Lease, Payment to be Received","documentation":"Amount of lease payments to be received by lessor for operating lease." } },"auth_ref":{"r420"},"us-gaap-LessorOperatingLeasePaymentsToBeReceivedFourYears":{"xbrltype":"monetaryItemType","nsuri":"http://fasb.org/us-gaap/2024","localname":"LessorOperatingLeasePaymentsToBeReceivedFourYears","crdr":"debit","calculation":{"http://www.autolus.com/role/LeasesSubleaseIncomeMaturityDetails":{"parentTag":"us-gaap-LessorOperatingLeasePaymentsToBeReceived","weight":1.0,"order":2.0},"presentation":{"http://www.autolus.com/role/LeasesSubleaseIncomeMaturityDetails"},"lang":{"en-us":{"role":{"terseLabel":"2028","label":"Lessor, Operating Lease, Payment to be Received, Year Four","documentation":"Amount of lease payment to be received by lessor for operating lease in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."} },"auth_ref":{"r420"},"us-gaap-LessorOperatingLeasePaymentsToBeReceivedMaturityTableTextBlock":{"xbrltype":"TextBlockItemType","nsuri":"http://fasb.org/us-gaap/2024","localname":"LessorOperatingLeasePaymentsToBeReceivedMaturityTableTextBlock","presentation":{"http://www.autolus.com/role/LeasesTables"},"lang":{"en-us":{"role":{"terseLabel":"Lease Receivable Maturity Schedule","label":"Lessor, Operating Lease, Payment to be Received, Maturity [Table Text Block]","documentation":"Tabular disclosure of maturity of undiscounted cash flows to be received by lessor on annual basis for operating lease." } },"auth_ref":{"r839"},"us-gaap-LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths":{"xbrltype":"monetaryItemType","nsuri":"http://fasb.org/us-gaap/2024","localname":"LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths","crdr":"debit","calculation":{"http://www.autolus.com/role/LeasesSubleaseIncomeMaturityDetails":{"parentTag":"us-gaap-LessorOperatingLeasePaymentsToBeReceived","weight":1.0,"order":5.0},"presentation":{"http://www.autolus.com/role/LeasesSubleaseIncomeMaturityDetails"},"lang":{"en-us":{"role":{"terseLabel":"2025","label":"Lessor, Operating Lease, Payment to be Received, Year One","documentation":"Amount of lease payment to be received by lessor for operating lease in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."} },"auth_ref":{"r420"},"us-gaap-LessorOperatingLeasePaymentsToBeReceivedRemainderOffFiscalYear":{"xbrltype":"monetaryItemType","nsuri":"http://fasb.org/us-gaap/2024","localname":"LessorOperatingLeasePaymentsToBeReceivedRemainderOffFiscalYear","crdr":"debit","calculation":{"http://www.autolus.com/role/LeasesSubleaseIncomeMaturityDetails":{"parentTag":"us-gaap-LessorOperatingLeasePaymentsToBeReceived","weight":1.0,"order":3.0},"presentation":{"http://www.autolus.com/role/LeasesSubleaseIncomeMaturityDetails"},"lang":{"en-us":{"role":{"terseLabel":"Remainder of 2024","label":"Lessor, Operating Lease, Payment to be Received, Remainder of Fiscal Year","documentation":"Amount of lease payment to be received by lessor for operating lease in remainder of current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."} },"auth_ref":{"r839"},"us-gaap-LessorOperatingLeasePaymentsToBeReceivedThreeYears":{"xbrltype":"monetaryItemType","nsuri":"http://fasb.org/us-gaap/2024","localname":"LessorOperatingLeasePaymentsToBe
```

Received, Year Two", "documentation": "Amount of lease payment to be received by lessor for operating lease in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."}}, {"auth_ref": "r420"}, {"us_gaap_Liabilities": {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Liabilities", "crdr": "credit", "calculation": {"http://www.autolus.com/role/UnauditedCondensedConsolidatedBalanceSheets": {"parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 1.0}}, {"presentation": {"http://www.autolus.com/role/UnauditedCondensedConsolidatedBalanceSheets": {"lang": {"en-us": {"role": {"totalLabel": "Total liabilities", "label": "Liabilities", "documentation": "Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others."}}}}, {"auth_ref": "r12", "r46", "r47", "r48", "r50", "r51", "r52", "r53", "r153", "r219", "r234", "r235", "r236", "r237", "r238", "r239", "r240", "r241", "r242", "r352", "r353", "r354", "r386", "r537", "r624", "r682", "r816", "r843", "r844"}, {"us_gaap_LiabilitiesAndStockholdersEquity": {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesAndStockholdersEquity", "crdr": "credit", "calculation": {"http://www.autolus.com/role/UnauditedCondensedConsolidatedBalanceSheets": {"parentTag": null, "weight": null, "order": null, "root": true}}, {"presentation": {"http://www.autolus.com/role/UnauditedCondensedConsolidatedBalanceSheets": {"lang": {"en-us": {"role": {"totalLabel": "Total liabilities and shareholders' equity", "label": "Liabilities and Equity", "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any."}}}}, {"auth_ref": "r60", "r93", "r480", "r655", "r793", "r806", "r830"}, {"us_gaap_LiabilitiesAndStockholdersEquityAbstract": {"xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesAndStockholdersEquityAbstract", "presentation": {"http://www.autolus.com/role/UnauditedCondensedConsolidatedBalanceSheets": {"lang": {"en-us": {"role": {"terseLabel": "Liabilities and shareholders' equity", "label": "Liabilities and Equity [Abstract]", "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any."}}}}, {"auth_ref": null}, {"us_gaap_LiabilitiesCurrent": {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesCurrent", "crdr": "credit", "calculation": {"http://www.autolus.com/role/UnauditedCondensedConsolidatedBalanceSheets": {"parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 2.0}}, {"presentation": {"http://www.autolus.com/role/UnauditedCondensedConsolidatedBalanceSheets": {"lang": {"en-us": {"role": {"totalLabel": "Total current liabilities", "label": "Liabilities, Current", "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer."}}}}, {"auth_ref": "r48", "r128", "r153", "r219", "r234", "r235", "r236", "r237", "r238", "r239", "r240", "r241", "r242", "r352", "r353", "r354", "r386", "r655", "r816", "r843", "r844"}, {"us_gaap_LiabilitiesCurrentAbstract": {"xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesCurrentAbstract", "presentation": {"http://www.autolus.com/role/UnauditedCondensedConsolidatedBalanceSheets": {"lang": {"en-us": {"role": {"terseLabel": "Current liabilities", "label": "Liabilities, Current [Abstract]", "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer."}}}}, {"auth_ref": null}, {"us_gaap_LiabilitiesNoncurrentAbstract": {"xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesNoncurrentAbstract", "presentation": {"http://www.autolus.com/role/UnauditedCondensedConsolidatedBalanceSheets": {"lang": {"en-us": {"role": {"terseLabel": "Non-current liabilities", "label": "Liabilities, Noncurrent [Abstract]", "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer."}}}}, {"auth_ref": null}, {"autl_LiabilityRelatedDebtArisingFinancialAgreementTableTextBlock": {"xbrltype": "textBlockItemType", "nsuri": "http://www.autolus.com/20240630", "localname": "LiabilityRelatedDebtArisingFinancialAgreementTableTextBlock", "presentation": {"http://www.autolus.com/role/Liabilitiesrelatedtofutureroyaltiesandmilestonesnet": {"lang": {"en-us": {"role": {"terseLabel": "Liability Related Debt Arising Financial Agreement", "label": "Liability Related Debt Arising Financial Agreement [Table Text Block]", "documentation": "Liability Related Debt Arising Financial Agreement", "auth_ref": null}, {"autl_LiabilityRelatedToSalesOfFutureRevenueNetTextBlock": {"xbrltype": "textBlockItemType", "nsuri": "http://www.autolus.com/20240630", "localname": "LiabilityRelatedToSalesOfFutureRevenueNetTextBlock", "presentation": {"http://www.autolus.com/role/Liabilitiesrelatedtofutureroyaltiesandmilestonesnet": {"lang": {"en-us": {"role": {"terseLabel": "Liabilities related to future royalties and milestones, net", "label": "Liability Related To Sales Of Future Revenue, Net [Text Block]", "documentation": "Liability Related To Sales Of Future Revenue, Net", "auth_ref": null}, {"autl_LiabilityRelatedToTheSaleOfFutureRoyaltiesAndSalesMilestonesNetMember": {"xbrltype": "domainItemType", "nsuri": "http://www.autolus.com/20240630", "localname": "LiabilityRelatedToTheSaleOfFutureRoyaltiesAndSalesMilestonesNetMember", "presentation": {"http://www.autolus.com/role/NatureoftheBusinessUnitsofAccountingDetails": {"lang": {"en-us": {"role": {"verboseLabel": "Liabilities related to future royalties and milestones, net (Obe-cel Product Revenue Interest)", "label": "Liability Related To The Sale Of Future Royalties And Sales Milestones, Net [Member]", "documentation": "Liability Related To The Sale Of Future Royalties And Sales Milestones, Net", "auth_ref": null}, {"autl_LicenseAndOptionsMember": {"xbrltype": "domainItemType", "nsuri": "http://www.autolus.com/20240630", "localname": "LicenseAndOptionsMember", "presentation": {"http://www.autolus.com/role/LicenseRevenueNarrativeDetails": {"http://www.autolus.com/role/NatureoftheBusinessNarrativeDetails": {"lang": {"en-us": {"role": {"terseLabel": "License And Options [Member]", "documentation": "License And Options", "auth_ref": null}, {"us_gaap_LicenseMember": {"xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LicenseMember", "presentation": {"http://www.autolus.com/role/LicenseRevenueDisaggregationOfRevenueDetails": {"http://www.autolus.com/role/UnauditedCondensedConsolidatedStatementsofOperationsandComprehensiveLoss": {"lang": {"en-us": {"role": {"terseLabel": "License revenue", "label": "License [Member]", "documentation": "Right to use intangible asset. Intangible asset includes, but is not limited to: patent, copyright, technology, manufacturing process, software or trademark", "auth_ref": "r819"}, {"autl_LicenseRevenueMember": {"xbrltype": "domainItemType", "nsuri": "http://www.autolus.com/20240630", "localname": "LicenseRevenueMember", "presentation": {"http://www.autolus.com/role/NatureoftheBusinessUnitsofAccountingDetails": {"lang": {"en-us": {"role": {"terseLabel": "License Revenue (Binder License)", "label": "License Revenue [Member]", "documentation": "License Revenue", "auth_ref": null}, {"dei_LocalPhoneNumber": {"xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "LocalPhoneNumber", "presentation": {"http://www.autolus.com/role/Cover": {"lang": {"en-us": {"role": {"verboseLabel": "Local Phone Number", "label": "Local Phone Number", "documentation": "Local phone number for entity", "auth_ref": null}, {"us_gaap_LongTermPurchaseCommitmentLineItems": {"xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermPurchaseCommitmentLineItems", "presentation": {"http://www.autolus.com/role/CommitmentsandContingenciesNarrativeDetails": {"lang": {"en-us": {"role": {"terseLabel": "Long-term Purchase Commitment [Line Items]", "label": "Long-Term Purchase Commitment [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table", "auth_ref": null}, {"us_gaap_LongTermPurchaseCommitmentTable": {"xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermPurchaseCommitmentTable", "presentation": {"http://www.autolus.com/role/CommitmentsandContingenciesNarrativeDetails": {"lang": {"en-us": {"role": {"terseLabel": "Long-term Purchase Commitment [Table]", "label": "Long-Term Purchase Commitment [Table]", "documentation": "Disclosure of information about long-term purchase arrangement. Includes, but is not limited to, term of arrangement with supplier, minimum quantity required, milestone, period covered by arrangement, and committed amount. Excludes short-term purchase arrangement and unconditional purchase obligation", "auth_ref": null}, {"us_gaap_LossContingencyAccrualAtCarryingValue": {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LossContingencyAccrualAtCarryingValue", "crdr": "credit", "presentation": {"http://www.autolus.com/role/CommitmentsandContingenciesNarrativeDetails": {"lang": {"en-us": {"role": {"terseLabel": "Loss contingency accrual", "label": "Loss Contingency Accrual", "documentation": "Amount of loss contingency liability", "auth_ref": "r233", "r771"}, {"srt_MajorCustomersAxis": {"xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "MajorCustomersAxis", "presentation": {"http://www.autolus.com/role/LicenseRevenueNarrativeDetails": {"lang": {"en-us": {"role": {"terseLabel": "Customer [Axis]", "label": "Customer [Axis]", "auth_ref": "r217", "r639", "r665", "r669", "r818", "r846", "r848", "r849", "r851", "r852", "r853", "r854", "r855", "r856", "r857", "r858", "r859", "r860", "r861", "r862", "r863", "r864", "r865", "r866", "r867", "r868", "r869", "r870", "r871", "r872", "r873", "r874", "r875"}, {"autl_ManufacturingCommercialServicesAgreementMCSAMember": {"xbrltype": "domainItemType", "nsuri": "http://www.autolus.com/20240630", "localname": "ManufacturingCommercialServicesAgreementMCSAMember", "presentation": {"http://www.autolus.com/role/NatureoftheBusinessUnitsofAccountingDetails": {"lang": {"en-us": {"role": {"terseLabel": "MCSA", "label": "Manufacturing Commercial Services Agreement (u201cMCSA[u201d] [Member]", "documentation": "Manufacturing Commercial Services Agreement (u201cMCSA[u201d])", "auth_ref": null}, {"autl_MartinPuleMember": {"xbrltype": "domainItemType", "nsuri": "http://www.autolus.com/20240630", "localname": "MartinPuleMember", "presentation": {"http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements": {"lang": {"en-us": {"role": {"label": "Martin Pule [Member]", "documentation": "Martin Pule", "auth_ref": null}, {"autl_MasterSupplyCommitmentsMember": {"xbrltype": "domainItemType", "nsuri": "http://www.autolus.com/20240630", "localname": "MasterSupplyCommitmentsMember", "presentation": {"http://www.autolus.com/role/CommitmentsandContingenciesNarrativeDetails": {"lang": {"en-us": {"role": {"terseLabel": "Master Supply Commitments", "label": "Master Supply Commitments [Member]", "documentation": "Master Supply Commitments", "auth_ref": null}, {"ecd_MeasureAxis": {"xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MeasureAxis", "presentation": {"http://xbrl.sec.gov/ecd/role/PvpDisclosure": {"lang": {"en-us": {"role": {"terseLabel": "Measure", "label": "Measure [Axis]", "auth_ref": "r732"}, {"ecd_MeasureName": {"xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MeasureName", "presentation": {"http://xbrl.sec.gov/ecd/role/PvpDisclosure": {"lang": {"en-us": {"role": {"terseLabel": "Name", "label": "Measure Name", "auth_ref": "r732"}, {"autl_MiltienyiBiotechB.V.Co.KGMiltienyiMember": {"xbrltype": "domainItemType", "nsuri": "http://www.autolus.com/20240630", "localname": "MiltienyiBiotechB.V.Co.KGMiltienyiMember", "presentation": {"http://www.autolus.com/role/CommitmentsandContingenciesNarrativeDetails": {"lang": {"en-us": {"role": {"terseLabel": "Miltienyi Biotech B.V. & Co. KG (u'Miltienyi')", "label": "Miltienyi Biotech B.V. & Co. KG (u'Miltienyi') [Member]", "documentation": "Miltienyi Biotech B.V. & Co. KG (u'Miltienyi')", "auth_ref": null}, {"us_gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners": {"xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MinorityInterestOwnershipPercentageByNoncontrollingOwners", "presentation": {"http://www.autolus.com/role/RelatedpartytransactionsNarrativeDetails": {"lang": {"en-us": {"role": {"terseLabel": "Ownership percentage by noncontrolling owners (in percent)", "label": "Subsidiary Ownership Percentage, Noncontrolling Owner", "documentation": "The equity interest of noncontrolling shareholders, partners or other equity holders in consolidated entity", "auth_ref": null}, {"ecd_MnpdDiscTimedForCompValFlag": {"xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MnpdDiscTimedForCompValFlag", "presentation": {"http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure": {"lang": {"en-us": {"role": {"terseLabel": "MNPI Disclosure Timed for Compensation Value", "label": "MNPI Disclosure Timed for Compensation Value [Flag]", "auth_ref": "r751"}, {"us_gaap_MoneyMarketFundsMember": {"xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MoneyMarketFundsMember", "presentation": {"http://www.autolus.com/role/FairvaluemeasurementsDetails": {"lang": {"en-us": {"role": {"terseLabel": "Money market funds", "label": "Money Market Funds [Member]", "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities", "auth_ref": "r820"}, {"ecd_MtrlTermsOfTrdArrTextBlock": {"xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MtrlTermsOfTrdArrTextBlock", "presentation": {"http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements": {"lang": {"en-us": {"role": {"terseLabel": "Material Terms of Trading Arrangement", "label": "Material Terms of Trading Arrangement [Text Block]", "auth_ref": "r759"}, {"srt_NameOfMajorCustomerDomain": {"xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "NameOfMajorCustomerDomain", "presentation": {"http://www.autolus.com/role/LicenseRevenueNarrativeDetails": {"lang": {"en-us": {"role": {"terseLabel": "Customer [Domain]", "label": "Customer [Domain]", "auth_ref": "r217", "r639", "r665", "r669", "r818", "r846", "r848", "r849", "r851", "r852", "r853", "r854", "r855", "r856", "r857", "r858", "r859", "r860", "r861", "r862", "r863", "r864", "r865", "r866", "r867", "r868", "r869", "r870", "r871", "r872", "r873", "r874", "r875"}, {"ecd_NamedExecutiveOfficersFnTextBlock": {"xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NamedExecutiveOfficersFnTextBlock", "presentation": {"http://xbrl.sec.gov/ecd/role/PvpDisclosure": {"lang": {"en-us": {"role": {"terseLabel": "Named Executive Officers, Footnote", "label": "Named Executive Officers, Footnote [Text Block]", "auth_ref": "r733"}, {"us_gaap_NatureOfOperations": {"xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NatureOfOperations", "presentation": {"http://www.autolus.com/role/NatureoftheBusiness": {"lang": {"en-us": {"role": {"terseLabel": "Nature of the Business", "label": "Nature of Operations [Text Block]", "documentation": "The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward", "auth_ref": "r113", "r122"}, {"us_gaap_NetCashProvidedByUsedInFinancingActivities": {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInFinancingActivities", "crdr": "debit", "calculation": {"http://www.autolus.com/role/UnauditedCondensedConsolidatedStatementsofCashFlows": {"parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 2.0}}, {"presentation": {"http://www.autolus.com/role/UnauditedCondensedConsolidatedStatementsofCashFlows": {"lang": {"en-us": {"role": {"totalLabel": "Net cash provided by (used in) financing activities", "label": "Net Cash Provided by (Used in) Financing Activities", "documentation": "Amount of cash inflow (outflow) from

financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit. } } }, "auth_ref": { "r150" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "presentation": { "http://www.autolus.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows", "lang": { "en-us": { "role": { "terseLabel": "Cash flows from financing activities", "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]" } } }, "auth_ref": { "r150" }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInInvestingActivities", "crdr": "debit", "calculation": { "http://www.autolus.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows", "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 3.0 } }, "presentation": { "http://www.autolus.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows", "lang": { "en-us": { "role": { "totalLabel": "Net cash used in investing activities", "label": "Net Cash Provided by (Used in) Investing Activities", "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets. } } }, "auth_ref": { "r150" }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "presentation": { "http://www.autolus.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows", "lang": { "en-us": { "role": { "terseLabel": "Cash flows from investing activities", "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]" } } }, "auth_ref": { "r150" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInOperatingActivities", "calculation": { "http://www.autolus.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows", "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 4.0 } }, "presentation": { "http://www.autolus.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows", "lang": { "en-us": { "role": { "totalLabel": "Net cash used in operating activities", "label": "Net Cash Provided by (Used in) Operating Activities", "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities." } } }, "auth_ref": { "r68", "r69", "r71" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": { "http://www.autolus.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows", "lang": { "en-us": { "role": { "terseLabel": "Cash flows from operating activities", "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]" } } }, "auth_ref": { "r68", "r69", "r71" }, "us-gaap_NetIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetIncomeLoss", "crdr": "credit", "calculation": { "http://www.autolus.com/role/UnauditedCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss", "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0, "order": 1.0 }, "http://www.autolus.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows", "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 3.0 }, "presentation": { "http://www.autolus.com/role/NetLossPerOrdinaryShareScheduleOfNetLossPerShareDetails", "http://www.autolus.com/role/SummaryOfSignificantAccountingPoliciesNarrativeDetails", "http://www.autolus.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows", "http://www.autolus.com/role/UnauditedCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss", "http://www.autolus.com/role/UnauditedCondensedConsolidatedStatementsOfShareholdersEquity", "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "lang": { "en-us": { "role": { "totalLabel": "Net loss", "terseLabel": "Net loss", "verboseLabel": "Net loss", "label": "Net Income (Loss) Attributable to Parent", "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent." } } }, "auth_ref": { "r63", "r71", "r100", "r126", "r139", "r141", "r145", "r153", "r160", "r162", "r163", "r164", "r165", "r166", "r169", "r170", "r181", "r219", "r234", "r235", "r236", "r237", "r238", "r239", "r240", "r241", "r242", "r347", "r350", "r364", "r386", "r485", "r560", "r582", "r583", "r680", "r816" }, "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetIncomeLossAvailableToCommonStockholdersBasic", "crdr": "credit", "presentation": { "http://www.autolus.com/role/NetLossPerOrdinaryShareScheduleOfNetLossPerShareDetails", "lang": { "en-us": { "role": { "terseLabel": "Net loss - basic", "label": "Net Income (Loss) Available to Common Stockholders, Basic", "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders." } } }, "auth_ref": { "r149", "r162", "r163", "r164", "r165", "r172", "r173", "r182", "r185", "r350" }, "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetIncomeLossAvailableToCommonStockholdersDiluted", "crdr": "credit", "presentation": { "http://www.autolus.com/role/NetLossPerOrdinaryShareScheduleOfNetLossPerShareDetails", "lang": { "en-us": { "role": { "terseLabel": "Net loss - diluted", "label": "Net Income (Loss) Available to Common Stockholders, Diluted", "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) available to common shareholders." } } }, "auth_ref": { "r149", "r174", "r177", "r178", "r179", "r180", "r182", "r185" }, "us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetIncomeLossAvailableToCommonStockholdersDilutedAbstract", "presentation": { "http://www.autolus.com/role/NetLossPerOrdinaryShareScheduleOfNetLossPerShareDetails", "lang": { "en-us": { "role": { "terseLabel": "Numerator", "label": "Net Income (Loss) Available to Common Stockholders, Diluted [Abstract]" } } }, "auth_ref": { "r149", "r174", "r177", "r178", "r179", "r180", "r182", "r185" }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "presentation": { "http://www.autolus.com/role/SummaryOfSignificantAccountingPoliciesPolicies", "lang": { "en-us": { "role": { "terseLabel": "Recent Accounting Pronouncements Not Yet Adopted", "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact." } } }, "auth_ref": { "r149", "r174", "r177", "r178", "r179", "r180", "r182", "r185" }, "us-gaap_BooleanFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NoTradingSymbolFlag", "presentation": { "http://www.autolus.com/role/Cover", "lang": { "en-us": { "role": { "terseLabel": "No Trading Symbol Flag", "label": "No Trading Symbol Flag", "documentation": "Boolean flag that is true only for a security having no trading symbol." } } }, "auth_ref": { "r149", "r174", "r177", "r178", "r179", "r180", "r182", "r185" }, "us-gaap_NonGAPMeasureDescriptionTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonGAPMeasureDescriptionTextBlock", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "lang": { "en-us": { "role": { "terseLabel": "Non-GAAP Measure Description", "label": "Non-GAAP Measure Description [Text Block]" } } }, "auth_ref": { "r732" }, "us-gaap_NonNeosMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonNeosMember", "presentation": { "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "lang": { "en-us": { "role": { "terseLabel": "Non-NEOs", "label": "Non-NEOs [Member]" } } }, "auth_ref": { "r696", "r706", "r716", "r740", "r748" }, "us-gaap_NonPeoNeoAvgCompActuallyPaidAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonPeoNeoAvgCompActuallyPaidAmt", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "lang": { "en-us": { "role": { "terseLabel": "Non-PEO NEO Average Compensation Actually Paid Amount", "label": "Non-PEO NEO Average Compensation Actually Paid Amount", "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders." } } }, "auth_ref": { "r723" }, "us-gaap_NonPeoNeoAvgTotalCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonPeoNeoAvgTotalCompAmt", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "lang": { "en-us": { "role": { "terseLabel": "Non-PEO NEO Average Total Compensation Amount", "label": "Non-PEO NEO Average Total Compensation Amount", "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders." } } }, "auth_ref": { "r722" }, "us-gaap_NonPeoNeoMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonPeoNeoMember", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "lang": { "en-us": { "role": { "terseLabel": "Non-PEO NEO", "label": "Non-PEO NEO [Member]" } } }, "auth_ref": { "r740" }, "us-gaap_NonRule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonRule10b51ArrAdoptedFlag", "presentation": { "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "lang": { "en-us": { "role": { "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted", "label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]" } } }, "auth_ref": { "r759" }, "us-gaap_NonRule10b51ArrTrmndFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonRule10b51ArrTrmndFlag", "presentation": { "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "lang": { "en-us": { "role": { "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated", "label": "Non-Rule 10b5-1 Arrangement Terminated [Flag]" } } }, "auth_ref": { "r759" }, "us-gaap_NoncashOperatingLeaseExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://www.autolus.com/20240630", "localname": "NoncashOperatingLeaseExpense", "crdr": "debit", "calculation": { "http://www.autolus.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows", "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 15.0 }, "presentation": { "http://www.autolus.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows", "lang": { "en-us": { "role": { "terseLabel": "Non-cash operating lease expense", "label": "Noncash Operating Lease Expense", "documentation": "Noncash Operating Lease Expense" } } }, "auth_ref": { "r759", "r760", "r761", "r762", "r763", "r764", "r765", "r766", "r767", "r768", "r769", "r770", "r771", "r772", "r773", "r774", "r775", "r776", "r777", "r778", "r779", "r780", "r781", "r782", "r783", "r784", "r785", "r786", "r787", "r788", "r789", "r790", "r791", "r792", "r793", "r794", "r795", "r796", "r797", "r798", "r799", "r800", "r801", "r802", "r803", "r804", "r805", "r806", "r807", "r808", "r809", "r810", "r811", "r812", "r813", "r814", "r815", "r816", "r817", "r818", "r819", "r820", "r821", "r822", "r823", "r824", "r825", "r826", "r827", "r828", "r829", "r830", "r831", "r832", "r833", "r834", "r835", "r836", "r837", "r838", "r839", "r840", "r841", "r842", "r843", "r844", "r845", "r846", "r847", "r848", "r849", "r850", "r851", "r852", "r853", "r854", "r855", "r856", "r857", "r858", "r859", "r860", "r861", "r862", "r863", "r864", "r865", "r866", "r867", "r868", "r869", "r870", "r871", "r872", "r873", "r874", "r875", "r876", "r877", "r878", "r879", "r880", "r881", "r882", "r883", "r884", "r885", "r886", "r887", "r888", "r889", "r890", "r891", "r892", "r893", "r894", "r895", "r896", "r897", "r898", "r899", "r900", "r901", "r902", "r903", "r904", "r905", "r906", "r907", "r908", "r909", "r910", "r911", "r912", "r913", "r914", "r915", "r916", "r917", "r918", "r919", "r920", "r921", "r922", "r923", "r924", "r925", "r926", "r927", "r928", "r929", "r930", "r931", "r932", "r933", "r934", "r935", "r936", "r937", "r938", "r939", "r940", "r941", "r942", "r943", "r944", "r945", "r946", "r947", "r948", "r949", "r950", "r951", "r952", "r953", "r954", "r955", "r956", "r957", "r958", "r959", "r960", "r961", "r962", "r963", "r964", "r965", "r966", "r967", "r968", "r969", "r970", "r971", "r972", "r973", "r974", "r975", "r976", "r977", "r978", "r979", "r980", "r981", "r982", "r983", "r984", "r985", "r986", "r987", "r988", "r989", "r990", "r991", "r992", "r993", "r994", "r995", "r996", "r997", "r998", "r999", "r1000" }, "us-gaap_NonoperatingIncomeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NonoperatingIncomeExpense", "crdr": "credit", "calculation": { "http://www.autolus.com/role/UnauditedCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss", "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 2.0 }, "presentation": { "http://www.autolus.com/role/UnauditedCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss", "lang": { "en-us": { "role": { "totalLabel": "Total other income (expense), net", "label": "Nonoperating Income (Expense)", "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business)." } } }, "auth_ref": { "r65" }, "us-gaap_NonoperatingIncomeExpenseAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NonoperatingIncomeExpenseAbstract", "presentation": { "http://www.autolus.com/role/UnauditedCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss", "lang": { "en-us": { "role": { "terseLabel": "Other income (expense)", "label": "Nonoperating Income (Expense) [Abstract]" } } }, "auth_ref": { "r65", "r66", "r67", "r68", "r69", "r70", "r71", "r72", "r73", "r74", "r75", "r76", "r77", "r78", "r79", "r80", "r81", "r82", "r83", "r84", "r85", "r86", "r87", "r88", "r89", "r90", "r91", "r92", "r93", "r94", "r95", "r96", "r97", "r98", "r99", "r100", "r101", "r102", "r103", "r104", "r105", "r106", "r107", "r108", "r109", "r110", "r111", "r112", "r113", "r114", "r115", "r116", "r117", "r118", "r119", "r120", "r121", "r122", "r123", "r124", "r125", "r126", "r127", "r128", "r129", "r130", "r131", "r132", "r133", "r134", "r135", "r136", "r137", "r138", "r139", "r140", "r141", "r142", "r143", "r144", "r145", "r146", "r147", "r148", "r149", "r150", "r151", "r152", "r153", "r154", "r155", "r156", "r157", "r158", "r159", "r160", "r161", "r162", "r163", "r164", "r165", "r166", "r167", "r168", "r169", "r170", "r171", "r172", "r173", "r174", "r175", "r176", "r177", "r178", "r179", "r180", "r181", "r182", "r183", "r184", "r185", "r186", "r187", "r188", "r189", "r190", "r191", "r192", "r193", "r194", "r195", "r196", "r197", "r198", "r199", "r200", "r201", "r202", "r203", "r204", "r205", "r206", "r207", "r208", "r209", "r210", "r211", "r212", "r213", "r214", "r215", "r216", "r217", "r218", "r219", "r220", "r221", "r222", "r223", "r224", "r225", "r226", "r227", "r228", "r229", "r230", "r231", "r232", "r233", "r234", "r235", "r236", "r237", "r238", "r239", "r240", "r241", "r242", "r243", "r244", "r245", "r246", "r247", "r248", "r249", "r250", "r251", "r252", "r253", "r254", "r255", "r256", "r257", "r258", "r259", "r260", "r261", "r262", "r263", "r264", "r265", "r266", "r267", "r268", "r269", "r270", "r271", "r272", "r273", "r274", "r275", "r276", "r277", "r278", "r279", "r280", "r281", "r282", "r283", "r284", "r285", "r286", "r287", "r288", "r289", "r290", "r291", "r292", "r293", "r294", "r295", "r296", "r297", "r298", "r299", "r300", "r301", "r302", "r303", "r304", "r305", "r306", "r307", "r308", "r309", "r310", "r311", "r312", "r313", "r314", "r315", "r316", "r317", "r318", "r319", "r320", "r321", "r322", "r323", "r324", "r325", "r326", "r327", "r328", "r329", "r330", "r331", "r332", "r333", "r334", "r335", "r336", "r337", "r338", "r339", "r340", "r341", "r342", "r343", "r344", "r345", "r346", "r347", "r348", "r349", "r350", "r351", "r352", "r353", "r354", "r355", "r356", "r357", "r358", "r359", "r360", "r361", "r362", "r363", "r364", "r365", "r366", "r367", "r368", "r369", "r370", "r371", "r372", "r373", "r374", "r375", "r376", "r377", "r378", "r379", "r380", "r381", "r382", "r383", "r384", "r385", "r386", "r387", "r388", "r389", "r390", "r391", "r392", "r393", "r394", "r395", "r396", "r397", "r398", "r399", "r400", "r401", "r402", "r403", "r404", "r405", "r406", "r407", "r408", "r409", "r410", "r411", "r412", "r413", "r414", "r415", "r416", "r417", "r418", "r419", "r420", "r421", "r422", "r423", "r424", "r425", "r426", "r427", "r428", "r429", "r430", "r431", "r432", "r433", "r434", "r435", "r436", "r437", "r438", "r439", "r440", "r441", "r442", "r443", "r444", "r445", "r446", "r447", "r448", "r449", "r450", "r451", "r452", "r453", "r454", "r455", "r456", "r457", "r458", "r459", "r460", "r461", "r462", "r463", "r464", "r465", "r466", "r467", "r468", "r469", "r470", "r471", "r472", "r473", "r474", "r475", "r476", "r477", "r478", "r479", "r480", "r481", "r482", "r483", "r484", "r485", "r486", "r487", "r488", "r489", "r490", "r491", "r492", "r493", "r494", "r495", "r496", "r497", "r498", "r499", "r500", "r501", "r502", "r503", "r504", "r505", "r506", "r507", "r508", "r509", "r510", "r511", "r512", "r513", "r514", "r515", "r516", "r517", "r518", "r519", "r520", "r521", "r522", "r523", "r524", "r525", "r526", "r527", "r528", "r529", "r530", "r531", "r532", "r533", "r534", "r535", "r536", "r537", "r538", "r539", "r540", "r541", "r542", "r543", "r544", "r545", "r546", "r547", "r548", "r549", "r550", "r551", "r552", "r553", "r554", "r555", "r556", "r557", "r558", "r559", "r560", "r561", "r562", "r563", "r564", "r565", "r566", "r567", "r568", "r569", "r570", "r571", "r572", "r573", "r574", "r575", "r576", "r577", "r578", "r579", "r580", "r581", "r582", "r583", "r584", "r585", "r586", "r587", "r588", "r589", "r590", "r591", "r592", "r593", "r594", "r595", "r596", "r597", "r598", "r599", "r600", "r601", "r602", "r603", "r604", "r605", "r606", "r607", "r608", "r609", "r610", "r611", "r612", "r613", "r614", "r615", "r616", "r617", "r618", "r619", "r620", "r621", "r622", "r623", "r624", "r625", "r626", "r627", "r628", "r629", "r630", "r631", "r632", "r633", "r634", "r635", "r636", "r637", "r638", "r639", "r640", "r641", "r642", "r643", "r644", "r645", "r646", "r647", "r648", "r649", "r650", "r651", "r652", "r653", "r654", "r655", "r656", "r657", "r658", "r659", "r660", "r661", "r662", "r663", "r664", "r665", "r666", "r667", "r668", "r669", "r670", "r671", "r672", "r673", "r674", "r675", "r676", "r677", "r678", "r679", "r680", "r681", "r682", "r683", "r684", "r685", "r686", "r687", "r688", "r689", "r690", "r691", "r692", "r693", "r694", "r695", "r696", "r697", "r698", "r699", "r700", "r701", "r702", "r703", "r704", "r705", "r706", "r707", "r708", "r709", "r710", "r711", "r712", "r713", "r714", "r715", "r716", "r717", "r718", "r719", "r720", "r721", "r722", "r723", "r724", "r725", "r726", "r727", "r728", "r729", "r730", "r731", "r732", "r733", "r734", "r735", "r736", "r737", "r738", "r739", "r740", "r741", "r742", "r743", "r744", "r745", "r746", "r747", "r748", "r749", "r750", "r751", "r752", "r753", "r754", "r755", "r756", "r757", "r758", "r759", "r760", "r761", "r762", "r763", "r764", "r765", "r766", "r767", "r768", "r769", "r770", "r771", "r772", "r773", "r774", "r775", "r776", "r777", "r778", "r779", "r780", "r781", "r782", "r783", "r784", "r785", "r786", "r787", "r788", "r789", "r790", "r791", "r792", "r793", "r794", "r795", "r796", "r797", "r798", "r799", "r800", "r801", "r802", "r803", "r804", "r805", "r806", "r807", "r808", "r809", "r810", "r811", "r812", "r813", "r814", "r815", "r816", "r817", "r818", "r819", "r820", "r821", "r822", "r823", "r824", "r825", "r826", "r827", "r828", "r829", "r830", "r831", "r832", "r833", "r834", "r835", "r836", "r837", "r838", "r839", "r840", "r841", "r842", "r843", "r844", "r845", "r846", "r847", "r848", "r849", "r850", "r851", "r852", "r853", "r854", "r855", "r856", "r857", "r858", "r859", "r860", "r861", "r862", "r863", "r864", "r865", "r866", "r867", "r868", "r869", "r870", "r871", "r872", "r873", "r874", "r875", "r876", "r877", "r878", "r879", "r880", "r881", "r882", "r883", "r884", "r885", "r886", "r887", "r888", "r889", "r890", "r891", "r892", "r893", "r894", "r895", "r896", "r897", "r898", "r899", "r900", "r901", "r902", "r903", "r904", "r905", "r906", "r907", "r908", "r909", "r910", "r911", "r912", "r913", "r914", "r915", "r916", "r917", "r918", "r919", "r920", "r921", "r922", "r923", "r924", "r925", "r926", "r927", "r928", "r929", "r930", "r931", "r932", "r933", "r934", "r935", "r936", "r937", "r938", "r939", "r940", "r941", "r942", "r943", "r944", "r945", "r946", "r947", "r948", "r949", "r950", "r951", "r952", "r953", "r954", "r955", "r956", "r957", "r958", "r959", "r960", "r961", "r962", "r963", "r964", "r965", "r966", "r967", "r968", "r969", "r970", "r971", "r972", "r973", "r974", "r975", "r976", "r977", "r978", "r979", "r980", "r981", "r982", "r983", "r984", "r985", "r986", "r987", "r988", "r989", "r990", "r991", "r992", "r993", "r994", "r995", "r996", "r997", "r998", "r999", "r1000" }, "us-gaap_OfficeEquipmentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OfficeEquipmentMember", "presentation": {

"http://www.autolus.com/role/PropertyandEquipmentNetScheduleofPPEDetails", "lang": { "en-us": { "role": { "terseLabel": "Office equipment", "label": "Office Equipment [Member]", "documentation": "Tangible personal property used in an office setting. Examples include, but are not limited to, computers, copiers and fax machine." } } }, "auth_ref": { "us-gaap_OperatingExpensesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingExpensesAbstract", "presentation": { "http://www.autolus.com/role/UnauditedCondensedConsolidatedStatementsOfOperationsandComprehensiveLoss": { "lang": { "en-us": { "role": { "terseLabel": "Operating expenses", "label": "Operating Expenses [Abstract]" } } }, "auth_ref": { "us-gaap_OperatingIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingIncomeLoss", "crdr": "credit", "calculation": { "http://www.autolus.com/role/UnauditedCondensedConsolidatedStatementsOfOperationsandComprehensiveLoss": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 1.0 }, "presentation": { "http://www.autolus.com/role/UnauditedCondensedConsolidatedStatementsOfOperationsandComprehensiveLoss": { "lang": { "en-us": { "role": { "totalLabel": "Total operating expenses, net", "label": "Operating Income (Loss)", "documentation": "The net result for the period of deducting operating expenses from operating revenues." } } }, "auth_ref": { "r110", "r625", "r800", "r801", "r802", "r803", "r804" } } }, "us-gaap_OperatingLeaseCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseCost", "crdr": "debit", "calculation": { "http://www.autolus.com/role/LeasesLeaseCostDetails": { "parentTag": "us-gaap_LeaseCost", "weight": 1.0, "order": 1.0 }, "presentation": { "http://www.autolus.com/role/LeasesLeaseCostDetails": { "lang": { "en-us": { "role": { "terseLabel": "Operating lease costs", "label": "Operating Lease, Cost", "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability." } } }, "auth_ref": { "r410", "r654" } } }, "us-gaap_OperatingLeaseImpairmentLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseImpairmentLoss", "crdr": "debit", "calculation": { "http://www.autolus.com/role/UnauditedCondensedConsolidatedStatementsOfOperationsandComprehensiveLoss": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0, "order": 3.0 }, "http://www.autolus.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 4.0 } } }, "presentation": { "http://www.autolus.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0, "order": 3.0 } } }, "http://www.autolus.com/role/UnauditedCondensedConsolidatedStatementsOfOperationsandComprehensiveLoss": { "lang": { "en-us": { "role": { "negatedLabel": "Impairment of operating lease right-of-use assets and related property and equipment", "label": "Operating Lease, Impairment Loss", "documentation": "Amount of loss from impairment of right-of-use asset from operating lease." } } } }, "auth_ref": { "r835" } } }, "us-gaap_OperatingLeaseLeaseIncomeTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLeaseIncomeTableTextBlock", "presentation": { "http://www.autolus.com/role/LeasesTables": { "lang": { "en-us": { "role": { "terseLabel": "Sublease Classification", "label": "Operating Lease, Lease Income [Table Text Block]", "documentation": "Tabular disclosure of components of income from operating lease." } } } }, "auth_ref": { "r191", "r422" } } }, "us-gaap_OperatingLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiability", "crdr": "credit", "calculation": { "http://www.autolus.com/role/LeasesScheduleofMaturityPaymentsDetails": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 1.0 } } }, "presentation": { "http://www.autolus.com/role/LeasesScheduleofMaturityPaymentsDetails": { "lang": { "en-us": { "role": { "terseLabel": "Present value of lease liabilities", "label": "Operating Lease, Liability", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease." } } }, "auth_ref": { "r407" } } }, "us-gaap_OperatingLeaseLiabilityCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiabilityCurrent", "crdr": "credit", "calculation": { "http://www.autolus.com/role/UnauditedCondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 3.0 } } }, "presentation": { "http://www.autolus.com/role/UnauditedCondensedConsolidatedBalanceSheets": { "lang": { "en-us": { "role": { "terseLabel": "Operating lease liabilities, current", "label": "Operating Lease, Liability, Current", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current." } } } }, "auth_ref": { "r407" } } }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiabilityNoncurrent", "crdr": "credit", "calculation": { "http://www.autolus.com/role/UnauditedCondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesNoncurrent", "weight": 1.0, "order": 3.0 } } }, "presentation": { "http://www.autolus.com/role/UnauditedCondensedConsolidatedBalanceSheets": { "lang": { "en-us": { "role": { "terseLabel": "Operating lease liabilities, non-current", "label": "Operating Lease, Liability, Noncurrent", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent." } } } }, "auth_ref": { "r407" } } }, "us-gaap_OperatingLeasePayments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeasePayments", "crdr": "credit", "presentation": { "http://www.autolus.com/role/LeasesLeaseCostDetails": { "lang": { "en-us": { "role": { "terseLabel": "Operating cash outflows from operating leases", "label": "Operating Lease, Payments", "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use." } } } }, "auth_ref": { "r408", "r413" } } }, "us-gaap_OperatingLeaseRightOfUseAsset": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseRightOfUseAsset", "crdr": "debit", "calculation": { "http://www.autolus.com/role/UnauditedCondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 6.0 } } }, "presentation": { "http://www.autolus.com/role/UnauditedCondensedConsolidatedBalanceSheets": { "lang": { "en-us": { "role": { "terseLabel": "Operating lease right-of-use assets, net", "label": "Operating Lease, Right-of-Use Asset", "documentation": "Amount of lessee's right to use underlying asset under operating lease." } } } }, "auth_ref": { "r406" } } }, "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseWeightedAverageDiscountRatePercent", "presentation": { "http://www.autolus.com/role/LeasesLeaseCostDetails": { "lang": { "en-us": { "role": { "terseLabel": "Weighted average discount rate in 2014 operating leases (in percent)", "label": "Operating Lease, Weighted Average Discount Rate, Percent", "documentation": "Weighted average discount rate for operating lease calculated at point in time." } } } }, "auth_ref": { "r416", "r654" } } }, "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1", "presentation": { "http://www.autolus.com/role/LeasesLeaseCostDetails": { "lang": { "en-us": { "role": { "terseLabel": "Weighted average remaining lease term - operating leases", "label": "Operating Lease, Weighted Average Remaining Lease Term", "documentation": "Weighted average remaining lease term for operating lease, in PnYnMnDnTnHnMnS format, for example, P1Y5M13D represents reported fact of one year, five months, and thirteen days." } } } }, "auth_ref": { "r415", "r654" } } }, "autl_OrdinarySharesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.autolus.com/20240630", "localname": "OrdinarySharesMember", "presentation": { "http://www.autolus.com/role/Cover": "http://www.autolus.com/role/NatureoftheBusinessNarrativeDetails", "http://www.autolus.com/role/ShareholdersEquityNarrativeDetails": "http://www.autolus.com/role/UnauditedCondensedConsolidatedBalanceSheets", "http://www.autolus.com/role/UnauditedCondensedConsolidatedBalanceSheetsParentHeticals": "http://www.autolus.com/role/UnauditedCondensedConsolidatedStatementsOfShareholdersEquity", "lang": { "en-us": { "role": { "terseLabel": "Ordinary Shares", "verboseLabel": "Ordinary shares", "label": "Ordinary Shares [Member]", "documentation": "Ordinary Shares [Member]" } } }, "auth_ref": { "us-gaap_OrganizationConsolidationAndPresentationOffinancialStatementsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OrganizationConsolidationAndPresentationOffinancialStatementsAbstract", "lang": { "en-us": { "role": { "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]", "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]" } } }, "auth_ref": { "us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent", "crdr": "credit", "calculation": { "http://www.autolus.com/role/UnauditedCondensedConsolidatedStatementsOfOperationsandComprehensiveLoss": { "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0, "order": 2.0 } } }, "presentation": { "http://www.autolus.com/role/UnauditedCondensedConsolidatedStatementsOfOperationsandComprehensiveLoss": { "parentTag": "us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent", "weight": 1.0, "order": 2.0 } } }, "http://www.autolus.com/role/UnauditedCondensedConsolidatedStatementsOfShareholdersEquity": { "lang": { "en-us": { "role": { "terseLabel": "Foreign currency exchange translation adjustment", "verboseLabel": "Unrealized gain on foreign currency translation", "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent", "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term investment nature, attributable to parent entity." } } }, "auth_ref": { "r3", "r7", "r87" } } }, "us-gaap_OtherCurrentAssetsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherCurrentAssetsTextBlock", "presentation": { "http://www.autolus.com/role/PrepaidExpensesandOtherCurrentAssets": { "lang": { "en-us": { "role": { "terseLabel": "Prepaid Expenses and Other Current Assets", "label": "Other Current Assets [Text Block]", "documentation": "The entire disclosure for other current assets." } } } }, "auth_ref": { "us-gaap_OtherLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.autolus.com/role/AccruedExpensesandOtherLiabilitiesDetails": { "parentTag": "us-gaap_AccruedLiabilitiesandOtherLiabilities", "weight": 1.0, "order": 1.0 } } }, "presentation": { "http://www.autolus.com/role/AccruedExpensesandOtherLiabilitiesDetails": { "lang": { "en-us": { "role": { "terseLabel": "Other accrued liabilities", "label": "Other Liabilities, Current", "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer." } } } }, "auth_ref": { "r47", "r655" } } }, "us-gaap_OtherLiabilitiesNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherLiabilitiesNoncurrent", "crdr": "credit", "calculation": { "http://www.autolus.com/role/UnauditedCondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 4.0 } } }, "presentation": { "http://www.autolus.com/role/UnauditedCondensedConsolidatedBalanceSheets": { "lang": { "en-us": { "role": { "terseLabel": "Other long-term payables", "label": "Other Liabilities, Noncurrent", "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer." } } } }, "auth_ref": { "r51" } } }, "us-gaap_OtherNonoperatingIncomeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherNonoperatingIncomeExpense", "crdr": "credit", "calculation": { "http://www.autolus.com/role/UnauditedCondensedConsolidatedStatementsOfOperationsandComprehensiveLoss": { "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0, "order": 2.0 } } }, "presentation": { "http://www.autolus.com/role/UnauditedCondensedConsolidatedStatementsOfOperationsandComprehensiveLoss": { "lang": { "en-us": { "role": { "terseLabel": "Other income (expense), net", "label": "Other Nonoperating Income (Expense)", "documentation": "Amount of income (expense) related to nonoperating activities, classified as other." } } } }, "auth_ref": { "r66" } } }, "ecd_OtherPerfMeasureAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OtherPerfMeasureAmt", "presentation": { "http://xbrl.sec.gov/ecd/role/PypDisclosure": { "lang": { "en-us": { "role": { "terseLabel": "Other Performance Measure, Amount", "label": "Other Performance Measure, Amount" } } } }, "auth_ref": { "r732" } } }, "us-gaap_OtherReceivablesNetCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherReceivablesNetCurrent", "crdr": "debit", "calculation": { "http://www.autolus.com/role/PrepaidExpensesandOtherCurrentAssetsDetails": { "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent", "weight": 1.0, "order": 3.0 } } }, "presentation": { "http://www.autolus.com/role/PrepaidExpensesandOtherCurrentAssetsDetails": { "lang": { "en-us": { "role": { "terseLabel": "Other receivables", "label": "Other Receivables, Net, Current", "documentation": "Amount, after allowance, of receivables classified as other, due within one year or the operating cycle, if longer." } } } }, "auth_ref": { "autl_OtherTaxesReceivableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.autolus.com/20240630", "localname": "OtherTaxesReceivableCurrent", "crdr": "debit", "calculation": { "http://www.autolus.com/role/PrepaidExpensesandOtherCurrentAssetsDetails": { "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent", "weight": 1.0, "order": 9.0 } } }, "presentation": { "http://www.autolus.com/role/PrepaidExpensesandOtherCurrentAssetsDetails": { "lang": { "en-us": { "role": { "terseLabel": "Other taxes receivable", "label": "Other Taxes Receivable Current", "documentation": "Other Taxes Receivable Current" } } } }, "auth_ref": { "ecd_OutstandingAggtErrCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OutstandingAggtErrCompAmt", "presentation": { "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure": { "lang": { "en-us": { "role": { "terseLabel": "Outstanding Aggregate Erroneous Compensation Amount", "label": "Outstanding Aggregate Erroneous Compensation Amount" } } } }, "auth_ref": { "r694", "r704", "r714", "r746" } } }, "ecd_OutstandingRecoveryCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OutstandingRecoveryCompAmt", "presentation": { "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure": { "lang": { "en-us": { "role": { "terseLabel": "Compensation Amount", "label": "Outstanding Recovery Compensation Amount" } } } }, "auth_ref": { "r697", "r707", "r717", "r749" } } }, "ecd_OutstandingRecoveryIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OutstandingRecoveryIndName", "presentation": { "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure": { "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Outstanding Recovery, Individual Name" } } } }, "auth_ref": { "r697", "r707", "r717", "r749" } } }, "srt_OwnershipAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "OwnershipAxis", "presentation": { "http://www.autolus.com/role/RelatedpartyTransactionsNarrativeDetails": { "lang": { "en-us": { "role": { "terseLabel": "Ownership [Axis]", "label": "Ownership [Axis]" } } } } } }

}, "auth_ref": "I", "srt_OwnershipDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "OwnershipDomain", "presentation": { "http://www.autolus.com/role/RelatedPartyTransactionsNarrativeDetails": { "lang": { "en-us": { "role": { "terseLabel": "Ownership [Domain]", "label": "Ownership [Domain]", "auth_ref": "I" } } } }, "auth_ref": "I", "ecd_PayVsPerformanceDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PayVsPerformanceDisclosureLineItems", "lang": { "en-us": { "role": { "label": "Pay vs Performance Disclosure [Line Items]", "auth_ref": { "r721": { "us-gaap_PayablesAndAccrualsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PayablesAndAccrualsAbstract", "lang": { "en-us": { "role": { "terseLabel": "Payables and Accruals [Abstract]", "label": "Payables and Accruals [Abstract]", "auth_ref": "I" } } } }, "autl_PaymentOfContractWithCustomerLiabilityIssuanceCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://www.autolus.com/20240630", "localname": "PaymentOfContractWithCustomerLiabilityIssuanceCosts", "crdr": "credit", "calculation": { "http://www.autolus.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 3.0 } }, "presentation": { "http://www.autolus.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows": { "lang": { "en-us": { "role": { "negatedTerseLabel": "Payments of issuance costs related to the liabilities related to the sale of future royalties and milestones, net", "label": "Payment Of Contract With Customer, Liability, Issuance Costs", "documentation": "Payment Of Contract With Customer, Liability, Issuance Costs" } } } }, "auth_ref": "I", "us-gaap_PaymentOfFinancingAndStockIssuanceCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentOfFinancingAndStockIssuanceCosts", "crdr": "credit", "presentation": { "http://www.autolus.com/role/NatureoftheBusinessUnitsofAccountingDetails": { "lang": { "en-us": { "role": { "terseLabel": "Payment of equity issuance costs", "label": "Payment of Financing and Stock Issuance Costs", "documentation": "The total of the cash outflow during the period which has been paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt and the cost incurred directly for the issuance of equity securities." } } } }, "auth_ref": { "r16": { "us-gaap_PaymentsOfStockIssuanceCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsOfStockIssuanceCosts", "crdr": "credit", "calculation": { "http://www.autolus.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 5.0 } }, "presentation": { "http://www.autolus.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows": { "lang": { "en-us": { "role": { "negatedTerseLabel": "Payments of equity issuance costs", "label": "Payments of Stock Issuance Costs", "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security." } } } }, "auth_ref": { "r16": { "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "crdr": "credit", "calculation": { "http://www.autolus.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 1.0 } }, "presentation": { "http://www.autolus.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows": { "lang": { "en-us": { "role": { "negatedTerseLabel": "Purchases of property and equipment", "label": "Payments to Acquire Property, Plant, and Equipment", "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets." } } } }, "auth_ref": { "r67": { "ecd_PeerGroupIssuersFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeerGroupIssuersFnTextBlock", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure": { "lang": { "en-us": { "role": { "terseLabel": "Peer Group Issuers, Footnote", "label": "Peer Group Issuers, Footnote [Text Block]", "auth_ref": { "r731": { "ecd_PeerGroupTotalShareholderRtnAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeerGroupTotalShareholderRtnAmt", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure": { "lang": { "en-us": { "role": { "terseLabel": "Peer Group Total Shareholder Return Amount", "label": "Peer Group Total Shareholder Return Amount", "auth_ref": { "r731": { "ecd_PeoActuallyPaidCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoActuallyPaidCompAmt", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure": { "lang": { "en-us": { "role": { "terseLabel": "PEO Actually Paid Compensation Amount", "label": "PEO Actually Paid Compensation Amount", "auth_ref": { "r723": { "ecd_PeoMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoMember", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure": { "lang": { "en-us": { "role": { "terseLabel": "PEO", "label": "PEO [Member]", "auth_ref": { "r740": { "ecd_PeoName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoName", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure": { "lang": { "en-us": { "role": { "terseLabel": "PEO Name", "label": "PEO Name", "auth_ref": { "r733": { "ecd_PeoTotalCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoTotalCompAmt", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure": { "lang": { "en-us": { "role": { "terseLabel": "PEO Total Compensation Amount", "label": "PEO Total Compensation Amount", "auth_ref": { "r722": { "us-gaap_PerformanceSharesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PerformanceSharesMember", "presentation": { "http://www.autolus.com/role/SharebasedCompensationNarrativeDetails": { "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure": { "lang": { "en-us": { "role": { "terseLabel": "Performance Shares", "label": "Performance Shares [Member]", "documentation": "Share-based payment arrangement awarded for meeting performance target." } } } }, "auth_ref": "I", "ecd_PnsnAdjsPrrSvcCstMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PnsnAdjsPrrSvcCstMember", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure": { "lang": { "en-us": { "role": { "terseLabel": "Pension Adjustments Prior Service Cost", "label": "Pension Adjustments Prior Service Cost [Member]", "auth_ref": { "r724": { "ecd_PnsnAdjsSvcCstMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PnsnAdjsSvcCstMember", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure": { "lang": { "en-us": { "role": { "terseLabel": "Pension Adjustments Service Cost", "label": "Pension Adjustments Service Cost [Member]", "auth_ref": { "r768": { "ecd_PnsnBnftsAdjFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PnsnBnftsAdjFnTextBlock", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure": { "lang": { "en-us": { "role": { "terseLabel": "Pension Benefits Adjustments, Footnote", "label": "Pension Benefits Adjustments, Footnote [Text Block]", "auth_ref": { "r723": { "us-gaap_PortionAtFairValueFairValueDisclosureMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PortionAtFairValueFairValueDisclosureMember", "presentation": { "http://www.autolus.com/role/NatureoftheBusinessUnitsofAccountingDetails": { "lang": { "en-us": { "role": { "terseLabel": "Portion at Fair Value Measurement", "label": "Portion at Fair Value Measurement [Member]", "documentation": "Measured at fair value for financial reporting purposes." } } } }, "auth_ref": { "r384": { "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PrepaidExpenseAndOtherAssetsCurrent", "crdr": "debit", "calculation": { "http://www.autolus.com/role/UnauditedCondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": { "http://www.autolus.com/role/PrepaidExpensesAndOtherCurrentAssetsDetails": { "http://www.autolus.com/role/UnauditedCondensedConsolidatedBalanceSheets": { "lang": { "en-us": { "role": { "terseLabel": "Prepaid expenses and other current assets", "totalLabel": "Prepaid expenses and other current assets", "label": "Prepaid Expense and Other Assets, Current", "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer." } } } }, "auth_ref": { "r781": { "us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PrepaidExpenseAndOtherAssetsNoncurrent", "crdr": "debit", "calculation": { "http://www.autolus.com/role/UnauditedCondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 4.0 } }, "presentation": { "http://www.autolus.com/role/UnauditedCondensedConsolidatedBalanceSheets": { "lang": { "en-us": { "role": { "verboseLabel": "Prepaid expenses and other non-current assets", "label": "Prepaid Expense and Other Assets, Noncurrent", "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed after one year or the normal operating cycle, if longer." } } } }, "auth_ref": { "r88": { "us-gaap_PrepaidExpenseCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PrepaidExpenseCurrent", "crdr": "debit", "calculation": { "http://www.autolus.com/role/PrepaidExpensesAndOtherCurrentAssetsDetails": { "http://www.autolus.com/role/PrepaidExpensesAndOtherCurrentAssetsDetails": { "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent", "weight": 1.0, "order": 5.0 } }, "presentation": { "http://www.autolus.com/role/PrepaidExpensesAndOtherCurrentAssetsDetails": { "lang": { "en-us": { "role": { "terseLabel": "Prepayments", "label": "Prepaid Expense, Current", "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer." } } } }, "auth_ref": { "r137": "r222": "r223": "r619": { "us-gaap_ProceedsFromIssuanceOfCommonStock": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromIssuanceOfCommonStock", "crdr": "debit", "calculation": { "http://www.autolus.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 2.0 } }, "presentation": { "http://www.autolus.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows": { "lang": { "en-us": { "role": { "terseLabel": "Proceeds of issuance of ordinary shares", "label": "Proceeds from Issuance of Common Stock", "documentation": "The cash inflow from the additional capital contribution to the entity." } } } }, "auth_ref": { "r2": { "autl_ProceedsFromIssuanceOfContractWithCustomerLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://www.autolus.com/20240630", "localname": "ProceedsFromIssuanceOfContractWithCustomerLiability", "crdr": "credit", "calculation": { "http://www.autolus.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 4.0 } }, "presentation": { "http://www.autolus.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows": { "lang": { "en-us": { "role": { "negatedTerseLabel": "Proceeds from liabilities related to future royalties and milestones, net", "label": "Proceeds From Issuance Of Contract With Customer, Liability", "documentation": "Proceeds From Issuance Of Contract With Customer, Liability" } } } }, "auth_ref": "I", "us-gaap_ProceedsFromStockOptionsExercised": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromStockOptionsExercised", "crdr": "debit", "calculation": { "http://www.autolus.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 1.0 } }, "presentation": { "http://www.autolus.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows": { "lang": { "en-us": { "role": { "terseLabel": "Proceeds from the exercise of share options", "label": "Proceeds from Stock Options Exercised", "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement." } } } }, "auth_ref": { "r2": "r11": { "us-gaap_ProductInformationLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProductInformationLineItems", "presentation": { "http://www.autolus.com/role/NatureoftheBusinessNarrativeDetails": { "lang": { "en-us": { "role": { "terseLabel": "Product Information [Line Items]", "label": "Product Information [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } } }, "auth_ref": "I", "srt_ProductOrServiceAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ProductOrServiceAxis", "presentation": { "http://www.autolus.com/role/LiabilitiesrelatedtofutureroyaltiesandmilestonesnetNarrativeDetails": { "http://www.autolus.com/role/LicenseRevenueDisaggregationofRevenueDetails": { "http://www.autolus.com/role/LicenserevenueNarrativeDetails": { "http://www.autolus.com/role/NatureoftheBusinessNarrativeDetails": { "http://www.autolus.com/role/UnauditedCondensedConsolidatedStatementsOfOperationsandComprehensiveLoss": { "lang": { "en-us": { "role": { "terseLabel": "Product and Service [Axis]", "label": "Product and Service [Axis]", "auth_ref": { "r214": "r437": "r491": "r492": "r493": "r494": "r495": "r496": "r497": "r616": "r637": "r664": "r666": "r667": "r670": "r671": "r814": "r815": "r818": "r846": "r848": "r849": "r850": "r851": "r852": "r853": "r854": "r855": "r856": "r857": "r858": "r859": "r860": "r861": "r862": "r863": "r864": "r865": "r866": "r867": "r868": "r869": "r870": "r871": "r872": "r873": "r874": "r875": { "srt_ProductsAndServicesDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ProductsAndServicesDomain", "presentation": { "http://www.autolus.com/role/LiabilitiesrelatedtofutureroyaltiesandmilestonesnetNarrativeDetails": { "http://www.autolus.com/role/LicenseRevenueDisaggregationofRevenueDetails": { "http://www.autolus.com/role/LicenserevenueNarrativeDetails": { "http://www.autolus.com/role/NatureoftheBusinessNarrativeDetails": { "http://www.autolus.com/role/UnauditedCondensedConsolidatedStatementsOfOperationsandComprehensiveLoss": { "lang": { "en-us": { "role": { "terseLabel": "Product and Service [Domain]", "label": "Product and Service [Domain]", "auth_ref": { "r214": "r437": "r491": "r492": "r493": "r494": "r495": "r496": "r497": "r616": "r637": "r664": "r666": "r667": "r670": "r671": "r814": "r815": "r818": "r846": "r848": "r849": "r850": "r851": "r852": "r853": "r854": "r855": "r856": "r857": "r858": "r859": "r860": "r861": "r862": "r863": "r864": "r865": "r866": "r867": "r868": "r869": "r870": "r871": "r872": "r873": "r874": "r875": { "us-gaap_PropertyPlantAndEquipmentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentAbstract", "lang": { "en-us": { "role": { "terseLabel": "Property, Plant and Equipment [Abstract]", "label": "Property, Plant and Equipment [Abstract]", "auth_ref": "I", "us-gaap_PropertyPlantAndEquipmentByTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentByTypeAxis", "presentation": { "http://www.autolus.com/role/PropertyandEquipmentNetScheduleofPPEDetails": { "lang": { "en-us": { "role": { "terseLabel": "Property, Plant and Equipment, Type [Axis]", "label": "Long-Lived Tangible Asset [Axis]", "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale." } } } }, "auth_ref": { "r6": "r418": { "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentDisclosureTextBlock", "presentation": { "http://www.autolus.com/role/PropertyandEquipmentNet": { "lang": { "en-

us": {"role": {"terseLabel": "Property and Equipment, Net", "label": "Property, Plant and Equipment Disclosure [Text Block]", "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections." }}, {"auth_ref": {"r76": "r116", "r119": "r120"}}, {"us-gaap_PropertyPlantAndEquipmentGross": {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentGross", "crdr": "debit", "calculation": {"parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": 1.0, "order": 1.0}}, {"presentation": {"http://www.autolus.com/role/PropertyandEquipmentNetScheduleofPPEDetails": {"parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": 1.0, "order": 1.0}}, {"http://www.autolus.com/role/PropertyandEquipmentNetScheduleofPPEDetails": {"lang": {"en-us": {"role": {"terseLabel": "Property and equipment, gross", "label": "Property, Plant and Equipment, Gross", "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures." }}, {"auth_ref": {"r77": "r130", "r483"}}, {"us-gaap_PropertyPlantAndEquipmentLineItems": {"xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentLineItems", "presentation": {"http://www.autolus.com/role/PropertyandEquipmentNetScheduleofPPEDetails": {"lang": {"en-us": {"role": {"terseLabel": "Property, Plant and Equipment", "label": "Property, Plant and Equipment [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." }}, {"auth_ref": {"r418"}}, {"us-gaap_PropertyPlantAndEquipmentNet": {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentNet", "crdr": "debit", "calculation": {"http://www.autolus.com/role/UnauditedCondensedConsolidatedBalanceSheets": {"parentTag": "us-gaap_Assets", "weight": 1.0, "order": 2.0}}, {"http://www.autolus.com/role/PropertyandEquipmentNetScheduleofPPEDetails": {"parentTag": null, "weight": null, "order": null, "root": true}}, {"presentation": {"http://www.autolus.com/role/PropertyandEquipmentNetScheduleofPPEDetails": {"http://www.autolus.com/role/UnauditedCondensedConsolidatedBalanceSheets": {"lang": {"en-us": {"role": {"terseLabel": "Property and equipment, net", "totalLabel": "Total property and equipment, net", "label": "Property, Plant and Equipment, Net", "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures." }}, {"auth_ref": {"r6": "r418", "r472", "r483", "r655"}}, {"us-gaap_PropertyPlantAndEquipmentTextBlock": {"xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentTextBlock", "presentation": {"http://www.autolus.com/role/PropertyandEquipmentNetTables": {"lang": {"en-us": {"role": {"terseLabel": "Schedule of Depreciation", "label": "Property, Plant and Equipment [Table Text Block]", "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated depreciation." }}, {"auth_ref": {"r6": "r418"}}, {"us-gaap_PropertyPlantAndEquipmentTypeDomain": {"xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentTypeDomain", "presentation": {"http://www.autolus.com/role/PropertyandEquipmentNetScheduleofPPEDetails": {"lang": {"en-us": {"role": {"terseLabel": "Property, Plant and Equipment, Type {Domain}", "label": "Long-Lived Tangible Asset {Domain}", "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software." }}, {"auth_ref": {"r77", "r418"}}, {"autl_PublicStockOfferingMember": {"xbrltype": "domainItemType", "nsuri": "http://www.autolus.com/20240630", "localname": "PublicStockOfferingMember", "presentation": {"http://www.autolus.com/role/ShareholdersEquityNarrativeDetails": {"lang": {"en-us": {"role": {"terseLabel": "Underwriters public offering", "label": "Public Stock Offering [Member]", "documentation": "Public Stock Offering [Member]"}, {"auth_ref": {}}, {"ecd_PvpTable": {"xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PvpTable", "presentation": {"http://xbrl.sec.gov/ecd/role/PvpDisclosure": {"lang": {"en-us": {"role": {"terseLabel": "Pay vs Performance Disclosure", "label": "Pay vs Performance Disclosure [Table]"}, {"auth_ref": {"r721"}}, {"ecd_PvpTableTextBlock": {"xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PvpTableTextBlock", "presentation": {"http://xbrl.sec.gov/ecd/role/PvpDisclosure": {"lang": {"en-us": {"role": {"terseLabel": "Pay vs Performance Disclosure, Table", "label": "Pay vs Performance [Table Text Block]"}, {"auth_ref": {"r721"}}, {"ecd_RecoveryOfErrCompDisclosureLineItems": {"xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RecoveryOfErrCompDisclosureLineItems", "lang": {"en-us": {"role": {"label": "Recovery of Erroneously Awarded Compensation Disclosure [Line Items]"}, {"auth_ref": {"r689", "r699", "r709", "r741"}}, {"us-gaap_RelatedPartyDomain": {"xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyDomain", "presentation": {"http://www.autolus.com/role/NatureoftheBusinessUnitsofAccountingDetails": {"lang": {"en-us": {"role": {"terseLabel": "Related Party {Domain}", "label": "Related and Nonrelated Parties {Domain}", "documentation": "Related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest." }}, {"auth_ref": {"r218", "r297", "r427", "r428", "r475", "r481", "r532", "r533", "r534", "r535", "r536", "r556", "r558", "r591"}}, {"us-gaap_RelatedPartyTransactionAmountsOfTransaction": {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyTransactionAmountsOfTransaction", "crdr": "debit", "presentation": {"http://www.autolus.com/role/NatureoftheBusinessUnitsofAccountingDetails": {"lang": {"en-us": {"role": {"terseLabel": "Amounts of related party transaction", "label": "Related Party Transaction, Amounts of Transaction", "documentation": "Amount of transactions with related party during the financial reporting period." }}, {"auth_ref": {"r44", "r427"}}, {"autl_RelatedPartyTransactionAmountsOfTransactionAllocatedBasedOnRelativeFairValue": {"xbrltype": "monetaryItemType", "nsuri": "http://www.autolus.com/20240630", "localname": "RelatedPartyTransactionAmountsOfTransactionAllocatedBasedOnRelativeFairValue", "crdr": "debit", "presentation": {"http://www.autolus.com/role/NatureoftheBusinessUnitsofAccountingDetails": {"lang": {"en-us": {"role": {"terseLabel": "Allocated consideration based on relative fair value", "label": "Related Party Transaction, Amounts Of Transaction, Allocated Based On Relative Fair Value", "documentation": "Related Party Transaction, Amounts Of Transaction, Allocated Based On Relative Fair Value"}, {"auth_ref": {}}, {"autl_RelatedPartyTransactionAmountsOfTransactionNetOfIssuanceCost": {"xbrltype": "monetaryItemType", "nsuri": "http://www.autolus.com/20240630", "localname": "RelatedPartyTransactionAmountsOfTransactionNetOfIssuanceCost", "crdr": "debit", "presentation": {"http://www.autolus.com/role/NatureoftheBusinessUnitsofAccountingDetails": {"lang": {"en-us": {"role": {"terseLabel": "Net allocated consideration based on relative fair value after transaction costs", "label": "Related Party Transaction, Amounts Of Transaction, Net Of Issuance Cost", "documentation": "Related Party Transaction, Amounts Of Transaction, Net Of Issuance Cost"}, {"auth_ref": {}}, {"us-gaap_RelatedPartyTransactionAxis": {"xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyTransactionAxis", "presentation": {"http://www.autolus.com/role/LiabilitiesrelatedtofutureroyaltiesandmilestonesnetNarrativeDetails": {"http://www.autolus.com/role/NatureoftheBusinessNarrativeDetails": {"http://www.autolus.com/role/NatureoftheBusinessUnitsofAccountingDetails": {"lang": {"en-us": {"role": {"terseLabel": "Related Party Transaction [Axis]", "label": "Related Party Transaction [Axis]", "documentation": "Information by type of related party transaction." }}, {"auth_ref": {"r427", "r428", "r442"}}, {"us-gaap_RelatedPartyTransactionDomain": {"xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyTransactionDomain", "presentation": {"http://www.autolus.com/role/LiabilitiesrelatedtofutureroyaltiesandmilestonesnetNarrativeDetails": {"http://www.autolus.com/role/NatureoftheBusinessNarrativeDetails": {"http://www.autolus.com/role/NatureoftheBusinessUnitsofAccountingDetails": {"lang": {"en-us": {"role": {"terseLabel": "Related Party Transaction {Domain}", "label": "Related Party Transaction {Domain}", "documentation": "Transaction between related party." }}, {"auth_ref": {}}, {"us-gaap_RelatedPartyTransactionLineItems": {"xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyTransactionLineItems", "presentation": {"http://www.autolus.com/role/RelatedpartytransactionsNarrativeDetails": {"lang": {"en-us": {"role": {"terseLabel": "Related Party Transaction", "label": "Related Party Transaction [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." }}, {"auth_ref": {"r218", "r564", "r565", "r568"}}, {"us-gaap_RelatedPartyTransactionsAbstract": {"xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyTransactionsAbstract", "lang": {"en-us": {"role": {"terseLabel": "Related Party Transactions [Abstract]", "label": "Related Party Transactions [Abstract]"}, {"auth_ref": {}}, {"us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {"xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyTransactionsByRelatedPartyAxis", "presentation": {"http://www.autolus.com/role/NatureoftheBusinessUnitsofAccountingDetails": {"lang": {"en-us": {"role": {"terseLabel": "Related Party [Axis]", "label": "Related and Nonrelated Parties [Axis]", "documentation": "Information by related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest." }}, {"auth_ref": {"r218", "r297", "r427", "r428", "r475", "r481", "r532", "r533", "r534", "r535", "r536", "r556", "r558", "r591", "r442"}}, {"us-gaap_RelatedPartyTransactionsDisclosureTextBlock": {"xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyTransactionsDisclosureTextBlock", "presentation": {"http://www.autolus.com/role/Relatedpartytransactions": {"lang": {"en-us": {"role": {"terseLabel": "Related party transactions", "label": "Related Party Transactions Disclosure [Text Block]", "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates." }}, {"auth_ref": {"r424", "r425", "r426", "r428", "r430", "r513", "r514", "r515", "r566", "r567", "r568", "r588", "r590"}}, {"srt_RepurchaseAgreementCounterpartyNameDomain": {"xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "RepurchaseAgreementCounterpartyNameDomain", "presentation": {"http://www.autolus.com/role/CommitmentsandContingenciesNarrativeDetails": {"http://www.autolus.com/role/LiabilitiesrelatedtofutureroyaltiesandmilestonesnetNarrativeDetails": {"http://www.autolus.com/role/LicenserevenueNarrativeDetails": {"http://www.autolus.com/role/NatureoftheBusinessNarrativeDetails": {"http://www.autolus.com/role/NatureoftheBusinessUnitsofAccountingDetails": {"http://www.autolus.com/role/RelatedpartytransactionsNarrativeDetails": {"http://www.autolus.com/role/ShareholdersEquityNarrativeDetails": {"lang": {"en-us": {"role": {"terseLabel": "Counterparty Name {Domain}", "label": "Counterparty Name {Domain}"}, {"auth_ref": {"r154", "r155", "r246", "r263", "r429", "r436", "r473", "r621", "r622"}}, {"autl_ResearchAndDevelopmentClaimsReceivableCurrent": {"xbrltype": "monetaryItemType", "nsuri": "http://www.autolus.com/20240630", "localname": "ResearchAndDevelopmentClaimsReceivableCurrent", "crdr": "debit", "calculation": {"http://www.autolus.com/role/PrepaidExpensesandOtherCurrentAssetsDetails": {"parentTag": "us-gaap_PrepaidExpenseandOtherAssetsCurrent", "weight": 1.0, "order": 1.0}}, {"presentation": {"http://www.autolus.com/role/PrepaidExpensesandOtherCurrentAssetsDetails": {"lang": {"en-us": {"role": {"terseLabel": "Research and development claims receivable", "label": "Research And Development Claims Receivable, Current", "documentation": "Research and Development Claims Receivable, Current"}, {"auth_ref": {}}, {"us-gaap_ResearchAndDevelopmentExpense": {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ResearchAndDevelopmentExpense", "crdr": "debit", "calculation": {"http://www.autolus.com/role/UnauditedCondensedConsolidatedStatementsOfOperationsandComprehensiveLoss": {"parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0, "order": 1.0}}, {"presentation": {"http://www.autolus.com/role/UnauditedCondensedConsolidatedStatementsOfOperationsandComprehensiveLoss": {"lang": {"en-us": {"role": {"negatedTerseLabel": "Research and development", "label": "Research and Development Expense", "documentation": "Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity." }}, {"auth_ref": {"r336", "r615", "r628", "r845"}}, {"us-gaap_ResearchAndDevelopmentExpenseMember": {"xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ResearchAndDevelopmentExpenseMember", "presentation": {"http://www.autolus.com/role/SharebasedCompensationSharebasedCompensationAllocationDetails": {"lang": {"en-us": {"role": {"terseLabel": "Research and development", "label": "Research and Development Expense [Member]", "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included." }}, {"auth_ref": {}}, {"ecd_RestatementDateAxis": {"xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RestatementDateAxis", "presentation": {"http://xbrl.sec.gov/ecd/role/ErrCompDisclosure": {"lang": {"en-us": {"role": {"terseLabel": "Restatement Determination Date", "label": "Restatement Determination Date [Axis]"}, {"auth_ref": {"r690", "r700", "r710", "r742"}}, {"ecd_RestatementDeterminationDate": {"xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RestatementDeterminationDate", "presentation": {"http://xbrl.sec.gov/ecd/role/ErrCompDisclosure": {"lang": {"en-us": {"role": {"terseLabel": "Restatement Determination Date", "label": "Restatement Determination Date"}, {"auth_ref": {"r691", "r701", "r711", "r743"}}, {"ecd_RestatementDoesNotRequireRecoveryTextBlock": {"xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RestatementDoesNotRequireRecoveryTextBlock", "presentation": {"http://xbrl.sec.gov/ecd/role/ErrCompDisclosure": {"lang": {"en-us": {"role": {"terseLabel": "Restatement does not require Recovery", "label": "Restatement Does Not Require Recovery [Text Block]"}, {"auth_ref": {"r698", "r708", "r718", "r750"}}, {"us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember": {"xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-

gaap/2024", "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember", "presentation": {
"http://www.autolus.com/role/FairvaluemeasurementsDetails": {
"lang": { "en-us": { "role": { "terseLabel": "Cash and Cash Equivalents [Domain]", "label": "Cash and Cash
Equivalents [Domain]", "documentation": "Type of cash and cash equivalent. Cash is currency on hand as well as demand deposits with banks or financial institutions.
Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily
convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } },
"auth_ref": { "r129" } }, "us-gaap RestrictedCashCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"RestrictedCashCurrent", "crdr": "debit", "calculation": { "http://www.autolus.com/role/UnauditedCondensedConsolidatedBalanceSheets": { "parentTag": "us-
gaap_AssetsCurrent", "weight": 1.0, "order": 2.0 }, "http://www.autolus.com/role/UnauditedCondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-
gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "weight": 1.0, "order": 2.0 } }, "presentation": {
"http://www.autolus.com/role/UnauditedCondensedConsolidatedBalanceSheets": "http://www.autolus.com/role/UnauditedCondensedConsolidatedStatementsofCashFlows"
}, "lang": { "en-us": { "role": { "terseLabel": "Restricted cash", "verboseLabel": "Restricted cash", "label": "Restricted Cash, Current", "documentation": "Amount of cash
restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions,
and other accounts with general characteristics of demand deposits." } } }, "auth_ref": { "r776", "r790" } }, "us-gaap RestrictedStockUnitsRSUMember": { "xbrltype":
"domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestrictedStockUnitsRSUMember", "presentation": {
"http://www.autolus.com/role/NetlossperordinaryshareScheduleofAntidilutiveSecuritiesDetails":
"http://www.autolus.com/role/ShareBasedCompensationRestrictedStockUnitsDetails", "http://www.autolus.com/role/SharebasedCompensationNarrativeDetails",
"http://www.autolus.com/role/ShareholdersEquityNarrativeDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure": { "lang": { "en-us": { "role": { "terseLabel":
"Unvested restricted stock units", "label": "Restricted Stock Units (RSUs) [Member]", "documentation": "Share instrument which is convertible to stock or an equivalent
amount of cash, after a specified period of time or when specified performance conditions are met." } } }, "auth_ref": { } }, "us-
gaap_RetainedEarningsAccumulatedDeficit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"RetainedEarningsAccumulatedDeficit", "crdr": "credit", "calculation": { "http://www.autolus.com/role/UnauditedCondensedConsolidatedBalanceSheets": { "parentTag":
"us-gaap_StockholdersEquity", "weight": 1.0, "order": 4.0 } }, "presentation": { "http://www.autolus.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails",
"http://www.autolus.com/role/UnauditedCondensedConsolidatedBalanceSheets": { "lang": { "en-us": { "role": { "terseLabel": "Accumulated deficit", "label": "Retained
Earnings (Accumulated Deficit)", "documentation": "Amount of accumulated undistributed earnings (deficit)." } } }, "auth_ref": { "r57", "r83", "r479", "r503", "r505",
"r512", "r540", "r655" } }, "us-gaap_RetainedEarningsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"RetainedEarningsMember", "presentation": { "http://www.autolus.com/role/UnauditedCondensedConsolidatedStatementsofShareholdersEquity": { "lang": { "en-us": {
"role": { "terseLabel": "Accumulated deficit", "label": "Retained Earnings [Member]", "documentation": "Accumulated undistributed earnings (deficit)." } } }, "auth_ref": {
"r125", "r157", "r158", "r159", "r161", "r166", "r170", "r220", "r221", "r224", "r341", "r342", "r344", "r345", "r346", "r348", "r349", "r350", "r355", "r357", "r358",
"r360", "r362", "r402", "r404", "r506", "r562", "r516", "r779" } }, "us-gaap_RevenueFromContractWithCustomerAbstract": { "xbrltype": "stringItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "RevenueFromContractWithCustomerAbstract", "lang": { "en-us": { "role": { "label": "Revenue from Contract with Customer
[Abstract]" } } }, "auth_ref": { } }, "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-
gaap/2024", "localname": "RevenueFromContractWithCustomerExcludingAssessedTax", "crdr": "credit", "presentation": {
"http://www.autolus.com/role/LicenseRevenueDisaggregationofRevenueDetails": "http://www.autolus.com/role/LicenseRevenueNarrativeDetails": { "lang": { "en-us": {
"role": { "terseLabel": "Total license revenue", "verboseLabel": "Revenue from contract with customer", "label": "Revenue from Contract with Customer, Excluding
Assessed Tax", "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good
or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing
transaction, including, but not limited to, sales, use, value added and excise." } } }, "auth_ref": { "r108", "r109", "r190", "r196", "r197", "r210", "r212", "r214", "r215",
"r217", "r287", "r288", "r437" } }, "us-gaap_RevenueFromContractWithCustomerTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "RevenueFromContractWithCustomerTextBlock", "presentation": { "http://www.autolus.com/role/LicenseRevenue": { "lang": { "en-us": { "role": {
"terseLabel": "License Revenue", "label": "Revenue from Contract with Customer [Text Block]", "documentation": "The entire disclosure of revenue from contract with
customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract
with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer.
Excludes insurance and lease contracts." } } }, "auth_ref": { "r123", "r279", "r280", "r281", "r282", "r283", "r284", "r285", "r286", "r290" } }, "us-
gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"RevenueFromExternalCustomersByGeographicAreasTableTextBlock", "presentation": { "http://www.autolus.com/role/LicenseRevenueTables": { "lang": { "en-us": { "role":
"terseLabel": "Schedule of Revenue by Geographic Locations", "label": "Revenue from External Customers by Geographic Areas [Table Text Block]", "documentation":
"Tabular disclosure of revenue from external customers by geographic areas attributed to the entity's country of domicile and to foreign countries from which the entity
derives revenue." } } }, "auth_ref": { "r74" } }, "autl_RevenueRemainingPerformanceObligationMaximumConsiderationAmount": { "xbrltype": "monetaryItemType",
"nsuri": "http://www.autolus.com/20240630", "localname": "RevenueRemainingPerformanceObligationMaximumConsiderationAmount", "crdr": "credit", "presentation": {
"http://www.autolus.com/role/NatureoftheBusinessNarrativeDetails": { "lang": { "en-us": { "role": { "terseLabel": "Revenue, remaining performance obligation, maximum
consideration, amount", "label": "Revenue, Remaining Performance Obligation, Maximum Consideration, Amount", "documentation": "Revenue, Remaining Performance
Obligation, Maximum Consideration, Amount" } } }, "auth_ref": { } }, "autl_RevenueRemainingPerformanceObligationVariableConsiderationAmount": { "xbrltype":
"monetaryItemType", "nsuri": "http://www.autolus.com/20240630", "localname": "RevenueRemainingPerformanceObligationVariableConsiderationAmount", "crdr":
"credit", "presentation": { "http://www.autolus.com/role/LiabilitiesrelatedtofutuorvaliesandmilestonesnetNarrativeDetails",
"http://www.autolus.com/role/LicenseRevenueNarrativeDetails", "http://www.autolus.com/role/NatureoftheBusinessNarrativeDetails": { "lang": { "en-us": { "role": {
"terseLabel": "Remaining performance obligation, variable consideration amount", "label": "Revenue, Remaining Performance Obligation, Variable Consideration
Amount", "documentation": "Revenue, Remaining Performance Obligation, Variable Consideration Amount" } } }, "auth_ref": { } }, "us-gaap_Revenues": { "xbrltype":
"monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Revenues", "crdr": "credit", "calculation": {
"http://www.autolus.com/role/UnauditedCondensedConsolidatedStatementsofOperationsandComprehensiveLoss": { "parentTag": "us-gaap_OperatingIncomeLoss",
"weight": 1.0, "order": 5.0 } }, "presentation": { "http://www.autolus.com/role/UnauditedCondensedConsolidatedStatementsofOperationsandComprehensiveLoss": { "lang":
"en-us": { "role": { "terseLabel": "License revenue", "label": "Revenues", "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance
premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when
recognized as a component of revenue, and sales and trading gain (loss)." } } }, "auth_ref": { "r108", "r109", "r146", "r153", "r190", "r196", "r197", "r210", "r212", "r214",
"r215", "r217", "r219", "r234", "r235", "r236", "r237", "r238", "r239", "r240", "r241", "r242", "r386", "r471", "r628", "r616" } }, "us-
gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability", "crdr": "debit", "presentation": {
"http://www.autolus.com/role/UnauditedCondensedConsolidatedStatementsofCashFlows": { "lang": { "en-us": { "role": { "terseLabel": "Leased assets obtained in exchange
for operating lease liabilities", "label": "Right of Use Asset Obtained in Exchange for Operating Lease Liability", "documentation": "Amount of increase in right-of-use
asset obtained in exchange for operating lease liability." } } }, "auth_ref": { "r414", "r654" } }, "autl_RightOfUseAssetsTerminatedAndObtainedInExchangeForOperatingLeaseLiabilityNet": { "xbrltype": "monetaryItemType", "nsuri":
"http://www.autolus.com/20240630", "localname": "RightOfUseAssetsTerminatedAndObtainedInExchangeForOperatingLeaseLiabilityNet", "crdr": "debit", "presentation": {
"http://www.autolus.com/role/UnauditedCondensedConsolidatedStatementsofCashFlows": { "lang": { "en-us": { "role": { "terseLabel": "Leased assets terminated and
obtained in exchange for operating lease liabilities, net", "label": "Right of Use Assets Terminated and Obtained in Exchange for Operating Lease Liability, Net",
"documentation": "Right of Use Assets Terminated and Obtained in Exchange for Operating Lease Liability, Net" } } }, "auth_ref": { } }, "ecd_Rule10b51ArrAdoptedFlag": {
"xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "Rule10b51ArrAdoptedFlag", "presentation": {
"http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements": { "lang": { "en-us": { "role": { "terseLabel": "Rule 10b5-1 Arrangement Adopted", "label": "Rule 10b5-1
Arrangement Adopted [Flag]" } } }, "auth_ref": { "r759" } }, "ecd_Rule10b51ArrTrmtdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024",
"localname": "Rule10b51ArrTrmtdFlag", "presentation": { "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements": { "lang": { "en-us": { "role": { "terseLabel": "Rule
10b5-1 Arrangement Terminated", "label": "Rule 10b5-1 Arrangement Terminated [Flag]" } } }, "auth_ref": { "r759" } }, "us-
gaap_SaleOfStockConsiderationReceivedOnTransaction": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"SaleOfStockConsiderationReceivedOnTransaction", "crdr": "debit", "presentation": { "http://www.autolus.com/role/NatureoftheBusinessNarrativeDetails",
"http://www.autolus.com/role/ShareholdersEquityNarrativeDetails": { "lang": { "en-us": { "role": { "terseLabel": "Proceeds of issuance of ordinary shares, net of issuance
costs", "label": "Sale of Stock, Consideration Received on Transaction", "documentation": "Cash received on stock transaction after deduction of issuance costs." } } },
"auth_ref": { } }, "us-gaap_SaleOfStockNameOfTransactionDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"SaleOfStockNameOfTransactionDomain", "presentation": { "http://www.autolus.com/role/ShareholdersEquityNarrativeDetails": { "lang": { "en-us": { "role": {
"terseLabel": "Sale of Stock [Domain]", "label": "Sale of Stock [Domain]", "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering
(IPO) and private placement." } } }, "auth_ref": { } }, "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": { "xbrltype": "sharesItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "SaleOfStockNumberOfSharesIssuedInTransaction", "presentation": {
"http://www.autolus.com/role/NatureoftheBusinessNarrativeDetails": "http://www.autolus.com/role/ShareholdersEquityNarrativeDetails": { "lang": { "en-us": { "role": {
"terseLabel": "Number of shares issued in transaction (in shares)", "label": "Sale of Stock, Number of Shares Issued in Transaction", "documentation": "The number of
shares issued or sold by the subsidiary or equity method investee per stock transaction." } } }, "auth_ref": { } }, "us-gaap_SaleOfStockPricePerShare": { "xbrltype":
"perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SaleOfStockPricePerShare", "presentation": {
"http://www.autolus.com/role/NatureoftheBusinessNarrativeDetails", "http://www.autolus.com/role/ShareholdersEquityNarrativeDetails": { "lang": { "en-us": { "role": {
"terseLabel": "Per share price of issuance (usd per share)", "label": "Sale of Stock, Price Per Share", "documentation": "Per share amount received by subsidiary or equity
investee for each share of common stock issued or sold in the stock transaction." } } }, "auth_ref": { } }, "us-gaap_SalesRevenueNetMember": { "xbrltype":
"domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SalesRevenueNetMember", "presentation": {
"http://www.autolus.com/role/LicenseRevenueNarrativeDetails": { "lang": { "en-us": { "role": { "terseLabel": "Revenue Benchmark", "label": "Revenue Benchmark
[Member]", "documentation": "Revenue from sale of product and rendering of service and other sources of income, when it serves as benchmark in concentration of risk
calculation." } } }, "auth_ref": { "r217", "r772" } }, "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-
gaap/2024", "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock", "presentation": { "http://www.autolus.com/role/AccruedExpensesandOtherLiabilitiesTables": {
"lang": { "en-us": { "role": { "terseLabel": "Schedule of Accrued Expenses and Other Liabilities", "label": "Schedule of Accrued Liabilities [Table Text Block]",
"documentation": "Tabular disclosure of the components of accrued liabilities." } } }, "auth_ref": { } }, "us-
gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable", "presentation": {
"http://www.autolus.com/role/NetlossperordinaryshareScheduleofAntidilutiveSecuritiesDetails": { "lang": { "en-us": { "role": { "terseLabel": "Schedule of Antidilutive
Securities Excluded from Computation of Earnings Per Share [Table]", "label": "Antidilutive Security, Excluded EPS Calculation [Table]", "documentation": "Disclosure of
information about security that could potentially dilute basic earnings per share (EPS) in future that was not included in calculation of diluted EPS." } } }, "auth_ref": {
"r22" } }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": { "xbrltype": "textBlockItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "presentation": {
"http://www.autolus.com/role/NetlossperordinaryshareTables": { "lang": { "en-us": { "role": { "terseLabel": "Schedule of Anti-dilutive Securities", "label": "Schedule of
Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]", "documentation": "Tabular disclosure of securities (including those
issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of
diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities." } } }, "auth_ref": {
"r22" } }, "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "presentation": {

```


"ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "presentation": [{"http://www.autolus.com/role/NetLossPerOrdinaryShareTables"}], "lang": {"en-us": {"role": {"terseLabel": "Schedule of Loss Per Share, Basic and Diluted", "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]", "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per share computations for income from continuing operations."}}}, "auth_ref": {"r799"}}, {"us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {"xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "presentation": [{"http://www.autolus.com/role/SharebasedCompensationTables"}], "lang": {"en-us": {"role": {"terseLabel": "Schedule of Share-Based Compensation Expense", "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]", "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement."}}}, "auth_ref": {"r38"}}, {"us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock": {"xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfNonvestedShareActivityTableTextBlock", "presentation": [{"http://www.autolus.com/role/SharebasedCompensationTables"}], "lang": {"en-us": {"role": {"terseLabel": "Schedule of Nonvested Share Activity", "label": "Schedule of Nonvested Share Activity [Table Text Block]", "documentation": "Tabular disclosure of the changes in outstanding nonvested shares."}}}, "auth_ref": {"r85"}}, {"us-gaap_ScheduleOfProductInformationTable": {"xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfProductInformationTable", "presentation": [{"http://www.autolus.com/role/NatureoftheBusinessNarrativeDetails"}], "lang": {"en-us": {"role": {"terseLabel": "Schedule of Product Information [Table]", "label": "Nature of Operation, Product Information, Concentration of Risk [Table]", "documentation": "Disclosure of information about concentration risk of product within nature of operation."}}}, "auth_ref": {"r1}}, {"us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {"xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfPropertyPlantAndEquipmentTable", "presentation": [{"http://www.autolus.com/role/PropertyandEquipmentNetScheduleofPPEDetails"}], "lang": {"en-us": {"role": {"terseLabel": "Property, Plant and Equipment [Table]", "label": "Property, Plant and Equipment [Table]", "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated depreciation."}}}, "auth_ref": {"r6"}, {"r418"}}, {"us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": {"xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable", "presentation": [{"http://www.autolus.com/role/RelatedPartyTransactionsNarrativeDetails"}], "lang": {"en-us": {"role": {"terseLabel": "Schedule of Related Party Transactions, by Related Party [Table]", "label": "Related Party Transaction [Table]", "documentation": "Disclosure of information about related party transaction."}}}, "auth_ref": {"r43"}, {"r44"}, {"r564"}, {"r565"}, {"r568"}}, {"us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {"xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "presentation": [{"http://www.autolus.com/role/ShareBasedCompensationRestrictedStockUnitsDetails"}], "lang": {"en-us": {"role": {"terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]", "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]", "documentation": "Disclosure of information about share-based payment arrangement."}}}, "auth_ref": {"r299"}, {"r301"}, {"r303"}, {"r304"}, {"r305"}, {"r306"}, {"r307"}, {"r308"}, {"r309"}, {"r310"}, {"r311"}, {"r312"}, {"r313"}, {"r314"}, {"r315"}, {"r316"}, {"r317"}, {"r318"}, {"r319"}, {"r320"}, {"r321"}, {"r322"}, {"r323"}, {"r324"}, {"r325"}, {"r326"}, {"r327"}, {"r328"}}, {"us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {"xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "presentation": [{"http://www.autolus.com/role/SharebasedCompensationTables"}], "lang": {"en-us": {"role": {"terseLabel": "Stock Option Rollforward", "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]", "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value."}}}, "auth_ref": {"r9"}, {"r10"}, {"r84"}}, {"us-gaap_ScheduleOfStockByClassTable": {"xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfStockByClassTable", "presentation": [{"http://www.autolus.com/role/NatureoftheBusinessUnitsofAccountingDetails"}], "lang": {"en-us": {"role": {"terseLabel": "Schedule of Stock by Class [Table]", "label": "Stock, Class of Stock [Table]", "documentation": "Disclosure of information about stock by class. Includes, but is not limited to, common, convertible, and preferred stocks."}}}, "auth_ref": {"r30"}, {"r31"}, {"r32"}, {"r33"}, {"r34"}, {"r35"}, {"r79"}, {"r81"}, {"r82"}, {"r83"}, {"r133"}, {"r134"}, {"r135"}, {"r193"}, {"r261"}, {"r262"}, {"r263"}, {"r265"}, {"r268"}, {"r273"}, {"r275"}, {"r508"}, {"r509"}, {"r510"}, {"r511"}, {"r636"}, {"r770"}, {"r794"}}, {"dei_Security12bTitle": {"xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "Security12bTitle", "presentation": [{"http://www.autolus.com/role/Cover"}], "lang": {"en-us": {"role": {"terseLabel": "Title of 12(b) Security", "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security."}}}, "auth_ref": {"r683"}}, {"dei_SecurityExchangeName": {"xbrltype": "securityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "SecurityExchangeName", "presentation": [{"http://www.autolus.com/role/Cover"}], "lang": {"en-us": {"role": {"terseLabel": "Security Exchange Name", "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered."}}}, "auth_ref": {"r685"}}, {"srt_SegmentGeographicalDomain": {"xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "SegmentGeographicalDomain", "presentation": [{"http://www.autolus.com/role/LicenseRevenueDisaggregationofRevenueDetails"}], "lang": {"en-us": {"role": {"terseLabel": "Geographical [Domain]", "label": "Geographical [Domain]", "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were exercised or put into effect as a result of the occurrence of a terminating event."}}}, "auth_ref": {"r215"}, {"r216"}, {"r438"}, {"r439"}, {"r440"}, {"r441"}, {"r442"}, {"r443"}, {"r444"}, {"r445"}, {"r446"}, {"r447"}, {"r448"}, {"r449"}, {"r450"}, {"r451"}, {"r452"}, {"r453"}, {"r454"}, {"r455"}, {"r456"}, {"r457"}, {"r458"}, {"r459"}, {"r460"}, {"r461"}, {"r462"}, {"r463"}, {"r464"}, {"r465"}, {"r466"}, {"r467"}, {"r528"}, {"r529"}, {"r530"}, {"r592"}, {"r593"}, {"r594"}, {"r595"}, {"r602"}, {"r605"}, {"r606"}, {"r607"}, {"r608"}, {"r610"}, {"r611"}, {"r612"}, {"r613"}, {"r614"}, {"r617"}, {"r638"}, {"r656"}, {"r657"}, {"r658"}, {"r659"}, {"r660"}, {"r661"}, {"r662"}, {"r663"}, {"r668"}, {"r674"}, {"r818"}, {"r846"}, {"r848"}, {"r849"}, {"r851"}, {"r852"}, {"r853"}, {"r854"}, {"r855"}, {"r856"}, {"r857"}, {"r858"}, {"r859"}, {"r860"}, {"r861"}, {"r862"}, {"r863"}, {"r864"}, {"r865"}, {"r866"}, {"r867"}, {"r868"}, {"r869"}, {"r870"}, {"r871"}, {"r872"}, {"r873"}, {"r874"}, {"r875"}}, {"us-gaap_SegmentReportingPolicyTextBlock": {"xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SegmentReportingPolicyTextBlock", "presentation": [{"http://www.autolus.com/role/SummaryofSignificantAccountingPoliciesPolicies"}], "lang": {"en-us": {"role": {"terseLabel": "Segment Information", "label": "Segment Reporting, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for segment reporting."}}}, "auth_ref": {"r203"}, {"r204"}, {"r205"}, {"r206"}, {"r207"}, {"r208"}, {"r209"}, {"r213"}, {"r215"}, {"r627"}, {"r630"}}, {"us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {"xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod", "presentation": [{"http://www.autolus.com/role/ShareBasedCompensationRestrictedStockUnitsDetails"}], "lang": {"en-us": {"role": {"negatedTerseLabel": "Forfeited (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period", "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were exercised or put into effect as a result of the occurrence of a terminating event."}}}, "auth_ref": {"r319"}}, {"us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": {"xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue", "presentation": [{"http://www.autolus.com/role/ShareBasedCompensationRestrictedStockUnitsDetails"}], "lang": {"en-us": {"role": {"terseLabel": "Forfeited (in usd per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value", "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event."}}}, "auth_ref": {"r319"}}, {"us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {"xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "presentation": [{"http://www.autolus.com/role/ShareBasedCompensationRestrictedStockUnitsDetails"}], "lang": {"en-us": {"role": {"periodStartLabel": "Unvested and outstanding beginning balance (in shares)", "periodEndLabel": "Unvested and outstanding ending balance (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number", "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date."}}}, "auth_ref": {"r314"}, {"r315"}}, {"us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": {"xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward", "presentation": [{"http://www.autolus.com/role/ShareBasedCompensationRestrictedStockUnitsDetails"}], "lang": {"en-us": {"role": {"verboseLabel": "Number-u00a0of restricted units", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."}}}, "auth_ref": {"r1}}, {"us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {"xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue", "presentation": [{"http://www.autolus.com/role/ShareBasedCompensationRestrictedStockUnitsDetails"}], "lang": {"en-us": {"role": {"periodStartLabel": "Unvested and outstanding beginning balance (in usd per share)", "periodEndLabel": "Unvested and outstanding ending balance (in usd per share)", "label": "Share-Based Compensation Arrangement by


```

Compensation Arrangement by Share-based Payment Award, "label": "Share-Based Compensation Arrangement by Share-based Payment Award [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": { "r299", "r301", "r303", "r304", "r305", "r306", "r307", "r308", "r309", "r310", "r311", "r312", "r313", "r314", "r315", "r316", "r317", "r318", "r319", "r320", "r321", "r322", "r323", "r324", "r325", "r326", "r327", "r328" } }, "autl_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsNotIssuedVestedNumber": { "xbrltype": "sharesItemType", "nsuri": "http://www.autolus.com/20240630", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsNotIssuedVestedNumber", "presentation": { "http://www.autolus.com/role/ShareholdersEquityNarrativeDetails": { "lang": { "en-us": { "role": { "terseLabel": "Vested not issued (in shares)", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Not Issued, Vested, Number", "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Not Issued, Vested, Number" } } }, "auth_ref": { "r329", "r330", "r331", "r332", "r333", "r334", "r335", "r336", "r337", "r338" } }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract", "presentation": { "http://www.autolus.com/role/ShareBasedCompensationShareOptionsRollforwardDetails": { "lang": { "en-us": { "role": { "verboseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract]", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract]" } } }, "auth_ref": { "r339", "r340", "r341", "r342", "r343", "r344", "r345", "r346", "r347", "r348", "r349", "r350", "r351", "r352", "r353", "r354", "r355", "r356", "r357", "r358", "r359", "r360", "r361", "r362", "r363", "r364", "r365", "r366", "r367", "r368", "r369", "r370", "r371", "r372", "r373", "r374", "r375", "r376", "r377", "r378", "r379", "r380", "r381", "r382", "r383", "r384", "r385", "r386", "r387", "r388", "r389", "r390", "r391", "r392", "r393", "r394", "r395", "r396", "r397", "r398", "r399", "r400", "r401", "r402", "r403", "r404", "r405", "r406", "r407", "r408", "r409", "r410", "r411", "r412", "r413", "r414", "r415", "r416", "r417", "r418", "r419", "r420", "r421", "r422", "r423", "r424", "r425", "r426", "r427", "r428", "r429", "r430", "r431", "r432", "r433", "r434", "r435", "r436", "r437", "r438", "r439", "r440", "r441", "r442", "r443", "r444", "r445", "r446", "r447", "r448", "r449", "r450", "r451", "r452", "r453", "r454", "r455", "r456", "r457", "r458", "r459", "r460", "r461", "r462", "r463", "r464", "r465", "r466", "r467", "r468", "r469", "r470", "r471", "r472", "r473", "r474", "r475", "r476", "r477", "r478", "r479", "r480", "r481", "r482", "r483", "r484", "r485", "r486", "r487", "r488", "r489", "r490", "r491", "r492", "r493", "r494", "r495", "r496", "r497", "r498", "r499", "r500", "r501", "r502", "r503", "r504", "r505", "r506", "r507", "r508", "r509", "r510", "r511", "r512", "r513", "r514", "r515", "r516", "r517", "r518", "r519", "r520", "r521", "r522", "r523", "r524", "r525", "r526", "r527", "r528", "r529", "r530", "r531", "r532", "r533", "r534", "r535", "r536", "r537", "r538", "r539", "r540", "r541", "r542", "r543", "r544", "r545", "r546", "r547", "r548", "r549", "r550", "r551", "r552", "r553", "r554", "r555", "r556", "r557", "r558", "r559", "r560", "r561", "r562", "r563", "r564", "r565", "r566", "r567", "r568", "r569", "r570", "r571", "r572", "r573", "r574", "r575", "r576", "r577", "r578", "r579", "r580", "r581", "r582", "r583", "r584", "r585", "r586", "r587", "r588", "r589", "r590", "r591", "r592", "r593", "r594", "r595", "r596", "r597", "r598", "r599", "r600", "r601", "r602", "r603", "r604", "r605", "r606", "r607", "r608", "r609", "r610", "r611", "r612", "r613", "r614", "r615", "r616", "r617", "r618", "r619", "r620", "r621", "r622", "r623", "r624", "r625", "r626", "r627", "r628", "r629", "r630", "r631", "r632", "r633", "r634", "r635", "r636", "r637", "r638", "r639", "r640", "r641", "r642", "r643", "r644", "r645", "r646", "r647", "r648", "r649", "r650", "r651", "r652", "r653", "r654", "r655", "r656", "r657", "r658", "r659", "r660", "r661", "r662", "r663", "r664", "r665", "r666", "r667", "r668", "r669", "r670", "r671", "r672", "r673", "r674", "r675", "r676", "r677", "r678", "r679", "r680", "r681", "r682", "r683", "r684", "r685", "r686", "r687", "r688", "r689", "r690", "r691", "r692", "r693", "r694", "r695", "r696", "r697", "r698", "r699", "r700", "r701", "r702", "r703", "r704", "r705", "r706", "r707", "r708", "r709", "r710", "r711", "r712", "r713", "r714", "r715", "r716", "r717", "r718", "r719", "r720", "r721", "r722", "r723", "r724", "r725", "r726", "r727", "r728", "r729", "r730", "r731", "r732", "r733", "r734", "r735", "r736", "r737", "r738", "r739", "r740", "r741", "r742", "r743", "r744", "r745", "r746", "r747", "r748", "r749", "r750", "r751", "r752", "r753", "r754", "r755", "r756", "r757", "r758", "r759", "r760", "r761", "r762", "r763", "r764", "r765", "r766", "r767", "r768", "r769", "r770", "r771", "r772", "r773", "r774", "r775", "r776", "r777", "r778", "r779", "r780", "r781", "r782", "r783", "r784", "r785", "r786", "r787", "r788", "r789", "r790", "r791", "r792", "r793", "r794", "r795", "r796", "r797", "r798", "r799", "r800", "r801", "r802", "r803", "r804", "r805", "r806", "r807", "r808", "r809", "r810", "r811", "r812", "r813", "r814", "r815", "r816", "r817", "r818", "r819", "r820", "r821", "r822", "r823", "r824", "r825", "r826", "r827", "r828", "r829", "r830", "r831", "r832", "r833", "r834", "r835", "r836", "r837", "r838", "r839", "r840", "r841", "r842", "r843", "r844", "r845", "r846", "r847", "r848", "r849", "r850", "r851", "r852", "r853", "r854", "r855", "r856", "r857", "r858", "r859", "r860", "r861", "r862", "r863", "r864", "r865", "r866", "r867", "r868", "r869", "r870", "r871", "r872", "r873", "r874", "r875", "r876", "r877", "r878", "r879", "r880", "r881", "r882", "r883", "r884", "r885", "r886", "r887", "r888", "r889", "r890", "r891", "r892", "r893", "r894", "r895", "r896", "r897", "r898", "r899", "r900", "r901", "r902",

Number", "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur." } } }, "auth_ref": { "r322" } }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice", "presentation": { "http://www.autolus.com/role/ShareBasedCompensationShareOptionsRollforwardDetails": { "lang": { "en-us": { "role": { "terseLabel": "Vested and expected to vest (in usd per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price", "documentation": "Weighted average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur." } } }, "auth_ref": { "r322" } }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost", "crdr": "debit", "presentation": { "http://www.autolus.com/role/SharebasedCompensationNarrativeDetails": { "lang": { "en-us": { "role": { "terseLabel": "Incremental share-based compensation expense", "label": "Share-Based Payment Arrangement, Plan Modification, Incremental Cost", "documentation": "An excess of the fair value of the modified award over the fair value of the award immediately before the modification." } } }, "auth_ref": { "r332" } }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "presentation": { "http://www.autolus.com/role/ShareBasedCompensationRestrictedStockUnitsDetails": "http://www.autolus.com/role/SharebasedCompensationNarrativeDetails", "http://www.autolus.com/role/ShareholdersEquityNarrativeDetails": "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure": { "lang": { "en-us": { "role": { "terseLabel": "Award Type {Domain}", "label": "Award Type {Domain}", "documentation": "Award under share-based payment arrangement." } } }, "auth_ref": { "r303", "r304", "r305", "r306", "r307", "r308", "r309", "r310", "r311", "r312", "r313", "r314", "r315", "r316", "r317", "r318", "r319", "r320", "r321", "r322", "r323", "r324", "r325", "r326", "r327", "r328" } } }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice", "presentation": { "http://www.autolus.com/role/ShareBasedCompensationShareOptionsRollforwardDetails": { "lang": { "en-us": { "role": { "terseLabel": "Exercised (in usd per share)", "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price", "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares." } } }, "auth_ref": { "r311" } }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice", "presentation": { "http://www.autolus.com/role/ShareBasedCompensationShareOptionsRollforwardDetails": { "lang": { "en-us": { "role": { "terseLabel": "Expired (in usd per share)", "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price", "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired." } } }, "auth_ref": { "r313" } }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice", "presentation": { "http://www.autolus.com/role/ShareBasedCompensationShareOptionsRollforwardDetails": { "lang": { "en-us": { "role": { "terseLabel": "Forfeited (in usd per share)", "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price", "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated." } } }, "auth_ref": { "r312" } }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "presentation": { "http://www.autolus.com/role/ShareBasedCompensationShareOptionsRollforwardDetails": { "lang": { "en-us": { "role": { "terseLabel": "Granted (in usd per share)", "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price", "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options." } } }, "auth_ref": { "r310" } }, "autl_ShareBasedPaymentArrangementPlanModificationSharesModified": { "xbrltype": "sharesItemType", "nsuri": "http://www.autolus.com/20240630", "localname": "ShareBasedPaymentArrangementPlanModificationSharesModified", "presentation": { "http://www.autolus.com/role/SharebasedCompensationNarrativeDetails": { "lang": { "en-us": { "role": { "terseLabel": "Number of shares modified (in shares)", "label": "Share-Based Payment Arrangement, Plan Modification, Shares Modified", "documentation": "Share-Based Payment Arrangement, Plan Modification, Shares Modified" } } }, "auth_ref": { "r312" } }, "us-gaap_ShareBasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue", "crdr": "debit", "presentation": { "http://www.autolus.com/role/ShareBasedCompensationShareOptionsRollforwardDetails": { "lang": { "en-us": { "role": { "terseLabel": "Options exercisable", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value", "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable." } } }, "auth_ref": { "r37" } }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm", "presentation": { "http://www.autolus.com/role/ShareBasedCompensationShareOptionsRollforwardDetails": { "lang": { "en-us": { "role": { "terseLabel": "Weighted average contractual term exercisable", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term", "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": { "r37" } }, "us-gaap_ShareBasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm", "presentation": { "http://www.autolus.com/role/ShareBasedCompensationShareOptionsRollforwardDetails": { "lang": { "en-us": { "role": { "terseLabel": "Weighted average contractual term outstanding", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term", "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": { "r86" } }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm", "presentation": { "http://www.autolus.com/role/ShareBasedCompensationShareOptionsRollforwardDetails": { "lang": { "en-us": { "role": { "terseLabel": "Weighted average contractual term vested and expected to vest", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term", "documentation": "Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur." } } }, "auth_ref": { "r322" } }, "us-gaap_ShortTermLeaseCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShortTermLeaseCost", "crdr": "debit", "calculation": { "http://www.autolus.com/role/LeasesLeaseCostDetails": { "parentTag": "us-gaap_LeaseCost", "weight": 1.0, "order": 2.0 } }, "presentation": { "http://www.autolus.com/role/LeasesLeaseCostDetails": { "lang": { "en-us": { "role": { "terseLabel": "Short term lease costs", "label": "Short-Term Lease, Cost", "documentation": "Amount of short-term lease cost, excluding expense for lease with term of one month or less." } } }, "auth_ref": { "r411", "r654" } }, "us-gaap_StatementClassOfStockAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementClassOfStockAxis", "presentation": { "http://www.autolus.com/role/Cover": "http://www.autolus.com/role/NatureoftheBusinessNarrativeDetails", "http://www.autolus.com/role/ShareholdersEquityNarrativeDetails": "http://www.autolus.com/role/UnauditedCondensedConsolidatedBalanceSheets": "http://www.autolus.com/role/UnauditedCondensedConsolidatedBalanceSheetsParenteticals": "http://www.autolus.com/role/UnauditedCondensedConsolidatedStatementsofShareholdersEquity": { "lang": { "en-us": { "role": { "terseLabel": "Class of Stock {Axis}", "label": "Class of Stock {Axis}", "documentation": "Information by the different classes of stock of the entity." } } }, "auth_ref": { "r124", "r133", "r134", "r135", "r153", "r175", "r176", "r183", "r185", "r193", "r194", "r219", "r234", "r236", "r237", "r238", "r241", "r242", "r261", "r262", "r265", "r268", "r275", "r386", "r508", "r509", "r510", "r511", "r516", "r517", "r518", "r519", "r520", "r521", "r522", "r523", "r524", "r525", "r526", "r527", "r539", "r561", "r584", "r596", "r597", "r598", "r599", "r600", "r770", "r791", "r798" } } }, "us-gaap_StatementEquityComponentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementEquityComponentsAxis", "presentation": { "http://www.autolus.com/role/UnauditedCondensedConsolidatedStatementsofShareholdersEquity": { "lang": { "en-us": { "role": { "terseLabel": "Equity Components {Axis}", "label": "Equity Components {Axis}", "documentation": "Information by component of equity." } } }, "auth_ref": { "r8", "r55", "r58", "r59", "r125", "r143", "r144", "r145", "r157", "r158", "r159", "r161", "r166", "r168", "r170", "r192", "r220", "r221", "r224", "r276", "r341", "r342", "r344", "r345", "r346", "r348", "r349", "r350", "r355", "r356", "r357", "r358", "r359", "r360", "r362", "r393", "r394", "r395", "r396", "r397", "r398", "r402", "r404", "r423", "r486", "r580", "r581", "r582", "r516", "r584" } } }, "srt_StatementGeographicalAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "StatementGeographicalAxis", "presentation": { "http://www.autolus.com/role/LicenseRevenueDisaggregationofRevenueDetails": { "lang": { "en-us": { "role": { "terseLabel": "Geographical {Axis}", "label": "Geographical {Axis}" } } }, "auth_ref": { "r215", "r216", "r438", "r439", "r440", "r441", "r442", "r443", "r444", "r445", "r446", "r447", "r448", "r449", "r450", "r451", "r452", "r453", "r454", "r455", "r456", "r457", "r458", "r459", "r460", "r461", "r462", "r463", "r464", "r465", "r466", "r467", "r528", "r529", "r530", "r532", "r533", "r534", "r535", "r536", "r539", "r542", "r543", "r544", "r545", "r546", "r547", "r548", "r549", "r550", "r552", "r553", "r554", "r555", "r556", "r557", "r558", "r559", "r560", "r561", "r562", "r563", "r569", "r570", "r571", "r572", "r573", "r574", "r575", "r576", "r577", "r578", "r579", "r580", "r584", "r675" } } }, "us-gaap_StatementOfCashFlowsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfCashFlowsAbstract", "lang": { "en-us": { "role": { "terseLabel": "Statement of Cash Flows {Abstract}", "label": "Statement of Cash Flows {Abstract}" } } }, "auth_ref": { "r1" } }, "us-gaap_StatementOffinancialPositionAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOffinancialPositionAbstract", "lang": { "en-us": { "role": { "terseLabel": "Statement of Financial Position {Abstract}", "label": "Statement of Financial Position {Abstract}" } } }, "auth_ref": { "r1" } }, "us-gaap_StatementOfStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfStockholdersEquityAbstract", "lang": { "en-us": { "role": { "terseLabel": "Statement of Stockholders Equity {Abstract}", "label": "Statement of Stockholders Equity {Abstract}" } } }, "auth_ref": { "r1" } }

"stringItemType": "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfStockholdersEquityAbstract", "lang": { "en-us": { "role": { "terseLabel": "Statement of Stockholders' Equity [Abstract]", "label": "Statement of Stockholders' Equity [Abstract]" } } }, "auth_ref": { "us-gaap-StatementTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementTable", "presentation": { "http://www.autolus.com/role/UnauditedCondensedConsolidatedBalanceSheets", "http://www.autolus.com/role/UnauditedCondensedConsolidatedBalanceSheetsParenteticals", "http://www.autolus.com/role/UnauditedCondensedConsolidatedStatementsofOperationsandComprehensiveLoss", "http://www.autolus.com/role/UnauditedCondensedConsolidatedStatementsofShareholdersEquity" } }, "lang": { "en-us": { "role": { "terseLabel": "Statement [Table]", "label": "Statement [Table]", "documentation": "Disclosure of information about statement of comprehensive income, income, other comprehensive income, financial position, cash flows, and shareholders' equity" } } }, "auth_ref": { "r157", "r158", "r159", "r192", "r218", "r404", "r437", "r507", "r527", "r531", "r532", "r533", "r534", "r535", "r536", "r539", "r542", "r543", "r544", "r545", "r546", "r547", "r548", "r549", "r550", "r552", "r553", "r554", "r555", "r556", "r558", "r562", "r563", "r569", "r570", "r571", "r572", "r573", "r574", "r575", "r576", "r577", "r578", "r579", "r580", "r584", "r675" } }, "ecd_StkPrCrrOrTsrEstimationMethodTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "StkPrCrrOrTsrEstimationMethodTextBlock", "presentation": { "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" } }, "lang": { "en-us": { "role": { "terseLabel": "Stock Price or TSR Estimation Method", "label": "Stock Price or TSR Estimation Method [Text Block]" } } }, "auth_ref": { "r693", "r703", "r713", "r745" } }, "us-gaap-StockAppreciationRightsSARSMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockAppreciationRightsSARSMember", "presentation": { "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" } }, "lang": { "en-us": { "role": { "terseLabel": "Stock Appreciation Rights (SARs)", "label": "Stock Appreciation Rights (SARs) [Member]", "documentation": "Right to receive cash or shares equal to appreciation of predetermined number of grantor's shares during predetermined time period" } } }, "auth_ref": { "us-gaap-StockIssuedDuringPeriodSharesNewIssues": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesNewIssues", "presentation": { "http://www.autolus.com/role/UnauditedCondensedConsolidatedStatementsofShareholdersEquity" } }, "lang": { "en-us": { "role": { "verboselabel": "Issuance of ordinary shares, net of issuance costs (in shares)", "label": "Stock Issued During Period, Shares, New Issues", "documentation": "Number of new stock issued during the period" } } }, "auth_ref": { "r8", "r54", "r55", "r83", "r508", "r584", "r597" } }, "us-gaap-StockIssuedDuringPeriodSharesStockOptionsExercised": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "presentation": { "http://www.autolus.com/role/ShareBasedCompensationShareOptionsRollforwardDetails", "http://www.autolus.com/role/UnauditedCondensedConsolidatedStatementsofShareholdersEquity" } }, "lang": { "en-us": { "role": { "terseLabel": "Exercise of share options (in shares)", "negatedTerseLabel": "Exercised (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period", "documentation": "Number of share options (or share units) exercised during the current period" } } }, "auth_ref": { "r8", "r54", "r55", "r83", "r311" } }, "us-gaap-StockIssuedDuringPeriodValueNewIssues": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodValueNewIssues", "crdr": "credit", "presentation": { "http://www.autolus.com/role/UnauditedCondensedConsolidatedStatementsofShareholdersEquity" } }, "lang": { "en-us": { "role": { "terseLabel": "Issuance of ordinary shares, net of issuance costs", "label": "Stock Issued During Period, Value, New Issues", "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering" } } }, "auth_ref": { "r8", "r54", "r55", "r83", "r516", "r584", "r597", "r681" } }, "us-gaap-StockIssuedDuringPeriodValueStockOptionsExercised": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodValueStockOptionsExercised", "crdr": "credit", "presentation": { "http://www.autolus.com/role/UnauditedCondensedConsolidatedStatementsofShareholdersEquity" } }, "lang": { "en-us": { "role": { "terseLabel": "Exercise of share options", "label": "Stock Issued During Period, Value, Stock Options Exercised", "documentation": "Value of stock issued as a result of the exercise of stock options" } } }, "auth_ref": { "r8", "r55", "r58", "r59", "r83" } }, "autl-StockVestedDuringPeriodSharesRestrictedStock": { "xbrltype": "sharesItemType", "nsuri": "http://www.autolus.com/20240630", "localname": "StockVestedDuringPeriodSharesRestrictedStock", "presentation": { "http://www.autolus.com/role/UnauditedCondensedConsolidatedStatementsofShareholdersEquity" } }, "lang": { "en-us": { "role": { "terseLabel": "Vesting of restricted stock unit awards net of shares withheld to cover tax withholding (in shares)", "label": "Stock Vested During Period, Shares, Restricted Stock", "documentation": "Stock Vested During Period, Value, Restricted Stock" } } }, "auth_ref": { "us-gaap-StockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquity", "crdr": "credit", "calculation": { "http://www.autolus.com/role/UnauditedCondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap-LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 2.0 } }, "presentation": { "http://www.autolus.com/role/UnauditedCondensedConsolidatedBalanceSheets", "http://www.autolus.com/role/UnauditedCondensedConsolidatedStatementsofShareholdersEquity" } }, "lang": { "en-us": { "role": { "totalLabel": "Total shareholders' equity", "periodStartLabel": "Beginning balance", "periodEndLabel": "Ending balance", "label": "Equity, Attributable to Parent", "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest" } } }, "auth_ref": { "r55", "r58", "r59", "r75", "r541", "r557", "r585", "r586", "r655", "r682", "r793", "r806", "r830", "r879" } }, "us-gaap-StockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquityAbstract", "presentation": { "http://www.autolus.com/role/UnauditedCondensedConsolidatedBalanceSheets", "http://www.autolus.com/role/UnauditedCondensedConsolidatedBalanceSheetsParenteticals" } }, "lang": { "en-us": { "role": { "terseLabel": "Shareholders' equity", "label": "Equity, Attributable to Parent [Abstract]" } } }, "auth_ref": { "http://www.autolus.com/20240630", "localname": "StockholdersEquityCommonStockConversionRatio", "presentation": { "http://www.autolus.com/role/UnauditedCondensedConsolidatedBalanceSheetsParenteticals" } }, "lang": { "en-us": { "role": { "terseLabel": "Shareholders' equity", "label": "Equity, Attributable to Parent [Abstract]" } } }, "auth_ref": { "http://www.autolus.com/20240630", "localname": "StockholdersEquityCommonStockConversionRatio", "presentation": { "http://www.autolus.com/role/UnauditedCondensedConsolidatedBalanceSheetsParenteticals" } }, "lang": { "en-us": { "role": { "terseLabel": "Shareholders' equity, common stock, conversion ratio", "label": "Stockholders' Equity, Common Stock, Conversion Ratio", "documentation": "Stockholders' Equity, Common Stock, Conversion Ratio" } } }, "auth_ref": { "us-gaap-StockholdersEquityNoteDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquityNoteDisclosureTextBlock", "presentation": { "http://www.autolus.com/role/ShareholdersEquityNarrativeDetails" } }, "lang": { "en-us": { "role": { "terseLabel": "Shareholders' equity", "label": "Equity [Text Block]", "documentation": "The entire disclosure for equity" } } }, "auth_ref": { "r80", "r152", "r260", "r262", "r264", "r265", "r266", "r267", "r268", "r269", "r270", "r271", "r272", "r274", "r276", "r361", "r587", "r589", "r601" } }, "us-gaap-SubleaseIncome": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubleaseIncome", "crdr": "credit", "presentation": { "http://www.autolus.com/role/LeasesSubleaseClassificationDetails" } }, "lang": { "en-us": { "role": { "terseLabel": "Total sublease rental income", "label": "Sublease Income", "documentation": "Amount of sublease income excluding finance and operating lease expense" } } }, "auth_ref": { "r412", "r654" } }, "autl-SubleaseLeaseTerm2Member": { "xbrltype": "domainItemType", "nsuri": "http://www.autolus.com/20240630", "localname": "SubleaseLeaseTerm2Member", "presentation": { "http://www.autolus.com/role/LeasesNarrativeDetails" } }, "lang": { "en-us": { "role": { "terseLabel": "Sublease, Lease Term 2", "label": "Sublease, Lease Term 2 [Member]", "documentation": "Sublease, Lease Term 2" } } }, "auth_ref": { "autl-SubleaseLeaseTermOneMember": { "xbrltype": "domainItemType", "nsuri": "http://www.autolus.com/20240630", "localname": "SubleaseLeaseTermOneMember", "presentation": { "http://www.autolus.com/role/LeasesNarrativeDetails" } }, "lang": { "en-us": { "role": { "terseLabel": "Sublease, Lease Term 1", "label": "Sublease, Lease Term One [Member]", "documentation": "Sublease, Lease Term One" } } }, "auth_ref": { "autl-SubsequentADSSRepresentingOrdinarySharesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.autolus.com/20240630", "localname": "SubsequentADSSRepresentingOrdinarySharesMember", "presentation": { "http://www.autolus.com/role/NatureoftheBusinessUnitsAccountingDetails" } }, "lang": { "en-us": { "role": { "terseLabel": "Subsequent ADSS, representing ordinary shares", "label": "Subsequent ADSS, Representing Ordinary Shares [Member]", "documentation": "Subsequent ADSS, Representing Ordinary Shares" } } }, "auth_ref": { "us-gaap-SubsequentEventsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventsAbstract", "lang": { "en-us": { "role": { "terseLabel": "Subsequent Events [Abstract]", "label": "Subsequent Events [Abstract]" } } }, "auth_ref": { "us-gaap-SubsequentEventsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventsTextBlock", "presentation": { "http://www.autolus.com/role/SubsequentEvents" } }, "lang": { "en-us": { "role": { "terseLabel": "Subsequent Events", "label": "Subsequent Events [Text Block]", "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business" } } }, "auth_ref": { "r431", "r432" } }, "us-gaap-SubsidiarySaleOfStockAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsidiarySaleOfStockAxis", "presentation": { "http://www.autolus.com/role/ShareholdersEquityNarrativeDetails" } }, "lang": { "en-us": { "role": { "terseLabel": "Sale of Stock [Axis]", "label": "Sale of Stock [Axis]", "documentation": "Information by type of sale of the entity's stock" } } }, "auth_ref": { "us-gaap-SupplementalCashFlowInformationAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SupplementalCashFlowInformationAbstract", "presentation": { "http://www.autolus.com/role/UnauditedCondensedConsolidatedStatementsofCashFlows" } }, "lang": { "en-us": { "role": { "terseLabel": "Unaudited supplemental cash flow information", "label": "Supplemental Cash Flow Information [Abstract]" } } }, "auth_ref": { "ecd-TabularListTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TabularListTableTextBlock", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure" } }, "lang": { "en-us": { "role": { "terseLabel": "Tabular List, Table", "label": "Tabular List [Table Text Block]" } } }, "auth_ref": { "r739" } }, "autl-TechnologyOptionsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.autolus.com/20240630", "localname": "TechnologyOptionsMember", "presentation": { "http://www.autolus.com/role/LicensesRevenueNarrativeDetails" } }, "lang": { "en-us": { "role": { "terseLabel": "Technology Options", "label": "Technology Options [Member]", "documentation": "Technology Options" } } }, "auth_ref": { "ecd-TotalShareholderRtnAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TotalShareholderRtnAmt", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure" } }, "lang": { "en-us": { "role": { "terseLabel": "Total Shareholder Return Amount", "label": "Total Shareholder Return Amount" } } }, "auth_ref": { "r731" } }, "ecd-TotalShareholderRtnVsPeerGroupTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TotalShareholderRtnVsPeerGroupTextBlock", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure" } }, "lang": { "en-us": { "role": { "terseLabel": "Total Shareholder Return Vs Peer Group", "label": "Total Shareholder Return Vs Peer Group [Text Block]" } } }, "auth_ref": { "r738" } }, "ecd-TradingArrAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TradingArrAxis", "presentation": { "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" } }, "lang": { "en-us": { "role": { "terseLabel": "Trading Arrangement", "label": "Trading Arrangement [Axis]" } } }, "auth_ref": { "r758" } }, "ecd-TradingArrByIndTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TradingArrByIndTable", "presentation": { "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" } }, "lang": { "en-us": { "role": { "terseLabel": "Trading Arrangements, by individual", "label": "Trading Arrangements, by Individual [Table]" } } }, "auth_ref": { "r760" } }, "dei-TradingSymbol": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "TradingSymbol", "presentation": { "http://www.autolus.com/role/Cover" } }, "lang": { "en-us": { "role": { "terseLabel": "Trading Symbol", "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange" } } }, "auth_ref": { "ecd-TrdArrAdoptionDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrAdoptionDate", "presentation": { "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" } }, "lang": { "en-us": { "role": { "terseLabel": "Adoption Date", "label": "Trading Arrangement Adoption Date" } } }, "auth_ref": { "r761" } }, "ecd-TrdArrDuration": { "xbrltype": "durationItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrDuration", "presentation": { "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" } }, "lang": { "en-us": { "role": { "terseLabel": "Arrangement Duration", "label": "Trading Arrangement Duration" } } }, "auth_ref": { "r762" } }, "ecd-TrdArrExpirationDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrExpirationDate", "presentation": { "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" } }, "lang": { "en-us": { "role": { "terseLabel": "Expiration Date", "label": "Trading Arrangement Expiration Date" } } }, "auth_ref": { "r762" } }, "ecd-TrdArrIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrIndName", "presentation": { "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" } }, "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Trading Arrangement, Individual Name" } } }, "auth_ref": { "r760" } }, "ecd-TrdArrIndTitle": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrIndTitle", "presentation": { "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" } }, "lang": { "en-us": { "role": { "terseLabel": "Title", "label": "Trading Arrangement, Individual Title" } } }, "auth_ref": { "r760" } }, "ecd-TrdArrSecuritiesAggAvailAmt": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrSecuritiesAggAvailAmt", "presentation": { "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" } }, "lang": { "en-us": { "role": { "terseLabel": "Aggregate Available", "label": "Trading Arrangement, Securities Aggregate Available Amount" } } }, "auth_ref": { "r763" } }, "ecd-TrdArrTerminationDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrTerminationDate", "presentation": {

"http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "lang": {"en-us": {"role": {"terseLabel": "Termination Date", "label": "Trading Arrangement Termination Date"}}, "auth_ref": {"r761": {"country": "US", "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/country/2024", "localname": "US", "presentation": {"http://www.autolus.com/role/LicenseRevenueDisaggregationOfRevenueDetails", "lang": {"en-us": {"role": {"terseLabel": "United States", "label": "UNITED STATES"}}, "auth_ref": {"r228": "r229", "r231", "r232"}, "ecd_UndrlygSecurityMktPriceChngPct": {"xbrltype": "pureItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "UndrlygSecurityMktPriceChngPct", "presentation": {"http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "lang": {"en-us": {"role": {"terseLabel": "Underlying Security Market Price Change", "label": "Underlying Security Market Price Change, Percent"}}, "auth_ref": {"r757": {"autl_UnitsOfAccounting": {"xbrltype": "integerItemType", "nsuri": "http://www.autolus.com/20240630", "localname": "UnitsOfAccounting", "presentation": {"http://www.autolus.com/role/NatureOftheBusinessNarrativeDetails", "lang": {"en-us": {"role": {"terseLabel": "Units of accounting", "label": "Units Of Accounting", "documentation": {"Units Of Accounting"}}, "auth_ref": {"autl_UnitsOfAccountingFromFinancingAgreementTableTextBlock": {"xbrltype": "textBlockItemType", "nsuri": "http://www.autolus.com/20240630", "localname": "UnitsOfAccountingFromFinancingAgreementTableTextBlock", "presentation": {"http://www.autolus.com/role/NatureOftheBusinessTables", "lang": {"en-us": {"role": {"terseLabel": "Units of Accounting From Financing Agreement", "label": "Units Of Accounting From Financing Agreement [Table Text Block]", "documentation": {"Units Of Accounting From Financing Agreement"}}, "auth_ref": {"us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceSheetAmount": {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "UnrecordedUnconditionalPurchaseObligationBalanceSheetAmount", "crdr": "credit", "presentation": {"http://www.autolus.com/role/CommitmentsandContingenciesNarrativeDetails", "lang": {"en-us": {"role": {"terseLabel": "Unconditional purchase obligations for capital expenditures", "label": "Unrecorded Unconditional Purchase Obligation", "documentation": {"Amount of unrecorded obligation to transfer funds in future for fixed or minimum amount or quantity of product and service at fixed or minimum price. Includes, but is not limited to, lease not yet commenced and take-or-pay and throughput contracts"}}, "auth_ref": {"r229": "r836"}, "us-gaap_UnrecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis": {"xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "UnrecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis", "presentation": {"http://www.autolus.com/role/CommitmentsandContingenciesNarrativeDetails", "lang": {"en-us": {"role": {"terseLabel": "Unrecorded Unconditional Purchase Obligation by Category of Item Purchased [Axis]", "label": "Unrecorded Unconditional Purchase Obligation by Category of Item Purchased [Axis]", "documentation": {"Information by category of product and service for unrecorded unconditional purchase arrangement to acquire product or service or both"}}, "auth_ref": {"r228": "r229", "r231"}, "us-gaap_UseOfEstimates": {"xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "UseOfEstimates", "presentation": {"http://www.autolus.com/role/SummaryOfSignificantAccountingPoliciesPolicies", "lang": {"en-us": {"role": {"terseLabel": "Use of Estimates", "label": "Use of Estimates, Policy [Policy Text Block]", "documentation": {"Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles"}}, "auth_ref": {"r25": "r26", "r27", "r114", "r15", "r117", "r118"}, "us-gaap_ValueAddedTaxReceivableCurrent": {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ValueAddedTaxReceivableCurrent", "crdr": "debit", "calculation": {"http://www.autolus.com/role/PrepaidExpensesandOtherCurrentAssetsDetails", "lang": {"en-us": {"role": {"terseLabel": "Prepaid Expense And Other Assets Current", "weight": 1.0, "order": 2.0}, "presentation": {"http://www.autolus.com/role/PrepaidExpensesandOtherCurrentAssetsDetails", "lang": {"en-us": {"role": {"terseLabel": "VAT receivable", "label": "Value Added Tax Receivable, Current", "documentation": {"Carrying amount as of the balance sheet date of value added taxes due either from customers arising from sales on credit terms, or as previously overpaid to tax authorities. For classified balance sheets, represents the current amount receivable, that is amounts expected to be collected within one year or the normal operating cycle, if longer"}}, "auth_ref": {"r779": {"autl_VariableLeaseCostNetOfReversal": {"xbrltype": "monetaryItemType", "nsuri": "http://www.autolus.com/20240630", "localname": "VariableLeaseCostNetOfReversal", "crdr": "debit", "calculation": {"http://www.autolus.com/role/LeasesLeaseCostDetails", "lang": {"en-us": {"role": {"terseLabel": "Variable costs", "label": "Variable Lease, Cost, Net Of Reversal", "documentation": {"Variable Lease, Cost, Net Of Reversal"}}, "auth_ref": {"ecd_VstngDtrFrValOfEqtyAwrdGrntdAndVstdInCvrdYrMember": {"xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "VstngDtrFrValOfEqtyAwrdGrntdAndVstdInCvrdYrMember", "presentation": {"http://xbrl.sec.gov/ecd/role/PvpDisclosure", "lang": {"en-us": {"role": {"terseLabel": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year", "label": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member]", "auth_ref": {"r727": {"us-gaap_WarrantMember": {"xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WarrantMember", "presentation": {"http://www.autolus.com/role/NetLossperordinaryshareScheduleofAntidilutiveSecuritiesDetails", "lang": {"en-us": {"role": {"terseLabel": "Warrants", "label": "Warrant [Member]", "documentation": {"Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount"}}, "auth_ref": {"r672": "r673", "r676", "r677", "r678", "r679"}, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {"xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "presentation": {"http://www.autolus.com/role/NetLossperordinaryshareScheduleofNetLossPerShareDetails", "lang": {"en-us": {"role": {"terseLabel": "Weighted average diluted ordinary shares (in shares)", "verboseLabel": "Weighted-average number of ordinary shares used in net loss per share - diluted (in shares)", "label": "Weighted Average Number of Shares Outstanding, Diluted", "documentation": {"The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period"}}, "auth_ref": {"r174": "r185"}, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {"xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "presentation": {"http://www.autolus.com/role/NetLossperordinaryshareScheduleofNetLossPerShareDetails", "lang": {"en-us": {"role": {"terseLabel": "Weighted average basic ordinary shares (in shares)", "verboseLabel": "Weighted-average number of ordinary shares used in net loss per share - basic (in shares)", "label": "Weighted Average Number of Shares Outstanding, Basic", "documentation": {"Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period"}}, "auth_ref": {"r172": "r185"}, "us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract": {"xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract", "presentation": {"http://www.autolus.com/role/NetLossperordinaryshareScheduleofNetLossPerShareDetails", "lang": {"en-us": {"role": {"terseLabel": "Denominator", "label": "Weighted Average Number of Shares Outstanding Reconciliation [Abstract]", "auth_ref": {"ecd_YrEndFrValOfEqtyAwrdGrntdInCvrdYrOutsdngAndUnvstdMember": {"xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "YrEndFrValOfEqtyAwrdGrntdInCvrdYrOutsdngAndUnvstdMember", "presentation": {"http://xbrl.sec.gov/ecd/role/PvpDisclosure", "lang": {"en-us": {"role": {"terseLabel": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested", "label": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member]", "auth_ref": {"r725": {"std_ref": {"r0": {"role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14", "SubTopic": "230", "Topic": "830", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1", "r1": {"role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A", "r2": {"role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14", "r3": {"role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10", "SubTopic": "810", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-20", "r4": {"role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28", "r5": {"role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28", "r6": {"role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "360", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1", "r7": {"role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(c)(3)", "SubTopic": "10", "Topic": "810", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A", "r8": {"role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "SubTopic": "10", "Topic": "505", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2", "r9": {"role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2", "r10": {"role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2", "r11": {"role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2A", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2A", "r12": {"role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22))", "SubTopic": "10", "Topic": "210", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-599-1", "r13": {"role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14", "r14": {"role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "14A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14A", "r15": {"role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-5", "r16": {"role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15", "r17": {"role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-4", "r18": {"role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2", "r19": {"role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-3", "r20": {"role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18", "r21": {"role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-20", "r22": {"role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-4", "r23": {"role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-8", "r24": {"role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-9",

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

!SPV7@*S,6T@L\$= #FH)@!X?IF!2Wd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f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

0R5SL1ZGZ;E33HTS9H1Z1;#UNUAM0/BEK7/CI#M215Q66A"TCP66.M2=218M.VWXY#6R98DQK QSZ9NF7-#1C66#6UHA#NB=>FUI.QJ6V.#=V
MB9B16H2XCTD7AASFW.11)@=#HD+56/10/203DRDJ4:GA(1#JVA.M1EO.0A10E.0A12N=N>N(NZKS:Q1JQX4R01GZ:CF13MS566VLXN:4ST7VC.M.U9Z19N2M-
CNF74M).5.HH.G3.X.DMV+1+I04E4X"1>0>9.5NZU/1A16XR9.M0.G4KFISICS(5#MD7K0E.H2(9R3>96WP9MGPB9C9NDUM/PZM3Q=5FW6/PAB0I
HENT(UKRO4RP(=UW3C2XC(=N27G9+1>C>STCGH+H+U9+1HLU">MOVRS&60M95-VTVU8:N8D3C99>7FJ+1MRW=6W+B2N1UM6U0+3F6.3FD2M
M.0M9S9KRC(1C40EN)=5H5Z.TKZ2Y<=>M3G+H+7+16.ASMD00<SX/QUA#M9#ANU#DUH66<5Z03K=>2(I&IG-5C6D+HV+12)00C.=J3FHEEQM/KLV8I
MGLU+>A9PX#5#(5/>5=>R7IG1CIAV50#8A:4.1>#>224T551UGD-3>10-6<D&KUZNM23#JU=H9W9>6B5G:1HK7&0:TKS#1.22SF5Z0BB4.P4#WMTE#MWDYB
M.Y5#B6QBI#04&L292K30UN8V8PU0/(V60.19U:N218157E.4=3IW.M5Y1.SK=7%<P27N.7.MFV55WJ2+JY&8&B.PLZ.4-Z7PYZL2<=>DP#9+4+3VAFIP#T:C9J5:2>4CF
ML61=7X7.8T(0%79.1.CU+HJ1J2V7MY170HX5907&=>75E64.YT=7>54Y7M.M:RG74#RS<9CNYOZN*Z"%44+>V.N.G7.S>B1<RNUH#YGKP5UL4H.ITC
MVUI0189VL:PX1.S>BV+Y21.L#.#@3D.417133P<3U/C1>#>VPFY(E>V>P#15+U@>0<6N1:BUWOM+Q=K1VY1G=(1&5Y&I0FJIS/=MTFV=5M?2?=>(D0?8N1?>
547V-MGOAGC:PG:1H-15M7H-7S)=>@INTAMT&G+L1&60L9=>1BYVE<5WQ60Z&4B@X#HJ:8.5#HHR&581+NQ>7QXB50:7KB0P=456E0Y=>+1F&E27KX+H6
MM.VT6=8C1<=>N81SRVY6L&LMA0#ALW+13IG63J.P=M=1TA07HJ1Y3X0FIE7.MDSHBR#E.6318.L1HH%UAC%5.0PDI10<6JN%5#SZ-660:KRH36Y8<PCL-55.M.HRV>JH:=5-
6>52IG9HR.Q2I&5N%6/<N&R.F6-BR&X&0/8GU=JP-M=10H91X9.0%0932QCMSCN48HU=6H8MTX#D78&SZM1B5XHOKHGHS&E
M.:60ZLZV%LOOX*140UDP68F.XM#D1H#YF+Z>JZ<75J#7IU#OTZ10#DX# MB79GU5:(1+>W.O=6<-1CM/7>R"B3:PG6I.JLDN7CW#&ODDI^V.G#JH@2&M&@<
MK53RI0LH61H2D.TS8F>1PPDHJH3C.RABNC1N1<@10/N282(5VC)1#1.MN1B8195.VS.9RNM1#PZMS5X1XHH=IUPE04&AOGIM.M21Q.1+1L#1=7?PK#>X1/WZ
MIM:ARW1WK+UYO&+OS+>AWM90.TL">A3V34>+TSJHFG=-91J#SZ@ MKL3*FQ>FZFD2J6N<3K>6<5A#H4V+YLMU.V4/7>M>B13LQWLMN1N3# M2E-
IPW009F+8+N>1V7H1V+UW91+KGLPI.PYVRU#P0W1+MOXIA0X1&5=MI@<P.SNOP.M7=FU=U3X1Y7S<6%L3Y>678XE181Y5E5H:TP>3R.BW+>B141QV#
M050#11N1Z>L<8.QW5?#9EL5S4241.MX1A.#1>5XRGKZ+Q3"P#K74N1<LGO1ML3X0+I6.M.s191H7B6FX1/PP+1&5Y1E1H1G1LVR57ZP>Q.CYVOC/16ZPHU(10EA
MIE+>3Y1I+0)<@I7G3IT4V00BOH.V.0EY1<=>L0Y5KKO1F0.&R<1TS%52*.MD1MVZKY2(K&ATUXR9VZP8^N<3?+>VC==RL?>%.FJ3I@SRIHOC<S1>..M?<
Q5#14.M.519:GJZE2/F1LH3/4N9>2ZA/M=3+JAI<1SL&=>O2Z2UM.MY1.6.WMB.IB+P.R:7Q405.RHBS@/T61RU1>#*K*.G2P1Z5#08+1>1>G
M.BZ0=61=JHMLX+>@K1MB1-081>3#>L&SEQD.9VSHKH#M0U@OGU.MN?=>F#0M2#PL6&8S4G1&U#>1&3E0H&E2H.K41591#S8-(0#>M?>MVP.T+>Q0>+8CZ>IGX#<
95<GIU>=>N<8Q15(GE1A/H6)*B#>6<(VEV9C.MTQPVY#BCI^C9N<@<G.60H0H.BS.B+>0>S>#>W0Q8ZC#JUR<75<+1J1.OT.YTF.M6ZMBBIE.9.=>B/W(3.M#>80?<
N1VCW9>Q1#Q61H39GNC=EX&A#>@05B7)5Z.1UR#11C6MP<=>4&1F4W1Y.MQ.UYIES.&88&G(6-HZ.95?0..2=>QO<8ZVZ2&#>H1#(H1G+X)MZA&C#<
0&C330\$S\$&XP5#<@Y#0XG44A@Z50:12Y.8.Z03-UM2GKV/(P4@<TH.EL51IY0.MTH021^5X4>#>J14"&=&H#J+<1X0L9^9ZAS#BPWY5/M3.Y67<
+1C61F%W0.T+M2>X>UE301F+>W<S16GRKDKQ&D17:6=>8Z.MQU:9JS=>151A5+>YPIQ11(HFS1#(Q1QY^N.GH1^>0)OIF)M4#Q=PR-IDDDA=&
(8ZYHCQSXOX"X=>4ML#1A:1P5X.MKX.N1N1J<6-8&M#2P1H7-M&B&UHGBY>T@C0@>A1@E01LC#UCTI6HVS1L1FXF#MMXAKX#X861Y3E^YQ@T=IHOENX0P#PT/Q?+<
M1N+>#D/OA(AGS<U7L#24DPP5.GP<#3#1L.CGA>TWRKE.MGME/0#3IK.M#M2M#<XEX#S07K#1E4W95/S>3>4EM1NGC7#>0JZZ>1UF318DV29X1L<
M1EQQWIT=K0FX<=>T#>M2#5HJYVM@.19ZMJ495-74.6.Q#>2.T.HK06>16NBN.MC.WOWE25<1+2+78.P312=>8;KKUTD.WZJ2P53.TEWK1K70W2#BJM1+<5<
M.WRFJ=1GPZ=FOJ/D8PL\$5+L:5A9\$JC3>C^N)1JAU=>K&DDUHOK8443E.C7KU1MNR520JDK4@U13EVZA1ZR/92.4PM1W#AKJ17Z5Z0\$5JSF9T0-4RKIX%<
M.HMIE.BJM51#..MN2=>1JHH6.PZG4.RQ#L2H2=>JMZP#W5E5TFM>>0.M.A.F."DDH(LH1#>Q1YI>A>7>15B).TQ?G.Y4Y#>5HPL&KJH7B02GKH<
MHF13L1A14&BS>Q>IV>=>..C3M.H4.VYI>B>2M.TA=GLU.C@P15>..2A.M.R.WK1^VE=>S\$)2SIDH1P#>2#9210156602F60C0YCHU4Z1A<R5N>1A.R44D%Y%<
<1^<@1L>1+1SF0@YQ.GUF.Y8.643.VI+GH1P/GILCO.7)ICAR<=>#Q.2E=60+1ML32INSH41#D=>#>DX841+2.D">Z+15F@LUK&FGL&MCG6.VU0&9#<
IP>5&F.XR@U:6&X&6#19&Y514>V>VY1TR.5>*>B.N>9IBT.H7.HV.51Z>VW0XW<3<3N.240.XV>..0&EK6@DNUI4(X4X#A1Y#>1DGC.H<
M#Z9=5AVVZ7>+VS:6DH@I&#>LGI2INLKMJ1@/<=V1.O:66X#W=NVKPUN1.MW.MJ1@/<=V1.O:66X#W=NVKPUN1W.L5.M.U^K+IKD=YM&AIOE8X8Q%*M<
M44CV>>V1=U1G.0&ZM&BNR.6&.4D4D9Q?7P.M.6&BHT7U1U+>Y15?T.N/F.NFMP(M7M16MTJMT71#1"1M(EVA;IK&L.EME#UHM.MC3K#<1QYQ>-?#<%N+J?<
&@>01&K&U@>088UX13PP5VYCU1M.T7K7Q6.MX<^&6BHS13ZK&2WXS&L&6#<U#WRT5BI+>7VH1Y.MD+W:K540UWH#>@<
MOVDIS1<17WG0ID71#>1&5&H&S.8S9Y25566<("RS#13DT-VU.8:4X0Z3C.M177.M9UHVY5Y#1.H1A+U1W15&63D142M191.C2P29?>PRHT=RGG1OK#1N<<
ME=>+MP.Z3ZHZD>90/>#*717H19.6L4XQSA&K1U6=X<=>TFLU1.0.MW551LX.129X8655IP.MU1+>0Y10(VYDTS1L:PVA/RHX#T77JCU<
MZ>ZUZGZ#U&GYM19

[illegible]

[illegible]

[illegible]

[illegible]

MMY25*U1\$2:5IHNN33Z^~^IK|0PPI*69IUA6GN\$D(SI:8ZVUPHX#s16^~^450Q=M^AL^NY53I86G\$2M937B4B>E)LLKR-485W^ZD/UML?D:IV^~T0UHUD8:T=MI\$8Y&D2PAYI4\$Z>0IUK(QI>~U^IX=Z16&5D?*=WO(LI^IZKPCI#V=N%M:QWGW^~C7IHD8S_A=2KH=YB2HRXU5^IRL\$2T1960=KHBZ)I^R(G^Q^Q^XMT?>FVEFRIU<^JT@#^?H&X\$3.AR8W37H^FTWY5C^H21#1^MAE@|H48?>J<=1M2M.6K06W+4I4G:~.B.D9HUX.KUN2F2:0==>M^R<+1^MWO:L6Z3XIQ(C^P^BAJPXE0Q^M5NZU>N)9U5?>/(LGK/M<IP1^XAD|.BTGQ MXI(U@V^EUXKW9J&C^&=K^W^3H7B;HT?<==Y180G/6B7L+EL^4(M5XQO?>2X)I783HIO(FG5\$HHF&L=8C@9*+S2?3@^~1G^W9T(F#?3^WG3Z&R M685<~RLBN^YUN\$9X(1<#>=)M^W>Z^O4A^I:~s1^W^6=MLZ^Y6GL3L6G&4V^S=J^H^TDFDZNN3B42\$(APK(4^85ATR^285A^~MMGL3V.&CZ825^#C FGZ5T74I^%<+^~5S&^~5C?>7P1P109A2G8U^M&D^L^S^P^U^>B^X^Z40:D^U^%IS2^Y7+K4WNM&K\$VNL^XND?2+>fE3Z/68 MH9W(C^TAPDDE^5H^UR0Q1^0I&V5K.R#F6ELIF^!^L^MJK?9CB>5+1U^XIASI@~@=V1QI^O&W>3^WNB21<4@?3^9ORZQOPXW\$2I6=M~7X476^%Y\$8BI(A^P\$)T^6I6<+H^+2BIOIM5G7Z>K\$;H&+T2EDL=5HG^MT^O4P^BL^FEMT@U^M^S^"(A7^4^>5/GEEKP02O~GO2B2I9W\$H>OQ;Z1^#>3V2EJ004NON+<MPK-P&K=U^4(KR0=H3G.3UXA=IS^PMV2^0M^)#10T806P2H1^9@+X.A2\$H06.M2IU^P22^40HQ(QED^2012WIU\$^X13L^KE7485O^FLFP(15HBL7^99K.M^SYBK90+<\$K.W^J^T^W^GBM17^QJKPJUNXN-D^HW3>~UL^G^P\$F9AVH7K.M^X.PD17^+H3JPH7M^PQ3<~?7G2^Q^K=FE^E\$^P^M^COTG50?>N<E^<=1^TTHWU9^M9R>?>Z3I(NG08W4^Y8P#M^U4DEHJES&B1<16H+>J8Y0+1^FQI@Y1M.SfQM?>B~<G\$1>2AQIK&K>L12^~I2&F5BUBVJBX.XRE98OR<4\$AVH7MKL<V2^3F.M.Z9RU1^3P@M1000?9EWF7448K447>?1^G.C3<1^ISC&0=4G14FP^P^M^?M2IG^1<@KX<3^03K3^R+LX5GPEKKW05X^<KH@ID^M.DBI4H7L\$S)&^~.5IE4I^1.24EX8@F.F8H1=9A4RI?>PCO;MC6IDP^QC.M.N8NH1=1=\$M\$<GV^Y/IP=15X757LPHN19=BD(TTIR^J0D1U/+1=FG.M^6Z3I9W@6\$;L68R&H&N1L9JG<JOWAQ^2ICY<Y^H:OXTIZGE7E^2_s1^M^+19051^A.G.IU16@10^5MC8CF^SVFG36TX^~+>U&Y^YVYOFKCI>ZM^?<@?>2^MTC=6^1H1U<4O1M7^DIDU9^Q^OIS^~UL6^MQL=671=B9G013@.\$\$(=0FNH1X.MR8\$PX53.AOD41^R<?>A8L^E.NN1+S^M^MALOY\$B1@H@>H1-M^6:U3QKOAQ>="L7C^L4AISI5\$5F8R^5H0WJUM^6M7N\$~0MI7H?#>?#WG(H@9.W.H2S2\$?>AIBV76NF@E26^1MAOBYE75IRPAW9^X.M^8=Q\$8>A^~J51=2^YWZ;1%<1^HIC9G/AIG:75V3G160B\$>B9J^XQF9^MX^~2S(ZKIDSIPG8WM.N5MJ.PZR.HF7471F<9IT><44O^U@HP^#44^7Z(L^MEI740DDLJQA;fE^4^A10UCU4.Y<1PT9XOTQXN|GUPFDUCU478KX:1%YS4^MOF^AAMU>@fE^OCX&AMD5^F<?>0GB6IRI.CC+Y9<0.5^ZU:CAZ~NV^MB.MIVN(>7^LE)Y\$;S/P\$*MBN7@:MM C1\$8SE22+4F7R0PQ^1L<60IYW=\$X\$HC.M^J>6Z^~^=IAMJ+NGQ>GTRKD6Y(MBYB^9J@Q&068N95PWFK1\$(>?>0:M@UP^MSB^PIDYCR>J&30T\$UM=6W9QV^>1RE&K\$<~>L^G&N1H\$X#>~?T08?^MI@=GA.G9.MRV5=Q5E^L^1^W6RGL2?<~>?YELDCN\$C85W^T1\$ER GOV^HJD^B?>MYM&A^1+>U\$K6V01925\$D1NR5D1M\$G(TA^1^Y.AT.VOW^&Y9K=NQ=5&RM.MJNH<1^JL^~WG3^XIZ^F4^K4MA.ZXG)PN8+1UH.BV2^E^8&&Z135HG6_XN^M^K1^>D-Q\$DFO.9E+RWML^W^L1.8.DFPIR.DFC\$M^72155V821H5;LH^M^%Y+3^HHD@914X?TZ4B.*GY^\$E&U^B74IOF^M^P1=IQ^UXIEIQ>?T M^H7C3M6.XG)|DPZ>?JTURR1^+D6I9M.%\$3A+F^>M&L1+1^MH151=J^K74A^Y=DN^643@3X993I91N|O1F1P1\$~+J3^MLQO>?>^%<=G7KZK4IYASS&AF\$W^W^~AC4+2ZB73XR;L^70^X213UY7F&^1^4^>8V^2Q.8T^<FMJRZU0^MR.3^~3&15DC^I4J0~>3&3HYH^U^P0A^UAM;SW3HAZK@L~M^1^Z1^%&=GPK.ZRTOF<3NKT^MOGE^F^>E^LO6IMFXSF^5\$JXK?^OHN.LBS1^DIQ^8V>4;1^F3>DGD^HM^M^HNR&D10AC7FCCA~<C=1^0AF3R^?>O&HAI3H^X1\$Y^E.IGXU4RH25U^MY?>9.F#E98H1X^L1585CJ3.VY03G6&HP?>D.V1\$X5G6OLK&X7E6K^M^\$XRL^%<C^V^L^TW1\$?>6Z^X9B9N\$D\$W5;G15.1WV1^>1L5FD^A1.95W.M^5^/AH3\$<S1^FL13B3=N^B.^3FQW8^W161<@OH>D>@>M^Y^~+1%>Z^H^1N1Z1SIVE^M4V.2T1NL8I.H.R1C^K>~>^WP#618Z?H?7H^XNBQD.SBC.M(9#^JIT^E2X<@H>@>J/=&XFU^7+3>U~.8GGC^7T^~4^B1V3JE^CVYT/LOD^MF8#0\$U^C4+R^2.Q.8JS^G8PPP~.W+C+B\$9Y~9+O?WOJHWD331^D^X1Y<01^M^P1^?>090.145J(MG^4+HYFAG1ZQYN|POHLK43AAHF^~<V^GB=3O(Z^29F^M74R1.9H.CLEYD^V1V^~M^K34424=1%5MXT@<=2WQ9^2^C^XYP^>8&N^2G16Z46AD^H^BWT&X3^X^%WGDGR7U2^<1^?VBI^M^Q&L^1^J@>?7^U9^~?>ZEL#^>)>B\$HGFTEFWP?P^%YOL=RO13=JQOSAY^M74R^E4T1I5C@P2^SEJH^UHP87FROD419^YDW7Y<1^01?F^OUIUHL^SO.M^X@<9>1&8^>E^P.7+4^S2^?170IV^>B.Y@W^U3U^NAT^?P^L9L3H^M97K^HGCT=SA>?>S~.1HL72P2<=WA.M1.UX^D70C(E@A1^?>1)15>~WM+>9\$T2^RINGS&7.M^<0L1<=.%#^3CP3(10@C?>?>1J5ZQ1^9IC1B9WYH1=(>U2^IYZ.H1^MH^LZ?~>S&\$^<UJRG6>)=13\$56G)H5G(M0640=1TCJ8POT@MKMANI0P0/R1&A7X.E7P^XC+G.0N0NZ1@/RC6P1^M^BYU&QZ.CL6^DTB+IY44>2^J~.QVGC\$3K1I^23.W3%G^A^UR@G^L^M=1%ZHTDZSP~1=4G^4BG0^<SOQBH^Q~O1P^5722R.X^@A^K6^8U&@&2T34.CJHPDG^PI^M^MYHN^U^<@<R=5(7^J^WM7?>2S91+2C^KUS+1^R~>JGCL6MA5BDIL^*MI8BYU+K+L^<1%SNFM^<Z^Q&N@1^01^&W=U^AML^8KEF^O^/1@P2\$.MCP5(L^G>3P2RC^10BP&X&52W^6K&S1=PL^7FD^NTTFK1+Z^LSIUZ^MI03&T7@<1^UWJT^4L11DW9^3^6IAL=^E^M8=6FX^M^<0P^PVU+2^1^W2NKKX^0^~1^J^330<1ZD1^IR3.ARX(T^X^W7.M^1T+L^@&T=1^121^PG>M^4EP^Q17U3(H^&A)RT\$4B5U^A^D1^M^G.9W6K15\$5<0^K\$#GR4^N1^M^B&PL^W6VZDDOR7^BV&6K\$M^%1^<45D1^8^>1\$M1.O>Q0E7L^Y^~U^AUM^MNI9VW+OQ^%G4E^+1H+S26015^"POHA.(L0^B.^2TAIYZ=J>F@16W^NT+MT>9.2^NP>>1M^J^GPIQ^<G^JIP^5^KO+5^

[illegible]

[illegible]

[illegible]

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i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

[illegible]

#001730463

gaap:CommonStockMember 2022-12-31-0001730463 us-gaap:AdditionalPaidInCapitalMember 2022-12-31-0001730463 us-
gaap:AccumulatedOtherComprehensiveIncomeMember 2022-12-31-0001730463 us-gaap:RetainedEarningsMember 2022-12-31-0001730463 2022-12-31-0001730463 us-
gaap:AdditionalPaidInCapitalMember 2023-01-012023-03-31-0001730463 2023-01-012023-03-31-0001730463 us-gaap:AccumulatedOtherComprehensiveIncomeMember
2023-01-012023-03-31-0001730463 us-gaap:RetainedEarningsMember 2023-01-012023-03-31-0001730463 autl:OrdinarySharesMemberus-gaap:CommonStockMember
2023-03-31-0001730463 autl:DeferredClassASharesMemberus-gaap:CommonStockMember 2023-03-31-0001730463 autl:DeferredClassBSharesMemberus-
gaap:CommonStockMember 2023-03-31-0001730463 autl:DeferredClassCSSharesMemberus-gaap:CommonStockMember 2023-03-31-0001730463 us-
gaap:AdditionalPaidInCapitalMember 2023-03-31-0001730463 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-03-31-0001730463 us-
gaap:RetainedEarningsMember 2023-03-31-0001730463 2023-03-31-0001730463 us-gaap:AdditionalPaidInCapitalMember 2023-04-012023-06-30-0001730463
autl:OrdinarySharesMemberus-gaap:CommonStockMember 2023-04-012023-06-30-0001730463 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-04-
012023-06-30-0001730463 us-gaap:RetainedEarningsMember 2023-04-012023-06-30-0001730463 autl:OrdinarySharesMemberus-gaap:CommonStockMember 2023-06-30-
0001730463 autl:DeferredClassASharesMemberus-gaap:CommonStockMember 2023-06-30-0001730463 autl:DeferredClassBSharesMemberus-
gaap:CommonStockMember 2023-06-30-0001730463 autl:DeferredClassCSSharesMemberus-gaap:CommonStockMember 2023-06-30-0001730463 us-
gaap:AdditionalPaidInCapitalMember 2023-06-30-0001730463 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-06-30-0001730463 us-
gaap:RetainedEarningsMember 2023-06-30-0001730463 2023-06-30-0001730463 autl:BioNTechMemberautl:OrdinarySharesMember 2024-02-06-0001730463
autl:OrdinarySharesMember 2024-02-132024-02-13-0001730463 autl:OrdinarySharesMember 2024-02-13-0001730463 autl:BioNTechMember 2024-02-132024-02-13
0001730463 autl:OrdinarySharesMemberautl:BioNTechMember 2024-02-13-0001730463 autl:OrdinarySharesMemberautl:BioNTechMember 2024-02-132024-02-13
0001730463 autl:OrdinarySharesMemberautl:BioNTechMember 2024-02-062024-02-06-0001730463 autl:BioNTechMember 2024-02-062024-02-06-0001730463
autl:BioNTechMember 2024-02-062024-02-06-0001730463 autl:BioNTechMemberautl:LicenseAndOptionsMember 2024-02-06-0001730463
autl:BioNTechMemberautl:LicenseAndOptionsMember 2024-02-062024-02-06-0001730463 autl:BlackstoneMemberautl:ObeCelProductMembersrt:AffiliatedEntityMember
2021-11-012021-11-30-0001730463 autl:BlackstoneMemberautl:ObeCelProductMembersrt:AffiliatedEntityMember 2021-11-06-0001730463
autl:BlackstoneCollaborationAgreementMember 2024-06-30-0001730463 autl:BioNTechLicenseAndOptionsAgreementMember 2024-06-30-0001730463
autl:BioNTechMemberautl:InitialADSSRepresentingOrdinarySharesMemberus-gaap:InvestorMember 2024-01-012024-06-30-0001730463 autl:BioNTechMemberus-
gaap:EstimateOffFairValueFairValueDisclosureMemberautl:InitialADSSRepresentingOrdinarySharesMemberus-gaap:InvestorMember 2024-01-012024-06-30-0001730463
autl:BioNTechMemberautl:SubsequentADSSRepresentingOrdinarySharesMemberus-gaap:InvestorMember 2024-01-012024-06-30-0001730463 autl:BioNTechMemberus-
gaap:EstimateOffFairValueFairValueDisclosureMemberautl:SubsequentADSSRepresentingOrdinarySharesMemberus-gaap:InvestorMember 2024-01-012024-06-30-
0001730463 autl:BioNTechMemberautl:BioNTechLicenseAndOptionsAgreementMemberus-gaap:InvestorMember 2024-01-012024-06-30-0001730463
autl:BioNTechMemberus-gaap:EstimateOffFairValueFairValueDisclosureMemberautl:BioNTechLicenseAndOptionsAgreementMemberus-gaap:InvestorMember 2024-01-
012024-06-30-0001730463 autl:BioNTechMemberautl:LiabilityRelatedToTheSaleOfFutureRoyaltiesAndSalesMilestonesNetMemberus-gaap:InvestorMember 2024-01-
012024-06-30-0001730463 autl:BioNTechMemberus-
gaap:EstimateOffFairValueFairValueDisclosureMemberautl:LiabilityRelatedToTheSaleOfFutureRoyaltiesAndSalesMilestonesNetMemberus-gaap:InvestorMember 2024-01-
012024-06-30-0001730463 autl:BioNTechMemberautl:LicenseRevenueMemberus-gaap:InvestorMember 2024-01-012024-06-30-0001730463 autl:BioNTechMemberus-
gaap:EstimateOffFairValueFairValueDisclosureMemberautl:LicenseRevenueMemberus-gaap:InvestorMember 2024-01-012024-06-30-0001730463
autl:BioNTechMemberautl:ManufacturingCommercialServicesAgreementMCAMemberus-gaap:InvestorMember 2024-01-012024-06-30-0001730463
autl:BioNTechMemberus-gaap:EstimateOffFairValueFairValueDisclosureMemberautl:ManufacturingCommercialServicesAgreementMCAMemberus-gaap:InvestorMember
2024-01-012024-06-30-0001730463 autl:BioNTechMemberus-gaap:InvestorMember 2024-01-012024-06-30-0001730463 autl:BioNTechMemberus-
gaap:EstimateOffFairValueFairValueDisclosureMemberus-gaap:InvestorMember 2024-01-012024-06-30-0001730463 autl:BioNTechMember 2024-01-012024-06-30-
0001730463 us-gaap:LicenseMembercountry:US 2024-04-012024-06-30-0001730463 us-gaap:LicenseMembercountry:US 2023-04-012023-06-30-0001730463 us-
gaap:LicenseMembercountry:DE 2024-01-012024-06-30-0001730463 us-gaap:LicenseMembercountry:DE 2023-04-012023-06-30-0001730463 us-
gaap:LicenseMembercountry:DE 2024-01-012024-06-30-0001730463 us-gaap:LicenseMembercountry:DE 2023-01-012023-06-30-0001730463
autl:BioNTechAndCabalettaMemberus-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember 2024-01-012024-06-30-0001730463
autl:BioNTechAndCabalettaMemberus-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember 2023-01-012023-06-30-0001730463
autl:BioNTechMemberus-gaap:LicenseMember 2024-01-012024-03-31-0001730463 autl:BioNTechMemberus-gaap:LicenseMember 2024-04-012024-06-30-0001730463
autl:BioNTechMemberautl:TechnologyOptionsMember 2024-01-012024-06-30-0001730463 autl:CabalettaBioIncCabalettaMemberus-gaap:LicenseMember 2023-01-
092023-01-09-0001730463 autl:CabalettaBioIncCabalettaMemberus-gaap:LicenseMember 2023-01-012023-06-30-0001730463 autl:CabalettaBioIncCabalettaMemberus-
gaap:LicenseMember 2024-04-012024-06-30-0001730463 autl:CabalettaBioIncCabalettaMemberus-gaap:LicenseMember 2024-01-012024-06-30-0001730463 us-
gaap:RestrictedStockUnitsRSUMember 2024-01-012024-06-30-0001730463 us-gaap:RestrictedStockUnitsRSUMember 2024-04-012024-06-30-0001730463 us-
gaap:RestrictedStockUnitsRSUMember 2023-01-012023-06-30-0001730463 us-gaap:RestrictedStockUnitsRSUMember 2023-04-012023-06-30-0001730463 us-
gaap:EmployeeStockOptionMember 2024-01-012024-06-30-0001730463 us-gaap:EmployeeStockOptionMember 2024-04-012024-06-30-0001730463 us-
gaap:EmployeeStockOptionMember 2023-04-012023-06-30-0001730463 us-gaap:EmployeeStockOptionMember 2023-01-012023-06-30-0001730463 us-
gaap:WarrantMember 2024-04-012024-06-30-0001730463 us-gaap:WarrantMember 2024-01-012024-06-30-0001730463 us-gaap:WarrantMember 2023-04-012023-06-30-
0001730463 us-gaap:WarrantMember 2023-01-012023-06-30-00

Food and Drug Administration ("FDA") for its lead product candidate obecabtagene autoleucel ("obe-cel") for the treatment of relapsed/refractory ("r/r") adult B-cell Acute Lymphoblastic Leukemia ("B-ALL"), with a Prescription Drug User Fee Act ("PDUFA") target action date of November 16, 2024.

The Company is subject to risks and uncertainties common to companies in the biotechnology industry, including, but not limited to, development by competitors of new technological innovations, dependence on key personnel, protection of proprietary technology, compliance with government regulations and the ability to secure additional capital to fund operations. Obe-cel and the Company's other product candidates currently under development will require significant additional research and development efforts, including preclinical and clinical testing and regulatory approval, prior to commercialization. Even if obe-cel is approved by the FDA, the Company will need to incur significant additional costs to prepare for its commercialization. These efforts will require significant amounts of capital, adequate personnel and infrastructure and extensive compliance capabilities. Even if the Company's product development efforts for obe-cel and its other product candidates are successful, it is uncertain when, if ever, the Company will realize revenue from its product sales.

The Company concurrently entered into a (i) Securities Purchase Agreement (the "BioNTech Securities Purchase Agreement"), (ii) a Registration Rights Agreement (the "BioNTech Registration Rights Agreement"), (iii) a Letter Agreement (the "BioNTech Letter Agreement") and (iv) a License and Option Agreement (the "BioNTech License and Option Agreement"), collectively called the "BioNTech Agreements", with BioNTech. The BioNTech Agreements were entered into and in contemplation of one another and, accordingly, the Company assessed the accounting for these agreements in the aggregate. The following descriptions of the BioNTech Agreements do not purport to be complete and are qualified in their entirety by reference to the full text of such agreements.

Pursuant to the BioNTech Securities Purchase Agreement the Company sold to BioNTech ADSs, each representing one ordinary share with a nominal value of \$0.000042 per share, of the Company (the "Ordinary Shares") in a private placement transaction (the "Private Placement").

Ordinary Shares

Aggregate net proceeds to the Company, after underwriting discounts and offering expenses, were \$193.8 million.

In the event that BioNTech and the Company enter into a Manufacturing and Commercial Services Agreement (as defined below) within 18 months of the initial closing of the Private Placement, BioNTech will purchase additional ADSs (the "Subsequent ADSs" and, together with the Initial ADSs, the "Private Placement ADSs"), not to exceed 15,000,000 ADSs, for an aggregate purchase price of up to \$20.0 million. The total number of Subsequent ADSs that may be issued is subject to additional limitations and restrictions.

The BioNTech Securities Purchase Agreement contains customary representations, warranties, and covenants of each of the Company and BioNTech.

(ii) BioNTech Registration Rights Agreement

Pursuant to the BioNTech Registration Rights Agreement the Company agreed to file a registration statement with the SEC to register the resale of the Private Placement ADSs.

(iii) BioNTech Letter Agreement

The BioNTech Letter Agreement provides BioNTech with certain additional rights and subjects BioNTech's investment in the Company to certain restrictions. BioNTech received the right to nominate a director to the Company's board of directors. If BioNTech acquires beneficial ownership of at least 30% of the issued and outstanding Ordinary Shares of the Company (including in the form of ADSs) within five years of the Execution Date, BioNTech will have the right to designate an additional director who shall be independent. BioNTech's director nomination rights shall automatically terminate upon BioNTech's ownership of Ordinary Shares dropping below certain specified percentages. Additionally, BioNTech has the right to purchase equity securities sold by the Company in bona fide financing transactions in amounts that are based on BioNTech maintaining specified ownership thresholds following such financing transactions.

Subject to specified exceptions, BioNTech may not sell the Private Placement ADSs without the Company's approval for a period of six months following the applicable closing date for such ADSs.

The BioNTech Letter Agreement terminates upon the earlier of (a) the later of (i) February 6, 2027 and (ii) such time as no securities of the Company are held by BioNTech or its affiliates and (b) the consummation of a change of control transaction involving the Company.

(iv) BioNTech License and Option Agreement

several time-limited options (the "Options") to acquire additional rights to specified clinical-stage product candidates, binders and technologies of the Company, described in more detail below.

an exclusive, worldwide, sublicenseable license (the "Binder License") to certain binders and to exploit products that express in vivo such binders (collectively, the "Binder Licensed Products"), and

an option to obtain exclusive rights to co-fund development costs of the Company's development-stage programs AUTO1/22 and AUTO6NG ("Product Options"), in return for agreed upon economic terms, including an option exercise fee, milestone payments and a profit-sharing arrangement for each such product candidate, with additional options to co-promote or co-commercialize each such product candidate.

an option to obtain an exclusive worldwide license to exploit products that express certain additional binders in vivo or, with respect to certain binders, in an antibody drug conjugate (the "Binder Option"),

an option to obtain an exclusive worldwide license to exploit products that express in vivo the Company's modules for activity enhancement, with a non-exclusive right, in certain agreed instances, to exploit products that include Company's modules for activity enhancement but do not express in vivo such modules (the "Activity Enhancement Option"); and

an option to obtain an exclusive worldwide license to exploit products that express in vivo the Company's modules for activity enhancement but do not express in vivo such modules (the "Activity Enhancement Option").

In consideration for the Binder License and the Technology Options, BioNTech made an initial payment to the Company of \$10.0 million. In the event that all Options are fully exercised, the Company would be eligible to receive maximum aggregate payments of up to \$592.0 million pursuant to the License Agreement. This maximum amount includes the potential milestone payments for the Binder Licensed Products described below, all option exercise fees and potential milestone payments for licenses to optioned products and technologies, and additional payments that BioNTech may pay to the Company for an increased revenue interest with respect to the Company's product candidate obe-cel as described below.

The option exercise fee for each Technology Option is a low seven-digit amount. Each of the Activity Enhancement Option and the Safety Switch Option must be exercised with respect to a given biological target or combination of targets. There is a cap on the total option exercise fee if multiple options are exercised with respect to a given target.

There is also a cap on milestone payments across all agreements entered into as the result of BioNTech exercising one or more of the Technology Options and a cap on the royalty rate payable on any given product for which multiple Options are exercised.

Obe-cel Product Revenue Interest

BioNTech has also agreed to financially support the expansion of the clinical development program for, and planned commercialization of obe-cel. In exchange for the grant of rights to future revenues from the sales of obe-cel products, BioNTech made an upfront payment to the Company of \$40.0 million. The Company will pay BioNTech a low single-digit percentage of annual net sales of obe-cel products, which may be increased up to a mid-single digit percentage in exchange for milestone payments of up to \$100.0 million in the aggregate on achievement of certain regulatory events for specific new indications upon BioNTech's election.

Manufacturing and Commercial Services Agreement

Under the terms of the BioNTech License and Option Agreement, the Company has agreed to grant BioNTech the option to negotiate a joint manufacturing and commercial services agreement pursuant to which the parties may access and leverage each other's manufacturing and commercial capabilities, in addition to Autolus' commercial site network and infrastructure, with respect to certain of each parties' CAR T products,

[illegible]

[illegible]

[illegible]

Background

The accompanying unaudited condensed consolidated financial statements of the Company have been prepared in accordance with generally accepted accounting principles in the US ("U.S. GAAP") and are presented in U.S. dollars. All intercompany accounts and transactions between the Company and its subsidiaries have been eliminated upon consolidation.

The significant accounting policies used in the preparation of these unaudited condensed consolidated financial statements are consistent with those discussed in Note 2, "Summary of Significant Accounting Policies" in the Company's Annual Report on Form 10-K for the year ended December 31, 2023 as filed with the Securities and Exchange Commission on March 21, 2024 (the "Annual Report").

Certain information and footnote disclosures have been condensed or omitted as permitted under U.S. GAAP. The information included in these unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and the related notes thereto as of and for the year ended December 31, 2023, included in the Annual Report. However, these interim financial statements include all adjustments, consisting only of normal recurring adjustments, which are, in the opinion of management, necessary to fairly state the results of the interim period. The interim results are not necessarily indicative of results to be expected for the full year ending December 31, 2024, any other interim periods, or any future year or period.

Going Concern

The Company expects to continue to generate operating losses in the foreseeable future. The Company's inability to raise additional capital as and when needed could have a negative impact on its financial condition and ability to pursue its business strategies. There can be no assurances, however, that the current operating plan will be achieved or that additional funding will be available on terms acceptable to the Company, or at all. The Company expects that its cash and cash equivalents at June 30, 2024 of \$705.9 million will be sufficient to fund the Company's operations for at least twelve months from the issuance date of these unaudited condensed consolidated financial statements and accordingly they have been prepared on a going concern basis. As the Company continues to incur losses, the transition to profitability is dependent upon the successful development, approval and commercialization of its product candidates and achieving a level of revenues adequate to support its cost structure. Even if the Company achieves such milestones, there can be no assurance that the Company will achieve sustained profitability.

Foreign Currency Translation

The reporting currency of the Company is U.S. dollars. The Company has determined that its functional currency of the ultimate parent company, Autolus Therapeutics plc., is British Pound Sterling. The functional currency of each subsidiary's operations is the applicable local currency. Monetary assets and liabilities denominated in currencies other than the Company's functional currency are translated into the functional currency at rates of exchange prevailing at the balance sheet dates. Non-monetary assets and liabilities denominated in foreign currencies are translated into the functional currency at the exchange rates prevailing at the date of the transaction.

The Company recorded foreign exchange gains of \$1.2 million and \$0.4 million for the three months ended June 30, 2024 and 2023, respectively, and foreign exchange losses of \$0.5 million and foreign exchange gains of \$1.3 million for the six months ended June 30, 2024 and 2023, respectively, which are included in other income (expense), net in the unaudited condensed Consolidated Statements of Operations and Comprehensive Loss.

For financial reporting purposes, the financial statements of the Company have been translated into U.S. dollars. Assets and liabilities have been translated at the exchange rates at the balance sheet dates, while revenue and expenses are translated at the average exchange rates over the reporting period and shareholders' equity amounts are translated based on historical exchange rates as of the date of each transaction. Translation adjustments are not included in determining net income (loss) but are included in foreign exchange adjustment to other comprehensive loss, a component of shareholders' equity.

Segment Information

The Company operates through two segments: the Commercial Segment and the Research & Development Segment. The Commercial Segment consists of the Company's operations in the United States and certain international markets where the Company's products are marketed. The Research & Development Segment consists of the Company's operations in the United Kingdom and certain international markets where the Company is conducting research and development activities.

The chief operating decision maker (the "CODM"), its Chief Executive Officer, manages the Company's operations on a global basis. The Company and the CODM view the Company's operations and manage its business as a single operating segment, which is the business of developing and commercializing CAR T therapies.

Financial performance, the CODM reviews total revenue, total expenses and expenses by function and makes decisions using this information on a global basis. The Company and the CODM view the Company's operations and manage its business as a single operating segment, which is the business of developing and commercializing CAR T therapies.

Use of Estimates

The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of income and expenses during the reporting periods. Significant estimates and assumptions reflected in these consolidated financial statements include, but are not limited to, the accrual for research and development expenses, share-based compensation including assessing the probability of meeting performance conditions, income taxes, initial fair value of warrants, and interest expense on liability related to future royalties and milestones, net and related cumulative catch-up adjustment, initial lease term of the Company's new manufacturing facility ("The Nucleus"). An assessment of the allocation of transaction price using the relative standalone selling price was required for the three and six months ended June 30, 2024 and 2023 for the BioNTech License and Option Agreement and the Option and License Agreement with Cabaletta Bio Inc. ("Cabaletta"). incremental borrowing rates related to the Company's leased properties and allocation of transaction price using the relative standalone selling price. Estimates are periodically reviewed in light of changes in circumstances, facts and experience. Actual results could differ from those estimates.

Allocation of transaction price using the relative standalone selling price

Liability related to future royalties and milestones, net and cumulative catch-up adjustments

The Company accounted for each of the Blackstone Collaboration Agreement (See Note 12) ("Blackstone Collaboration Agreement Liability") and the BioNTech Obe cel Product Revenue Interest ("BioNTech Liability") as liabilities measured at amortized cost based on an effective interest rate determined at the outset of the arrangement. The Blackstone Collaboration Agreement Liability related to future royalties and milestones, net is measured based on the Company's current estimates of the timing and amount of expected future royalties, milestone payments to be paid and the milestones receivable upon the achievement of certain specified clinical, manufacturing and regulatory milestones (each such payment, a "Blackstone Development Payment" and collectively, the "Blackstone Development Payments") expected to be received over the estimated term of the agreement.

Similarly, the BioNTech Liability related to future royalties and milestones, net is measured based on the Company's current estimates of the timing and amount of expected future royalties, milestone payments to be paid and the milestones receivable upon the achievement of certain specified clinical, manufacturing and regulatory milestones (each such payment, a "BioNTech Development Payment" and collectively, the "BioNTech Development Payments") expected to be received over the estimated term of the agreement. Milestone payments pursuant to the BioNTech License and Option Agreement ("BioNTech Milestone Payments") are payable upon BioNTech's election, and therefore have not been included in the determination of the effective interest rate or in the measurement of the liability.

The liabilities are amortized using the effective interest rate, resulting in recognition of interest expense over the estimated term of the agreement. Each reporting period the Company assesses the estimated probability, timing and amount of the future expected royalty, milestone payments, the Blackstone Development Payment over the estimated term. If there are changes to the estimates, the Company recognizes the impact to the liability's amortization schedule and the related interest expense using the catch-up method.

estimate of the probability, timing and amount of expected future royalties and milestones to be paid by the Company and the expected Blackstone Development Payment to be paid to the Company, considers significant unobservable inputs. These inputs include regulatory approval, the estimated patient population, estimated selling price, estimated sales, estimated peak sales and sales ramp, timing of the expected launch and its impact on the royalties as well as the overall probability of a success. Additionally, the transaction costs associated with the liability will be amortized to interest expense over the estimated term of the agreements.

The carrying amount of the Blackstone Collaboration Agreement Liability and BioNTech Liability is based on the carrying amount of the future royalties, milestones to be paid to Blackstone by the Company and the expected Blackstone Development Payment to be received over the life of the arrangement as discounted using the initial effective interest rate. The excess estimated present value of future royalty, milestone payments and the future Blackstone Development Payment received over the carrying amount is recognized as a cumulative catch-up adjustment within interest expense using the effective interest rate.

Recent Accounting Pronouncements Not Yet Adopted

In November 2023, the Financial Accounting Standards Board, ("FASB"), issued Accounting Standards Update, or ("ASU"), 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures, or ("ASU 2023-07"), which expanded the disclosures for reportable segments made by public entities. These amendments within ASU 2023-07 retained the existing disclosure requirements in ASC 280 – Segment Reporting and expanded upon them to require public entities to disclose significant expenses for reportable segments in both interim and annual reporting periods, as well as items that were previously disclosed only annually on an interim basis, including disclosures related to a reportable segment's profit or loss and assets. In addition, entities with a single reportable segment must provide all segment disclosures required in ASC 280, including the new disclosures for reportable segments under the amendments in ASU 2023-07. The amendments did not change the existing guidance on how a public entity identified and determined its reportable segments. A public entity should apply the amendments in ASU 2023-07 retrospectively to all prior periods presented in the financial statements. Upon transition, the segment expense categories and amounts disclosed in the prior periods should be based on the significant segment expense categories identified and disclosed in the period of adoption. The amendments in ASU 2023-07 are effective for annual periods for all public entities in fiscal years beginning after December 15, 2023, and in interim periods within fiscal years beginning after December 15, 2024. The Company will comply with any new applicable disclosures in its Annual Report on Form 10-K for the year ending December 31, 2024. The Company does not expect the adoption to have a material effect on its financial statements and related disclosures.

In December 2023, the FASB issued ASU 2023-09, Improvements to Income Tax Disclosures. This ASU improves the transparency of income tax disclosure by requiring consistent categories and greater disaggregation of information in the rate reconciliation, and income taxes paid disaggregated by jurisdiction. This guidance is effective for the Company for the year beginning January 1, 2025, with early adoption permitted. The amendments should be applied on a prospective basis, with retrospective application permitted. The Company intends to adopt the guidance in the fiscal year beginning January 1, 2025. The Company does not expect the adoption of ASU 2023-09 to have a material effect on its financial statements and related disclosures.

Unless otherwise discussed, the impact of recently issued standards that are not yet effective are not expected to have a material impact on the consolidated financial statements and disclosures in this report and for the full year ending December 31, 2024.

Basis of Presentation

The accompanying unaudited condensed consolidated financial statements of the Company have been prepared in accordance with generally accepted accounting principles in the US ("U.S. GAAP") and are presented in U.S. dollars. All intercompany accounts and transactions between the Company and its subsidiaries have been eliminated upon consolidation.

The significant accounting policies used in the preparation of these unaudited condensed consolidated financial statements are consistent with those discussed in Note 2, "Summary of Significant Accounting Policies" in the Company's Annual Report on Form 10-K for the year ended December 31, 2023 as filed with the Securities and Exchange Commission on March 21, 2024 (the "Annual Report").

Certain information and footnote disclosures have been condensed or omitted as permitted under U.S. GAAP. The information included in these unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and the related notes thereto as of and for the year ended December 31, 2023, included in the Annual Report. However, these interim financial statements include all adjustments, consisting only of normal recurring adjustments, which are, in the opinion of management, necessary to fairly state the results of the interim period. The interim results are not necessarily indicative of results to be expected for the full year ending December 31, 2024, any other interim periods, or any future year or period.

Going Concern

The Company has incurred recurring losses since its inception, including net losses of \$58.3 million and \$45.6 million for the three months ended June 30, 2024 and 2023, respectively and \$11.0 million and \$85.4 million for the six months ended June 30, 2024 and 2023, respectively. The Company had an accumulated deficit of \$989.5 million and \$878.6 million as of June 30, 2024 and December 31, 2023, respectively. The Company expects to continue to generate operating losses in the foreseeable future. The Company's inability to raise additional capital as and when needed could have a negative impact on its financial condition and ability to pursue its business strategies. There can be no assurances, however, that the current operating plan will be achieved or that additional funding will be available on terms acceptable to the Company, or at all. The Company expects that its cash and cash equivalents at June 30, 2024 of \$705.9 million will be sufficient to fund the Company's operations for at least twelve months from the issuance date of these unaudited condensed consolidated financial statements and accordingly they have been prepared on a going concern basis. As the Company continues to incur losses, the transition to profitability is dependent upon the successful development, approval and commercialization of its product candidates and achieving a level of revenues adequate to support its cost structure. Even if the

height:120%>Company's planned regulatory submissions for its products are approved, and the Company is successful in its commercialization efforts, additional funding will be needed before the Company is expected to reach cash breakeven.</div>-58300000-45600000-111000000-0-85400000-989500000-786000000-705900000</div style="margin-top:9pt;text-align:justify">Foreign Currency Translation</div><div style="margin-top:6pt;text-align:justify;text-indent:31.5pt">The reporting currency of the Company is U.S. dollars. The Company has determined that its functional currency of the ultimate parent company, Autolus Therapeutics plc, is British Pound Sterling. The functional currency of each subsidiary's operations is the applicable local currency. Monetary assets and liabilities denominated in currencies other than the Company's functional currency are translated into the functional currency at rates of exchange prevailing at the balance sheet dates. Non-monetary assets and liabilities denominated in foreign currencies are translated into the functional currency at the exchange rates prevailing at the date of the transaction.</div><div style="margin-top:9pt;text-align:justify;text-indent:31.5pt">The Company recorded foreign exchange gains of \$1.2 million and \$0.4 million for the three months ended June 30, 2024 and 2023, respectively, and foreign exchange losses of \$0.5 million and foreign exchange gains of \$1.3 million for the six months ended June 30, 2024 and 2023, respectively, which are included in other income (expense), net in the unaudited condensed Consolidated Statements of Operations and Comprehensive Loss.</div><div style="margin-top:6pt;text-align:justify;text-indent:31.5pt">For financial reporting purposes, the financial statements of the Company have been translated into U.S. dollars. Assets and liabilities have been translated at the exchange rates at the balance sheet dates, while revenue and expenses are translated at the average exchange rates over the reporting period and shareholders' equity amounts are translated based on historical exchange rates as of the date of each transaction. Translation adjustments are not included in determining net income (loss) but are included in foreign exchange adjustment to other comprehensive loss, a component of shareholders' equity.</div>1200000400000-5000001300000<div style="margin-bottom:6pt;margin-top:12pt;text-align:justify">Segment Information</div><div style="margin-top:6pt;text-align:justify;text-indent:36pt">TheCompany's chief operating decision maker (the "CODM"), its Chief Executive Officer, manages theCompany's operations on an integrated basis for the purpose of appropriately allocating resources. When evaluating theCompany's financial performance, the CODM reviews total revenue, total expenses and expenses by function and makes decisions using this information on a global basis. The Company and the CODM view the Company's operations and manage its business as asingle operating segment, which is the business of developing and commercializing CAR T therapies.</div><div style="margin-top:12pt;text-align:justify">Use of Estimates</div><div style="margin-top:6pt;text-align:justify;text-indent:36pt">The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of income and expenses during the reporting periods. Significant estimates and assumptions reflected in these consolidated financial statements include, but are not limited to, the accrual for research and development expenses, share-based compensation including assessing the probability of meeting performance conditions, income taxes, initial fair value of warrants, and interest expense on liability related to future royalties and milestones, net and related cumulative catch-up adjustment, initial lease term of the Company's new manufacturing facility ("The Nucleus" incremental borrowing rates related to the Company's leased properties and allocation of transaction price using the relative standalone selling price. Estimates are periodically reviewed in light of changes in circumstances, facts and experience. Actual results could differ from those estimates.</div><div style="margin-top:12pt;text-align:justify;text-indent:36pt">Allocation of transaction price using the relative standalone selling price</div><div style="margin-top:6pt;text-align:justify;text-indent:36pt">Upfront payments are allocated between performance obligations using theCompany's best estimate of the relative standalone selling price of the performance obligation. The relative standalone selling price is estimated by determining the market values of development and license obligations. As these inputs are not directly observable, the estimate is determined considering all reasonably available information including internal pricing objectives used in negotiating the contract, taking into account the different stage of development of each development program and consideration of adjusted market data from comparable arrangements. Where performance obligations have been identified relating to material rights, the determination of the relative standalone selling price of these performance obligations also includes an assessment of the likelihood that the options will be exercised and any payments by the customer that are triggered upon exercising the right. This assessment involves significant judgment and could have a significant impact on the amount and timing of revenue recognition.</div><div style="margin-top:6pt;text-align:justify;text-indent:36pt">An assessment of the allocation of transaction price using the relative standalone selling price was required for the three and six months ended June 30, 2024 and 2023 for the BioNTech License and Option Agreement and the Option and License Agreement with Cabaletta Bio Inc. ("Cabaletta" respectively. See Note 3 for additional information on the allocation of the transaction price for those agreements.</div><div style="margin-top:12pt;text-align:justify;text-indent:36pt">Liability related to future royalties and milestones, net and cumulative catch-up adjustments</div><div style="margin-top:6pt;text-align:justify;text-indent:36pt">12 ("Blackstone Collaboration Agreement Liability") and the BioNTech Obe-cel Product Revenue Interest ("BioNTech Liability") as liabilities measured at amortized cost based on an effective interest rate determined at the outset of the arrangement. The Blackstone Collaboration Agreement Liability related to future royalties and milestones, net is measured based on the Company's current estimates of the timing and amount of expected future royalties, milestone payments to be paid and the milestones receivable upon the achievement of certain specified clinical, manufacturing and regulatory milestones (each such payment, a "Blackstone Development Payment" and collectively, the "Blackstone Development Payments") expected to be received over the estimated term of the agreement.Similarly, the BioNTech Liability related to future royalties is measured based on theCompany's current estimates of the timing and amount of expected future royalty expected to be paid over the estimated term of the agreement. Milestone payments pursuant to the BioNTech License and Option Agreement ("BioNTech Milestone Payments") are payable upon BioNTech's election, and therefore have not been included in the determination of the effective interest rate or in the measurement of the liability.</div><div style="margin-top:6pt;text-align:justify;text-indent:36pt">The liabilities are amortized using the effective interest rate, resulting in recognition of interest expense over the estimated term of the agreement. Each reporting period the Company assesses the estimated probability, timing and amount of the future expected royalty, milestone payments, the Blackstone Development Payment over the estimated term. If there are changes to the estimates, the Company recognizes the impact to the liability's amortization schedule and the related interest expense using the catch-up method.</div><div style="margin-top:6pt;text-align:justify;text-indent:36pt">TheCompany's estimate of the probability, timing and amount of expected future royalties and milestones to be paid by the Company and the expected Blackstone Development Payment to be paid to the Company, considers significant unobservable inputs. These inputs include regulatory approval, the estimated patient population, estimated selling price, estimated sales, estimated peak sales and sales ramp, timing of the expected launch and its impact on the royalties as well as the overall probability of a success. Additionally, the transaction costs associated with the liability will be amortized to interest expense over the estimated term of the agreements.</div>The carrying amount of the Blackstone Collaboration Agreement Liability and BioNTech Liability is based on theCompany's estimate of the future royalties, milestones to be paid to Blackstone by the Company and the expected Blackstone Development Payment to be received over the life of the arrangement as discounted using the initial effective interest rate. The excess estimated present value of future royalty, milestone payments and the future Blackstone Development Payment received over the carrying amount is recognized as a cumulative catch-up adjustment within interest expense using the effective interest rate.</div style="margin-top:12pt;text-align:justify">Recent Accounting Pronouncements Not Yet Adopted</div><div style="margin-top:6pt;text-align:justify;text-indent:36pt">In November 2023, the Financial Accounting Standards Board, ("FASB"), issued Accounting Standards Update, or ("ASU"), 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures, or ("ASU 2023-07"), which expanded the disclosures for reportable segments made by public entities. These amendments within ASU 2023-07 retained the existing disclosure requirements in ASC 280 -Segment Reporting and expanded upon them to require public entities to disclose significant expenses for reportable segments in both interim and annual reporting periods, as well as items that were previously disclosed only annually on an interim basis, including disclosures related to a reportable segment's profit or loss and assets. In addition, entities with a single reportable segment must provide all segment disclosures required in ASC 280, including the new disclosures for reportable segments under the amendments in ASU 2023-07. The amendments did not change the existing guidance on how a public entity identified and determined its reportable segments. A public entity should apply the amendments in ASU 2023-07 retrospectively to all prior periods presented in the financial statements. Upon transition, the segment expense categories and amounts disclosed in the prior periods should be based on the significant segment expense categories identified and disclosed in the period of adoption. The amendments in ASU 2023-07 are effective for annual periods for all public entities in fiscal years beginning after December 15, 2023, and in interim periods within fiscal years beginning after December 15, 2024. The Company will comply with any new applicable disclosures in its Annual Report on Form 10-K for the year ending December 31, 2024. The Company does not expect the adoption to have a material effect on its financial statements and related disclosures.</div><div style="margin-top:6pt;text-align:justify;text-indent:36pt">In December 2023, the FASB issued ASU 2023-09, Improvements to Income Tax Disclosures. This ASU improves the transparency of income tax disclosure by requiring consistent categories and greater disaggregation of information in the rate reconciliation, and income taxes paid disaggregated by jurisdiction. This guidance is effective for the Company for the year beginning January 1, 2025, with early adoption permitted. The amendments should be applied on a prospective basis, with retrospective application permitted. The Company intends to adopt the guidance in the fiscal

[illegible]

has been accounted for as one freestanding financial instrument with various embedded features, including the Binder License and related transfer of know-how, Technology Options, and Product Options, the Company is required to consider if the embedded features are required to be bifurcated from the host contract and therefore accounted for as a separate derivative. The Company concluded the Binder License and related transfer of know-how, Technology Options, and Product Options meet the scope exception set out in ASC 815-10-15-59(d) and therefore not accounted for as derivatives under ASC 815.

Binder License

The Company applied ASC 606 to account for the Binder License and related know-how as functional intellectual property. The Binder License and related transfer of know-how were not distinct from one another and must be combined as a performance obligation, as BioNTech requires the know-how to derive benefit from the license. Based on these determinations, the Company identified one combined distinct performance obligation at the inception of the BioNTech License and Option Agreement.

The Company further determined the consideration received included in the transaction price at contract inception, is to be allocated to the one combined performance obligation. The Company determined that the performance obligation was recognized at a point-in-time, upon the delivery of the transfer of know-how and Binder License to BioNTech. The Company recognized total license revenue of \$10.1 million (net of foreign exchange differences), related to the BioNTech License and Option Agreement for the three months ended March 31, 2024. No license revenue was recognized during the three months ended June 30, 2024.

Technology Options

As the Technology Options are outside the scope of ASC 815, the Company considered other relevant accounting guidance to apply to this component of the BioNTech License and Option Agreement. The Company therefore applied ASC 606, considering particularly the accounting guidance related to any options granted to customers to purchase additional goods or services at a future date as this could provide a material right to the customer. A material right is a promise embedded in a current contract that should be accounted for as a separate performance obligation. The Company determined the Technology Options were not offered at a significant and incremental discount. Accordingly, the Technology Options granted to BioNTech do not represent a material right and, therefore, were not a performance obligation at the outset of the arrangement. The Technology Option exercise fee equates to the standalone selling price of the technologies underlying each option and consequently, the transaction price of \$10.0 million was not allocated to the Technology Options' performance obligation. No Technology Options were exercised during the three and six months ended June 30, 2024.

Product Options

As the Product Options are precluded from being accounted for under ASC 815 due to the scope exception, management considered the terms of the Product Options and concluded that they should be accounted for as a gain contingency under the scope of ASC 450.

Contingencies are subject to negotiation as to the specific activities to be performed by each party, which will be determined and agreed before the Product Options can be exercised, and 2) have not been exercised upon signature of the BioNTech License and Option Agreement. As a result, Product Options are not accounted for under ASC 606, and no recognition is required under ASC 450, until the Product Options are exercised. No Product Options were exercised during the three and six months ended June 30, 2024.

Option and License Agreement with Cabaletta

On January 9, 2023, the Company entered into an Option and License Agreement (the "Cabaletta Agreement") with Cabaletta, pursuant to which the Company granted to Cabaletta a non-exclusive license to research, develop, manufacture, have manufactured, use, and commercialize products incorporating the ROR8 technology (the "ROR8 technology"). Upon the execution of the Cabaletta Agreement, the Company made available the ROR8 licensed know-how to Cabaletta for a non-refundable license fee of \$1.2 million. The Company has no further material performance obligations related to the Cabaletta Agreement.

The Company further granted to Cabaletta the option to expand the rights and licenses granted under the Cabaletta Agreement to include the research, development, manufacture, use, or commercialization of licensed products up to a predetermined number of target options upon payment of an option exercise fee.

The Company identified the following material promises relating to the granting of a non-exclusive license for research, development, manufacturing and commercialization activities as well as the initial transfer of know-how and information to Cabaletta. The Company determined the option exercise fee is not offered at a significant and incremental discount. Accordingly, the option granted to Cabaletta does not represent a material right and, therefore, is not a performance obligation at the outset of the arrangement. The Company determined that the granting of the research license and the initial transfer of know-how were not distinct from one another and must be combined as a performance obligation, as Cabaletta requires the know-how to derive benefit from the license. Based on these determinations, the Company identified one distinct performance obligation at the inception of the contract.

The Company further determined that the license fee payable constituted the entirety of the consideration included in the transaction price at contract inception, which was allocated to the one performance obligation. The amount of the transaction price allocated to the performance obligation is recognized as or when the Company satisfies the performance obligation. The Company determined that the performance obligation was recognized at a point-in-time, upon the delivery of the transfer of know-how and research license to Cabaletta. The Company recognized total license revenue of \$1.2 million related to the Cabaletta Agreement for the six months ended June 30, 2023.

Table of License Revenue

Period	License Revenue
Three months ended June 30, 2024	\$0.0
Six months ended June 30, 2024	\$0.0
Three months ended June 30, 2023	\$1.2
Six months ended June 30, 2023	\$1.2

[illegible]

```
<div><table border=
```

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

Outstanding as of December 31, 2023

Exercised

Forfeited

Expired

Outstanding as of June 30, 2024

Exercisable as of June 30, 2024

[illegible]

[illegible]

[illegible]

[illegible]

Balance at March 31, 2023

Interest expense on liability related to future royalties and milestones, net

Balance at June 30, 2023

Initial recognition of BioNTech liability

Interest expense on liability related to future royalties and milestones, net

Balance at September 30, 2023

Cumulative catch-up adjustment

Interest expense on liability related to future royalties and milestones, net

Balance at December 31, 2023

Initial recognition of BioNTech liability

Interest expense on liability related to future royalties and milestones, net

Balance at March 31, 2024

Interest expense on liability related to future royalties and milestones, net

Balance at June 30, 2024

During the three months ended June 30, 2024 and 2023, interest expense on liabilities related to future royalties and milestones, net amounted to \$10.2 million and \$5.0 million, respectively. During the six months ended June 30, 2024 and 2023, interest expense on liabilities related to future royalties and milestones, net amounted to \$18.6 million and \$9.9 million, respectively. During the three months ended June 30, 2024 and 2023 and six months ended June 30, 2023, there was no cumulative catch-up adjustment (included in interest expense). During the six months ended June 30, 2024, the cumulative catch-up adjustment amounted to \$1.9 million.

Blackstone Collaboration Agreement

On November 6, 2021, the Company concurrently entered into the following agreements with BXL V - Autobahn L.P. ("Blackstone"): (i) Strategic Collaboration Agreement (the "Blackstone Collaboration Agreement"), (ii) Securities Purchase Agreement (the "Blackstone Securities Purchase Agreement"), (iii) Warrant Agreement (the "Blackstone Warrant") and (iv) a Registration Rights Agreement (the "Blackstone Registration Rights Agreement"). The Blackstone Collaboration Agreement, the Blackstone Securities Purchase Agreement, the Blackstone Warrant and the Blackstone Registration Rights Agreement are collectively referred to as the "Blackstone Agreements". The Blackstone Agreements were entered into and in contemplation of one another and, accordingly, the Company assessed the accounting for the Blackstone Agreements in the aggregate.

For further details on the terms and accounting treatment considerations for these contracts, please refer to following notes to the Company's consolidated financial statements contained in the

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

the Company is obligated to make specified payments to Adaptive upon the achievement and receipt of certain regulatory approvals and achievement of commercial milestones in connection with the

Company's

use of the Adaptive assay. During the year ended December 31, 2023, the Company recognized all contractual milestones relating to this contract, and as a result no contractual milestones were recognized during the three and six months ended June 30, 2024.

In previous periods, the Company has entered into agreements with certain advisory firms. The Company is obligated to make specified payments upon the achievement of certain strategic transactions involving the Company. During the three and six months ended June 30, 2024, the Company paid a fee under these agreements.

The Company has estimated the probability of the Company achieving each potential milestone in relation to the agreements with UCLB, Noile, Miltenyi and its agreements with certain advisory firms in accordance with ASC 450. The Company considers the regulatory approval, commercial milestones and execution of collaboration agreements probable when actually achieved. Furthermore, the Company recognizes expenses for clinical milestones when their achievement is deemed probable. The Company concluded that, as of June 30, 2024, there were no other milestones for which the likelihood of achievement was currently probable.

Capital Commitments

As of June 30, 2024, the Company's unconditional purchase obligations for capital expenditures totaled \$9.7 million and included signed orders for capital equipment and capital expenditures for construction and related expenditures relating to its properties in the U.K. and the US. The Company expects to incur the full amount of these obligations within one year.

Master Supply Commitments

As of June 30, 2024, the Company's unconditional purchase obligations with Miltenyi Biotec GmbH for reagents and disposables totaled \$1.1 million, which the Company expects to incur within one year.

Distribution Commitments

The Company entered into an Exclusive Distribution Agreement, effective as of April 25, 2024 (the "Effective Date"), with Cardinal Health 105, LLC ("Cardinal Health"). Pursuant to, and subject to the terms and conditions of, the Exclusive Distribution Agreement, the Company engaged Cardinal Health as its exclusive third-party logistics distribution agent for sales of obe-cel in the US. The Exclusive Distribution Agreement runs for an initial term of three years following commercial launch and automatically renews for additional terms of one year each, unless either party elects not to renew. In addition, the Company can terminate the Exclusive Distribution Agreement without cause, subject to the payment of termination fees if such termination occurs during the initial three-year term. Under the terms of the Exclusive Distribution Agreement, the Company must pay to Cardinal Health a one-time start-up fee, and if the Company proceeds with commercialization of obe-cel, upon its launch, a monthly account management fee, and other fees for various services, including post-launch program implementation, information systems, warehouse operations and financial services.

Blackstone and BioNTech Agreements

The Company entered into a freestanding financial instrument, the Company assessed if the Product Options should be accounted for as a derivative under ASC 815. However, the Company determined the Product Options met the scope exception for derivative accounting under ASC 815 and therefore should be accounted for a gain contingency under the scope of ASC 450. As of June 30, 2024, Product Options were not exercised and therefore no amounts were recognized.

Legal Proceedings

From time to time, the Company may be a party to litigation or subject to claims incident to the ordinary course of business. Regardless of the outcome, litigation can have an adverse impact on the Company because of defense and settlement costs, diversion of management resources and other factors. The Company was not a party to any litigation and did not have contingency reserves established for any liabilities as of June 30, 2024 and December 31, 2023.

Indemnification Agreements

In the normal course of business, the Company enters into contracts and agreements that contain a variety of representations and warranties and provide for general indemnification. The Company's exposure under these agreements is unknown because they involve claims that may be made against the Company in the future. To date, the Company has not paid any claims or been required to defend any action related to its indemnification obligations. However, the Company may record charges in the future as a result of these indemnification obligations.

In accordance with the indemnification agreements entered into with relevant individuals in accordance with the Company's Articles of Association, the Company has indemnification obligations to its directors, officers and members of senior management for certain events or occurrences, subject to certain limits, while they are serving at the Company's request in such capacity. There have been no claims to date under these indemnification agreements, and the Company has director and officer insurance that may enable it to recover a portion of any amounts paid for future potential claims.

Related party transactions

Blackstone Agreements

In November 2021, the Company concurrently entered into the Blackstone Agreements. As of the execution of the Blackstone Agreements, Blackstone became a related party of the Company, as Blackstone became the owner of more than 10% of the Company.

outstanding voting securities. In addition, Blackstone received and exercised its right to nominate one director to the board of directors of the Company and is therefore considered to be one of the principal owners of the Company.

As of June 30, 2024, the carrying amount of the Blackstone Collaboration Agreement Liability was \$195.9 million which included aggregated cumulative non-cash interest expense and cumulative catch-up adjustment of \$25.0 million.

As of December 31, 2023, the carrying amount of the Blackstone Collaboration Agreement Liability was \$170.9 million which included aggregated cumulative non-cash interest expense (including cumulative catch-up adjustments), of \$45.0 million.

Refer to Note 12, Liabilities related to future royalties and milestones, net

As of June 30, 2024, the carrying amount of the BioNTech Agreements was \$42.8 million which included aggregated cumulative interest expense and cumulative catch-up adjustment of \$2.7 million. Refer to Note 12, "Liabilities related to future royalties and milestones, net" for further details.

Subsequent Events

The Company evaluated subsequent events through August 8, 2024, the date on which these unaudited condensed consolidated financial statements were issued. The Company has concluded that no subsequent event has occurred that requires disclosure.

On June 14, 2024, Martin Pule, our Chief Scientific Officer, adopted a "Rule 10b5-1 trading arrangement" as defined in Item 408(a) of Regulation S-K, which is intended to satisfy the affirmative defense of Rule 10b5-1(c). The sales plan has an initial term ending on March 21, 2025 and covers the sale of a total of 698,741 ADSs, each representing one ordinary share with a nominal value of \$0.000042 per share, of the Company.

June 14, 2024

Martin Pule

Chief Scientific Officer

March 21, 2025

698741